
<html lang="en"     class="pb-page"  data-request-id="aae23239-7979-47b2-886a-5d74fdaae240"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.1c00291;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer’s Disease" /></meta><meta name="dc.Creator" content="Min Jae  Lee" /></meta><meta name="dc.Creator" content="Deepak  Bhattarai" /></meta><meta name="dc.Creator" content="Hyeryung  Jang" /></meta><meta name="dc.Creator" content="Ahreum  Baek" /></meta><meta name="dc.Creator" content="In Jun  Yeo" /></meta><meta name="dc.Creator" content="Seongsoo  Lee" /></meta><meta name="dc.Creator" content="Zachary  Miller" /></meta><meta name="dc.Creator" content="Sukyeong  Lee" /></meta><meta name="dc.Creator" content="Jin Tae  Hong" /></meta><meta name="dc.Creator" content="Dong-Eun  Kim" /></meta><meta name="dc.Creator" content="Wooin  Lee" /></meta><meta name="dc.Creator" content="Kyung Bo  Kim" /></meta><meta name="dc.Description" content="Previously, we reported that immunoproteasome (iP)-targeting linear peptide epoxyketones improve cognitive function in mouse models of Alzheimer’s disease (AD) in a manner independent of amyloid β...." /></meta><meta name="Description" content="Previously, we reported that immunoproteasome (iP)-targeting linear peptide epoxyketones improve cognitive function in mouse models of Alzheimer’s disease (AD) in a manner independent of amyloid β...." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 26, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00291" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00291" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00291" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00291" /></link>
        
    
    

<title>Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer’s Disease | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00291" /></meta><meta property="og:title" content="Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer’s Disease" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0011.jpeg" /></meta><meta property="og:description" content="Previously, we reported that immunoproteasome (iP)-targeting linear peptide epoxyketones improve cognitive function in mouse models of Alzheimer’s disease (AD) in a manner independent of amyloid β. However, these compounds’ clinical prospect for AD is limited due to potential issues, such as poor brain penetration and metabolic instability. Here, we report the development of iP-selective macrocyclic peptide epoxyketones prepared by a ring-closing metathesis reaction between two terminal alkenes attached at the P2 and P3/P4 positions of linear counterparts. We show that a lead macrocyclic compound DB-60 (20) effectively inhibits the catalytic activity of iP in ABCB1-overexpressing cells (IC50: 105 nM) and has metabolic stability superior to its linear counterpart. DB-60 (20) also lowered the serum levels of IL-1α and ameliorated cognitive deficits in Tg2576 mice. The results collectively suggest that macrocyclic peptide epoxyketones have improved CNS drug properties than their linear counterparts and offer promising potential as an AD drug candidate." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00291"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00291">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00291&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00291&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00291&amp;href=/doi/10.1021/acs.jmedchem.1c00291" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, XXXX</span><span class="cit-fg-issue">, XXX</span><span class="cit-fg-pageRange">, XXX-XXX</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/0/0" title="Return to Articles ASAP" id="returnToASAP" class="content-navigation__btn--return"><span>RETURN TO ARTICLES ASAP</span></a><a href="/doi/10.1021/acs.jmedchem.1c00957" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c01089" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer’s Disease</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Min Jae Lee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Min Jae Lee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, University of Kentucky, 789 South Limestone, Lexington, Kentucky 40536-0596, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Min+Jae++Lee">Min Jae Lee</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Deepak Bhattarai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Deepak Bhattarai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, University of Kentucky, 789 South Limestone, Lexington, Kentucky 40536-0596, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Deepak++Bhattarai">Deepak Bhattarai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hyeryung Jang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hyeryung Jang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hyeryung++Jang">Hyeryung Jang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ahreum Baek</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ahreum Baek</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ahreum++Baek">Ahreum Baek</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">In Jun Yeo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">In Jun Yeo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk 28160, Republic of Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=In+Jun++Yeo">In Jun Yeo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Seongsoo Lee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Seongsoo Lee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Seongsoo++Lee">Seongsoo Lee</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zachary Miller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zachary Miller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, University of Kentucky, 789 South Limestone, Lexington, Kentucky 40536-0596, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zachary++Miller">Zachary Miller</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sukyeong Lee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sukyeong Lee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sukyeong++Lee">Sukyeong Lee</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jin Tae Hong</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jin Tae Hong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk 28160, Republic of Korea</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#543e3d3a203c3b3a3314373c213a3336213f7a35377a3f26"><span class="__cf_email__" data-cfemail="395350574d5156575e795a514c575e5b4c5217585a17524b">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jin+Tae++Hong">Jin Tae Hong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dong-Eun Kim</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dong-Eun Kim</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#ed8684808988ad868283869886c38c8ec3869f"><span class="__cf_email__" data-cfemail="2f4446424b4a6f444041445a44014e4c01445d">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dong-Eun++Kim">Dong-Eun Kim</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-6545-8387" title="Orcid link">https://orcid.org/0000-0001-6545-8387</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wooin Lee</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wooin Lee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#b1c6deded8df9fddd4d4f1c2dfc49fd0d29fdac3"><span class="__cf_email__" data-cfemail="1d6a72727473337178785d6e7368337c7e33766f">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wooin++Lee">Wooin Lee</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-7805-869X" title="Orcid link">https://orcid.org/0000-0001-7805-869X</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Kyung Bo Kim</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kyung Bo Kim</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, University of Kentucky, 789 South Limestone, Lexington, Kentucky 40536-0596, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#107b727b797d2250657b693e757465"><span class="__cf_email__" data-cfemail="5d363f3634306f1d28362473383928">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kyung+Bo++Kim">Kyung Bo Kim</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-4744-2466" title="Orcid link">https://orcid.org/0000-0003-4744-2466</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00291&amp;href=/doi/10.1021%2Facs.jmedchem.1c00291" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, XXXX</span><span class="cit-issue">, XXX</span><span class="cit-pageRange">, XXX-XXX</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 26, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 February 2021</li><li><span class="item_label"><b>Published</b> online</span>26 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00291" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00291</a></div><div class="article_header-article-copyright"><strong>© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMin%2BJae%2BLee%252C%2BDeepak%2BBhattarai%252C%2BHyeryung%2BJang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D0%26issueNum%3D0%26contentID%3Dacs.jmedchem.1c00291%26title%3DMacrocyclic%2BImmunoproteasome%2BInhibitors%2Bas%2Ba%2BPotential%2BTherapy%2Bfor%2BAlzheimer%25E2%2580%2599s%2BDisease%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D17%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00291"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">310</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00291" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer’s Disease&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Min&quot;,&quot;last_name&quot;:&quot;Jae Lee&quot;},{&quot;first_name&quot;:&quot;Deepak&quot;,&quot;last_name&quot;:&quot;Bhattarai&quot;},{&quot;first_name&quot;:&quot;Hyeryung&quot;,&quot;last_name&quot;:&quot;Jang&quot;},{&quot;first_name&quot;:&quot;Ahreum&quot;,&quot;last_name&quot;:&quot;Baek&quot;},{&quot;first_name&quot;:&quot;In&quot;,&quot;last_name&quot;:&quot;Jun Yeo&quot;},{&quot;first_name&quot;:&quot;Seongsoo&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Zachary&quot;,&quot;last_name&quot;:&quot;Miller&quot;},{&quot;first_name&quot;:&quot;Sukyeong&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Jin&quot;,&quot;last_name&quot;:&quot;Tae Hong&quot;},{&quot;first_name&quot;:&quot;Dong-Eun&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Wooin&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Kyung&quot;,&quot;last_name&quot;:&quot;Bo Kim&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;26&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;volume&quot;:&quot;0&quot;,&quot;pages&quot;:&quot;&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00291&quot;},&quot;abstract&quot;:&quot;Previously, we reported that immunoproteasome (iP)-targeting linear peptide epoxyketones improve cognitive function in mouse models of Alzheimer’s disease (AD) in a manner independent of amyloid β. However, these compounds’ clinical prospect for AD is limited due to potential issues, such as poor brain penetration and metabolic instability. Here, we report the development of iP-selective macrocyclic peptide epoxyketones prepared by a ring-closing metathesis reaction between two terminal alkenes attached at the P2 and P3/P4 positions of linear counterparts. We show that a lead macrocyclic compound DB-60 (20) effectively inhibits the catalytic activity of iP in ABCB1-overexpressing cells (IC50: 105 nM) and has metabolic stability superior to its linear counterpart. DB-60 (20) also lowered the serum levels of IL-1α and ameliorated cognitive deficits in Tg2576 mice. The results collectively suggest that macrocyclic peptide epoxyketones have improved CNS drug properties than their linear counterparts and offer pro&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00291&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00291" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00291&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00291" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00291&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00291" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00291&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00291&amp;href=/doi/10.1021/acs.jmedchem.1c00291" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00291" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00291" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00291%26sid%3Dliteratum%253Aachs%26pmid%3D34309393%26genre%3Darticle%26aulast%3DLee%26date%3D2021%26atitle%3DMacrocyclic%2BImmunoproteasome%2BInhibitors%2Bas%2Ba%2BPotential%2BTherapy%2Bfor%2BAlzheimer%25E2%2580%2599s%2BDisease%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D0%26issue%3D0%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/0/0" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00291&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Previously, we reported that immunoproteasome (iP)-targeting linear peptide epoxyketones improve cognitive function in mouse models of Alzheimer’s disease (AD) in a manner independent of amyloid β. However, these compounds’ clinical prospect for AD is limited due to potential issues, such as poor brain penetration and metabolic instability. Here, we report the development of iP-selective macrocyclic peptide epoxyketones prepared by a ring-closing metathesis reaction between two terminal alkenes attached at the P2 and P3/P4 positions of linear counterparts. We show that a lead macrocyclic compound DB-60 (<b>20</b>) effectively inhibits the catalytic activity of iP in ABCB1-overexpressing cells (IC<sub>50</sub>: 105 nM) and has metabolic stability superior to its linear counterpart. DB-60 (<b>20</b>) also lowered the serum levels of IL-1α and ameliorated cognitive deficits in Tg2576 mice. The results collectively suggest that macrocyclic peptide epoxyketones have improved CNS drug properties than their linear counterparts and offer promising potential as an AD drug candidate.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36836" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36836" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the past decades, almost all drugs developed based on their ability to intervene with the amyloid β (Aβ) pathway have failed in clinical trials for Alzheimer’s disease (AD).<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> As a result, much attention has been paid to developing anti-tau drugs, but no approved anti-tau therapies are available so far.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Strategies of targeting neuroinflammation (regarded as a significant contributing factor to the progression of AD) have also drawn considerable attention.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> Such strategies are further corroborated by recent findings that inflammatory cytokines released by activated microglia can induce astrocytes-mediated<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> or tau-mediated neurotoxicity.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Nevertheless, multiple clinical trials of FDA-approved anti-inflammatory agents targeting cyclooxygenases (COXs) or tumor necrosis factor (TNF)-α signaling have yielded no effective AD therapies.<a onclick="showRef(event, 'ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12">(9−12)</a> Thus, identifying new therapeutic agents not reliant on conventional AD targets has become increasingly crucial in AD drug discovery efforts. However, the lack of promising novel drug targets is a major obstacle in making real progress toward developing effective AD drugs.</div><div class="NLM_p">In mammalian cells, there exist two main types of 20S proteasomes: the constitutive proteasome (cP) and immunoproteasome (iP), which are constitutively expressed in immune cells. The multiprotease complex 20S cP has three catalytic subunits (β1, β2, β5) on inner two β-rings displaying three unique substrate preferences: referred to as caspase-like (C-L), trypsin-like (T-L), and chymotrypsin-like (CT-L) activities, respectively. The cP subunits β1, β2, and β5, which are also commonly referred to as Y, Z, and X, respectively, are replaced by three immunosubunits β1i, β2i, and β5i, commonly referred to as LMP2 (low-molecular-mass polypeptide-2), MECL-1 (multicatalytic endopeptidase complex subunit-1), and LMP7 (low-molecular-mass polypeptide-7), respectively, to form the iP. Functionally, the iP has been shown to modulate inflammatory responses.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13−15)</a> As such, iP-targeting inhibitors have been investigated in preclinical and clinical trials as potential anti-inflammatory agents. For example, KZR-616, an iP-selective linear peptide epoxyketone (targeting both LMP7 and LMP2, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>a), is currently being evaluated in clinical trials for systemic lupus erythematosus.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Studies also revealed that the iP is upregulated in the brain of AD patients compared with healthy controls<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17−19)</a> and that iP expression is closely linked to the activated microglia, which are widely considered as a primary culprit behind AD progression,<a onclick="showRef(event, 'ref17 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref17 ref20 ref21">(17,20,21)</a> suggesting a potential connection between the iP and AD.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Previously reported linear peptide epoxyketones targeting the immunoproteasome (iP) catalytic subunits LMP7 (a) and LMP2 (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00291&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, we reported that iP-targeting linear peptide epoxyketones (e.g., DB-310, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b) have a previously unrecognized effect of alleviating cognitive deficits in mouse models of AD in a manner independent of Aβ and tau aggregation.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> We also showed that the iP inhibitors lower the levels of serum interleukin-1α (IL-1α) and protect the retinal pigment epithelium (RPE) layer from the structural destruction caused by Aβ-triggered inflammation in Tg2576 mice, potentially representing a new class of AD drugs that aim at a previously untapped pathway in AD drug discovery efforts. Despite promising efficacy, however, these linear peptide epoxyketones’ clinical prospect seems limited at this time due to issues commonly associated with linear peptides, such as poor brain penetration and metabolic instability (mainly attributable to transporter-mediated efflux and enzymatic metabolism).<a onclick="showRef(event, 'ref23 ref26 ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref23 ref26 ref27 ref28 ref29 ref30">(23,26−30)</a> Yet, the peptide epoxyketone family (“short peptides with C-terminal α′,β′-epoxyketone warhead”) provides an attractive drug development platform for related diseases due to pharmacological advantages conferred by their proven target specificity for the proteasomes and long-term safety in the clinic.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_p">Macrocycles, prepared via constraining the freely rotatable peptide bond, are often introduced to improve linear peptides’ physicochemical (drug-like) properties.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> This strategy has been used to boost the potency and chemical stability of linear peptides and improve metabolic stability, penetration across the blood–brain barrier (BBB), and membrane permeability.<a onclick="showRef(event, 'ref34 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36 ref37">(34−37)</a> Typically, for short linear peptides like the iP inhibitor DB-310 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b), a macrocycle can be introduced by a ring-closing reaction between the (<i>n</i>) and (<i>n</i> + 2) residues,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> forming a β-turn mimic macrocyclic peptide.</div><div class="NLM_p last">Here, we report the development of iP-targeting macrocyclic peptide epoxyketones prepared via a ring-closing metathesis reaction between two terminal alkenes attached at the P2 and P3/P4 residues of their linear counterparts in the presence of a second-generation Grubbs catalyst. We show that a lead macrocyclic peptide epoxyketone DB-60 (<b>20</b>) potently inhibits the catalytic activity of the iP catalytic subunit LMP2 with an IC<sub>50</sub> of 105 nM in cells overexpressing ABCB1 (a major efflux transporter at the BBB), suggesting minimal interactions between DB-60 (<b>20</b>) and ABCB1. DB-60 (<b>20</b>) also showed no interaction with ABCG2, another major efflux transporter that can limit the BBB penetration. Furthermore, DB-60 (<b>20</b>) displayed metabolic stability superior to its linear counterpart. When injected into Tg2576 mice, DB-60 (<b>20</b>) lowered the serum levels of IL-1α and improved cognitive function while showing no gross adverse effects. The results suggest that iP-targeting macrocyclic peptide epoxyketones may offer a new AD drug class that warrants further investigation for clinical potential.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87847" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87847" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Structure-Guided Design of Macrocyclic Peptide Epoxyketones</h3><div class="NLM_p">To assess the feasibility of macrocycle formation, we first built an LMP2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNF">3UNF</a>) molecular model complexed with DB-310, previously developed by us as an LMP2-selective linear peptide epoxyketone.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, both P2-phenylalanine (blue circle) and P4-glycine/<i>N</i>-cap-pyrazine (pink circle) residues of DB-310 are predicted to extend to the surface of the LMP2 catalytic cavity, potentially providing structural flexibility necessary to form a macrocyclic ring between the P2 and P3/P4 residues without disrupting its interactions with LMP2. Based on the molecular analysis, the P3-proline is expected to play a crucial role as an anchor residue by allowing P2 and P3/P4 residues to be positioned for macrocyclization (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure-aided design strategy for macrocyclic peptide epoxyketones. (a) Predicted docking model of DB-310 bound to LMP2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNF">3UNF</a>) from the mouse 20S immunoproteasome. (b) Proposed macrocyclization strategy between the P2 and P3/P4 residues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00291&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemistry</h3><div class="NLM_p">Our synthetic approach relied on a convergent strategy that separately synthesizes α′,β′-epoxy amino acid right-hand fragments and macrocyclic peptide left-hand fragments before coupling via a conventional amide bond formation reaction. The right-hand epoxyketone fragments of macrocyclic compounds were prepared from Boc-protected respective amino acids (<b>1</b>) using a previously reported procedure to yield Boc-deprotected <b>4a</b>–<b>4c</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>a).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> For the macrocyclic left-hand fragments (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>b), dipeptide intermediates <b>6a</b> and <b>6b</b> were first prepared from serine or tyrosine benzyl ester (<b>5</b>) using conventional amide coupling reactions. O-alkylation of <b>6a</b> in the presence of potassium carbonate furnished the terminal alkene intermediate <b>7</b> in good yield. On the other hand, O-alkylated terminal alkene <b>10</b> was prepared from <b>6b</b> using allyl methyl carbonate and a palladium catalyst, whereas <b>13</b> was prepared by adding Boc-Gly to the N-terminus of <b>10</b>. Di-ene intermediates (<b>8</b>, <b>11</b>, and <b>14</b>) were prepared from their respective monoalkene precursors (<b>7</b>, <b>10</b>, and <b>13</b>, respectively) via conventional amide coupling reactions.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Strategy for Macrocyclic Analogues of DB-310<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00291&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: a: (a) HN(CH<sub>3</sub>)OCH<sub>3</sub>, HOBt, EDCI·HCl, DIPEA, DCM, rt, 12 h; (b) isopropenylmagnesium bromide, THF, −78 °C, 12 h; (c) (i) benzonitrile, H<sub>2</sub>O<sub>2</sub>, DIPEA, methanol, 0 °C to rt, 2 h; (ii) TFA, DCM, rt, 1 h, then evaporated and vacuum-dried. b: (a) HBTU, HOBt, DIPEA, DCM, rt, 18 h; (b) potassium carbonate, 4-bromo-1-butane, DMF, rt, 6 h; (c) allyl methyl carbonate, Pd(PPh<sub>3</sub>)<sub>4</sub>, THF, 60 °C, 3 h; (d) (i) TFA, DCM, rt, 1 h, then evaporated and dried; (ii) <i>N</i>-Boc-glycine (for compound <b>13</b>) or alkenyl carboxylic acid, HBTU, HOBt, DIPEA, DCM, rt, 18 h; (e) (i) Grubb’s second-generation catalyst, toluene, 90 °C, 1 h, purified by flash column chromatography; (ii) H<sub>2</sub>, Pd/C, methanol, rt, 1 h; (f) amine-deprotected epoxyketone (<b>4a</b>, <b>4b</b> or <b>4c</b>), HBTU, HOBt, DIPEA, DCM, rt, 18 h.</p></p></figure><div class="NLM_p">A ring-closing metathesis reaction in the presence of Grubb’s second-generation catalyst provided alkene-bridged macrocyclic analogues. Reduction of the cycloalkenes and deprotection of the benzyl ester were simultaneously performed via hydrogenation to afford the macrocyclic left-hand fragments (<b>9</b>, <b>12</b>, and <b>15</b>), which were then coupled to the right-hand epoxyketone fragments (<b>4a</b>–<b>4c</b>) to provide the final products (<b>16</b>–<b>27</b>) in moderate to good yields.</div><div class="NLM_p">Compound <b>21</b> (<i>n</i> = 1), chosen based on the initial assessment of its inhibitory potency, selectivity toward LMP2, and low molecular weight, was further modified to provide additional macrocyclic peptide epoxyketones, in which its P3-proline anchor was substituted by proline mimics having different ring sizes, fluorinated or methylated proline (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Due to the common constrained macrocyclic structures, we expected that these additional analogues would have similar molecular properties to <b>21</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Macrocyclic Analogues of DB-310 with P3-Proline Substitutions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00291&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) allyl methyl carbonate, Pd(PPh<sub>3</sub>)<sub>4</sub>, THF, 60 °C, 3 h; (b) TFA, DCM, rt, 1 h, then evaporated and dried, <i>N</i>-Boc-proline derivative, HBTU, HOBt, DIPEA, DCM, rt, 18 h; (c) (1) TFA, DCM, rt, 1 h, then evaporated and dried; (2) alkenyl carboxylic acid, HBTU, HOBt, DIPEA, DCM, rt, 18 h; (d) (1) Grubb’s second-generation catalyst, toluene, 90 °C, 1 h, purified by flash column chromatography; (2) H<sub>2</sub>, Pd/C, methanol, rt, 1 h; (e) amine-deprotected epoxyketone (<b>4a</b>), HBTU, HOBt, DIPEA, DCM, rt, 18 h.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> SAR Analysis of Macrocyclic Peptide Epoxyketones</h3><div class="NLM_p">Seventeen macrocyclic analogues of DB-310 were successfully synthesized and tested for their in vitro activity using purified proteasomes and subunit-selective fluorogenic substrates (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Most of the macrocyclic compounds inhibited the iP (primarily LMP2) with high selectivity and good potency. Notably, the tetrapeptide backbone-based macrocyclic compounds (<b>26</b> and <b>27</b>, resulted from a macrocyclization between P2-serine and P4-glycine) potently inhibited LMP2, with an IC<sub>50</sub> value comparable to the previously optimized LMP2-selective linear peptide epoxyketone DB-310: 65.6-69.4 nM for <b>26</b> and <b>27</b> and 70.8 nM for DB-310. While the tripeptide-based products with P2-tyrosine (<b>16</b>–<b>20</b>) were overall effective against the iP (for LMP2, IC<sub>50</sub> = 129–420 nM), <b>17</b>–<b>19</b> containing a longer linker or cyclohexyl residue at the P1 exhibited additional inhibitory activity against the constitutive proteasome (cP) subunits X and Y. The tripeptide-based macrocyclic analogues with P2-serine (<b>21</b>–<b>25</b>) also provided good IC<sub>50</sub> values against LMP2 (158-563 nM) but with higher selectivity for the iP (specifically LMP2) than the P2-tyrosine-containing ones. Similarly, P1-leucine substitution with cyclohexyl or phenyl residues (<b>17</b> vs <b>19</b> and <b>20</b>; <b>21</b> vs <b>24</b> and <b>25</b>) yielded only mild variations in the proteasome inhibition profile. On the other hand, the P3-proline substitution of <b>21</b> with 4-(<i>cis</i>)-fluoroproline (<b>32</b>), 2-methylproline (<b>34</b>), or cyclohexane (<b>36</b>) resulted in a substantial decrease in the LMP2 inhibitory potency, while <b>33</b> (with P3-4,4-difluoroproline) and <b>35</b> (with P3-azetidine) displayed LMP2 inhibitory potency similar to <b>21</b>. Collectively, we chose the most potent LMP2 inhibitors (<b>26</b> and <b>27</b>), two P2-tyrosine-derived macrocyclic compounds (<b>17</b> and <b>20</b>, lacking X inhibition), and a P2-serine-derived one (<b>21</b>, having the smallest MW) for further testing.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. <i>In Vitro</i> Proteasome Inhibition Profiles by Macrocyclic Peptide Epoxyketones<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0010.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char="±">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="±">LMP2</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">LMP7</th><th class="colsep0 rowsep0" align="center">X</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">YU102</td><td class="colsep0 rowsep0" align="char" char="±">105.2 ± 6.2</td><td class="colsep0 rowsep0" align="left">206.7 ± 5.5</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KZR-504</td><td class="colsep0 rowsep0" align="char" char="±">157.9 ± 8.5</td><td class="colsep0 rowsep0" align="left">4763 ± 54</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DB-310</td><td class="colsep0 rowsep0" align="char" char="±">70.8 ± 1.7</td><td class="colsep0 rowsep0" align="left">589.9 ± 4.7</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="char" char="±">422.8 ± 68.0</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="char" char="±">129.3 ± 21.8</td><td class="colsep0 rowsep0" align="left">715.1 ± 88.0</td><td class="colsep0 rowsep0" align="left">1516 ± 337</td><td class="colsep0 rowsep0" align="left">4766 ± 549</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="char" char="±">414.5 ± 30.1</td><td class="colsep0 rowsep0" align="left">414.5 ± 62.7</td><td class="colsep0 rowsep0" align="left">341.8 ± 50.9</td><td class="colsep0 rowsep0" align="left">4998 ± 704</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="char" char="±">167.7 ± 39.4</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">2686 ± 489</td><td class="colsep0 rowsep0" align="left">4998 ± 704</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="char" char="±">184.1 ± 19.0</td><td class="colsep0 rowsep0" align="left">8385 ± 847</td><td class="colsep0 rowsep0" align="left">399.3 ± 27.6</td><td class="colsep0 rowsep0" align="left">4640 ± 781</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="char" char="±">412.8 ± 151.1</td><td class="colsep0 rowsep0" align="left">1503 ± 398</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">1081 ± 223</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="char" char="±">563.4 ± 87.0</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">4640 ± 781</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="char" char="±">158.1 ± 30.4</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="char" char="±">522.6 ± 67.5</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">5773 ± 1007</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="char" char="±">251.1 ± 35.8</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="char" char="±">69.4 ± 12.8</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="char" char="±">65.6 ± 14.5</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="char" char="±">2,131 ± 383</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="char" char="±">237.7 ± 24.4</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char="±">4,583 ± 601</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="char" char="±">261.5 ± 53.2</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="char" char="±">1245 ± 200</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The activity of individual proteasome subunits was measured using purified human 20S proteasomes and the respective fluorogenic substrates, Ac-PAL-AMC (for LMP2), Ac-nLPnLD-AMC (for Y), Ac-ANW-AMC (for LMP7), and Ac-WLA-AMC (for X). Data were obtained based on the results of three replicates per compound. N.D. denotes “not determined.”.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Macrocyclic Compounds Are More Resistant to the ABCB1-Mediated Efflux than Linear Counterparts</h3><div class="NLM_p">To assess the potential ability to cross the BBB, we evaluated the interaction of the representative macrocyclic inhibitors (<b>17</b>, <b>20</b>, <b>21</b>, <b>26</b>, and <b>27</b>) with ABCB1 by comparing their LMP2 inhibitory potency in the cell line model overexpressing ABCB1 (RPMI-8226/ABCB1, previously established by us<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a>) to that in the parental RPMI-8226 cells. Linear peptide epoxyketones, including carfilzomib (a known substrate of ABCB1<a onclick="showRef(event, 'ref30 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref30 ref39 ref40">(30,39,40)</a>), were used for comparison. As expected, carfilzomib required higher concentrations to inhibit the proteasome chymotrypsin-like (CT-L) activity in RPMI-8226/ABCB1 cells than in parental RPMI-8226 cells (∼39-fold difference in IC<sub>50</sub> values, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a). The potency of two linear LMP2 inhibitors was also affected by ABCB1 (6.9-fold for YU102 and 7.3-fold KZR-504) but to a lesser extent than carfilzomib. The fold differences in the LMP2 inhibitory potency of the macrocyclic compounds were notably less than the linear counterparts: 3.3-, 4.1-, and 4.7-fold for <b>20</b>, <b>21</b>, and <b>17</b>, respectively. On the other hand, the tetrapeptide-based macrocyclic compounds <b>26</b> and <b>27</b> displayed no LMP2 inhibition in either cell line (likely attributable in part to low membrane permeability), despite their potent LMP2 inhibitory activity in purified human 20S proteasomes (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The LMP7 inhibition in RPMI-8226/ABCB1 and RPMI-8226 parental cells by compound <b>20</b> showed a similar pattern (about twofold decrease, Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_001.pdf" class="ext-link">Table S1</a>) as the LMP2 inhibition by <b>20</b>, confirming a moderate interaction between <b>20</b> and ABCB1. Similar results were obtained when <b>20</b> was incubated with another ABCB1-overexpressing cell line (NCI/ADR-RES) in the presence and absence of ABCB1 inhibitor, verapamil (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_001.pdf" class="ext-link">Table S2</a>). These results cautiously support that the tripeptide-based macrocyclic peptide epoxyketones (<b>17</b>, <b>20</b>, and <b>21</b>) are affected by the ABCB1-mediated efflux to a much lesser extent than linear counterparts.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) LMP2 inhibitory activity of DB-60 (<b>20</b>) and other compounds in ABCB1-overexpressing RPMI-8226 cells. ABCB1-overexpressing RPMI-8226 cells or the parental RPMI-8226 cells were incubated with varying concentrations of respective compounds (<i>n</i> = 3 replicates per concentration). After 72 h, cell lysates were prepared to measure proteasome catalytic subunit activities (LMP2 and LMP7). Curve fitting analysis was performed to calculate IC<sub>50</sub> values reported as the mean ± SD. *Due to carfilzomib’s cytotoxic effect (a dual inhibitor of cP and iP), cells were incubated for 3 h, followed by the measurement of chymotrypsin-like (CT-L) activity. (b) Lack of interactions between DB-60 (<b>20</b>) and ABCG2. The inhibitory interactions with ABCG2 were assessed by measuring the changes in the cellular accumulation of pheophorbide A (PhA, a fluorescent ABCG2 substrate) using MDCKII cells stably expressing ABCG2 (established in our previous study41) and parental cells. The known ABCG2 inhibitor Ko143 was used as a positive control. After cells were preincubated in the complete medium containing PhA (1 μM) with Ko143 (0.2 μM) or DB-60 (<b>20</b>) (2 or 5 μM) at 37 °C for 30 min, cells were then washed with ice-cold medium and incubated again with Ko143 or DB-60 (<b>20</b>) for 45 min at 37 °C. Subsequently, the fluorescent signal was measured via flow cytometry using the excitation and emission wavelengths of 635 and 670 nm, respectively. Colored lines represent the following groups: gray, PhA only; orange, PhA in the presence of <b>20</b> (2 μM); red, PhA in the presence of <b>20</b> (5 μM); purple, PhA in the presence of Ko143 (0.2 μM) (<i>n</i> = 2 per group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00291&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">For compound <b>20</b> (labeled “DB-60”) (least affected by the ABCB1-mediated efflux in cell line studies), we further examined for its potential interaction with ABCG2, another major efflux transporter that can limit the BBB penetration.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> We used the MDCKII cells stably expressing ABCG2 to test whether DB-60 (<b>20</b>) can inhibit the efflux of the fluorescent probe substrate pheophorbide A (PhA). The known ABCG2 inhibitor Ko143 (0.2 μM) markedly increased the cellular accumulation of PhA as expected (purple distribution showing a rightward shift, left panel, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b). Under the same conditions, DB-60 (<b>20</b>) (2 or 5 μM) showed no inhibition of the ABCG2-mediated efflux of PhA (leading to no red shift, left panel, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b), suggesting a lack of interaction between DB-60 (<b>20</b>) and ABCG2. The extent of LMP2 inhibition by DB-60 (<b>20</b>) was similar between MDCKII/ABCG2 and parental MDCKII cells (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_001.pdf" class="ext-link">Table S3</a>). Based on these results, we then selected DB-60 (<b>20</b>) as a lead macrocyclic LMP2 inhibitor for further study.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Metabolic Stability and Microglial LMP2 Inhibition Efficiency of DB-60 (<b>20</b>)</h3><div class="NLM_p">To assess whether macrocyclic peptide epoxyketones are more resistant to enzymatic metabolism than linear peptide epoxyketones, we examined the metabolic stability of DB-60 (<b>20</b>) using whole blood and liver homogenates harvested from ICR mice (male, 7 weeks old). The linear counterpart YU102 (containing the same P3-proline as DB-60) was included for comparison. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a, DB-60 (<b>20</b>) displayed greater metabolic stability than YU102. In particular, DB-60 (<b>20</b>) stability in liver homogenates, rich in metabolizing enzymes, including epoxide hydrolases and peptidases (major contributors to the metabolism of linear peptide epoxyketones), was superior to YU102. DB-60 (<b>20</b>) was also more effective in suppressing the catalytic activity of LMP2 in inflammatory microglial cells than the linear compounds (YU102, KZR-504) (left panel, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b). Besides, the treatment of DB-60 (<b>20</b>) decreased the release of IL-1α by LPS-activated microglial BV-2 cells (right panel, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b), further verifying that iP-targeting macrocyclic peptide epoxyketones retain the inflammation suppression activity of linear counterparts mediated by iP inhibition.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Encouraged by these results, we investigated the brain permeability of DB-60 (<b>20</b>) via single intravenous dosing (10 mg/kg) to the ICR mice (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_001.pdf" class="ext-link">Figure S1</a>). When we analyzed brain tissue homogenates 1 h postdosing, the brain homogenates contained a detectable but low level of compound DB-60 (<b>20</b>) (3.50 ± 1.46 pmole/g tissue). When the same brain homogenates were analyzed for LMP2 activity (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_001.pdf" class="ext-link">Figure S1</a>), however, the results showed no appreciable inhibition of the LMP2 activity (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_001.pdf" class="ext-link">Figure S1</a>).</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) <i>In vitro</i> metabolic stability of DB-60 (<b>20</b>) in the whole blood or liver homogenates from mice. The whole blood and the liver were collected from ICR mice and incubated with the test compounds for the indicated time. The remaining drug levels were quantified (details provided in the Methods). <i>P</i> values were calculated using Student’s <i>t</i>-test (GraphPad Prism, v.8.4.1). (b) Effects of DB-60 (<b>20</b>) on LMP2 inhibition and IL-1α release in microglial BV-2 cells stimulated with lipopolysaccharide (LPS) (1 μg/mL). Error bars indicate standard deviation derived from three technical replicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00291&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> DB-60 (<b>20</b>) Ameliorates Cognitive Impairment in Tg2576 Mice</h3><div class="NLM_p">Despite modest brain permeability shown in the single intravenous dosing study, we examined whether macrocyclic iP inhibitors are efficacious in a mouse model of AD. Specifically, DB-60 (<b>20</b>) (10 mg/kg) was injected to Tg2576 mice (9-month old) twice weekly for 3 weeks, followed by the assessment of cognitive function via the Morris water maze test for 5 trial days, a single probe trial on day 6, and passive avoidance test on days 7 and 8.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Similar to the results obtained from its linear counterparts,<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> mice treated with DB-60 (<b>20</b>) improved the cognitive function of Tg2576 mice. Specifically, Tg2576 mice treated with DB-60 (<b>20</b>) were more efficient at locating the platform in a pool of water during training days 4 and 5, thus escaping the water with lower latency and shorter distance compared to vehicle-treated mice (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a).</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) DB-60 (<b>20</b>) improves cognitive function in Tg2576 mice. The Morris water maze test was performed to measure cognitive function: escape distance (upper) and escape latency time (lower). Statistical analyses were performed using two-way ANOVA. *Difference in days 4–5 between control and DB-60 (<b>20</b>)-treated mice was statistically significant (<i>p</i>-value < 0.05, <i>n</i> = 12 for control and <i>n</i> = 5 for DB-60 (<b>20</b>)-treated mice). (b) Probe trial (on day 6, upper panel) and the passive avoidance test (on days 7 and 8, lower panel) were performed following the Morris water maze test on days 1–5. Student’s <i>t</i>-test was used for statistical analyses of probe trials and passive avoidance. Differences in time spent in the target quadrant or step-through latency between control and DB-60 (<b>20</b>)-treated mice were statistically significant (<i>p</i>-value < 0.05, <i>n</i> = 5). (c) Serum samples collected from mice treated with vehicle or DB-60 (<b>20</b>) were used to quantify IL-1α levels via ELISA (<i>p</i>-value < 0.05, <i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00291&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The probe trial results showed that the percentages of time spent in the target quadrant (the quadrant with the hidden platform) for DB-60 (<b>20</b>)-treated Tg2576 mice were higher than those for control mice (upper panel, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b), demonstrating improved spatial learning and memory in drug-treated Tg2576 mice. Similarly, mice treated with DB-60 (<b>20</b>) performed better in a fear-aggravated test (passive avoidance) than control mice (lower panel, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b). The serum levels of IL-1α were lower in Tg2576 mice receiving DB-60 (<b>20</b>) treatment than the control mice receiving the vehicle only (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>c), demonstrating the impact of DB-60 (<b>20</b>)-mediated iP inhibition in inflammatory cytokine production. Taken together, we observed that the multiple dosing of DB-60 (<b>20</b>) improved cognitive function in AD mice. As no appreciable brain LMP2 inhibition was observed in diseased mice that received a single dose of DB-60 (<b>20</b>) (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_001.pdf" class="ext-link">Figure S1</a>), we hypothesize that the efficacy of DB-60 (<b>20</b>) in mouse AD models may be due to the gradual accumulation of LMP2:DB-60 (<b>20</b>) covalent adduct in the brain resulting from repeated administration.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> DB-60 (<b>20</b>) Protects Mouse Retinal Pigment Epithelial (RPE) from Inflammation-Triggered Structural Destruction</h3><div class="NLM_p">As visual evidence for the potential involvement of the iP in neuroinflammatory responses, we previously reported that iP-targeting linear peptide epoxyketones inhibit RPE (retinal pigment epithelium) degeneration caused by Aβ-triggered inflammation in Tg2576 mice.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> We examined whether the macrocyclic DB-60 (<b>20</b>) can also suppress inflammation-triggered RPE degeneration by assessing the RPE samples from Tg2576 mice that completed the Morris water maze and probe/passive avoidance tests. When immunostained using an anti-β-catenin antibody, RPE’s orderly standard structure was prominent in age-matched nontransgenic ICR mice (upper panel, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a). In contrast, the orderly structure of RPE was severely damaged in Tg2576 mice treated with vehicle only (upper panel, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b), as reported previously by us and others.<a onclick="showRef(event, 'ref22 ref23 ref43'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref43">(22,23,43)</a></div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Protection of Tg2576 mice from retinal pigment epithelium (RPE) destruction by DB-60 (<b>20</b>). Upon completing behavior tests for Tg2576 mice treated with DB-60 (<b>20</b>), RPE samples were collected and immunostained using an anti-β-catenin antibody for visualization. A parallel experiment was also performed using age-matched nontransgenic ICR mice. The images are representative of three independent replicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00291&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">On the other hand, RPE collected from Tg2576 mice treated with DB-60 (<b>20</b>) displayed the orderly structure (lower panel, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a), demonstrating the ability of DB-60 (<b>20</b>) to block RPE destruction caused by Aβ-triggered inflammation. RPE’s structural integrity in nontransgenic ICR mice was not affected by DB-60 (<b>20</b>) treatment (lower panel, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a). No sign of overt toxicity was observed in Tg2576 or nontransgenic ICR mice treated with DB-60 (<b>20</b>) during the test period, which is consistent with our previous results obtained from iP-targeting linear peptide epoxyketones.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46685" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46685" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">With the failure of nearly all clinical trials for Aβ or tau-targeting AD drugs in the pipeline to date, identifying a new class of drug candidates has become imperative to bring about effective AD therapies. A major obstacle has been a lack of promising new drug targets unrelated to the events leading to the accumulation of the Aβ and tau protein. We previously reported that linear peptide epoxyketones inhibiting the iP, a previously untapped target in AD drug discovery efforts, have promising anti-AD efficacy in mouse models, potentially offering a new class of AD drugs.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> However, inherent issues associated with the linear peptides prohibit further clinical development. Therefore, in the current study, we aimed to improve the iP-targeting peptide epoxyketones’ CNS druggability to be further investigated as potential AD drug candidates in preclinical and clinical studies.</div><div class="NLM_p">One common strategy to improve linear peptide-based drug candidates’ CNS druggability is to form a macrocycle by constraining the freely rotatable linear peptide backbone. To this end, we were able to synthesize 17 macrocyclic peptides retaining the epoxyketone pharmacophore. These macrocyclic peptide epoxyketones are highly selective to iP, unlike the previously reported macrocyclic analogues of the anti-cancer agent oprozomib, which targets both cP and iP.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Besides, these compounds are structurally unique, having a proline or proline mimic at the P3 position as a handle for P2–P3 or P2–P4 macrocyclization. In particular, our lead macrocyclic iP inhibitor, DB-60 (<b>20</b>), showed significantly improved metabolic stability and decreased interaction with the two major drug transporters in the BBB, ABCB1 and ABCG2. Further, DB-60 (<b>20</b>) effectively reduced serum IL-1α and enhanced the cognitive function of Tg2576 mice. Our results support that iP-targeting macrocyclic peptide epoxyketones have promising potential for further preclinical and clinical investigations as AD drugs, not reliant on the strategies of targeting Aβ or tau protein accumulation.</div><div class="NLM_p last">In addition to its role in cognitive deficits, accumulating evidence support that Aβ-triggered inflammation plays a crucial role in RPE degeneration in APP (human amyloid precursor protein) transgenic mouse models including Tg2576.<a onclick="showRef(event, 'ref24 ref25 ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref45 ref46 ref47">(24,25,45−47)</a> The pathological role of Aβ in the eye has been further supported by the detection of Aβ in RPE and drusen (extracellular waste deposits that accumulate near the RPE region) obtained from patients with age-related macular degeneration (AMD).<a onclick="showRef(event, 'ref43 ref48 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref43 ref48 ref49 ref50">(43,48−50)</a> This has led researchers to suggest a common neuroinflammation-associated pathogenic mechanism between AMD and AD. Accordingly, the idea of using the retina structure as a potential diagnostic tool in AD has been proposed lately.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> In the current study, the iP-selective inhibitor DB-60 (<b>20</b>) completely protected RPE from an inflammation-triggered structural abnormality in Tg2576 mice, supporting that iP is potentially linked to RPE degeneration and AD. Taken together, iP-targeting macrocyclic peptide epoxyketones may also have the potential for AMD treatment.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21004" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21004" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Chemistry</h3><div class="NLM_p last">All of the reagents and solvents used in experiments were purchased commercially and used without additional purification. A precoated TLC plate was used to monitor the reaction progress. The different spots were detected by UV or/and staining solutions such as phosphomolybdic acid hydrate (PMA), iodine, and potassium permanganate. All of the reactions were performed under inert conditions unless otherwise mentioned. Purification of intermediates and final compounds was performed by flash column chromatography on 60 Å silica gel, 230–400 mesh (Merck) unless otherwise reported. A 400 MHz Varian spectrometer was used to record <sup>1</sup>H and <sup>13</sup>C NMR spectra. Chemical shifts were reported in parts per million (ppm) and coupling constants (J) in Hz with tetramethylsilane as a reference standard. Proton NMR multiplicities were reported using different abbreviations such as singlet (s), doublet (d), triplet (t), quartet (q), and multiplet (m). LC/MS data of final compounds were recorded by an Agilent Technologies 6120 Quadrupole using a 0.1% formic acid solution of (A) H<sub>2</sub>O and (B) acetonitrile (CH<sub>3</sub>CN) as an eluent. An Agilent Eclipse XBD-C18 column with 5 μm particle size, 4.6 mm diameter, and 150 mm length was used in the system with solvent gradient B/A from 5:95 to 90:10 over 18 min and then 100:0 over 7 min. The flow rate of the eluent was 0.4 mL/min. The same solvent gradient, column, and flow rate were used to determine the purity of all final compounds in an Agilent Technologies 1200 series equipped with a UV detector at 254 nm. The purity of most of the final compounds was determined to be ≥95%. KZR-504 and YU102 used in experiments were synthesized using the previously reported method.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General Procedure for the Boc Deprotection Reaction</h3><div class="NLM_p last">Excess of TFA was added to the stirred solution of the Boc-protected intermediate in DCM at room temperature. The reaction mixture was further stirred at the same temperature for 2 h. The reaction solution was concentrated under reduced pressure, and the resulting residue was dried under a strong vacuum. Dry TFA salt was used in the next step without further purification.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Procedure for the Synthesis of Macrocyclic Carboxylic Acids</h3><div class="NLM_p last">The second-generation Grubbs catalyst (10 mol %) was added at room temperature to the stirred solution of diolefin in toluene. The reaction temperature was increased gradually to 100 °C, and the reaction solution was stirred for 1 h at the same temperature. After cooling, the solvent was removed under reduced pressure, and the resulting residue was purified by flash chromatography using 50% ethyl acetate in hexane. The above-purified product (a mixture of geometric isomers) was dissolved in methanol, activated palladium in charcoal (10 mol %) was added, and the reaction mixture was stirred under a hydrogen gas environment at room temperature for 2 h. The reaction solution was then filtered through Celite, and the filtrate was concentrated to yield the corresponding macrocyclic carboxylic acid, which was used in the next step without further purification.</div></div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General Procedure for the Preparation of Weinreb Amide <b>2a</b>–<b>2c</b></h3><div id="s0081" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> (<i>S</i>)-<i>tert</i>-Butyl 1-(Methoxy(methyl)amino)-4-methyl-1-oxopentan-2-ylcarbamate (<b>2a</b>)</h4><div class="NLM_p last">To the DCM solution of Boc-leucine (2 g, 8.64 mmol), EDCI·HCl (2.48 g, 12.96 mmol), HOBt (1.17 g, 8.64 mmol), <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride (0.84 g, 8.64 mmol), and DIPEA (3.77 mL, 21.6 mmol) were added. The reaction solution was stirred at the same temperature overnight. The solvent was removed under reduced pressure, and the residue was purified by flash column chromatography using 20% ethyl acetate in hexane to yield the pure product as a sticky colorless solid (2.1 g, 89%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.05 (d, <i>J</i> = 9.5 Hz, 1H), 4.70 (s, 1H), 3.76 (s, 3H), 3.17 (s, 3H), 1.69 (dt, <i>J</i> = 6.7, 13.5 Hz, 1H), 1.46-1.37 (m, 11H), 0.92 (dd, <i>J</i> = 6.6, 14.0 Hz, 6H).</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> (<i>S</i>)-<i>tert</i>-Butyl 3-Cyclohexyl-1-(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate (<b>2b</b>)</h4><div class="NLM_p last"><b>2b</b> was prepared from <b>1b</b> using the same general procedure for the preparation of Weinreb amide as colorless oil (90%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.00 (d, <i>J</i> = 9.5 Hz, 1H), 4.71 (s, 1H), 3.75 (s, 3H), 3.16 (s, 3H), 1.87 (d, <i>J</i> = 13.0 Hz, 1H), 1.72–1.53 (m, 4H), 1.40 (s, 12H), 1.17 (m, 3H), 1.01–0.78 (m, 2H).</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> (<i>S</i>)-<i>tert</i>-Butyl 1-(Methoxy(methyl)amino)-1-oxo-3-phenylpropan-2-ylcarbamate (<b>2c</b>)</h4><div class="NLM_p last"><b>2c</b> was prepared from <b>1c</b> using the same general procedure for the preparation of Weinreb amide as colorless thick oil (86%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.25 (d, <i>J</i> = 8.2 Hz, 2H), 7.24–7.19 (m, 1H), 7.15 (d, <i>J</i> = 7.4 Hz, 2H), 5.13 (d, <i>J</i> = 9.0 Hz, 1H), 4.93 (s, 1H), 3.64 (s, 3H), 3.15 (s, 3H), 3.03 (dd, <i>J</i> = 6.1, 13.6 Hz, 1H), 2.86 (t, <i>J</i> = 10.5 Hz, 1H), 1.37 (s, 9H).</div></div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Procedure for the Preparation of Enone <b>3a</b>–<b>3c</b></h3><div id="s0082" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (<i>S</i>)-<i>tert</i>-Butyl 2,6-Dimethyl-3-oxohept-1-en-4-ylcarbamate (<b>3a</b>)</h4><div class="NLM_p last">A 0.5 M isopropenylmagnesium bromide solution in THF (58 mL, 29.15 mmol) was added dropwise to the stirred solution of <b>2a</b> (2 g, 7.28 mmol) in THF at −78 °C, and the reaction mixture was stirred at the same temperature overnight. The reaction solution was warmed gradually to room temperature, and the reaction was quenched with a saturated solution of ammonium chloride. The reaction product was extracted with ethyl acetate three times. The combined organic layer was dried in sodium sulfate, filtered, and concentrated. The crude product was purified by flash column chromatography using 5% ethyl acetate in hexane to yield the pure product as colorless oil (1.2 g, 64%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.06 (s, 1H), 5.86 (s, 1H), 5.20–4.96 (m, 2H), 1.83 (s, 3H), 1.81–1.64 (m, 1H), 1.41 (s, 9H), 1.36–1.18 (m, 2H), 0.98 (d, <i>J</i> = 6.5 Hz, 3H), 0.89 (d, <i>J</i> = 6.7 Hz, 3H).</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (<i>S</i>)-<i>tert</i>-Butyl 1-Cyclohexyl-4-methyl-3-oxopent-4-en-2-ylcarbamate (<b>3b</b>)</h4><div class="NLM_p last"><b>3b</b> was prepared from <b>2b</b> using the same general procedure for the preparation of enone as a white solid (76%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.04 (s, 1H), 5.84 (s, 1H), 5.07 (d, <i>J</i> = 6.7 Hz, 2H), 1.87 (s, 3H), 1.75–1.46 (m, 6H), 1.41 (s, 10H), 1.32–1.05 (m, 4H), 1.00–0.78 (m, 2H).</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (<i>S</i>)-<i>tert</i>-Butyl 4-Methyl-3-oxo-1-phenylpent-4-en-2-ylcarbamate (<b>3c</b>)</h4><div class="NLM_p last"><b>3c</b> was prepared from <b>2c</b> using the same general procedure for the preparation of enone as a white solid (79%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.30–7.12 (m, 3H), 7.05 (d, <i>J</i> = 7.2 Hz, 2H), 5.99 (s, 1H), 5.83 (p, <i>J</i> = 1.5 Hz, 1H), 5.25 (d, <i>J</i> = 8.7 Hz, 2H), 3.19–3.01 (m, 1H), 2.97–2.80 (m, 1H), 1.84 (s, 3H), 1.39 (s, 9H).</div></div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure for the Preparation of Epoxide <b>4a</b>–<b>4c</b></h3><div id="s0083" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>tert</i>-Butyl (<i>S</i>)-4-Methyl-1-((<i>R</i>)-2-methyloxiran-2-yl)-1-oxopentan-2-ylcarbamate (<b>4a</b>)</h4><div class="NLM_p last">DIPEA (6.83 mL, 39.14 mmol) was added dropwise to the stirred solution of <b>3a</b> (1 g, 3.91 mmol), hydrogen peroxide (6.64 mL, 97.75 mmol), and benzonitrile (4.0 mL, 39.14 mmol) in methanol at 0 °C. The reaction mixture was stirred at the same temperature for 3 h. Water was added to the solution, and methanol was removed under reduced pressure. The aqueous layer was extracted with ethyl acetate three times. The collected organic layer was dried with sodium sulfate, filtered, and concentrated. The resulting crude product was purified by flash column chromatography using 5% ethyl acetate in hexane to yield the pure product as a sticky white solid (0.6 g, 57%).<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.82 (d, <i>J</i> = 8.9 Hz, 1H), 4.35–4.24 (m, 1H), 3.27 (d, <i>J</i> = 5.0 Hz, 1H), 2.87 (d, <i>J</i> = 5.0 Hz, 1H), 1.78–1.64 (m, 1H), 1.50 (s, 4H), 1.39 (s, 9H), 1.15 (ddd, <i>J</i> = 4.3, 10.5, 14.3 Hz, 1H), 0.93 (dd, <i>J</i> = 6.6, 13.0 Hz, 6H).</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>tert</i>-Butyl (<i>S</i>)-3-Cyclohexyl-1-((<i>R</i>)-2-methyloxiran-2-yl)-1-oxopropan-2-ylcarbamate (<b>4b</b>)</h4><div class="NLM_p last"><b>4b</b> was prepared from 3b using the same general procedure for the preparation of epoxide as a sticky white solid (41%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.79 (d, <i>J</i> = 8.8 Hz, 1H), 4.32 (td, <i>J</i> = 3.0, 8.6, 9.8 Hz, 1H), 3.26 (d, <i>J</i> = 5.1 Hz, 1H), 2.86 (d, <i>J</i> = 5.0 Hz, 1H), 1.93–1.79 (m, 1H), 1.74–1.51 (m, 5H), 1.49 (s, 3H), 1.39 (s, 9H), 1.28–1.05 (m, 5H), 1.01–0.84 (m, 2H).</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>tert</i>-Butyl (<i>S</i>)-1-((<i>R</i>)-2-Methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-ylcarbamate (<b>4c</b>)</h4><div class="NLM_p last"><b>4c</b> was prepared from 3c using the same general procedure for the preparation of epoxide as a white solid (32%), <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.33–7.19 (m, 3H), 7.19–7.09 (m, 2H), 4.98–4.86 (m, 1H), 4.62–4.49 (m, 1H), 3.27 (d, <i>J</i> = 5.0 Hz, 1H), 3.09 (dd, <i>J</i> = 5.0, 13.9 Hz, 1H), 2.88 (d, <i>J</i> = 5.0 Hz, 1H), 2.72 (dd, <i>J</i> = 7.8, 13.9 Hz, 1H), 1.48 (s, 3H), 1.35 (s, 9H).</div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (<i>S</i>)-<i>tert</i>-Butyl 2-((<i>S</i>)-1-(Benzyloxy)-3-(4-hydroxyphenyl)-1-oxopropan-2-ylcarbamoyl)pyrrolidine-1-carboxylate (<b>6a</b>)</h4><div class="NLM_p last">The general amide coupling reaction was used to prepare <b>6a</b> from tyrosine benzyl ester and Boc-proline as colorless oil (88%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.83 (s, 1H), 7.41–7.27 (m, 5H), 6.89 (d, <i>J</i> = 8.1 Hz, 2H), 6.76–6.67 (m, 2H), 5.12 (d, <i>J</i> = 5.9 Hz, 2H), 4.80–4.76 (s, 1H), 4.63–4.52 (m, 1H), 3.42–3.22 (m, 2H), 3.08 (dd, <i>J</i> = 5.9, 14.0 Hz, 1H), 2.95 (dd, <i>J</i> = 6.4, 14.0 Hz, 1H), 2.02–1.95 (m, 2H), 1.76–1.70 (m, 2H), 1.41 (s, 9H).</div></div><div id="sec4_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>S</i>)-<i>tert</i>-Butyl 2-((<i>S</i>)-1-(Benzyloxy)-3-hydroxy-1-oxopropan-2-ylcarbamoyl)pyrrolidine-1-carboxylate (<b>6b</b>)</h4><div class="NLM_p last">The general procedure for the amide coupling reaction is as follows. To the stirred solution of serine benzyl ester hydrochloride (1 g, 4.31 mmol) in DCM, Boc-proline (0.93 g, 4.31 mmol), HATU (3.26 g, 8.62 mmol), HOBt (1.16 g, 8.62 mmol), and DIPEA (3.0 mL, 17.42 mmol) were added respectively at room temperature. The reaction solution was stirred at the same temperature overnight. The reaction mixture was then washed with water, and the organic solution was collected. It was dried over sodium sulfate, filtered, and concentrated. The crude product was purified through flash column chromatography using 50% ethyl acetate in hexane to yield the pure product as colorless oil (1.37 g, 81%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.33 (d, <i>J</i> = 2.6 Hz, 5H), 7.17–7.02 (m, 1H), 5.20 (s, 2H), 4.62 (s, 1H), 4.16 (s, 1H), 4.11–3.80 (m, 2H), 3.52–3.31 (m, 2H), 2.25–2.09 (m, 1H), 2.09–1.95 (m, 2H), 1.83 (d, <i>J</i> = 5.7 Hz, 2H), 1.42 (s, 9H).</div></div><div id="sec4_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>S</i>)-<i>tert</i>-Butyl 2-((<i>S</i>)-1-(Benzyloxy)-3-(4-(but-3-enyloxy)phenyl)-1-oxopropan-2-ylcarbamoyl)pyrrolidine-1-carboxylate (<b>7</b>)</h4><div class="NLM_p last">The DMF solution of <b>6a</b> (0.5 g, 1.06 mmol), potassium carbonate (0.44 g, 3.18 mmol), and 4-bromo-1-butene (0.22 mL, 2.13 mmol) was stirred at room temperature for 6 h. Water was added to the reaction mixture, and the product was extracted with ethyl acetate. The combined solution of ethyl acetate was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified through flash column chromatography using 50% ethyl acetate in hexane to yield the pure product as colorless oil (0.45 g, 81%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.42–7.18 (m, 5H), 6.96–6.81 (m, 2H), 6.71 (dq, <i>J</i> = 2.9, 8.9 Hz, 2H), 6.47 (s, 1H), 5.95–5.71 (m, 1H), 5.20–5.00 (m, 4H), 4.81 (s, 1H), 4.21 (d, <i>J</i> = 31.8 Hz, 1H), 3.93 (tq, <i>J</i> = 2.9, 5.5 Hz, 2H), 3.48–3.19 (m, 2H), 3.07 (ddq, <i>J</i> = 2.9, 5.5, 14.4 Hz, 1H), 2.96 (ddq, <i>J</i> = 2.8, 6.0, 14.1 Hz, 1H), 2.58–2.43 (m, 2H), 1.92 (m, 4H), 1.50–1.25 (s, 9H).</div></div><div id="sec4_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (<i>S</i>)-Benzyl 3-(4-(But-3-enyloxy)phenyl)-2-((<i>S</i>)-1-pent-4-enoylpyrrolidine-2-carboxamido)propanoate (<b>8a</b>)</h4><div class="NLM_p last">Boc-deprotected <b>7</b> was coupled with 4-pentenoic acid using the general procedure for the amide coupling reaction to prepare <b>8a</b> as colorless oil (63%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 7.47–7.21 (m, 5H), 6.91 (dd, <i>J</i> = 6.8, 8.8 Hz, 2H), 6.79–6.62 (m, 2H), 6.08–5.91 (m, 1H), 5.84–5.63 (m, 1H), 5.37 (dq, <i>J</i> = 1.6, 17.3 Hz, 1H), 5.25 (dq, <i>J</i> = 1.6, 10.5 Hz, 1H), 5.19–4.88 (m, 4H), 4.75 (td, <i>J</i> = 5.9, 7.2 Hz, 1H), 4.54 (dd, <i>J</i> = 1.9, 8.1 Hz, 1H), 4.45 (tt, <i>J</i> = 1.5, 5.3 Hz, 2H), 3.35 (ddt, <i>J</i> = 4.5, 9.2, 13.2 Hz, 2H), 3.07 (dd, <i>J</i> = 5.8, 14.0 Hz, 1H), 2.98–2.89 (m, 1H), 2.36–2.26 (m, 1H), 2.20 (ddd, <i>J</i> = 6.8, 8.4, 10.8 Hz, 1H), 2.16–2.04 (m, 2H), 2.04–1.86 (m, 3H), 1.81–1.55 (m, 3H).</div></div><div id="sec4_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>S</i>)-Benzyl 3-(4-(But-3-enyloxy)phenyl)-2-((<i>S</i>)-1-hex-5-enoylpyrrolidine-2-carboxamido)propanoate (<b>8b</b>)</h4><div class="NLM_p last">Boc-deprotected <b>7</b> was coupled with 5-hexenoic acid using the general procedure for the amide coupling reaction to prepare <b>8b</b> as colorless oil (69%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.50–7.25 (m, 5H), 6.92 (d, <i>J</i> = 8.6 Hz, 2H), 6.70 (d, <i>J</i> = 8.6 Hz, 2H), 5.96–5.62 (m, 2H), 5.19–5.06 (m, 4H), 5.06–4.92 (m, 2H), 4.75 (ddd, <i>J</i> = 5.8, 6.9, 7.6 Hz, 1H), 4.54 (dd, <i>J</i> = 1.9, 8.1 Hz, 1H), 3.93 (t, <i>J</i> = 6.7 Hz, 2H), 3.44–3.27 (m, 2H), 3.07 (dd, <i>J</i> = 5.8, 14.0 Hz, 1H), 2.93 (dd, <i>J</i> = 6.9, 14.1 Hz, 1H), 2.50 (qt, <i>J</i> = 1.4, 6.7 Hz, 2H), 2.37–2.14 (m, 3H), 2.14–2.02 (m, 2H), 2.02–1.84 (m, 2H), 1.84–1.58 (m, 3H).</div></div><div id="sec4_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>S</i>)-Benzyl 3-(4-(But-3-enyloxy)phenyl)-2-((<i>S</i>)-1-hept-6-enoylpyrrolidine-2-carboxamido)propanoate (<b>8c</b>)</h4><div class="NLM_p last">Boc-deprotected <b>7</b> was coupled with 6-heptenoic acid using the general procedure for the amide coupling reaction to prepare <b>8c</b> as colorless oil (70%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.44 (dd, <i>J</i> = 2.3, 7.7 Hz, 1H), 7.37–7.14 (m, 5H), 6.89 (tt, <i>J</i> = 4.3, 8.2 Hz, 2H), 6.69 (dd, <i>J</i> = 2.5, 8.7 Hz, 2H), 5.81 (ddddd, <i>J</i> = 3.4, 6.6, 10.4, 14.1, 33.6 Hz, 2H), 5.21–5.01 (m, 4H), 5.01–4.86 (m, 2H), 4.74 (dd, <i>J</i> = 2.2, 7.2 Hz, 1H), 4.59–4.43 (m, 1H), 3.91 (td, <i>J</i> = 2.4, 6.7 Hz, 2H), 3.46–3.23 (m, 2H), 3.05 (ddd, <i>J</i> = 2.4, 5.9, 14.0 Hz, 1H), 2.92 (ddd, <i>J</i> = 2.4, 6.9, 14.1 Hz, 1H), 2.57–2.40 (m, 2H), 2.35–1.82 (m, 7H), 1.74 (dq, <i>J</i> = 3.5, 10.7 Hz, 1H), 1.66–1.49 (m, 2H), 1.41 (qd, <i>J</i> = 2.3, 7.8 Hz, 2H).</div></div><div id="sec4_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>S</i>)-<i>tert</i>-Butyl 2-((<i>S</i>)-3-(Allyloxy)-1-(benzyloxy)-1-oxopropan-2-ylcarbamoyl)pyrrolidine-1-carboxylate (<b>10</b>)</h4><div class="NLM_p last">To the solution of <b>6b</b> (1 g, 2.54 mmol) in THF, Pd(PPh<sub>3</sub>)<sub>4</sub> (0.15 g, 0.12 mmol) and allyl methyl carbonate (0.43 mL, 3.82 mmol) were added under the anhydrous condition at room temperature. The reaction mixture was stirred at 60 °C for 2 h and then quenched with water. The crude product was extracted with ethyl acetate three times. The combined organic layer was dried under sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified through flash column chromatography using 30% ethyl acetate in hexane as yellowish oil (94%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.30 (d, <i>J</i> = 3.5 Hz, 5H), 6.83 (s, 1H), 5.71 (d, <i>J</i> = 16.8 Hz, 1H), 5.31–5.03 (m, 4H), 4.73 (s, 1H), 4.26 (d, <i>J</i> = 27.6 Hz, 1H), 3.98–3.73 (m, 3H), 3.61 (d, <i>J</i> = 9.1 Hz, 1H), 3.43 (d, <i>J</i> = 8.2 Hz, 2H), 2.10 (s, 2H), 1.84 (q, <i>J</i> = 6.3, 6.8 Hz, 2H), 1.42 (s, 9H).</div></div><div id="sec4_3_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>S</i>)-Benzyl 3-(Allyloxy)-2-((<i>S</i>)-1-pent-4-enoylpyrrolidine-2-carboxamido)propanoate (<b>11a</b>)</h4><div class="NLM_p last">Boc-deprotected <b>10</b> was coupled with 4-pentenoic acid using the general procedure for the amide coupling reaction to yield 11a as colorless oil (46%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.42–7.25 (m, 5H), 5.94–5.64 (m, 2H), 5.28–5.07 (m, 4H), 5.07–4.87 (m, 2H), 4.68 (dt, <i>J</i> = 3.5, 7.5 Hz, 1H), 4.54 (dd, <i>J</i> = 2.6, 8.1 Hz, 1H), 3.97–3.78 (m, 3H), 3.69–3.48 (m, 2H), 3.41 (td, <i>J</i> = 6.6, 9.3 Hz, 1H), 2.47–2.31 (m, 4H), 2.31–2.13 (m, 1H), 2.13–1.97 (m, 1H), 1.97–1.80 (m, 2H).</div></div><div id="sec4_3_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>S</i>)-Benzyl 3-(Allyloxy)-2-((<i>S</i>)-1-hex-5-enoylpyrrolidine-2-carboxamido)propanoate (<b>11b</b>)</h4><div class="NLM_p last">Boc-deprotected <b>10</b> was coupled with 5-hexenoic acid using the general procedure for the amide coupling reaction to yield 11b as colorless oil (54%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.43–7.22 (m, 5H), 5.83–5.63 (m, 2H), 5.27–5.05 (m, 4H), 5.05–4.85 (m, 2H), 4.67 (dt, <i>J</i> = 3.5, 8.1 Hz, 1H), 4.53 (dd, <i>J</i> = 2.5, 8.3 Hz, 1H), 3.96–3.78 (m, 3H), 3.65–3.47 (m, 2H), 3.39 (td, <i>J</i> = 6.7, 9.3 Hz, 1H), 2.35–2.14 (m, 3H), 2.14–1.97 (m, 3H), 1.89 (dddd, <i>J</i> = 2.7, 5.6, 10.3, 11.8 Hz, 2H), 1.81–1.61 (m, 2H).</div></div><div id="sec4_3_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (<i>S</i>)-Benzyl 3-(Allyloxy)-2-((<i>S</i>)-1-hept-6-enoylpyrrolidine-2-carboxamido)propanoate (<b>11c</b>)</h4><div class="NLM_p last">Boc-deprotected <b>10</b> was coupled with 6-heptenoic acid using the general procedure for the amide coupling reaction to provide <b>11c</b> as colorless oil (64%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.43–7.18 (m, 5H), 5.73 (dtd, <i>J</i> = 3.4, 7.0, 17.2 Hz, 2H), 5.28–5.02 (m, 4H), 5.02–4.81 (m, 2H), 4.65 (dd, <i>J</i> = 3.6, 7.8 Hz, 1H), 4.52 (dd, <i>J</i> = 4.3, 7.2 Hz, 1H), 3.96–3.74 (m, 3H), 3.68–3.44 (m, 2H), 3.38 (dt, <i>J</i> = 3.1, 6.3 Hz, 1H), 2.37–2.11 (m, 3H), 2.11–1.95 (m, 3H), 1.89 (dt, <i>J</i> = 5.6, 16.5 Hz, 2H), 1.61 (tt, <i>J</i> = 5.5, 10.8 Hz, 2H), 1.39 (td, <i>J</i> = 2.9, 7.7 Hz, 2H).</div></div><div id="sec4_3_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (<i>S</i>)-Benzyl 3-(Allyloxy)-2-((<i>S</i>)-1-(2-(tert-butoxycarbonylamino)acetyl)pyrrolidine-2-carboxamido)propanoate (<b>13</b>)</h4><div class="NLM_p last">Boc-deprotected <b>10</b> was coupled with Boc-glycine using the general procedure for the amide coupling reaction to provide <b>13</b> as colorless oil (57%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.41–7.27 (m, 5H), 7.15 (d, <i>J</i> = 8.2 Hz, 1H), 5.84–5.66 (m, 1H), 5.41 (s, 1H), 5.29–5.04 (m, 4H), 4.69 (dt, <i>J</i> = 3.3, 8.1 Hz, 1H), 4.53 (dd, <i>J</i> = 2.7, 8.1 Hz, 1H), 4.03–3.78 (m, 5H), 3.63 (dd, <i>J</i> = 3.4, 9.6 Hz, 1H), 3.52 (ddd, <i>J</i> = 3.2, 8.1, 9.9 Hz, 1H), 3.38 (td, <i>J</i> = 6.7, 9.2 Hz, 1H), 2.31–2.17 (m, 1H), 2.17–2.02 (m, 1H), 1.95 (tdd, <i>J</i> = 4.1, 7.4, 9.6 Hz, 2H), 1.42 (s, 9H).</div></div><div id="sec4_3_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (<i>S</i>)-Benzyl 3-(Allyloxy)-2-((<i>S</i>)-1-(2-pent-4-enamidoacetyl)pyrrolidine-2-carboxamido)propanoate (<b>14a</b>)</h4><div class="NLM_p last">Boc-deprotected <b>13</b> was coupled with 4-pentenoic acid using the general procedure for the amide coupling reaction to prepare <b>14a</b> as colorless oil (78%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32 (m, 5H), 7.03 (d, <i>J</i> = 8.2 Hz, 1H), 6.47 (s, 1H), 5.77 (dddd, <i>J</i> = 4.9, 10.6, 16.1, 17.9 Hz, 2H), 5.33–5.18 (m, 2H), 5.17–4.91 (m, 4H), 4.71 (dt, <i>J</i> = 3.3, 8.1 Hz, 1H), 4.52 (dd, <i>J</i> = 3.0, 8.1 Hz, 1H), 4.09 (dd, <i>J</i> = 4.7, 17.8 Hz, 1H), 4.02–3.83 (m, 4H), 3.64 (dd, <i>J</i> = 3.3, 9.5 Hz, 1H), 3.55 (ddd, <i>J</i> = 3.2, 7.9, 10.7 Hz, 1H), 3.42 (dd, <i>J</i> = 6.8, 9.3 Hz, 1H), 2.45–2.18 (m, 5H), 2.18–2.03 (m, 1H), 1.98 (dtd, <i>J</i> = 4.0, 7.3, 13.4 Hz, 2H).</div></div><div id="sec4_3_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (<i>S</i>)-Benzyl 3-(Allyloxy)-2-((<i>S</i>)-1-(2-hex-5-enamidoacetyl)pyrrolidine-2-carboxamido)propanoate (<b>14b</b>)</h4><div class="NLM_p last">Boc-deprotected <b>13</b> was coupled with 5-hexenoic acid using the general procedure for the amide coupling reaction to prepare <b>14b</b> as colorless oil (68%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.40–7.26 (m, 5H), 7.07 (d, <i>J</i> = 8.2 Hz, 1H), 6.53 (t, <i>J</i> = 4.2 Hz, 1H), 5.84–5.64 (m, 2H), 5.32–5.06 (m, 4H), 5.06–4.90 (m, 2H), 4.71 (dt, <i>J</i> = 3.3, 8.2 Hz, 1H), 4.51 (dd, <i>J</i> = 3.0, 8.0 Hz, 1H), 4.10 (dd, <i>J</i> = 4.6, 17.8 Hz, 1H), 4.03–3.82 (m, 4H), 3.63 (dd, <i>J</i> = 3.3, 9.5 Hz, 1H), 3.55 (ddd, <i>J</i> = 3.4, 7.9, 10.6 Hz, 1H), 3.41 (dt, <i>J</i> = 7.6, 9.9 Hz, 1H), 2.31 (t, <i>J</i> = 7.5 Hz, 1H), 2.27–2.15 (m, 3H), 2.15–1.90 (m, 4H), 1.79–1.62 (m, 2H).</div></div><div id="sec4_3_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (1<sup>2</sup><i>S</i>,4<i>S</i>)-<i>N</i>-((<i>S</i>)-4-Methyl-1-((<i>R</i>)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-2,14-dioxo-7-oxa-3-aza-1(2,1)-pyrrolidina-6(1,4)-benzenacyclotetradecaphane-4-carboxamide (<b>16</b>)</h4><div class="NLM_p last">Macrocyclic carboxylic acid intermediate <b>9a</b> was prepared from <b>8a</b> using the general procedure for synthesis of macrocyclic carboxylic acid. <b>9a</b> was coupled with right-hand Boc-deprotected epoxyketone intermediate <b>4a</b> using the general procedure for the amide coupling reaction to prepare 16 as a white solid (41%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.08 (d, <i>J</i> = 8.3 Hz, 1H), 7.01–6.89 (m, 2H), 6.86–6.76 (m, 2H), 5.85 (d, <i>J</i> = 9.3 Hz, 1H), 4.69–4.57 (m, 2H), 4.44 (td, <i>J</i> = 3.6, 9.2 Hz, 2H), 4.06 (td, <i>J</i> = 2.4, 11.7 Hz, 1H), 3.55–3.39 (m, 3H), 3.38 (d, <i>J</i> = 5.0 Hz, 1H), 2.88–2.81 (m, 1H), 2.64 (dd, <i>J</i> = 6.3, 13.8 Hz, 1H), 2.22 (ddd, <i>J</i> = 3.4, 6.8, 13.7 Hz, 1H), 2.18–2.07 (m, 1H), 2.07–1.78 (m, 6H), 1.66–1.48 (m, 2H), 1.48–1.29 (m, 7H), 1.29–1.17 (m, 2H), 1.11 (d, <i>J</i> = 3.3 Hz, 1H), 0.97 (d, <i>J</i> = 6.5 Hz, 3H), 0.88 (d, <i>J</i> = 6.6 Hz, 3H).<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 207.42, 173.50, 171.00, 169.98, 156.20, 130.52, 127.24, 115.85, 66.97, 61.00, 59.19, 52.31, 52.29, 50.24, 47.59, 38.64, 35.41, 33.43, 28.92, 26.38, 24.91, 24.61, 23.63, 23.13, 21.28, 20.65, 16.75. LC–MS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>44</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup> 542.3, found: 542.3; purity: ≥96% and retention time is 19.07 min by HPLC analysis.</div></div><div id="sec4_3_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (1<sup>2</sup><i>S</i>,4<i>S</i>)-<i>N</i>-((<i>S</i>)-4-Methyl-1-((<i>R</i>)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-2,15-dioxo-7-oxa-3-aza-1(2,1)-pyrrolidina-6(1,4)-benzenacyclopentadecaphane-4-carboxamide (<b>17</b>)</h4><div class="NLM_p last">Macrocyclic carboxylic acid intermediate <b>9b</b> was prepared from <b>8b</b> using the general procedure for synthesis of macrocyclic carboxylic acid. <b>9b</b> was coupled with right-hand Boc-deprotected epoxyketone intermediate <b>4a</b> using the general procedure for the amide coupling reaction to prepare <b>17</b> as a white solid (48%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.01 (d, <i>J</i> = 8.3 Hz, 1H), 6.98–6.90 (m, 2H), 6.86–6.74 (m, 2H), 6.16 (d, <i>J</i> = 9.0 Hz, 1H), 4.73–4.54 (m, 2H), 4.46 (dd, <i>J</i> = 3.1, 8.5 Hz, 1H), 4.11 (t, <i>J</i> = 5.4 Hz, 2H), 3.56–3.38 (m, 3H), 3.37 (d, <i>J</i> = 5.2 Hz, 1H), 2.85 (d, <i>J</i> = 5.1 Hz, 1H), 2.67 (dd, <i>J</i> = 5.5, 13.9 Hz, 1H), 2.27 (ddd, <i>J</i> = 2.6, 5.6, 12.0 Hz, 1H), 2.15–1.90 (m, 5H), 1.71 (dt, <i>J</i> = 6.8, 10.3 Hz, 3H), 1.50–1.25 (m, 10H), 0.94 (d, <i>J</i> = 6.1 Hz, 3H), 0.86 (d, <i>J</i> = 6.2 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 207.66, 173.74, 170.95, 170.42, 158.22, 130.52, 130.33, 127.20, 114.82, 66.64, 61.02, 59.15, 52.79, 52.33, 50.16, 47.84, 38.96, 35.46, 34.61, 28.70, 27.83, 27.74, 26.28, 24.97, 24.57, 23.58, 23.24, 22.29, 20.87, 16.74. HRMS <i>m</i>/<i>z</i> calcd for C<sub>31</sub>H<sub>46</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup> 556.3342, found: 556.3393. LC–MS (ES+), found: 556.3; purity: ≥96% and retention time is 19.20 min by HPLC analysis.</div></div><div id="sec4_3_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (1<sup>2</sup><i>S</i>,4<i>S</i>)-<i>N</i>-((<i>S</i>)-4-Methyl-1-((<i>R</i>)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-2,16-dioxo-7-oxa-3-aza-1(2,1)-pyrrolidina-6(1,4)-benzenacyclohexadecaphane-4-carboxamide (<b>18</b>)</h4><div class="NLM_p last">Macrocyclic carboxylic acid intermediate <b>9c</b> was prepared from <b>8c</b> using the general procedure for synthesis of macrocyclic carboxylic acid. <b>9c</b> was coupled with right-hand Boc-deprotected epoxyketone intermediate <b>4a</b> using the general procedure for the amide coupling reaction to prepare <b>18</b> as a white solid (33%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.01 (d, <i>J</i> = 8.2 Hz, 1H), 6.98–6.88 (m, 2H), 6.83–6.71 (m, 2H), 6.16 (d, <i>J</i> = 9.4 Hz, 1H), 4.65 (ddd, <i>J</i> = 3.3, 5.5, 9.1 Hz, 1H), 4.61–4.51 (m, 1H), 4.47 (dd, <i>J</i> = 3.2, 8.8 Hz, 1H), 4.02 (dt, <i>J</i> = 4.1, 8.5 Hz, 1H), 3.92 (td, <i>J</i> = 2.8, 10.0 Hz, 1H), 3.52 (dd, <i>J</i> = 3.6, 6.9 Hz, 1H), 3.50–3.40 (m, 2H), 3.38 (d, <i>J</i> = 5.1 Hz, 1H), 2.84 (d, <i>J</i> = 5.1 Hz, 1H), 2.64 (dd, <i>J</i> = 5.6, 13.9 Hz, 1H), 2.29 (ddt, <i>J</i> = 3.7, 6.3, 12.7 Hz, 1H), 2.17–1.88 (m, 6H), 1.84–1.58 (m, 3H), 1.46 (d, <i>J</i> = 2.7 Hz, 3H), 1.43–1.13 (m, 11H), 0.93 (d, <i>J</i> = 5.8 Hz, 3H), 0.84 (d, <i>J</i> = 5.9 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 207.56, 173.67, 170.82, 170.17, 158.54, 130.36, 127.04, 114.16, 65.39, 61.15, 59.18, 52.72, 52.33, 50.16, 47.76, 38.74, 35.49, 34.96, 28.79, 27.54, 27.44, 26.28, 24.90, 24.37, 23.76, 23.67, 22.39, 22.07, 20.91, 16.75. HRMS <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>48</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup> 570.3498, found: 570.3534. LC–MS (ES+), found: 570.3; purity: ≥96% and retention time is 21.22 min by HPLC analysis.</div></div><div id="sec4_3_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (1<sup>2</sup><i>S</i>,4<i>S</i>)-<i>N</i>-((<i>S</i>)-3-Cyclohexyl-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-2,15-dioxo-7-oxa-3-aza-1(2,1)-pyrrolidina-6(1,4)-benzenacyclopentadecaphane-4-carboxamide (<b>19</b>)</h4><div class="NLM_p last">Macrocyclic carboxylic acid intermediate 9b was prepared from <b>8b</b> using the general procedure for synthesis of macrocyclic carboxylic acid. <b>9b</b> was coupled with right-hand Boc-deprotected epoxyketone intermediate <b>4b</b> using the general procedure for the amide coupling reaction to prepare <b>19</b> as a white solid (42%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.00 (d, <i>J</i> = 8.2 Hz, 1H), 6.97–6.91 (m, 2H), 6.86–6.75 (m, 2H), 6.23 (d, <i>J</i> = 8.9 Hz, 1H), 4.69–4.59 (m, 2H), 4.46 (dd, <i>J</i> = 3.2, 8.4 Hz, 1H), 4.17–4.08 (m, 2H), 3.49–3.36 (m, 3H), 3.34 (d, <i>J</i> = 5.0 Hz, 1H), 2.83 (d, <i>J</i> = 5.0 Hz, 1H), 2.70 (dd, <i>J</i> = 5.7, 14.1 Hz, 1H), 2.34–2.25 (m, 1H), 2.11–1.93 (m, 5H), 1.91–1.81 (m, 2H), 1.81–1.70 (m, 2H), 1.70–1.52 (m, 4H), 1.51–1.39 (m, 5H), 1.39–1.27 (m, 5H), 1.27–1.07 (m, 6H), 0.98–0.84 (m, 2H). <sup>13</sup>C NMR (101 MHz, cdcl<sub>3</sub>) δ 207.73, 173.64, 171.09, 170.53, 158.11, 130.35, 127.26, 114.83, 66.34, 60.83, 59.12, 52.75, 52.32, 49.46, 47.78, 37.70, 35.30, 34.57, 33.85, 33.71, 31.57, 28.50, 27.85, 27.59, 26.43, 26.14, 26.08, 25.95, 24.97, 22.91, 22.21, 16.78. HRMS <i>m</i>/<i>z</i> calcd for C<sub>34</sub>H<sub>50</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup> 596.3655, found: 596.3534. LC–MS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>34</sub>H<sub>50</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup> 596.3, found: 596.3; purity: ≥96% and retention time is 21.49 min by HPLC analysis.</div></div><div id="sec4_3_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (1<sup>2</sup><i>S</i>,4<i>S</i>)-<i>N</i>-((<i>S</i>)-1-((R)-2-Methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2,15-dioxo-7-oxa-3-aza-1(2,1)-pyrrolidina-6(1,4)-benzenacyclopentadecaphane-4-carboxamide (<b>20</b>)</h4><div class="NLM_p last">Macrocyclic carboxylic acid intermediate <b>9b</b> was prepared from <b>8b</b> using the general procedure for synthesis of macrocyclic carboxylic acid. <b>9b</b> was coupled with right-hand Boc-deprotected epoxyketone intermediate 4c using the general procedure for the amide coupling reaction to prepare <b>20</b> as a white solid (38%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34–7.16 (m, 5H), 7.08 (d, <i>J</i> = 8.7 Hz, 1H), 6.90–6.81 (m, 2H), 6.74–6.64 (m, 2H), 6.48 (d, <i>J</i> = 8.0 Hz, 1H), 4.94 (ddd, <i>J</i> = 5.0, 7.4, 8.4 Hz, 1H), 4.59 (dt, <i>J</i> = 5.5, 8.4 Hz, 1H), 4.50–4.41 (m, 1H), 4.19–4.02 (m, 2H), 3.37 (ddt, <i>J</i> = 3.5, 5.7, 7.8 Hz, 3H), 3.18 (dd, <i>J</i> = 5.8, 14.5 Hz, 1H), 3.11–3.00 (m, 1H), 2.84 (dd, <i>J</i> = 2.0, 5.0 Hz, 1H), 2.76 (ddd, <i>J</i> = 2.6, 8.0, 14.3 Hz, 2H), 2.31–2.23 (m, 1H), 2.08–1.88 (m, 5H), 1.88–1.70 (m, 2H), 1.64 (dt, <i>J</i> = 3.4, 6.9 Hz, 1H), 1.52–1.38 (m, 4H), 1.38–1.22 (m, 4H), 1.21–1.07 (m, 2H). <sup>13</sup>C NMR (101 MHz, cdcl<sub>3</sub>) δ 207.37, 173.63, 171.19, 170.96, 157.80, 136.46, 130.10, 129.16, 128.38, 127.15, 126.72, 114.90, 66.35, 60.35, 59.19, 52.98, 52.29, 52.02, 47.65, 36.80, 35.26, 34.51, 28.04, 27.72, 27.62, 26.11, 24.99, 23.07, 22.32, 16.41. HRMS (FAB) <i>m</i>/<i>z</i> calcd for for C<sub>34</sub>H<sub>44</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup> 590.3185, found: 590.3214. LC–MS (ES+), found: 590.3; purity: ≥96% and retention time is 18.53 min by HPLC analysis</div></div><div id="sec4_3_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (3<i>S</i>,15<i>aS</i>)-<i>N</i>-((<i>S</i>)-4-Methyl-1-((<i>R</i>)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-1,11-dioxotetradecahydropyrrolo[2,1-<i>f</i>][1]oxa[4,7]diazacyclotridecine-3-carboxamide (<b>21</b>)</h4><div class="NLM_p last">Macrocyclic carboxylic acid intermediate <b>12a</b> was prepared from <b>11a</b> using the general procedure for synthesis of macrocyclic carboxylic acid. <b>12a</b> was coupled with right-hand Boc-deprotected epoxyketone intermediate <b>4a</b> using the general procedure for the amide coupling reaction to prepare <b>21</b> as a white solid (60%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.68 (d, <i>J</i> = 7.9 Hz, 1H), 7.00 (d, <i>J</i> = 8.2 Hz, 1H), 4.82 (dd, <i>J</i> = 1.9, 8.1 Hz, 1H), 4.57 (ddd, <i>J</i> = 3.3, 8.2, 10.2 Hz, 1H), 4.39 (ddd, <i>J</i> = 3.7, 6.0, 7.9 Hz, 1H), 3.71 (dd, <i>J</i> = 6.0, 9.9 Hz, 1H), 3.58 (dt, <i>J</i> = 4.3, 10.9 Hz, 2H), 3.53–3.34 (m, 3H), 3.27 (d, <i>J</i> = 5.0 Hz, 1H), 2.83 (d, <i>J</i> = 5.0 Hz, 1H), 2.57–2.42 (m, 2H), 2.19 (ddd, <i>J</i> = 2.6, 8.2, 12.9 Hz, 1H), 2.08–1.94 (m, 2H), 1.94–1.73 (m, 3H), 1.73–1.61 (m, 2H), 1.61–1.43 (m, 6H), 1.43–1.28 (m, 2H), 0.91 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 207.80, 174.95, 171.38, 169.69, 69.53, 67.96, 59.50, 58.99, 53.81, 52.33, 50.12, 47.88, 40.04, 34.21, 27.51, 26.50, 25.14, 24.97, 23.85, 23.24, 21.88, 21.38, 16.71. LC–MS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>38</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup> 452.2, found: 452.2; purity: ≥96% and retention time is 15.21 min by HPLC analysis.</div></div><div id="sec4_3_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (3<i>S</i>,16<i>aS</i>)-<i>N</i>-((<i>S</i>)-4-Methyl-1-((<i>R</i>)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-1,12-dioxotetradecahydro-6<i>H</i>-pyrrolo[2,1-<i>f</i>][1]oxa[4,7]diazacyclotetradecine-3-carboxamide (<b>22</b>)</h4><div class="NLM_p last">Macrocyclic carboxylic acid intermediate <b>12b</b> was prepared from <b>11b</b> using the general procedure for synthesis of macrocyclic carboxylic acid. <b>12b</b> was coupled with right-hand Boc-deprotected epoxyketone intermediate <b>4a</b> using the general procedure for the amide coupling reaction to prepare <b>22</b> as a white solid (35%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.47 (d, <i>J</i> = 8.3 Hz, 1H), 6.97 (d, <i>J</i> = 8.5 Hz, 1H), 4.63 (ddt, <i>J</i> = 3.7, 9.0, 22.3 Hz, 2H), 4.30 (dd, <i>J</i> = 3.3, 8.3 Hz, 1H), 3.87 (dd, <i>J</i> = 2.4, 9.7 Hz, 1H), 3.76–3.61 (m, 1H), 3.61–3.43 (m, 3H), 3.41–3.31 (m, 1H), 3.29 (d, <i>J</i> = 5.2 Hz, 1H), 2.82 (d, <i>J</i> = 5.1 Hz, 1H), 2.62–2.47 (m, 1H), 2.38–2.19 (m, 2H), 2.13 (dd, <i>J</i> = 7.8, 13.1 Hz, 1H), 2.05–1.81 (m, 4H), 1.79–1.65 (m, 1H), 1.65–1.31 (m, 11H), 0.91 (t, <i>J</i> = 7.1 Hz, 6H).<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 207.41, 174.37, 170.61, 170.15, 72.15, 69.60, 60.93, 59.04, 53.67, 52.27, 50.27, 48.16, 39.54, 33.81, 28.42, 27.89, 27.64, 27.27, 25.01, 24.93, 24.69, 23.35, 21.10, 16.76. LC–MS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>40</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup> 466.2, found: 466.2; purity: ≥96% and retention time is 19.13 min by HPLC analysis.</div></div><div id="sec4_3_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (3<i>S</i>,17<i>aS</i>)-<i>N</i>-((<i>S</i>)-4-Methyl-1-((<i>R</i>)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-1,13-dioxohexadecahydropyrrolo[2,1-<i>f</i>][1]oxa[4,7]diazacyclopentadecine-3-carboxamide (<b>23</b>)</h4><div class="NLM_p last">Macrocyclic carboxylic acid intermediate <b>12c</b> was prepared from <b>11c</b> using the procedure for synthesis of macrocyclic carboxylic acid. <b>12c</b> was coupled with right-hand Boc-deprotected epoxyketone intermediate <b>4a</b> using the general procedure for amide coupling reaction to prepare <b>23</b> as a white solid (20%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.46 (d, <i>J</i> = 8.5 Hz, 1H), 6.89 (d, <i>J</i> = 9.0 Hz, 1H), 4.73–4.57 (m, 2H), 4.40 (ddd, <i>J</i> = 2.2, 3.2, 8.9 Hz, 1H), 3.86 (dd, <i>J</i> = 2.2, 9.1 Hz, 1H), 3.67 (ddd, <i>J</i> = 4.2, 7.2, 9.9 Hz, 1H), 3.57–3.42 (m, 3H), 3.42–3.34 (m, 1H), 3.33–3.24 (m, 1H), 2.83 (d, <i>J</i> = 5.0 Hz, 1H), 2.50–2.26 (m, 3H), 2.20–2.05 (m, 1H), 2.05–1.86 (m, 3H), 1.84–1.68 (m, 2H), 1.64–1.41 (m, 8H), 1.41–1.17 (m, 5H), 0.93 (dd, <i>J</i> = 4.7, 6.6 Hz, 6H).<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 207.63, 174.61, 170.89, 170.07, 72.34, 69.94, 61.32, 59.04, 54.10, 52.29, 50.13, 48.19, 39.66, 33.61, 29.16, 28.62, 28.43, 28.12, 28.08, 24.85, 24.83, 23.43, 23.10, 21.04, 16.76. LC–MS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>42</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup> 480.3, found: 480.3; purity: ≥96% and retention time is 14.82 min by HPLC analysis.</div></div><div id="sec4_3_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (3<i>S</i>,15<i>aS</i>)-<i>N</i>-((<i>S</i>)-3-Cyclohexyl-1-((<i>R</i>)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-1,11-dioxotetradecahydropyrrolo[2,1-<i>f</i>][1]oxa[4,7]diazacyclotridecine-3-carboxamide (<b>24</b>)</h4><div class="NLM_p last">Macrocyclic carboxylic acid intermediate <b>12a</b> was prepared from 11a using the general procedure for synthesis of macrocyclic carboxylic acid. <b>12a</b> was coupled with right-hand Boc-deprotected epoxyketone intermediate <b>4b</b> using the general procedure for the amide coupling reaction to prepare <b>24</b> as a white solid (33%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.66 (d, <i>J</i> = 7.9 Hz, 1H), 7.02 (d, <i>J</i> = 8.0 Hz, 1H), 4.82 (dd, <i>J</i> = 1.9, 8.2 Hz, 1H), 4.62–4.54 (m, 1H), 4.38 (ddd, <i>J</i> = 3.7, 5.9, 7.9 Hz, 1H), 3.75–3.70 (m, 1H), 3.59 (dd, <i>J</i> = 3.9, 10.1 Hz, 2H), 3.53–3.37 (m, 3H), 3.29 (d, <i>J</i> = 5.0 Hz, 1H), 2.83 (d, <i>J</i> = 5.0 Hz, 1H), 2.55–2.44 (m, 2H), 2.19 (ddd, <i>J</i> = 2.5, 8.2, 12.9 Hz, 1H), 2.01 (tdd, <i>J</i> = 2.8, 4.6, 8.4 Hz, 2H), 1.92–1.75 (m, 4H), 1.70–1.51 (m, 7H), 1.47 (s, 3H), 1.43–1.29 (m, 3H), 1.20–1.07 (m, 3H), 0.99–0.81 (m, 3H); <sup>13</sup>C NMR (101 MHz, cdcl<sub>3</sub>) δ 207.90, 174.93, 171.31, 169.75, 69.42, 68.07, 59.57, 59.05, 53.70, 52.35, 49.52, 47.90, 38.31, 34.34, 34.25, 33.87, 31.87, 27.60, 26.57, 26.38, 26.33, 26.04, 24.98, 24.01, 22.07, 16.73. LC–MS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>42</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup> 492.3, found: 492.3; purity: ≥96% and retention time is 17.81 min by HPLC analysis.</div></div><div id="sec4_3_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (3<i>S</i>,15<i>aS</i>)-<i>N</i>-((<i>S</i>)-1-((<i>R</i>)-2-Methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-1,11-dioxotetradecahydropyrrolo[2,1-<i>f</i>][1]oxa[4,7]diazacyclotridecine-3-carboxamide (<b>25</b>)</h4><div class="NLM_p last">Macrocyclic carboxylic acid intermediate <b>12a</b> was prepared from <b>11a</b> using the general procedure for synthesis of macrocyclic carboxylic acid. <b>12a</b> was coupled with right-hand Boc-deprotected epoxyketone intermediate 4c using the general procedure for the amide coupling reaction to prepare <b>25</b> as a white solid (31%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.77 (d, <i>J</i> = 7.7 Hz, 1H), 7.30–7.22 (m, 2H), 7.22–7.09 (m, 4H), 4.80 (td, <i>J</i> = 4.9, 8.2 Hz, 1H), 4.72 (dd, <i>J</i> = 1.7, 8.1 Hz, 1H), 4.38 (td, <i>J</i> = 3.8, 7.3 Hz, 1H), 3.62 (dd, <i>J</i> = 3.8, 10.1 Hz, 1H), 3.59–3.49 (m, 2H), 3.49–3.42 (m, 1H), 3.35 (ddt, <i>J</i> = 4.0, 8.7, 11.7 Hz, 2H), 3.30 (d, <i>J</i> = 4.9 Hz, 1H), 3.11 (dd, <i>J</i> = 4.9, 14.0 Hz, 1H), 2.85 (d, <i>J</i> = 4.9 Hz, 1H), 2.82–2.73 (m, 1H), 2.53–2.41 (m, 2H), 2.20 (ddd, <i>J</i> = 2.7, 7.1, 12.9 Hz, 1H), 2.00 (ddt, <i>J</i> = 3.5, 8.4, 12.2 Hz, 2H), 1.86–1.75 (m, 2H), 1.55 (tt, <i>J</i> = 5.7, 13.1 Hz, 3H), 1.45 (s, 3H), 1.42–1.30 (m, 2H); <sup>13</sup>C NMR (101 MHz, cdcl<sub>3</sub>) δ 207.05, 175.03, 171.64, 169.73, 135.97, 129.34, 128.35, 126.83, 69.05, 67.89, 59.20, 53.41, 52.39, 52.29, 47.85, 37.04, 34.08, 27.50, 26.13, 24.94, 23.87, 21.92, 16.48. LC–MS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>36</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup> 486.2, found: 486.2; purity: ≥96% and retention time is 15.50 min by HPLC analysis.</div></div><div id="sec4_3_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (3<i>S</i>,18<i>aS</i>)-<i>N</i>-((<i>S</i>)-4-Methyl-1-((<i>R</i>)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-1,11,14-trioxohexadecahydro-6<i>H</i>-pyrrolo[2,1-<i>f</i>][1]oxa[4,7,10]triazacyclohexadecine-3-carboxamide (<b>26</b>)</h4><div class="NLM_p last">Macrocyclic carboxylic acid intermediate <b>15a</b> was prepared from <b>14a</b> using the general procedure for synthesis of macrocyclic carboxylic acid. <b>15a</b> was coupled with right-hand Boc-deprotected epoxyketone intermediate <b>4a</b> using the general procedure for the amide coupling reaction to prepare <b>26</b> as a white solid (47%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.62 (d, <i>J</i> = 7.3 Hz, 1H), 6.95 (d, <i>J</i> = 8.4 Hz, 1H), 6.32 (d, <i>J</i> = 8.1 Hz, 1H), 4.76–4.66 (m, 2H), 4.62 (ddd, <i>J</i> = 3.3, 8.4, 9.9 Hz, 1H), 4.32 (dt, <i>J</i> = 3.5, 7.2 Hz, 1H), 3.72 (td, <i>J</i> = 3.6, 8.1, 8.9 Hz, 2H), 3.53 (dd, <i>J</i> = 3.1, 9.6 Hz, 1H), 3.49–3.31 (m, 4H), 3.27 (d, <i>J</i> = 4.9 Hz, 1H), 2.84 (d, <i>J</i> = 5.2 Hz, 1H), 2.56–2.43 (m, 1H), 2.43–2.32 (m, 1H), 2.12 (ddd, <i>J</i> = 2.9, 10.7, 13.7 Hz, 1H), 2.07–1.87 (m, 3H), 1.83–1.62 (m, 2H), 1.62–1.40 (m, 8H), 1.34 (ddd, <i>J</i> = 4.0, 9.3, 18.0 Hz, 2H), 0.92 (dd, <i>J</i> = 1.8, 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 208.16, 173.95, 170.41, 169.99, 169.43, 70.54, 69.06, 60.60, 58.93, 54.70, 52.33, 50.00, 47.01, 41.46, 40.18, 36.47, 29.05, 27.17, 25.24, 25.03, 24.73, 23.39, 21.30, 16.67. LC–MS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>41</sub>N<sub>4</sub>O<sub>7</sub> [M + H]<sup>+</sup> 509.2, found: 509.3; purity: ≥96% and retention time is 14.36 min by HPLC analysis.</div></div><div id="sec4_3_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (3<i>S</i>,19<i>aS</i>)-<i>N</i>-((<i>S</i>)-4-Methyl-1-((<i>R</i>)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-1,12,15-trioxooctadecahydropyrrolo[2,1-<i>f</i>][1]oxa[4,7,10]triazacycloheptadecine-3-carboxamide (<b>27</b>)</h4><div class="NLM_p last">Macrocyclic carboxylic acid intermediate <b>15b</b> was prepared from <b>14b</b> using the general procedure for synthesis of macrocyclic carboxylic acid. <b>15b</b> was coupled with right-hand Boc-deprotected epoxyketone intermediate <b>4a</b> using the general procedure for the amide coupling reaction to prepare <b>27</b> as a white solid (36%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.35 (d, <i>J</i> = 8.4 Hz, 1H), 7.00 (d, <i>J</i> = 8.4 Hz, 1H), 6.47 (d, <i>J</i> = 7.1 Hz, 1H), 4.70 (d, <i>J</i> = 6.3 Hz, 1H), 4.67–4.55 (m, 2H), 4.38 (dd, <i>J</i> = 2.9, 8.5 Hz, 1H), 3.81 (dd, <i>J</i> = 2.8, 9.4 Hz, 1H), 3.70–3.57 (m, 2H), 3.47–3.37 (m, 2H), 3.37–3.31 (m, 2H), 3.28 (d, <i>J</i> = 5.0 Hz, 1H), 2.85 (d, <i>J</i> = 5.0 Hz, 1H), 2.47 (dd, <i>J</i> = 3.0, 5.9 Hz, 1H), 2.41–2.28 (m, 1H), 2.27–2.16 (m, 1H), 2.00 (dd, <i>J</i> = 4.6, 7.5 Hz, 3H), 1.87 (s, 2H), 1.72 (dt, <i>J</i> = 3.0, 8.7 Hz, 1H), 1.54–1.27 (m, 11H), 0.94 (t, <i>J</i> = 7.1 Hz, 6H).<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 208.21, 173.43, 170.30, 169.76, 169.43, 71.27, 69.95, 60.96, 58.95, 54.44, 52.33, 49.97, 46.82, 41.58, 40.13, 36.24, 30.21, 29.23, 27.49, 25.39, 25.00, 24.66, 24.63, 23.58, 21.31, 16.67. LC–MS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>43</sub>N<sub>4</sub>O<sub>7</sub> [M + H]<sup>+</sup> 523.3, found: 523.3; purity: ≥96% and retention time is 14.75 min by HPLC analysis.</div></div><div id="sec4_3_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Benzyl <i>O</i>-Allyl-<i>N</i>-(<i>tert</i>-butoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-serinate (<b>28</b>)</h4><div class="NLM_p last">Intermediate <b>28</b> was prepared from Boc-serine benzyl ester and allyl methyl carbonate using the same procedure used for preparation of intermediate 10 as colorless oil (78%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32 (d, <i>J</i> = 3.1 Hz, 5H), 5.84–5.67 (m, 1H), 5.39 (d, <i>J</i> = 8.8 Hz, 1H), 5.31–5.19 (m, 2H), 5.13 (ddd, <i>J</i> = 3.6, 7.9, 12.4 Hz, 2H), 4.45 (dt, <i>J</i> = 3.2, 9.0 Hz, 1H), 3.96–3.80 (m, 3H), 3.63 (dd, <i>J</i> = 3.3, 9.4 Hz, 1H), 1.43 (s, 9H).</div></div><div id="sec4_3_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>tert</i>-Butyl (2<i>S</i>,4<i>S</i>)-2-(((<i>S</i>)-3-(Allyloxy)-1-(benzyloxy)-1-oxopropan-2-yl)carbamoyl)-4-fluoropyrrolidine-1-carboxylate (<b>29a</b>)</h4><div class="NLM_p last">Boc-deprotected <b>28</b> prepared from intermediate <b>28</b> using the general procedure for the Boc deprotection reaction was coupled with <i>N</i>-Boc-<i>cis</i>-4-fluoroproline using the general procedure for the amide coupling reaction to prepare <b>29a</b> as colorless oil (93%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.37–7.16 (m, 5H), 7.02 (s, 1H), 5.71 (ddt, <i>J</i> = 5.6, 10.4, 17.2 Hz, 1H), 5.34–4.97 (m, 4H), 4.75 (dd, <i>J</i> = 3.5, 7.5 Hz, 1H), 4.42 (s, 1H), 3.98–3.79 (m, 2H), 3.79–3.41 (m, 3H), 2.64 (s, 1H), 2.26 (d, <i>J</i> = 43.7 Hz, 1H), 1.43 (s, 9H).</div></div><div id="sec4_3_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>tert</i>-Butyl (<i>S</i>)-2-(((<i>S</i>)-3-(Allyloxy)-1-(benzyloxy)-1-oxopropan-2-yl)carbamoyl)-4,4-difluoropyrrolidine-1-carboxylate (<b>29b</b>)</h4><div class="NLM_p last">Boc-deprotected <b>28</b> prepared from intermediate <b>28</b> using the general procedure for the Boc deprotection reaction was coupled with <i>N</i>-Boc-4,4-difluoro-proline using the general procedure for the amide coupling reaction to prepare 29b as colorless oil (87%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.47–7.23 (m, 5H), 6.91 (s, 1H), 5.72 (tt, <i>J</i> = 5.3, 10.8 Hz, 1H), 5.34–5.01 (m, 4H), 4.73 (d, <i>J</i> = 8.1 Hz, 1H), 4.49 (s, 1H), 4.04–3.75 (m, 4H), 3.65 (dt, <i>J</i> = 10.7, 22.5 Hz, 2H), 2.69 (d, <i>J</i> = 60.0 Hz, 2H), 1.44 (s, 9H).</div></div><div id="sec4_3_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>tert</i>-Butyl (<i>S</i>)-2-(((<i>S</i>)-3-(Allyloxy)-1-(benzyloxy)-1-oxopropan-2-yl)carbamoyl)-2-methylpyrrolidine-1-carboxylate (<b>29c</b>)</h4><div class="NLM_p last">Boc-deprotected <b>28</b> prepared from intermediate <b>28</b> using the general procedure for the Boc deprotection reaction was coupled with <i>N</i>-Boc-α-methylproline using the general procedure for the amide coupling reaction to prepare <b>29c</b> as colorless oil (65%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.31 (s, 5H), 5.72 (tt, <i>J</i> = 5.4, 10.7 Hz, 1H), 5.29–5.04 (m, 4H), 4.75–4.63 (m, 1H), 3.98–3.78 (m, 3H), 3.63 (dd, <i>J</i> = 3.3, 9.5 Hz, 1H), 3.53 (s, 2H), 1.76 (m, 4H), 1.57 (d, <i>J</i> = 16.0 Hz, 3H), 1.50–1.32 (s, 9H).</div></div><div id="sec4_3_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>tert</i>-Butyl (<i>S</i>)-2-(((<i>S</i>)-3-(Allyloxy)-1-(benzyloxy)-1-oxopropan-2-yl)carbamoyl)azetidine-1-carboxylate (<b>29d</b>)</h4><div class="NLM_p last">Boc-deprotected <b>28</b> prepared from intermediate <b>28</b> using the general procedure for the Boc deprotection reaction was coupled with <i>N</i>-Boc-azetidine-2-carboxylic acid using the general procedure for the amide coupling reaction to prepare <b>29d</b> as colorless oil (92%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.43–7.17 (m, 5H), 5.74 (ddt, <i>J</i> = 5.6, 10.5, 17.3 Hz, 1H), 5.28–5.03 (m, 4H), 4.75 (dt, <i>J</i> = 3.3, 8.3 Hz, 1H), 4.63 (t, <i>J</i> = 8.1 Hz, 1H), 3.95–3.83 (m, 4H), 3.77 (td, <i>J</i> = 5.8, 8.3 Hz, 1H), 3.65 (dd, <i>J</i> = 3.3, 9.6 Hz, 1H), 2.38 (d, <i>J</i> = 20.2 Hz, 2H), 1.42 (s, 9H).</div></div><div id="sec4_3_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>tert</i>-Butyl (<i>S</i>)-2-(((<i>S</i>)-3-(Allyloxy)-1-(benzyloxy)-1-oxopropan-2-yl)carbamoyl)piperidine-1-carboxylate (<b>29e</b>)</h4><div class="NLM_p last">Boc-deprotected <b>28</b> prepared from intermediate <b>28</b> using the general procedure for the Boc deprotection reaction was coupled with <i>N</i>-Boc-2-piperidinecarboxylic acid using the general procedure for the amide coupling reaction to prepare <b>29e</b> as colorless oil (81%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.46–7.23 (m, 5H), 6.80 (d, <i>J</i> = 26.1 Hz, 1H), 5.72 (ddt, <i>J</i> = 5.6, 10.9, 17.3 Hz, 1H), 5.32–5.00 (m, 4H), 4.74 (d, <i>J</i> = 8.1 Hz, 2H), 3.98–3.79 (m, 4H), 3.70–3.59 (m, 2H), 2.93–2.65 (m, 1H), 2.24 (d, <i>J</i> = 12.1 Hz, 1H), 1.44 (m, 13H).</div></div><div id="sec4_3_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Benzyl <i>O</i>-Allyl-<i>N</i>-((2S,4S)-4-fluoro-1-(pent-4-enoyl)pyrrolidine-2-carbonyl)-<span class="smallcaps smallerCapital">l</span>-serinate (<b>30a</b>)</h4><div class="NLM_p last">Boc-deprotected <b>29a</b> prepared from intermediate <b>29a</b> using the general procedure for the Boc deprotection reaction was coupled with 4-pentenoic acid using the general procedure for the amide coupling reaction to prepare <b>30a</b> as colorless oil (83%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32 (m, 5H), 6.93 (d, <i>J</i> = 8.8 Hz, 1H), 5.91–5.64 (m, 2H), 5.36–4.91 (m, 6H), 4.75 (m, 1H), 4.47 (d, <i>J</i> = 9.9 Hz, 1H), 3.97–3.64 (m, 4H), 3.61 (dd, <i>J</i> = 3.4, 9.6 Hz, 1H), 3.51 (dd, <i>J</i> = 3.2, 9.5 Hz, 1H), 2.88–2.73 (m, 1H), 2.66 (t, <i>J</i> = 16.1 Hz, 1H), 2.57–2.07 (m, 5H).</div></div><div id="sec4_3_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Benzyl <i>O</i>-Allyl-<i>N</i>-((<i>S</i>)-4,4-difluoro-1-(pent-4-enoyl)pyrrolidine-2-carbonyl)-<span class="smallcaps smallerCapital">l</span>-serinate (<b>30b</b>)</h4><div class="NLM_p last">Boc-deprotected <b>29b</b> prepared from intermediate <b>29b</b> using the general procedure for the Boc deprotection reaction was coupled with 4-pentenoic acid using the general procedure for the amide coupling reaction to prepare <b>30b</b> as colorless oil (97%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.42–7.28 (m, 5H), 7.23 (d, <i>J</i> = 8.6 Hz, 1H), 5.91–5.67 (m, 2H), 5.32–4.93 (m, 6H), 4.81–4.66 (m, 2H), 3.99–3.74 (m, 5H), 3.63 (dd, <i>J</i> = 3.3, 9.6 Hz, 1H), 2.87–2.68 (m, 1H), 2.64–2.44 (m, 1H), 2.44–2.26 (m, 4H).</div></div><div id="sec4_3_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Benzyl <i>O</i>-Allyl-<i>N</i>-((<i>S</i>)-2-methyl-1-(pent-4-enoyl)pyrrolidine-2-carbonyl)-<span class="smallcaps smallerCapital">l</span>-serinate (<b>30c</b>)</h4><div class="NLM_p last">Boc-deprotected <b>29c</b> prepared from intermediate <b>29c</b> using the general procedure for the Boc deprotection reaction was coupled with 4-pentenoic acid using the general procedure for the amide coupling reaction to prepare <b>30c</b> as colorless oil (96%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.51 (d, <i>J</i> = 7.7 Hz, 1H), 7.36–7.22 (m, 5H), 5.92–5.65 (m, 2H), 5.28–4.87 (m, 6H), 4.76–4.58 (m, 1H), 3.96–3.78 (m, 3H), 3.65 (ddd, <i>J</i> = 0.8, 3.5, 9.6 Hz, 1H), 3.61–3.44 (m, 2H), 2.53–2.40 (m, 1H), 2.34 (s, 4H), 1.96–1.78 (m, 2H), 1.69 (ddd, <i>J</i> = 6.6, 8.7, 12.5 Hz, 1H), 1.63 (d, <i>J</i> = 0.8 Hz, 3H).</div></div><div id="sec4_3_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Benzyl <i>O</i>-Allyl-<i>N</i>-((<i>S</i>)-1-(pent-4-enoyl)azetidine-2-carbonyl)-<span class="smallcaps smallerCapital">l</span>-serinate (<b>30d</b>)</h4><div class="NLM_p last">Boc-deprotected <b>29d</b> prepared from intermediate <b>29d</b> using the general procedure for the Boc deprotection reaction was coupled with 4-pentenoic acid using the general procedure for the amide coupling reaction to prepare <b>30d</b> as colorless oil (78%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.30 (d, <i>J</i> = 7.8 Hz, 1H), 7.39–7.24 (m, 5H), 5.78 (dtd, <i>J</i> = 7.0, 10.5, 16.0 Hz, 2H), 5.30–4.91 (m, 6H), 4.87 (dd, <i>J</i> = 6.2, 9.4 Hz, 1H), 4.71 (dt, <i>J</i> = 3.9, 7.8 Hz, 1H), 4.10–3.98 (m, 2H), 3.92 (ddt, <i>J</i> = 1.4, 2.4, 4.0 Hz, 2H), 3.84 (dd, <i>J</i> = 4.0, 9.7 Hz, 1H), 3.65 (dd, <i>J</i> = 3.7, 9.6 Hz, 1H), 2.61 (ddd, <i>J</i> = 2.1, 5.7, 12.0 Hz, 1H), 2.39 (dq, <i>J</i> = 6.9, 22.3 Hz, 3H), 2.18 (dd, <i>J</i> = 5.8, 8.0 Hz, 2H).</div></div><div id="sec4_3_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Benzyl <i>O</i>-Allyl-<i>N</i>-((<i>S</i>)-1-(pent-4-enoyl)piperidine-2-carbonyl)-<span class="smallcaps smallerCapital">l</span>-serinate (<b>30e</b>)</h4><div class="NLM_p last">Boc-deprotected <b>29e</b> prepared from intermediate <b>29e</b> using the general procedure for the Boc deprotection reaction was coupled with 4-pentenoic acid using the general procedure for the amide coupling reaction to prepare <b>30e</b> as colorless oil (97%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39–7.25 (m, 5H), 6.74 (d, <i>J</i> = 7.9 Hz, 1H), 5.91–5.66 (m, 2H), 5.30–4.88 (m, 7H), 4.70 (dt, <i>J</i> = 3.4, 7.5 Hz, 1H), 3.94–3.79 (m, 3H), 3.77–3.69 (m, 1H), 3.65 (dd, <i>J</i> = 3.4, 9.6 Hz, 1H), 3.19 (td, <i>J</i> = 2.6, 13.1 Hz, 1H), 2.50–2.31 (m, 4H), 2.19 (dt, <i>J</i> = 2.5, 12.7 Hz, 1H), 1.71–1.48 (m, 4H), 1.48–1.32 (m, 1H).</div></div><div id="sec4_3_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> (3<i>S</i>,14<i>S</i>,15<i>aS</i>)-14-Fluoro-<i>N</i>-((<i>S</i>)-4-methyl-1-((<i>R</i>)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-1,11-dioxotetradecahydropyrrolo[2,1-<i>f</i>][1]oxa[4,7]diazacyclotridecine-3-carboxamide (<b>32</b>)</h4><div class="NLM_p last">Macrocyclic carboxylic acid intermediate <b>31b</b> was prepared from <b>30b</b> using the general procedure for synthesis of macrocyclic carboxylic acid. <b>31b</b> was coupled with right-hand Boc-deprotected epoxyketone intermediate <b>4a</b> using the general procedure for the amide coupling reaction to prepare <b>33</b> as a white solid (43%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.16 (d, <i>J</i> = 8.4 Hz, 1H), 7.04 (d, <i>J</i> = 8.0 Hz, 1H), 4.90 (d, <i>J</i> = 10.0 Hz, 1H), 4.61 (ddd, <i>J</i> = 3.8, 8.5, 9.6 Hz, 1H), 4.27 (ddd, <i>J</i> = 2.6, 3.6, 8.0 Hz, 1H), 4.03 (dd, <i>J</i> = 2.6, 9.7 Hz, 1H), 3.90 (ddd, <i>J</i> = 1.9, 12.4, 22.9 Hz, 1H), 3.82–3.69 (m, 1H), 3.53 (dt, <i>J</i> = 4.6, 9.1 Hz, 1H), 3.38–3.31 (m, 2H), 3.28 (d, <i>J</i> = 5.0 Hz, 1H), 2.92–2.85 (m, 1H), 2.83 (d, <i>J</i> = 4.9 Hz, 1H), 2.55 (ddd, <i>J</i> = 2.0, 8.0, 12.8 Hz, 1H), 2.30–2.15 (m, 2H), 1.92–1.77 (m, 3H), 1.71–1.58 (m, 3H), 1.54–1.38 (m, 7H), 0.91 (dd, <i>J</i> = 1.8, 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 207.52, 174.59, 169.68, 169.63, 93.17, 91.40, 69.60, 68.25, 58.98, 58.94, 54.64, 54.40, 53.87, 52.30, 50.14, 40.05, 34.69, 34.52, 34.30, 27.52, 25.00, 24.09, 23.26, 22.09, 21.33, 16.73. LC–MS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>37</sub>FN<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup> 470.2, found: 470.2; purity: ≥96% and retention time is 15.30 min by HPLC analysis.</div></div><div id="sec4_3_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (3<i>S</i>,15<i>aS</i>)-14,14-Difluoro-<i>N</i>-((<i>S</i>)-4-methyl-1-((<i>R</i>)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-1,11-dioxotetradecahydropyrrolo[2,1-<i>f</i>][1]oxa[4,7]diazacyclotridecine-3-carboxamide (<b>33</b>)</h4><div class="NLM_p last">Macrocyclic carboxylic acid intermediate <b>31a</b> was prepared from <b>30a</b> using the general procedure for synthesis of macrocyclic carboxylic acid. <b>31a</b> was coupled with right-hand Boc-deprotected epoxyketone intermediate <b>4a</b> using the general procedure for the amide coupling reaction to prepare <b>32</b> as a white solid (42%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.40 (d, <i>J</i> = 8.1 Hz, 1H), 6.83 (d, <i>J</i> = 8.3 Hz, 1H), 5.07 (dd, <i>J</i> = 3.7, 9.9 Hz, 1H), 4.58 (ddd, <i>J</i> = 3.2, 8.3, 10.2 Hz, 1H), 4.42 (ddd, <i>J</i> = 3.6, 5.3, 8.5 Hz, 1H), 4.00–3.81 (m, 2H), 3.80–3.75 (m, 1H), 3.54 (dd, <i>J</i> = 3.7, 9.8 Hz, 1H), 3.46 (dt, <i>J</i> = 3.9, 6.4 Hz, 1H), 3.40–3.34 (m, 1H), 3.26 (d, <i>J</i> = 5.0 Hz, 1H), 3.18–3.04 (m, 1H), 2.84 (d, <i>J</i> = 5.0 Hz, 1H), 2.56–2.40 (m, 2H), 2.26 (ddd, <i>J</i> = 2.6, 8.9, 13.0 Hz, 1H), 1.85–1.76 (m, 1H), 1.69–1.59 (m, 2H), 1.58–1.49 (m, 4H), 1.48 (s, 3H), 1.34 (ddd, <i>J</i> = 4.3, 10.3, 13.9 Hz, 2H), 0.91 (dd, <i>J</i> = 2.5, 6.5 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 207.83, 174.62, 169.20, 168.90, 69.55, 67.97, 58.99, 53.95, 52.33, 50.22, 40.11, 34.75, 34.21, 27.31, 25.14, 23.67, 23.25, 21.98, 21.36, 16.70. LC–MS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>36</sub>F<sub>2</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup> 488.2, found: 488.2; purity: ≥96% and retention time is 16.15 min by HPLC analysis.</div></div><div id="sec4_3_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> (3<i>S</i>,15<i>aS</i>)-15<i>a</i>-Methyl-<i>N</i>-((<i>S</i>)-4-methyl-1-((<i>R</i>)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-1,11-dioxotetradecahydropyrrolo[2,1-<i>f</i>][1]oxa[4,7]diazacyclotridecine-3-carboxamide (<b>34</b>)</h4><div class="NLM_p last">Macrocyclic carboxylic acid intermediate <b>31c</b> was prepared from <b>30c</b> using the general procedure for synthesis of macrocyclic carboxylic acid. <b>31c</b> was coupled with right-hand Boc-deprotected epoxyketone intermediate <b>4a</b> using the general procedure for the amide coupling reaction to prepare <b>34</b> as a white solid (32%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.60 (d, <i>J</i> = 8.6 Hz, 1H), 7.30 (d, <i>J</i> = 7.8 Hz, 1H), 4.66 (td, <i>J</i> = 6.6, 8.5 Hz, 1H), 4.23 (dt, <i>J</i> = 3.6, 7.7 Hz, 1H), 3.97 (dd, <i>J</i> = 3.1, 10.1 Hz, 1H), 3.74–3.61 (m, 2H), 3.53–3.45 (m, 2H), 3.36 (dt, <i>J</i> = 5.6, 8.8 Hz, 1H), 3.28 (d, <i>J</i> = 4.9 Hz, 1H), 2.83 (d, <i>J</i> = 4.9 Hz, 1H), 2.55 (ddd, <i>J</i> = 1.9, 9.1, 11.3 Hz, 1H), 2.49–2.42 (m, 1H), 2.21–2.11 (m, 1H), 1.98–1.83 (m, 4H), 1.80 (s, 4H), 1.71–1.62 (m, 2H), 1.53 (t, <i>J</i> = 5.4 Hz, 2H), 1.47 (d, <i>J</i> = 3.4 Hz, 5H), 1.39 (dd, <i>J</i> = 4.4, 14.2 Hz, 1H), 0.91 (dd, <i>J</i> = 6.6, 9.5 Hz, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 207.36, 174.21, 173.20, 170.07, 69.42, 68.95, 68.31, 58.90, 53.98, 52.27, 49.82, 49.75, 40.20, 39.00, 35.35, 27.74, 24.98, 24.40, 23.30, 23.17, 22.52, 22.40, 21.31, 16.76. LC–MS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>40</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup> 466.2, found: 466.2; purity: ≥96% and retention time is 16.98 min by HPLC analysis.</div></div><div id="sec4_3_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (10<i>S</i>,13<i>S</i>)-<i>N</i>-((<i>S</i>)-4-Methyl-1-((<i>R</i>)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-2,12-dioxo-8-oxa-1,11-diazabicyclo[11.2.0]pentadecane-10-carboxamide (<b>35</b>)</h4><div class="NLM_p last">Macrocyclic carboxylic acid intermediate <b>31d</b> was prepared from <b>30d</b> using the general procedure for synthesis of macrocyclic carboxylic acid. <b>31d</b> was coupled with right-hand Boc-deprotected epoxyketone intermediate <b>4a</b> using the general procedure for the amide coupling reaction to prepare <b>35</b> as a white solid (39%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.20 (d, <i>J</i> = 7.5 Hz, 1H), 6.98 (d, <i>J</i> = 8.1 Hz, 1H), 4.98 (dd, <i>J</i> = 5.4, 9.6 Hz, 1H), 4.55 (ddd, <i>J</i> = 3.3, 8.0, 10.2 Hz, 1H), 4.46 (td, <i>J</i> = 3.7, 7.9 Hz, 1H), 4.11 (td, <i>J</i> = 6.5, 8.6 Hz, 2H), 3.75 (dd, <i>J</i> = 3.7, 9.8 Hz, 1H), 3.57 (dd, <i>J</i> = 8.1, 9.8 Hz, 1H), 3.42 (ddd, <i>J</i> = 4.1, 9.0, 10.4 Hz, 2H), 3.27 (d, <i>J</i> = 5.0 Hz, 1H), 2.84 (d, <i>J</i> = 5.0 Hz, 1H), 2.68–2.47 (m, 2H), 2.14 (ddd, <i>J</i> = 2.4, 11.0, 13.2 Hz, 1H), 2.02 (ddd, <i>J</i> = 3.1, 6.6, 12.9 Hz, 1H), 1.78–1.68 (m, 2H), 1.66–1.56 (m, 2H), 1.56–1.45 (m, 5H), 1.34 (dddd, <i>J</i> = 3.4, 10.1, 14.1, 28.3 Hz, 3H), 0.94–0.83 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 207.98, 175.42, 172.10, 169.44, 69.56, 67.83, 61.28, 59.01, 53.94, 52.36, 50.09, 48.65, 40.08, 31.02, 27.76, 25.13, 23.26, 23.19, 21.37, 21.30, 18.24, 16.70. LC–MS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>36</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup> 438.2, found: 438.2; purity: ≥96% and retention time is 14.55 min by HPLC analysis.</div></div><div id="sec4_3_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> (3<i>S</i>,16<i>aS</i>)-<i>N</i>-((<i>S</i>)-4-Methyl-1-((<i>R</i>)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-1,11-dioxotetradecahydro-2H-pyrido[2,1-<i>f</i>][1]oxa[4,7]diazacyclotridecine-3-carboxamide (<b>36</b>)</h4><div class="NLM_p last">Macrocyclic carboxylic acid intermediate <b>31e</b> was prepared from <b>30e</b> using the general procedure for synthesis of macrocyclic carboxylic acid. <b>31e</b> was coupled with right-hand Boc-deprotected epoxyketone intermediate <b>4a</b> using the general procedure for the amide coupling reaction to prepare <b>36</b> as a white solid (28%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.83 (d, <i>J</i> = 8.4 Hz, 1H), 6.78 (d, <i>J</i> = 8.2 Hz, 1H), 5.42–5.35 (m, 1H), 4.54 (ddd, <i>J</i> = 3.3, 8.1, 10.1 Hz, 1H), 4.46 (dt, <i>J</i> = 3.8, 7.9 Hz, 1H), 3.97 (dd, <i>J</i> = 3.6, 9.3 Hz, 1H), 3.81 (d, <i>J</i> = 13.4 Hz, 1H), 3.55–3.47 (m, 1H), 3.35–3.23 (m, 3H), 2.97–2.89 (m, 1H), 2.83 (d, <i>J</i> = 4.9 Hz, 1H), 2.77 (s, 1H), 2.34 (dt, <i>J</i> = 2.6, 14.7 Hz, 1H), 2.19 (ddd, <i>J</i> = 2.2, 10.2, 12.7 Hz, 1H), 1.77–1.57 (m, 7H), 1.56–1.36 (m, 9H), 1.30 (ddd, <i>J</i> = 4.5, 10.2, 13.7 Hz, 1H), 0.90 (dd, <i>J</i> = 1.8, 6.6 Hz, 6H).<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 207.88, 173.51, 171.11, 169.52, 69.63, 67.76, 59.01, 53.07, 52.34, 51.43, 50.33, 44.73, 40.03, 38.56, 33.18, 27.11, 25.57, 25.22, 24.07, 23.22, 22.50, 22.12, 21.49, 20.36, 16.70. LC–MS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>40</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup> 466.2, found: 466.3; purity: ≥96% and retention time is 16.31 min by HPLC analysis.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Biology</h3><div class="NLM_p last">All animal study protocols were approved by the Animal Care and Use Committee (IACUC) of Chungbuk National University (Approval No. CBNUA-144-1001-01) and Seoul National University (SNU-200217-2). In addition, all cell culture experiments were performed following the guidelines and regulations of the University of Kentucky Biosafety Committee (Approval No. B17-3000-M).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Cell Culture</h3><div class="NLM_p last">BV-2 murine microglial cell line was a kind gift from Dr. Won-Gon Kim (Korea Research Institute of Bioscience & Biotechnology), and RPMI-8226 human multiple myeloma cell line was obtained from the ATCC (American Type Culture Collection). BV-2 cells and RPMI-8226 human multiple myeloma cells were cultured as reported previously.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> RPMI-8226 cells with acquired resistance to carfilzomib (RPMI-8226/ABCB1) previously established by us were used and maintained in 80 nM carfilzomib.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> To assess the <i>in cellulo</i> activity of macrocyclic proteasome inhibitors, RPMI-8226/ABCB1 cells were kept in a drug-free medium for two weeks after drug withdrawal.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Animals</h3><div class="NLM_p last">Nine-month-old Tg2576 mice were purchased from the Division of Laboratory Animal Resources (Korea FDA, Osong, South Korea). They were quarantined and acclimatized for a month before use. Animals were kept in groups of three per cage, allowed free access to water and food, and maintained on a 12 h light/dark cycle.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Proteasome Activity Assay</h3><div class="NLM_p last">The in vitro assay of 20S proteasome activities was performed as previously described.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Briefly, for the proteasome activity assay using purified human 20S proteasome (Boston Biochem: constitutive proteasome, Cat. No. E-360-050; immunoproteasome, Cat. No. E-370-025), 50 ng of diluted purified human 20S proteasomes in the 20S proteasome assay buffer (20 mM Tris–HCl, 0.5 mM EDTA, 0.035% SDS, pH 8.0) was transferred to a 96-well microtiter plate and incubated with eight concentrations of inhibitors (3, 10, 30, 100, 300, 1000, 3000, 10 000 nM) and control (DMSO only control) for 1 h. For the <i>in cellulo</i> proteasome activity assay using cells, cells were treated with proteasome inhibitors for 4 h and subsequently lysed using the passive lysis buffer (Promega). Cell lysates were centrifuged at 14 000<i>g</i> for 20 min at 4 °C. Cell lysates containing 5 μg of total protein (in 20S proteasome assay buffer; 20 mM Tris–HCl, 0.5 mM EDTA, 0.035% SDS, pH 8.0) were added to a 96-well microplate. To measure the proteasome subunit activity for purified proteasome or cell lysates, the fluorescence substrates were incubated, and fluorescence (360 nm excitation, 460 nm emission) was monitored on a SpectraMax M5 microplate reader every minute for 1 h. For individual proteasome subunit activity, the fluorescence substrates were used as follows: Suc-LLVY-AMC (CT-L activity, 100 μM), Ac-PAL-AMC (LMP2 activity, 100 μM), Ac-nLPnLD-AMC (β1 activity,100 μM), Ac-ANW-AMC (LMP7 activity, 100 μM), and Ac-WLA-AMC (β5 activity, 20 μM).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> <i>In Vitro</i> Metabolic Stability Assays</h3><div class="NLM_p last">The whole blood and the liver were collected from ICR mice (male, 7-week-old; DBL (Eumseong, Korea)). The whole blood was treated with 25 IU/mL heparin, and the liver was rinsed and homogenized in ice-cold phosphate-buffered saline (PBS, 2.5 mL/g tissue). Following preincubation at 37 °C, aliquots of whole blood or liver homogenates (396 μL) were mixed with the stock solutions of the test compounds (4 μL) to make the final concentration of 1 μM. From the reaction mixture, an aliquot (40 μL) was taken at the predetermined time points: 0, 10, and 30 min (for whole blood) and 0, 10, and 20 min (for liver homogenates). Samples were immediately mixed with acetonitrile (300 μL) containing 100 nM carfilzomib as an internal standard. After vortexing and centrifugation (13 000 rpm, 10 min, 4 °C), the supernatant’s drug levels were quantified via LC–MS/MS. Differences between the groups were assessed using Student’s <i>t</i>-test (GraphPad Prism, v.8.4.1), and <i>P</i> values less than 0.05 were considered statistically significant.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Quantitation of Drug Levels via LC–MS/MS</h3><div class="NLM_p last">YU102 and DB-60 (20) were quantified by an HPLC 1290 infinity II (Agilent, Palo Alto, CA) coupled to an Agilent 6460 triple quadrupole (Agilent, Palo Alto, CA) equipped with a Jet Stream Technology ion source interface operating in the positive ion mode. The chromatographic separation was performed on a Phenomenex Luna C18 column (50 mm × 2.0 mm id, 3 μm) with a mobile phase that consisted of 0.1% formic acid in water (A)–0.1% formic acid in acetonitrile (B) at a flow rate of 0.3 mL/min. The gradient is set up as follows: 0.5 min 85% A, 15% B; 3.5 min 100% B; 5.5 min 100% B; 5.6 min 85% A, 15% B; and 7.5 min 85% A, 15% B. The optimized parameters for the source-dependent mass spectrometry are as follows: gas temperature 325 °C; gas flow 11 L/min; nebulizing gas 35 psi; sheath gas flow 12 L/min; and capillary voltage 4500 V. The compound-dependent parameters, fragment voltage, collision energy (qualifier/quantifier), and cell accelerator voltage are set as follows: for YU102, 150, 25/20, and 4 V; for DB-60 (20), 176, 40/48, and 4 V; and for carfilzomib, 192, 29/29, and 4 V. Quantification was carried out in the selected reaction monitoring (SRM) mode using the following transition: for YU102, <i>m</i>/<i>z</i> 515.3 > 217.1 (qualifier), <i>m</i>/<i>z</i> 515.3 > 197.1 (quantifier); for DB-60 (20), <i>m</i>/<i>z</i> 590.3 > 260.2 (qualifier), <i>m</i>/<i>z</i> 590.3 > 70.2 (quantifier); and for carfilzomib, <i>m</i>/<i>z</i> 720.4 > 402.3 (qualifier), <i>m</i>/<i>z</i> 720.4 > 289.2 (qualifier). Linearity was verified in the following concentration ranges: for whole blood, 10–2500 nM; and for liver homogenates, 1–2000 nM.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> ABCG2 Interaction Assays</h3><div class="NLM_p last">The inhibitory interactions with ABCG2 were assessed by measuring the changes in the cellular accumulation of PhA (a fluorescent ABCG2 substrate) using MDCKII cells stably expressing ABCG2 (established in our previous study<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a>) and parental cells. The known ABCG2 inhibitor Ko143 was used as a positive control. Cells were preincubated in the complete medium containing pheophorbide A (1 μM) with Ko143 (0.2 μM) or DB-60 (20) (2 or 5 μM) at 37 °C for 30 min on a rotary shaker. Cells were then washed with an ice-cold medium and resuspended in the medium containing only Ko143 or DB-60 (20). After incubation for 45 min at 37 °C on a rotary shaker, cells were washed with 1 mL of ice-cold PBS containing 2% fetal bovine serum. After centrifugation, cell pellets were kept on ice until the fluorescent signal measurement via flow cytometry (FACSCalibur Flow Cytometry System, BD Biosciences, San Jose, CA) using the excitation and emission wavelengths of 635 and 670 nm, respectively.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Cytokine Enzyme-Linked Immunosorbent Assay (ELISA)</h3><div class="NLM_p last">This experiment was performed following a procedure reported previously by us.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Briefly, standards were diluted by seven serial twofold dilutions for the generation of a standard curve. Prepared standards and supernatants from BV-2 cells were incubated on a capture antibody-coated plate overnight at 4 °C. For IL-1α level measurement in Tg2576 mice serum, mouse serum samples were diluted 1:5 in the diluent before ELISA, and IL-1α standard and diluted serum samples were incubated at room temperature for 2 h. Then, the plates were washed five times with the washing solution. Next, a detection antibody was added and the plate was then incubated for 1 h, followed by the addition of avidin conjugated with horseradish peroxidase for 30 min. The plates were then washed five times and developed by adding substrate solution to each well, and afterward, the reaction was stopped by the addition of stop solution (2 N H<sub>2</sub>SO<sub>4</sub>). The absorbance at 450 nm wavelength was measured using a microplate reader.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Morris Water Maze Test</h3><div class="NLM_p last">The Morris water maze test was performed following a procedure described previously.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Briefly, the water inside a circular plastic pool was warmed at 25 ± 1 °C, and the escape platform was hidden 1–1.5 cm under the water level. The mice were released into the water with their head pointing to the pool wall and trained three times a day with randomized starting points over 5 days to promote the acquisition of the location of an escape platform in the pool (trial duration: 60 s). A camera was positioned directly above the center of the pool, which recorded the behaviors of mice. The video was analyzed, and the swimming speed, escape latency, and escape distance on every trial were calculated by the SMART-LD program (Panlab, Spain). A probe test was performed 24 h after the water maze test (i.e., day 6) to assess spatial memory consolidation based on the preference for the quadrant where the platform was placed. The swimming patterns of each mouse for 60 s were tracked and analyzed by the SMART-LD program.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Passive Avoidance</h3><div class="NLM_p last">As previously described by our group,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> the effects of proteasome inhibitors on learning and memory function in mice were evaluated using a step-through passive avoidance test. The passive avoidance test was performed 48 h after the probe test. A “step-through” apparatus (Med Associates Inc., Vermont) consists of two connected chambers (an illuminated chamber and a dark chamber) by a small gate. On the first day (i.e., day 7 of the behavior study), the mice were placed in the illuminated compartment facing away from the dark chamber for the learning trial. As soon as the mice entered the darkroom, they received a punishing electric shock (0.45 mA, 3 s duration). The testing trial was given 24 h after termination of the learning trial (i.e., day 8) using the same paradigm but without the electric shock. Each mouse was released in the lighted compartment, and the entrance latency until the mice re-entered the dark chamber was determined and defined as the step-through latency. The maximum latency time for entering the dark compartment was 120 s.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> RPE Flat Mounts</h3><div class="NLM_p last">RPE flat mounts were performed following the previously published protocols by our group.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Briefly, surgically isolated eyes of Tg2576 transgenic mice were first fixed in 4% paraformaldehyde for 1 h at room temperature. Next, anterior eyecups were dissected on ice-cold PBS, followed by the removal of the retina. The dissected RPE sheets were permeabilized with 0.2% Triton X-100 for 15 min and then blocked with 3% BSA for 1 h at room temperature. The sections were then incubated with β-catenin (1:100; Abcam, ab19381) overnight at 4 °C. After being rinsed in PBS containing 0.5% BSA, the tissues were incubated further with secondary antibodies coupled to Alexa 555 (1:1000; Invitrogen, A21422) for 2 h at room temperature and mounted. The RPE sheets were imaged using a confocal microscope (Carl Zeiss, LSM 800).</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Computational Docking</h3><div class="NLM_p last">AutoDock Vina was used to docking DB-310 into the atomic structure of mouse LMP2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNF">3UNF</a>).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> A 3D docking box of 30 Å width covering the ligand-binding site was used (for the PDB validation report, see the <a href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_001.pdf" class="ext-link">Supporting Information</a>). The highest-scoring, predicted ligand model, with the epoxyketone positioned near the N-terminal threonine for possible covalent interaction, was chosen for our investigations. The chosen model shows 95% calculated affinity compared to the highest-scoring model, with no covalent bond formation.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i84"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00291" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38461" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38461" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00291?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00291</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Proteasome catalytic subunit inhibition of DB-60 (<b>20</b>) in different cell lines; <sup>1</sup>H/<sup>13</sup>C NMR spectra of all macrocyclic compounds and HPLC elution profile of the lead compound DB-60 (<b>20</b>) (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Molecular docking models (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_003.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_001.pdf">jm1c00291_si_001.pdf (2.9 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_002.csv">jm1c00291_si_002.csv (2.22 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_003.pdb">jm1c00291_si_003.pdb (240.63 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00291" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68817" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68817" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jin Tae Hong</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy, Chungbuk National University, Cheongju, Chungbuk 28160, Republic of Korea</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b3d9daddc7dbdcddd4f3d0dbc6ddd4d1c6d89dd2d09dd8c1"><span class="__cf_email__" data-cfemail="f49e9d9a809c9b9a93b4979c819a9396819fda9597da9f86">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dong-Eun Kim</span> - <span class="hlFld-Affiliation affiliation">Department
of Bioscience and Biotechnology, Konkuk
University, Seoul 05029, Republic of Korea</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-6545-8387" title="Orcid link">https://orcid.org/0000-0001-6545-8387</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a4cfcdc9c0c1e4cfcbcacfd1cf8ac5c78acfd6"><span class="__cf_email__" data-cfemail="0c67656168694c676362677967226d6f22677e">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wooin Lee</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic
of Korea</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-7805-869X" title="Orcid link">https://orcid.org/0000-0001-7805-869X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#dbacb4b4b2b5f5b7bebe9ba8b5aef5bab8f5b0a9"><span class="__cf_email__" data-cfemail="8afde5e5e3e4a4e6efefcaf9e4ffa4ebe9a4e1f8">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kyung Bo Kim</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, University of
Kentucky, 789 South Limestone, Lexington, Kentucky 40536-0596, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-4744-2466" title="Orcid link">https://orcid.org/0000-0003-4744-2466</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5c373e3735316e1c29372572393829"><span class="__cf_email__" data-cfemail="d2b9b0b9bbbfe092a7b9abfcb7b6a7">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Min Jae Lee</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, University of
Kentucky, 789 South Limestone, Lexington, Kentucky 40536-0596, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deepak Bhattarai</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, University of
Kentucky, 789 South Limestone, Lexington, Kentucky 40536-0596, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hyeryung Jang</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic
of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ahreum Baek</span> - <span class="hlFld-Affiliation affiliation">Department
of Bioscience and Biotechnology, Konkuk
University, Seoul 05029, Republic of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">In Jun Yeo</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy, Chungbuk National University, Cheongju, Chungbuk 28160, Republic of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Seongsoo Lee</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic
of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zachary Miller</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, University of
Kentucky, 789 South Limestone, Lexington, Kentucky 40536-0596, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sukyeong Lee</span> - <span class="hlFld-Affiliation affiliation">Verna
and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas 77030, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>M.J.L. and D.B. contributed equally. K.B.K., D-E.K., S.L., W.L., and J.T.H. conceived the study, designed the experiments, and wrote the paper; D.B. (Schemes 1 and 2), M.J.L. (Table 1, Figures 3a, 4b, and 5c, and Supplementary Table 1), H.J. (Figures 3b and 4a), A.B. (Figure 6), Z.M. (Table 1), I.J.Y. (Figure 5a,b), and S.L. (Supplementary Tables 2 and 3) conducted experiments and acquired and analyzed the data. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e5231-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i86">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81654" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81654" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank the National Institutes of Health (R01 CA188354 to K.B.K. and R01 GM111084 to S.L.), the National Research Foundation of Korea (2017R1E1A1A01074656 to D-E.K. and MRC2017R A5A2015541 to J.T.H), and the Creative-Pioneering Researchers Program through Seoul National University (to W.L.) for financially supporting this work.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">Aβ</td><td class="NLM_def"><p class="first last">amyloid-β</p></td></tr><tr><td class="NLM_term">COX</td><td class="NLM_def"><p class="first last">cyclooxygenase</p></td></tr><tr><td class="NLM_term">TNF-α</td><td class="NLM_def"><p class="first last">tumor necrosis factor-α</p></td></tr><tr><td class="NLM_term">iP</td><td class="NLM_def"><p class="first last">immunoproteasome</p></td></tr><tr><td class="NLM_term">LMP2</td><td class="NLM_def"><p class="first last">low-molecular-mass polypeptide-2</p></td></tr><tr><td class="NLM_term">MECL-1</td><td class="NLM_def"><p class="first last">multicatalytic endopeptidase complex subunit-1</p></td></tr><tr><td class="NLM_term">LMP7</td><td class="NLM_def"><p class="first last">low-molecular-mass polypeptide-7</p></td></tr><tr><td class="NLM_term">RPE</td><td class="NLM_def"><p class="first last">retinal pigment epithelium</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">CT-L</td><td class="NLM_def"><p class="first last">chymotrypsin-like</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">lipopolysaccharide</p></td></tr><tr><td class="NLM_term">cP</td><td class="NLM_def"><p class="first last">constitutive proteasome</p></td></tr><tr><td class="NLM_term">AMD</td><td class="NLM_def"><p class="first last">age-related macular degeneration</p></td></tr><tr><td class="NLM_term">APP</td><td class="NLM_def"><p class="first last">amyloid precursor protein</p></td></tr><tr><td class="NLM_term">PhA</td><td class="NLM_def"><p class="first last">pheophorbide A</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i88">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37137" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37137" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 52 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yiannopoulou, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasiou, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachariou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelidou, S. H.</span></span> <span> </span><span class="NLM_article-title">Reasons for failed trials of disease-modifying treatments for Alzheimer disease and their contribution in recent research</span>. <i>Biomedicines</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">97</span> <span class="refDoi"> DOI: 10.3390/biomedicines7040097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.3390%2Fbiomedicines7040097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1SitLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&author=K.+G.+Yiannopoulouauthor=A.+I.+Anastasiouauthor=V.+Zachariouauthor=S.+H.+Pelidou&title=Reasons+for+failed+trials+of+disease-modifying+treatments+for+Alzheimer+disease+and+their+contribution+in+recent+research&doi=10.3390%2Fbiomedicines7040097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Reasons for failed trials of disease-modifying treatments for Alzheimer disease and their contribution in recent research</span></div><div class="casAuthors">Yiannopoulou, Konstantina G.; Anastasiou, Aikaterini I.; Zachariou, Venetia; Pelou, Sygkliti-Henrietta</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicines</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">97</span>CODEN:
                <span class="NLM_cas:coden">BIOMID</span>;
        ISSN:<span class="NLM_cas:issn">2227-9059</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The most probable explanations for failures of disease-modifying treatments (DMTs) for AD may include late initiation of treatments during the course of AD development, inappropriate drug dosages, erroneous selection of treatment targets, and mainly an inadequate understanding of the complex pathophysiol. of AD, which may necessitate combination treatments rather than monotherapy.  Drug-development research for AD is aimed to overcome these drawbacks.  Preclin. and prodromal AD populations, as well as traditionally investigated populations representing all the clin. stages of AD, are included in recent trials.  The application of amyloid, tau, and neurodegeneration biomarkers, including new biomarkers-such as Tau positron emission tomog., neurofilament light chain (blood and Cerebrospinal fluid (CSF) biomarker of axonal degeneration) and neurogranin (CSF biomarker of synaptic functioning)-to clin. trials allows more precise staging of AD.  Addnl., use of Bayesian statistics, modifiable clin. trial designs, and clin. trial simulators enrich the trial methodol.  Besides, combination therapy regimens are assessed in clin. trials.  The above-mentioned diagnostic and statistical advances, which have been recently integrated in clin. trials, are relevant to the recent failures of studies of disease-modifying treatments.  Their experiential rather than theor. origins may better equip potentially successful drug-development strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLyhykjjZkYrVg90H21EOLACvtfcHk0ljskgauoWJdEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1SitLbJ&md5=33a9c1d07f4ec3584a5dab2548c6448f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3390%2Fbiomedicines7040097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiomedicines7040097%26sid%3Dliteratum%253Aachs%26aulast%3DYiannopoulou%26aufirst%3DK.%2BG.%26aulast%3DAnastasiou%26aufirst%3DA.%2BI.%26aulast%3DZachariou%26aufirst%3DV.%26aulast%3DPelidou%26aufirst%3DS.%2BH.%26atitle%3DReasons%2520for%2520failed%2520trials%2520of%2520disease-modifying%2520treatments%2520for%2520Alzheimer%2520disease%2520and%2520their%2520contribution%2520in%2520recent%2520research%26jtitle%3DBiomedicines%26date%3D2019%26volume%3D7%26doi%3D10.3390%2Fbiomedicines7040097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtzman, D. M.</span></span> <span> </span><span class="NLM_article-title">Alzheimer disease: an update on pathobiology and treatment strategies</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2Fj.cell.2019.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=31564456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVylsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2019&pages=312-339&author=J.+M.+Longauthor=D.+M.+Holtzman&title=Alzheimer+disease%3A+an+update+on+pathobiology+and+treatment+strategies&doi=10.1016%2Fj.cell.2019.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer Disease: An Update on Pathobiology and Treatment Strategies</span></div><div class="casAuthors">Long, Justin M.; Holtzman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">312-339</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Alzheimer disease (AD) is a heterogeneous disease with a complex pathobiol.  The presence of extracellular β-amyloid deposition as neuritic plaques and intracellular accumulation of hyperphosphorylated tau as neurofibrillary tangles remains the primary neuropathol. criteria for AD diagnosis.  However, a no. of recent fundamental discoveries highlight important pathol. roles for other crit. cellular and mol. processes.  Despite this, no disease-modifying treatment currently exists, and numerous phase 3 clin. trials have failed to demonstrate benefits.  Here, we review recent advances in our understanding of AD pathobiol. and discuss current treatment strategies, highlighting recent clin. trials and opportunities for developing future disease-modifying therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIdXAv0NNRFbVg90H21EOLACvtfcHk0ljskgauoWJdEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVylsbrN&md5=b68edceb2c7ebe4515efded93c9281c3</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DJ.%2BM.%26aulast%3DHoltzman%26aufirst%3DD.%2BM.%26atitle%3DAlzheimer%2520disease%253A%2520an%2520update%2520on%2520pathobiology%2520and%2520treatment%2520strategies%26jtitle%3DCell%26date%3D2019%26volume%3D179%26spage%3D312%26epage%3D339%26doi%3D10.1016%2Fj.cell.2019.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blennow, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bateman, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinuevo, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touchon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellas, B.</span></span> <span> </span><span class="NLM_article-title">Anti-Tau trials for Alzheimer’s disease: a report from the EU/US/CTAD task force</span>. <i>J. Prev. Alzheimers Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.14283/jpad.2019.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.14283%2Fjpad.2019.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=31062825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BB3M7jtF2hsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=157-163&author=J.+Cummingsauthor=K.+Blennowauthor=K.+Johnsonauthor=M.+Keeleyauthor=R.+J.+Batemanauthor=J.+L.+Molinuevoauthor=J.+Touchonauthor=P.+Aisenauthor=B.+Vellas&title=Anti-Tau+trials+for+Alzheimer%E2%80%99s+disease%3A+a+report+from+the+EU%2FUS%2FCTAD+task+force&doi=10.14283%2Fjpad.2019.14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force</span></div><div class="casAuthors">Cummings J; Blennow K; Johnson K; Keeley M; Bateman R J; Molinuevo J L; Touchon J; Aisen P; Vellas B</div><div class="citationInfo"><span class="NLM_cas:title">The journal of prevention of Alzheimer's disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">157-163</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Efforts to develop effective disease-modifying treatments for Alzheimer's disease (AD) have mostly targeted the amyloid β (Aβ) protein; however, there has recently been increased interest in other targets including phosphorylated tau and other forms of tau.  Aggregated tau appears to spread in a characteristic pattern throughout the brain and is thought to drive neurodegeneration.  Both neuropathological and imaging studies indicate that tau first appears in the entorhinal cortex and then spreads to the neocortex.  Anti-tau therapies currently in Phase 1 or 2 trials include passive and active immunotherapies designed to prevent aggregation, seeding, and spreading, as well as small molecules that modulate tau metabolism and function.  EU/US/CTAD Task Force members support advancing the development of anti-tau therapies, which will require novel imaging agents and biomarkers, a deeper understanding of tau biology and the dynamic interaction of tau and Aβ protein, and development of multiple targets and candidate agents addressing the tauopathy of AD.  Incorporating tau biomarkers in AD clinical trials will provide additional knowledge about the potential to treat AD by targeting tau.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZi0VtAauolAMthz5_Rx5rfW6udTcc2eYFxMiqPmin_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7jtF2hsw%253D%253D&md5=47291042d489a89979f46cae42d06179</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.14283%2Fjpad.2019.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14283%252Fjpad.2019.14%26sid%3Dliteratum%253Aachs%26aulast%3DCummings%26aufirst%3DJ.%26aulast%3DBlennow%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DKeeley%26aufirst%3DM.%26aulast%3DBateman%26aufirst%3DR.%2BJ.%26aulast%3DMolinuevo%26aufirst%3DJ.%2BL.%26aulast%3DTouchon%26aufirst%3DJ.%26aulast%3DAisen%26aufirst%3DP.%26aulast%3DVellas%26aufirst%3DB.%26atitle%3DAnti-Tau%2520trials%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520a%2520report%2520from%2520the%2520EU%252FUS%252FCTAD%2520task%2520force%26jtitle%3DJ.%2520Prev.%2520Alzheimers%2520Dis.%26date%3D2019%26volume%3D6%26spage%3D157%26epage%3D163%26doi%3D10.14283%2Fjpad.2019.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Congdon, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigurdsson, E. M.</span></span> <span> </span><span class="NLM_article-title">Tau-targeting therapies for Alzheimer’s disease</span>. <i>Nat. Rev. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">399</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.1038/s41582-018-0013-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1038%2Fs41582-018-0013-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=29895964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFaks73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=399-415&author=E.+E.+Congdonauthor=E.+M.+Sigurdsson&title=Tau-targeting+therapies+for+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fs41582-018-0013-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Tau-targeting therapies for Alzheimer disease</span></div><div class="casAuthors">Congdon, Erin E.; Sigurdsson, Einar M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neurology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">399-415</span>CODEN:
                <span class="NLM_cas:coden">NRNACP</span>;
        ISSN:<span class="NLM_cas:issn">1759-4758</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Alzheimer disease (AD) is the most common form of dementia.  Pathol., AD is characterized by amyloid plaques and neurofibrillary tangles in the brain, with assocd. loss of synapses and neurons, resulting in cognitive deficits and eventually dementia.  Amyloid-β (Aβ) peptide and tau protein are the primary components of the plaques and tangles, resp.  In the decades since Aβ and tau were identified, development of therapies for AD has primarily focused on Aβ, but tau has received more attention in recent years, in part because of the failure of various Aβ-targeting treatments in clin. trials.  In this article, we review the current status of tau-targeting therapies for AD.  Initially, potential anti-tau therapies were based mainly on inhibition of kinases or tau aggregation, or on stabilization of microtubules, but most of these approaches have been discontinued because of toxicity and/or lack of efficacy.  Currently, the majority of tau-targeting therapies in clin. trials are immunotherapies, which have shown promise in numerous preclin. studies.  Given that tau pathol. correlates better with cognitive impairments than do Aβ lesions, targeting of tau is expected to be more effective than Aβ clearance once the clin. symptoms are evident.  With future improvements in diagnostics, these two hallmarks of the disease might be targeted prophylactically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT0IYIr5ElmbVg90H21EOLACvtfcHk0lhT8xjh-JM0Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFaks73M&md5=d26350964814206ce4860b7256c9d6a0</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fs41582-018-0013-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41582-018-0013-z%26sid%3Dliteratum%253Aachs%26aulast%3DCongdon%26aufirst%3DE.%2BE.%26aulast%3DSigurdsson%26aufirst%3DE.%2BM.%26atitle%3DTau-targeting%2520therapies%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2018%26volume%3D14%26spage%3D399%26epage%3D415%26doi%3D10.1038%2Fs41582-018-0013-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGeer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGeer, E. G.</span></span> <span> </span><span class="NLM_article-title">Inflammation, anti-inflammatory agents, and Alzheimer’s disease: the last 22 years</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">853</span>– <span class="NLM_lpage">857</span>, <span class="refDoi"> DOI: 10.3233/JAD-160488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.3233%2FJAD-160488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=27716676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BC2svotFGisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2016&pages=853-857&author=P.+L.+McGeerauthor=J.+Rogersauthor=E.+G.+McGeer&title=Inflammation%2C+anti-inflammatory+agents%2C+and+Alzheimer%E2%80%99s+disease%3A+the+last+22+years&doi=10.3233%2FJAD-160488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation, Antiinflammatory Agents, and Alzheimer's Disease: The Last 22 Years</span></div><div class="casAuthors">McGeer Patrick L; McGeer Edith G; Rogers Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's disease : JAD</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">853-857</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Two basic discoveries spurred research into inflammation as a driving force in the pathogenesis of Alzheimer's disease (AD).  The first was the identification of activated microglia in association with the lesions.  The second was the discovery that rheumatoid arthritics, who regularly consume anti-inflammatory agents, were relatively spared from the disease.  These findings led to an exploration of the inflammatory pathways that were involved in AD pathogenesis.  A pivotal advance was the discovery that amyloid-β protein (Aβ) activated the complement system.  This focused attention on anti-inflammatories as blockers of complement activation.  More than 15 epidemiological studies have since showed a sparing effect of non-steroidal anti-inflammatory drugs (NSAIDs) in AD.  A consistent finding has been that the longer the NSAIDs were used prior to clinical diagnosis, the greater the sparing effect.  The reason has since emerged from studies of biomarkers such as amyloid-β (Aβ) levels in the cerebrospinal fluid and Aβ deposits in brain.  They have established that the onset of AD commences at least a decade before cognitive decline permits clinical diagnosis.  Such biomarker studies have revealed that a huge window of opportunity exists when application of NSAIDs, other anti-inflammatory agents, or complement activation blockers, could arrest further progress of AD, thus eliminating its manifestation.  It can be anticipated that this principle will apply to many other chronic neurodegenerative diseases.  Neuroinflammation, discovered in AD more than 30 years ago, has now become a major field of brain research today.  Inhibiting it may be the key to successful treatment of many chronic neurological disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSzdOKynCN-UwlCcfExbvbfW6udTcc2ebayr2ANHH1M7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svotFGisg%253D%253D&md5=19d0eb6e39ba2b52a35e93e6e92bdee3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.3233%2FJAD-160488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-160488%26sid%3Dliteratum%253Aachs%26aulast%3DMcGeer%26aufirst%3DP.%2BL.%26aulast%3DRogers%26aufirst%3DJ.%26aulast%3DMcGeer%26aufirst%3DE.%2BG.%26atitle%3DInflammation%252C%2520anti-inflammatory%2520agents%252C%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520the%2520last%252022%2520years%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2016%26volume%3D54%26spage%3D853%26epage%3D857%26doi%3D10.3233%2FJAD-160488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellmann-Regen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costantini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reale, M.</span></span> <span> </span><span class="NLM_article-title">Neuroinflammation and Alzheimer’s disease: implications for microglial activation</span>. <i>Curr. Alzheimer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1140</span>– <span class="NLM_lpage">1148</span>, <span class="refDoi"> DOI: 10.2174/1567205014666170203141717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.2174%2F1567205014666170203141717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=28164764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BC1c3jsVKmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=1140-1148&author=F.+Regenauthor=J.+Hellmann-Regenauthor=E.+Costantiniauthor=M.+Reale&title=Neuroinflammation+and+Alzheimer%E2%80%99s+disease%3A+implications+for+microglial+activation&doi=10.2174%2F1567205014666170203141717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroinflammation and Alzheimer's Disease: Implications for Microglial Activation</span></div><div class="casAuthors">Regen Francesca; Hellmann-Regen Julian; Costantini Erica; Reale Marcella</div><div class="citationInfo"><span class="NLM_cas:title">Current Alzheimer research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1140-1148</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Microglial activation is a hallmark of neuroinflammation, seen in most acute and chronic neuropsychiatric conditions.  With growing knowledge about microglia functions in surveying the brain for alterations, microglial activation is increasingly discussed in the context of disease progression and pathogenesis of Alzheimer's disease (AD).  Underlying molecular mechanisms, however, remain largely unclear.  While proper microglial function is essentially required for its scavenging duties, local activation of the brain's innate immune cells also brings about many less advantageous changes, such as reactive oxygen species (ROS) production, secretion of proinflammatory cytokines or degradation of neuroprotective retinoids, and may thus unnecessarily put surrounding healthy neurons in danger.  In view of this dilemma, it is little surprising that both, AD vaccination trials, and also immunosuppressive strategies have consistently failed in AD patients.  Nevertheless, epidemiological evidence has suggested a protective effect for anti-inflammatory agents, supporting the hypothesis that key processes involved in the pathogenesis of AD may take place rather early in the time course of the disorder, likely long before memory impairment becomes clinically evident.  Activation of microglia results in a severely altered microenvironment.  This is not only caused by the plethora of secreted cytokines, chemokines or ROS, but may also involve increased turnover of neuroprotective endogenous substances such as retinoic acid (RA), as recently shown in vitro.  RESULTS:  We discuss findings linking microglial activation and AD and speculate that microglial malfunction, which brings about changes in local RA concentrations in vitro, may underlie AD pathogenesis and precede or facilitate the onset of AD.  Thus, chronic, "innate neuroinflammation" may provide a valuable target for preventive and therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR4-i3dKE7hx11C8OJBvdfbfW6udTcc2ebayr2ANHH1M7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3jsVKmsg%253D%253D&md5=0d790b9dfcb91be9eaa10ea0d31ce020</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2174%2F1567205014666170203141717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1567205014666170203141717%26sid%3Dliteratum%253Aachs%26aulast%3DRegen%26aufirst%3DF.%26aulast%3DHellmann-Regen%26aufirst%3DJ.%26aulast%3DCostantini%26aufirst%3DE.%26aulast%3DReale%26aufirst%3DM.%26atitle%3DNeuroinflammation%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520implications%2520for%2520microglial%2520activation%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2017%26volume%3D14%26spage%3D1140%26epage%3D1148%26doi%3D10.2174%2F1567205014666170203141717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liddelow, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guttenplan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirmer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munch, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilton, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frouin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napier, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panicker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckwalter, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowitch, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barres, B. A.</span></span> <span> </span><span class="NLM_article-title">Neurotoxic reactive astrocytes are induced by activated microglia</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>541</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1038/nature21029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1038%2Fnature21029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=28099414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Olt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=541&publication_year=2017&pages=481-487&author=S.+A.+Liddelowauthor=K.+A.+Guttenplanauthor=L.+E.+Clarkeauthor=F.+C.+Bennettauthor=C.+J.+Bohlenauthor=L.+Schirmerauthor=M.+L.+Bennettauthor=A.+E.+Munchauthor=W.+S.+Chungauthor=T.+C.+Petersonauthor=D.+K.+Wiltonauthor=A.+Frouinauthor=B.+A.+Napierauthor=N.+Panickerauthor=M.+Kumarauthor=M.+S.+Buckwalterauthor=D.+H.+Rowitchauthor=V.+L.+Dawsonauthor=T.+M.+Dawsonauthor=B.+Stevensauthor=B.+A.+Barres&title=Neurotoxic+reactive+astrocytes+are+induced+by+activated+microglia&doi=10.1038%2Fnature21029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotoxic reactive astrocytes are induced by activated microglia</span></div><div class="casAuthors">Liddelow, Shane A.; Guttenplan, Kevin A.; Clarke, Laura E.; Bennett, Frederick C.; Bohlen, Christopher J.; Schirmer, Lucas; Bennett, Mariko L.; Munch, Alexandra E.; Chung, Won-Suk; Peterson, Todd C.; Wilton, Daniel K.; Frouin, Arnaud; Napier, Brooke A.; Panicker, Nikhil; Kumar, Manoj; Buckwalter, Marion S.; Rowitch, David H.; Dawson, Valina L.; Dawson, Ted M.; Stevens, Beth; Barres, Ben A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">541</span>
        (<span class="NLM_cas:issue">7638</span>),
    <span class="NLM_cas:pages">481-487</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reactive astrocytes are strongly induced by central nervous system (CNS) injury and disease, but their role is poorly understood.  Here we show that a subtype of reactive astrocytes, which we termed A1, is induced by classically activated neuroinflammatory microglia.  We show that activated microglia induce A1 astrocytes by secreting Il-1α, TNF and C1q, and that these cytokines together are necessary and sufficient to induce A1 astrocytes.  A1 astrocytes lose the ability to promote neuronal survival, outgrowth, synaptogenesis and phagocytosis, and induce the death of neurons and oligodendrocytes.  Death of axotomized CNS neurons in vivo is prevented when the formation of A1 astrocytes is blocked.  Finally, we show that A1 astrocytes are abundant in various human neurodegenerative diseases including Alzheimer's, Huntington's and Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis.  Taken together these findings help to explain why CNS neurons die after axotomy, strongly suggest that A1 astrocytes contribute to the death of neurons and oligodendrocytes in neurodegenerative disorders, and provide opportunities for the development of new treatments for these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh7e-6d68IirVg90H21EOLACvtfcHk0lhzDzespKObgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Olt74%253D&md5=bec380f741ffc971ec2072b6acaa301b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature21029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature21029%26sid%3Dliteratum%253Aachs%26aulast%3DLiddelow%26aufirst%3DS.%2BA.%26aulast%3DGuttenplan%26aufirst%3DK.%2BA.%26aulast%3DClarke%26aufirst%3DL.%2BE.%26aulast%3DBennett%26aufirst%3DF.%2BC.%26aulast%3DBohlen%26aufirst%3DC.%2BJ.%26aulast%3DSchirmer%26aufirst%3DL.%26aulast%3DBennett%26aufirst%3DM.%2BL.%26aulast%3DMunch%26aufirst%3DA.%2BE.%26aulast%3DChung%26aufirst%3DW.%2BS.%26aulast%3DPeterson%26aufirst%3DT.%2BC.%26aulast%3DWilton%26aufirst%3DD.%2BK.%26aulast%3DFrouin%26aufirst%3DA.%26aulast%3DNapier%26aufirst%3DB.%2BA.%26aulast%3DPanicker%26aufirst%3DN.%26aulast%3DKumar%26aufirst%3DM.%26aulast%3DBuckwalter%26aufirst%3DM.%2BS.%26aulast%3DRowitch%26aufirst%3DD.%2BH.%26aulast%3DDawson%26aufirst%3DV.%2BL.%26aulast%3DDawson%26aufirst%3DT.%2BM.%26aulast%3DStevens%26aufirst%3DB.%26aulast%3DBarres%26aufirst%3DB.%2BA.%26atitle%3DNeurotoxic%2520reactive%2520astrocytes%2520are%2520induced%2520by%2520activated%2520microglia%26jtitle%3DNature%26date%3D2017%26volume%3D541%26spage%3D481%26epage%3D487%26doi%3D10.1038%2Fnature21029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ising, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venegas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiblich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieira-Saecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albasset, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McManus, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tejera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griep, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosseron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stunden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golenbock, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heneka, M. T.</span></span> <span> </span><span class="NLM_article-title">NLRP3 inflammasome activation drives tau pathology</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>575</i></span>,  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1038/s41586-019-1769-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1038%2Fs41586-019-1769-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=31748742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitF2qt7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=575&publication_year=2019&pages=669-673&author=C.+Isingauthor=C.+Venegasauthor=S.+Zhangauthor=H.+Scheiblichauthor=S.+V.+Schmidtauthor=A.+Vieira-Saeckerauthor=S.+Schwartzauthor=S.+Albassetauthor=R.+M.+McManusauthor=D.+Tejeraauthor=A.+Griepauthor=F.+Santarelliauthor=F.+Brosseronauthor=S.+Opitzauthor=J.+Stundenauthor=M.+Mertenauthor=R.+Kayedauthor=D.+T.+Golenbockauthor=D.+Blumauthor=E.+Latzauthor=L.+Bueeauthor=M.+T.+Heneka&title=NLRP3+inflammasome+activation+drives+tau+pathology&doi=10.1038%2Fs41586-019-1769-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">NLRP3 inflammasome activation drives tau pathology</span></div><div class="casAuthors">Ising, Christina; Venegas, Carmen; Zhang, Shuangshuang; Scheiblich, Hannah; Schmidt, Susanne V.; Vieira-Saecker, Ana; Schwartz, Stephanie; Albasset, Shadi; McManus, Roisin M.; Tejera, Dario; Griep, Angelika; Santarelli, Francesco; Brosseron, Frederic; Opitz, Sabine; Stunden, James; Merten, Maximilian; Kayed, Rakez; Golenbock, Douglas T.; Blum, David; Latz, Eicke; Buee, Luc; Heneka, Michael T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">575</span>
        (<span class="NLM_cas:issue">7784</span>),
    <span class="NLM_cas:pages">669-673</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Alzheimer's disease is characterized by the accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together resulting in neurodegeneration and cognitive decline1.  The inflammasome inflammasome assembles inside of microglia on activation, leading to increased cleavage and activity of caspase-1 and downstream interleukin-1β release2.  Although the NLRP3 inflammasome has been shown to be essential for the development and progression of amyloid-beta pathol. in mice3, the precise effect on tau pathol. remains unknown.  Here we show that loss of NLRP3 inflammasome function reduced tau hyperphosphorylation and aggregation by regulating tau kinases and phosphatases.  Tau activated the NLRP3 inflammasome and intracerebral injection of fibrillar amyloid-beta-contg. brain homogenates induced tau pathol. in an NLRP3-dependent manner.  These data identify an important role of microglia and NLRP3 inflammasome activation in the pathogenesis of tauopathies and support the amyloid-cascade hypothesis in Alzheimer's disease, demonstrating that neurofibrillary tangles develop downstream of amyloid-beta-induced microglial activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCaPXz72o9VrVg90H21EOLACvtfcHk0lhzDzespKObgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitF2qt7nE&md5=efd69ac9ce47699e362679c7c39265cc</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1769-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1769-z%26sid%3Dliteratum%253Aachs%26aulast%3DIsing%26aufirst%3DC.%26aulast%3DVenegas%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DScheiblich%26aufirst%3DH.%26aulast%3DSchmidt%26aufirst%3DS.%2BV.%26aulast%3DVieira-Saecker%26aufirst%3DA.%26aulast%3DSchwartz%26aufirst%3DS.%26aulast%3DAlbasset%26aufirst%3DS.%26aulast%3DMcManus%26aufirst%3DR.%2BM.%26aulast%3DTejera%26aufirst%3DD.%26aulast%3DGriep%26aufirst%3DA.%26aulast%3DSantarelli%26aufirst%3DF.%26aulast%3DBrosseron%26aufirst%3DF.%26aulast%3DOpitz%26aufirst%3DS.%26aulast%3DStunden%26aufirst%3DJ.%26aulast%3DMerten%26aufirst%3DM.%26aulast%3DKayed%26aufirst%3DR.%26aulast%3DGolenbock%26aufirst%3DD.%2BT.%26aulast%3DBlum%26aufirst%3DD.%26aulast%3DLatz%26aufirst%3DE.%26aulast%3DBuee%26aufirst%3DL.%26aulast%3DHeneka%26aufirst%3DM.%2BT.%26atitle%3DNLRP3%2520inflammasome%2520activation%2520drives%2520tau%2520pathology%26jtitle%3DNature%26date%3D2019%26volume%3D575%26spage%3D669%26epage%3D673%26doi%3D10.1038%2Fs41586-019-1769-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrivastav, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span> <span> </span><span class="NLM_article-title">Role of traditional nonsteroidal anti-inflammatory drugs in Alzheimer’s disease: a meta-analysis of randomized clinical trials</span>. <i>Am. J. Alzheimer’s Dis. Other Demen.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1177/1533317514542644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1177%2F1533317514542644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=25024454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BC2cbitFCrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2015&pages=178-182&author=P.+P.+Guptaauthor=R.+D.+Pandeyauthor=D.+Jhaauthor=V.+Shrivastavauthor=S.+Kumar&title=Role+of+traditional+nonsteroidal+anti-inflammatory+drugs+in+Alzheimer%E2%80%99s+disease%3A+a+meta-analysis+of+randomized+clinical+trials&doi=10.1177%2F1533317514542644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Role of traditional nonsteroidal anti-inflammatory drugs in Alzheimer's disease: a meta-analysis of randomized clinical trials</span></div><div class="casAuthors">Gupta Prem Prakash; Pandey Rishabh Dev; Jha Diwakar; Kumar Sandeep; Shrivastav Vikesh</div><div class="citationInfo"><span class="NLM_cas:title">American journal of Alzheimer's disease and other dementias</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The role of nonsteroidal anti-inflammatory drugs (NSAIDs) in prevention of Alzheimer's disease (AD) has been evaluated in many studies.  We performed a meta-analysis to summarize the existing evidence on the relation between use of classical NSAIDs and AD.  Randomized controlled trials (RCTs) evaluating the role of classical NSAIDs in AD was searched using different search engines.  The RCTs in patients who had the degree of AD measured on Mini-Mental State Examination (MMSE) or AD Assessment Scale-Cognitive subscale (ADAS-cog) were included in the study.  The RCTs and data (AD scores) were independently assessed by 2 reviewers, and data were included in meta-analysis only after a common consensus was reached.  The pooled results from the ADAS-cog and MMSE scores failed to show any difference between the treatment and the placebo groups as opposed to findings from some observational studies.  However, in view of heterogeneity of results, there is a need to conduct more RCTs to arrive at confirmatory findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR1kKqxjE0_lkNoizSOkG_FfW6udTcc2eZqP92vZ7-3Mbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbitFCrtg%253D%253D&md5=3e43f088e91631b405437d6aa737c0a9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1177%2F1533317514542644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1533317514542644%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DP.%2BP.%26aulast%3DPandey%26aufirst%3DR.%2BD.%26aulast%3DJha%26aufirst%3DD.%26aulast%3DShrivastav%26aufirst%3DV.%26aulast%3DKumar%26aufirst%3DS.%26atitle%3DRole%2520of%2520traditional%2520nonsteroidal%2520anti-inflammatory%2520drugs%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520a%2520meta-analysis%2520of%2520randomized%2520clinical%2520trials%26jtitle%3DAm.%2520J.%2520Alzheimer%25E2%2580%2599s%2520Dis.%2520Other%2520Demen.%26date%3D2015%26volume%3D30%26spage%3D178%26epage%3D182%26doi%3D10.1177%2F1533317514542644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chou, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghimire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gui, J.</span></span> <span> </span><span class="NLM_article-title">Treatment for rheumatoid arthritis and risk of Alzheimer’s disease: a nested case-control analysis</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1111</span>– <span class="NLM_lpage">1120</span>, <span class="refDoi"> DOI: 10.1007/s40263-016-0374-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1007%2Fs40263-016-0374-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=27470609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlWgur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=1111-1120&author=R.+C.+Chouauthor=M.+Kaneauthor=S.+Ghimireauthor=S.+Gautamauthor=J.+Gui&title=Treatment+for+rheumatoid+arthritis+and+risk+of+Alzheimer%E2%80%99s+disease%3A+a+nested+case-control+analysis&doi=10.1007%2Fs40263-016-0374-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment for Rheumatoid Arthritis and Risk of Alzheimer's Disease: A Nested Case-Control Analysis</span></div><div class="casAuthors">Chou, Richard C.; Kane, Michael; Ghimire, Sanjay; Gautam, Shiva; Gui, Jiang</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1111-1120</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Introduction: It is increasingly becoming accepted that inflammation may play an important role in the pathogenesis of Alzheimer's disease (AD), as several immune-related genes have been assocd. with AD.  Among these is tumor necrosis factor (TNF)-α, a proinflammatory cytokine known to play an important role in autoimmune disorders, including rheumatoid arthritis (RA).  Although AD and RA appear to involve similar pathol. mechanisms through the prodn. of TNF-α, the relationship between AD and RA remains unknown.  Objective: To det. the relative risk of AD among RA patients and non-RA patients, and whether anti-TNF therapy for RA was assocd. with a lower risk of AD in RA patients.  Methods: We performed a nested case-control study of more than 8.5 million com. insured adults (aged ≥18 years) in all 50 US states, Puerto Rico, and US Virgin Islands in the Verisk Health claims database.  We derived a sub-cohort of subjects with a diagnosis of RA (controls), or RA and AD (cases), matching cases and controls based on age, sex, exposure assessment period, and methotrexate treatment.  We also assessed relative risk of AD following exposure to std. RA therapies, including anti-TNF agents (infliximab, adalimumab, etanercept), methotrexate, prednisone, sulfasalazine, and rituximab.  Odds ratios were adjusted for comorbidities, including coronary artery disease, diabetes mellitus, and peripheral vascular disease.  Results: AD was more prevalent (p < 0.0001) among RA patients (0.79 %) than among those without RA (0.11 %).  Chronic conditions such as coronary artery disease (odds ratio [OR] 1.48; 95 % confidence interval [CI] 1.04-2.05; p = 0.03), diabetes (OR 1.86; 95 % CI 1.32-2.62; p = 0.0004), and peripheral vascular disease (OR 1.61; 95 % CI 1.06-2.43; p = 0.02) significantly increased the relative risk of AD among RA patients.  Exposure to anti-TNF agents as a class, but not other immunosuppressive drugs studied, was assocd. with lowered risk of AD among RA patients (unadjusted OR 0.44; 95 % CI 0.22-0.87; p = 0.02; adjusted OR 0.45; 95 % CI 0.23-0.90; p = 0.02).  Sub-group anal. demonstrated that of the three anti-TNF agents studied, only etanercept (unadjusted OR, 0.33; 95 % CI 0.08-0.94; p = 0.03; adjusted OR 0.30; 95 % CI 0.08-0.89; p = 0.02) was assocd. with a decreased risk of AD in RA patients.  Conclusion: There is an increased risk of AD in the studied RA population.  The relative risk of AD among RA subjects was lowered in those exposed to etanercept.  Anti-TNF therapy with etanercept shows promise as a potential treatment for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-UEOUpHXZ87Vg90H21EOLACvtfcHk0lirr0whfEo6Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlWgur7J&md5=7497cb4bf98a3725cf5a2b7e6da9264f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs40263-016-0374-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-016-0374-z%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DR.%2BC.%26aulast%3DKane%26aufirst%3DM.%26aulast%3DGhimire%26aufirst%3DS.%26aulast%3DGautam%26aufirst%3DS.%26aulast%3DGui%26aufirst%3DJ.%26atitle%3DTreatment%2520for%2520rheumatoid%2520arthritis%2520and%2520risk%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520a%2520nested%2520case-control%2520analysis%26jtitle%3DCNS%2520Drugs%26date%3D2016%26volume%3D30%26spage%3D1111%26epage%3D1120%26doi%3D10.1007%2Fs40263-016-0374-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Group, A. D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellwood, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hills, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crome, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raftery, J.</span></span> <span> </span><span class="NLM_article-title">Aspirin in Alzheimer’s disease (AD2000): a randomised open-label trial</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(07)70293-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2FS1474-4422%2807%2970293-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=18068522" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=41-49&author=A.+D.+C.+Groupauthor=P.+Benthamauthor=R.+Grayauthor=E.+Sellwoodauthor=R.+Hillsauthor=P.+Cromeauthor=J.+Raftery&title=Aspirin+in+Alzheimer%E2%80%99s+disease+%28AD2000%29%3A+a+randomised+open-label+trial&doi=10.1016%2FS1474-4422%2807%2970293-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2807%2970293-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252807%252970293-4%26sid%3Dliteratum%253Aachs%26aulast%3DGroup%26aufirst%3DA.%2BD.%2BC.%26aulast%3DBentham%26aufirst%3DP.%26aulast%3DGray%26aufirst%3DR.%26aulast%3DSellwood%26aufirst%3DE.%26aulast%3DHills%26aufirst%3DR.%26aulast%3DCrome%26aufirst%3DP.%26aulast%3DRaftery%26aufirst%3DJ.%26atitle%3DAspirin%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520%2528AD2000%2529%253A%2520a%2520randomised%2520open-label%2520trial%26jtitle%3DLancet%2520Neurol.%26date%3D2008%26volume%3D7%26spage%3D41%26epage%3D49%26doi%3D10.1016%2FS1474-4422%2807%2970293-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">The
Alzheimer’s Disease Anti-inflammatory Prevention Trial Research
Group</span> <span> </span><span class="NLM_article-title">Results of a follow-up
study to the randomized Alzheimer’s disease anti-inflammatory
prevention trial (ADAPT)</span>. <i>Alzheimer’s
Dementia</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">714</span>– <span class="NLM_lpage">723</span>, <span class="refDoi"> DOI: 10.1016/j.jalz.2012.11.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2Fj.jalz.2012.11.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=23562431" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=714-723&author=The%0AAlzheimer%E2%80%99s+Disease+Anti-inflammatory+Prevention+Trial+Research%0AGroup&title=Results+of+a+follow-up%0Astudy+to+the+randomized+Alzheimer%E2%80%99s+disease+anti-inflammatory%0Aprevention+trial+%28ADAPT%29&doi=10.1016%2Fj.jalz.2012.11.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2012.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2012.11.012%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DResults%2520of%2520a%2520follow-up%250Astudy%2520to%2520the%2520randomized%2520Alzheimer%25E2%2580%2599s%2520disease%2520anti-inflammatory%250Aprevention%2520trial%2520%2528ADAPT%2529%26jtitle%3DAlzheimer%25E2%2580%2599s%250ADementia%26date%3D2013%26volume%3D9%26spage%3D714%26epage%3D723%26doi%3D10.1016%2Fj.jalz.2012.11.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the immunoproteasome: current status and future directions</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4140</span>– <span class="NLM_lpage">4151</span>, <span class="refDoi"> DOI: 10.2174/1381612811319220018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.2174%2F1381612811319220018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=23181576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslyrtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4140-4151&author=Z.+Millerauthor=L.+Aoauthor=K.+B.+Kimauthor=W.+Lee&title=Inhibitors+of+the+immunoproteasome%3A+current+status+and+future+directions&doi=10.2174%2F1381612811319220018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the immunoproteasome: current status and future directions</span></div><div class="casAuthors">Miller, Zachary; Ao, Lin; Kim, Kyung Bo; Lee, Wooin</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4140-4151</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome system (UPS) plays a vital role in maintaining protein homeostasis and regulating numerous cellular processes.  The proteasome, a multi-protease complex, is the key component of the UPS and has been validated as a therapeutic target by the FDA's approval of bortezomib and carfilzomib.  These proteasome inhibitor drugs have substantially improved outcomes in patients with hematol. malignancies and are currently being investigated for other types of cancer as well as several other diseases.  These approved proteasome inhibitors target the catalytic activity of both the constitutive proteasome and the immunoproteasome indiscriminately, and their inhibitory effects on the constitutive proteasome in normal cells are believed to contribute to unwanted side effects.  In addn., selective immunoproteasome inhibition has been proposed to have unique effects on other diseases, including those involving aberrant immune function.  Initially recognized for its role in the adaptive immune response, the immunoproteasome is often upregulated in disease states such as inflammatory diseases and cancer, suggesting functions beyond antigen presentation.  In an effort to explore the immunoproteasome as a potential therapeutic target in these diseases, the development of immunoproteasome-specific inhibitors has become the focus of recent studies.  Owing to considerable efforts by both academic and industry groups, immunoproteasome-selective inhibitors have now been identified and tested against several disease models.  These inhibitors also provide a valuable set of chem. tools for investigating the biol. function of the immunoproteasome.  In this review, we will focus on the recent efforts towards the development of immunoproteasome-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiaZ1chVK_KrVg90H21EOLACvtfcHk0lirr0whfEo6Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslyrtrc%253D&md5=597fa7cdfee60647d64bad55a2bb0672</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F1381612811319220018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612811319220018%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DZ.%26aulast%3DAo%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DLee%26aufirst%3DW.%26atitle%3DInhibitors%2520of%2520the%2520immunoproteasome%253A%2520current%2520status%2520and%2520future%2520directions%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26spage%3D4140%26epage%3D4151%26doi%3D10.2174%2F1381612811319220018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">The immunoproteasome: a novel drug target for autoimmune diseases</span>. <i>Clin. Exp. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">S74</span>– <span class="NLM_lpage">S79</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=26458097" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=S74-S79&author=M.+Baslerauthor=S.+Mundtauthor=A.+Bitzerauthor=C.+Schmidtauthor=M.+Groettrup&title=The+immunoproteasome%3A+a+novel+drug+target+for+autoimmune+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DMundt%26aufirst%3DS.%26aulast%3DBitzer%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DC.%26aulast%3DGroettrup%26aufirst%3DM.%26atitle%3DThe%2520immunoproteasome%253A%2520a%2520novel%2520drug%2520target%2520for%2520autoimmune%2520diseases%26jtitle%3DClin.%2520Exp.%2520Rheumatol.%26date%3D2015%26volume%3D33%26spage%3DS74%26epage%3DS79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogorevc, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffrer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobec, S.</span></span> <span> </span><span class="NLM_article-title">A patent review of immunoproteasome inhibitors</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1080/13543776.2018.1484904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1080%2F13543776.2018.1484904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=29865878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFelsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=517-540&author=E.+Ogorevcauthor=E.+S.+Schiffrerauthor=I.+Sosicauthor=S.+Gobec&title=A+patent+review+of+immunoproteasome+inhibitors&doi=10.1080%2F13543776.2018.1484904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A patent review of immunoproteasome inhibitors</span></div><div class="casAuthors">Ogorevc, Eva; Schiffrer, Eva Shannon; Sosic, Izidor; Gobec, Stanislav</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">517-540</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome system is responsible for maintaining protein homeostasis and regulating a variety of cellular processes.  The constitutive proteasome is expressed in all cells while the immunoproteasome (IP) is predominantly found in cells of hematopoietic origin.  In other cells, the expression of IP can be induced under the influence of cytokines released by T cells during acute immune and stress responses.  Inhibitors of IP are of significant interest, because it is expected that selective inhibition of the IP would cause fewer adverse effects.  There is a considerable interest on patenting IP-specific inhibitors.  We also briefly report on the biochem. methods used in the patents to profile the characteristics of IP inhibitors.  Several selective inhibitors of IP with a promising ability to address autoimmune and inflammatory diseases are being developed.  Peptidic compds. are prevalent and the most advanced IP-selective compds. to date, ONX-0914 and KZR-616, are tripeptide epoxyketone-based mols.  However, some patents disclose that IP-selective inhibition is possible with compds. possessing non-peptidic scaffolds indicating countless possibilities to address inhibition of IP in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0dJE7LZsDw7Vg90H21EOLACvtfcHk0ljoZmXMff3QAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFelsLnL&md5=1cbc997fb71e37c456548601b977e15f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1080%2F13543776.2018.1484904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2018.1484904%26sid%3Dliteratum%253Aachs%26aulast%3DOgorevc%26aufirst%3DE.%26aulast%3DSchiffrer%26aufirst%3DE.%2BS.%26aulast%3DSosic%26aufirst%3DI.%26aulast%3DGobec%26aufirst%3DS.%26atitle%3DA%2520patent%2520review%2520of%2520immunoproteasome%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2018%26volume%3D28%26spage%3D517%26epage%3D540%26doi%3D10.1080%2F13543776.2018.1484904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, H. W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderl, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D. L.</span></span> <span> </span><span class="NLM_article-title">A required immunoproteasome subunit inhibition profile for anti-inflammatory efficacy and clinical candidate KZR-616 ((2S,3R)-N-((S)-3-(cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2 -yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)pr openamide)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">11127</span>– <span class="NLM_lpage">11143</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVKltLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=11127-11143&author=H.+W.+B.+Johnsonauthor=E.+Loweauthor=J.+L.+Anderlauthor=A.+Fanauthor=T.+Muchamuelauthor=S.+Bowersauthor=D.+Moebiusauthor=C.+Kirkauthor=D.+L.+McMinn&title=A+required+immunoproteasome+subunit+inhibition+profile+for+anti-inflammatory+efficacy+and+clinical+candidate+KZR-616+%28%282S%2C3R%29-N-%28%28S%29-3-%28cyclopent-1-en-1-yl%29-1-%28%28R%29-2-methyloxiran-2-yl%29-1-oxopropan-2+-yl%29-3-hydroxy-3-%284-methoxyphenyl%29-2-%28%28S%29-2-%282-morpholinoacetamido%29propanamido%29pr+openamide%29&doi=10.1021%2Facs.jmedchem.8b01201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)</span></div><div class="casAuthors">Johnson, Henry W. B.; Lowe, Eric; Anderl, Janet L.; Fan, Andrea; Muchamuel, Tony; Bowers, Simeon; Moebius, David C.; Kirk, Christopher; McMinn, Dustin L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11127-11143</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective immunoproteasome inhibition is a promising approach for treating autoimmune disorders, but optimal proteolytic active site subunit inhibition profiles remain unknown.  We reveal here our design of peptide epoxyketone-based selective low mol. mass polypeptide-7 (LMP7) and multicatalytic endopeptidase complex subunit-1 (MECL-1) subunit inhibitors.  Utilizing these and our previously disclosed low mol. mass polypeptide-2 (LMP2) inhibitor, we demonstrate a requirement of dual LMP7/LMP2 or LMP7/MECL-1 subunit inhibition profiles for potent cytokine expression inhibition and in vivo efficacy in an inflammatory disease model.  These and addnl. findings toward optimized soly. led the design and selection of KZR-616 disclosed here and presently in clin. trials for treatment of rheumatic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNq1pg3kpVXrVg90H21EOLACvtfcHk0ljoZmXMff3QAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVKltLfF&md5=70170b636fbb858edda5f571af45ca7f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01201%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DH.%2BW.%2BB.%26aulast%3DLowe%26aufirst%3DE.%26aulast%3DAnderl%26aufirst%3DJ.%2BL.%26aulast%3DFan%26aufirst%3DA.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DBowers%26aufirst%3DS.%26aulast%3DMoebius%26aufirst%3DD.%26aulast%3DKirk%26aufirst%3DC.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26atitle%3DA%2520required%2520immunoproteasome%2520subunit%2520inhibition%2520profile%2520for%2520anti-inflammatory%2520efficacy%2520and%2520clinical%2520candidate%2520KZR-616%2520%2528%25282S%252C3R%2529-N-%2528%2528S%2529-3-%2528cyclopent-1-en-1-yl%2529-1-%2528%2528R%2529-2-methyloxiran-2-yl%2529-1-oxopropan-2%2520-yl%2529-3-hydroxy-3-%25284-methoxyphenyl%2529-2-%2528%2528S%2529-2-%25282-morpholinoacetamido%2529propanamido%2529pr%2520openamide%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D11127%26epage%3D11143%26doi%3D10.1021%2Facs.jmedchem.8b01201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamphuis, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooves, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kooijman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimayuga Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hol, E. M.</span></span> <span> </span><span class="NLM_article-title">Reactive glia show increased immunoproteasome activity in Alzheimer’s disease</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">1415</span>– <span class="NLM_lpage">1431</span>, <span class="refDoi"> DOI: 10.1093/brain/awt083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1093%2Fbrain%2Fawt083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=23604491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BC3srmvFaisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2013&pages=1415-1431&author=M.+Orreauthor=W.+Kamphuisauthor=S.+Doovesauthor=L.+Kooijmanauthor=E.+T.+Chanauthor=C.+J.+Kirkauthor=V.+Dimayuga+Smithauthor=S.+Kootauthor=C.+Mamberauthor=A.+H.+Jansenauthor=H.+Ovaaauthor=E.+M.+Hol&title=Reactive+glia+show+increased+immunoproteasome+activity+in+Alzheimer%E2%80%99s+disease&doi=10.1093%2Fbrain%2Fawt083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive glia show increased immunoproteasome activity in Alzheimer's disease</span></div><div class="casAuthors">Orre Marie; Kamphuis Willem; Dooves Stephanie; Kooijman Lieneke; Chan Elena T; Kirk Christopher J; Dimayuga Smith Vanessa; Koot Sanne; Mamber Carlyn; Jansen Anne H; Ovaa Huib; Hol Elly M</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">Pt 5</span>),
    <span class="NLM_cas:pages">1415-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The proteasome is the major protein degradation system within the cell, comprised of different proteolytic subunits; amyloid-β is thought to impair its activity in Alzheimer's disease.  Neuroinflammation is a prominent hallmark of Alzheimer's disease, which may implicate an activation of the immunoproteasome, a specific proteasome variant induced by immune signalling that holds slightly different proteolytic properties than the constitutive proteasome.  Using a novel cell-permeable proteasome activity probe, we found that amyloid-β enhances proteasome activity in glial and neuronal cultures.  Additionally, using a subunit-specific proteasome activity assay we showed that in the cortex of the APPswePS1dE9 plaque pathology mouse model, immunoproteasome activities were strongly increased together with increased messenger RNA and protein expression in reactive glia surrounding plaques.  Importantly, this elevated activity was confirmed in human post-mortem tissue from donors with Alzheimer's disease.  These findings are in contrast with earlier studies, which reported impairment of proteasome activity in human Alzheimer's disease tissue and mouse models.  Targeting the increased immunoproteasome activity with a specific inhibitor resulted in a decreased expression of inflammatory markers in ex vivo microglia.  This may serve as a potential novel approach to modulate sustained neuroinflammation and glial dysfunction associated with Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtUv1o7ovLKYYPsCkJIw00fW6udTcc2eZ8CVBbmppUSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srmvFaisg%253D%253D&md5=8ae273c3ca26fd107d41a141afa4e0ef</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawt083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawt083%26sid%3Dliteratum%253Aachs%26aulast%3DOrre%26aufirst%3DM.%26aulast%3DKamphuis%26aufirst%3DW.%26aulast%3DDooves%26aufirst%3DS.%26aulast%3DKooijman%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DE.%2BT.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DDimayuga%2BSmith%26aufirst%3DV.%26aulast%3DKoot%26aufirst%3DS.%26aulast%3DMamber%26aufirst%3DC.%26aulast%3DJansen%26aufirst%3DA.%2BH.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DHol%26aufirst%3DE.%2BM.%26atitle%3DReactive%2520glia%2520show%2520increased%2520immunoproteasome%2520activity%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBrain%26date%3D2013%26volume%3D136%26spage%3D1415%26epage%3D1431%26doi%3D10.1093%2Fbrain%2Fawt083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mishto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellavista, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolzing, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligorio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacmias, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spazzafumo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiappelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licastro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorbi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pession, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grune, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, C.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome and LMP2 polymorphism in aged and Alzheimer’s disease brains</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2004.12.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2Fj.neurobiolaging.2004.12.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=16298241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1egsr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=54-66&author=M.+Mishtoauthor=E.+Bellavistaauthor=A.+Santoroauthor=A.+Stolzingauthor=C.+Ligorioauthor=B.+Nacmiasauthor=L.+Spazzafumoauthor=M.+Chiappelliauthor=F.+Licastroauthor=S.+Sorbiauthor=A.+Pessionauthor=T.+Ohmauthor=T.+Gruneauthor=C.+Franceschi&title=Immunoproteasome+and+LMP2+polymorphism+in+aged+and+Alzheimer%E2%80%99s+disease+brains&doi=10.1016%2Fj.neurobiolaging.2004.12.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains</span></div><div class="casAuthors">Mishto, Michele; Bellavista, Elena; Santoro, Aurelia; Stolzing, Alexandra; Ligorio, Claudia; Nacmias, Benedetta; Spazzafumo, Liana; Chiappelli, Martina; Licastro, Federico; Sorbi, Sandro; Pession, Annalisa; Ohm, Thomas; Grune, Tilman; Franceschi, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-66</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In this study, we investigated the presence and role of immunoproteasome and its LMP2 subunit polymorphism at codon 60 in Alzheimer's disease (AD).  Immunoproteasome was present in brain areas such as hippocampus and cerebellum and localized in neurons, astrocytes and endothelial cells.  A higher expression of immunoproteasome was found in brain of AD patients than in brain of non-demented elderly, being its expression in young brain negligible or absent.  Furthermore, AD affected regions showed a partial decrease in proteasome trypsin-like activity.  The study of LMP2 polymorphism (R/H) showed that it does not influence LMP2 expression (neither the mRNA nor mature protein) in brain tissue.  However, control brain areas of AD patients carrying the RR genotype showed an increased proteasome activity in comparison with RH carriers.  To test whether this effect of the genotype might be related to AD onset we performed a genetic study, which allowed us to exclude an assocn. of LMP2 codon 60 polymorphism with AD onset, despite its influence on the proteasome activity in human brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBR5TJqY4-frVg90H21EOLACvtfcHk0lhHBN0-laFA0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1egsr3E&md5=cb7aeff396023f3fcfd6664e775b2c06</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2004.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2004.12.004%26sid%3Dliteratum%253Aachs%26aulast%3DMishto%26aufirst%3DM.%26aulast%3DBellavista%26aufirst%3DE.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DStolzing%26aufirst%3DA.%26aulast%3DLigorio%26aufirst%3DC.%26aulast%3DNacmias%26aufirst%3DB.%26aulast%3DSpazzafumo%26aufirst%3DL.%26aulast%3DChiappelli%26aufirst%3DM.%26aulast%3DLicastro%26aufirst%3DF.%26aulast%3DSorbi%26aufirst%3DS.%26aulast%3DPession%26aufirst%3DA.%26aulast%3DOhm%26aufirst%3DT.%26aulast%3DGrune%26aufirst%3DT.%26aulast%3DFranceschi%26aufirst%3DC.%26atitle%3DImmunoproteasome%2520and%2520LMP2%2520polymorphism%2520in%2520aged%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%2520brains%26jtitle%3DNeurobiol.%2520Aging%26date%3D2006%26volume%3D27%26spage%3D54%26epage%3D66%26doi%3D10.1016%2Fj.neurobiolaging.2004.12.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mishto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonafe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvioli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, C.</span></span> <span> </span><span class="NLM_article-title">Age dependent impact of LMP polymorphisms on TNF-alpha-induced apoptosis in human peripheral blood mononuclear cells</span>. <i>Exp. Gerontol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1016/S0531-5565(01)00196-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2FS0531-5565%2801%2900196-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=11772516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BD38XitlGn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2002&pages=301-308&author=M.+Mishtoauthor=M.+Bonafeauthor=S.+Salvioliauthor=F.+Olivieriauthor=C.+Franceschi&title=Age+dependent+impact+of+LMP+polymorphisms+on+TNF-alpha-induced+apoptosis+in+human+peripheral+blood+mononuclear+cells&doi=10.1016%2FS0531-5565%2801%2900196-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Age dependent impact of LMP polymorphisms on TNFα-induced apoptosis in human peripheral blood mononuclear cells</span></div><div class="casAuthors">Mishto, M.; Bonafe, M.; Salvioli, S.; Olivieri, F.; Franceschi, C.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Gerontology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">301-308</span>CODEN:
                <span class="NLM_cas:coden">EXGEAB</span>;
        ISSN:<span class="NLM_cas:issn">0531-5565</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">As a consequence of inflammatory stimuli (such as TNFα and IFNγ), some constitutive subunits of the proteasome, the principal mediator of nonlysosomal protein degrdn., are replaced with other subunits, the large multifunctional proteases LMP2 and LMP7, thus originating the immunoproteasome.  An age-related alteration of proteasome activity and susceptibility to TNFα-induced apoptosis, in which LMP2 and the nuclear factor (NF)-κB activation play an important role has been recently reported.  In this paper, we investigated the possible influence of two LMP2 and LMP7 polymorphisms on susceptibility to TNFα-induced apoptosis.  Our data show that an increase in susceptibility to TNFα-induced apoptosis is evident in long-lived people (aged >88 yr) in comparison to young individuals.  Moreover, the modulation of LMP2 codon 60 polymorphism on TNFα-induced apoptosis is evident in long-lived subjects.  Genotyping of 311 young people and 157 nonagenarians and centenarians revealed no changes in LMP2 codon 60 genotype frequency distribution.  No correlation with TNFα-induced apoptosis and no difference in frequency between young people and nonagenarians/centenarians was obsd. when the LMP7 nucleotide 145 polymorphism was studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryPeO3AGCLR7Vg90H21EOLACvtfcHk0lh-dM0JUpp3QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitlGn&md5=f4fbae49fa294f53b0cf204f2bf9d2e7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0531-5565%2801%2900196-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0531-5565%252801%252900196-6%26sid%3Dliteratum%253Aachs%26aulast%3DMishto%26aufirst%3DM.%26aulast%3DBonafe%26aufirst%3DM.%26aulast%3DSalvioli%26aufirst%3DS.%26aulast%3DOlivieri%26aufirst%3DF.%26aulast%3DFranceschi%26aufirst%3DC.%26atitle%3DAge%2520dependent%2520impact%2520of%2520LMP%2520polymorphisms%2520on%2520TNF-alpha-induced%2520apoptosis%2520in%2520human%2520peripheral%2520blood%2520mononuclear%2520cells%26jtitle%3DExp.%2520Gerontol.%26date%3D2002%26volume%3D37%26spage%3D301%26epage%3D308%26doi%3D10.1016%2FS0531-5565%2801%2900196-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilling, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schormann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloetzel, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prokop, S.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome deficiency alters microglial cytokine response and improves cognitive deficits in Alzheimer’s disease-like APPPS1 mice</span>. <i>Acta Neuropathol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">52</span> <span class="refDoi"> DOI: 10.1186/s40478-017-0453-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1186%2Fs40478-017-0453-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=28646899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvF2qt7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&author=L.+K.+Wagnerauthor=K.+E.+Gillingauthor=E.+Schormannauthor=P.+M.+Kloetzelauthor=F.+L.+Heppnerauthor=E.+Krugerauthor=S.+Prokop&title=Immunoproteasome+deficiency+alters+microglial+cytokine+response+and+improves+cognitive+deficits+in+Alzheimer%E2%80%99s+disease-like+APPPS1+mice&doi=10.1186%2Fs40478-017-0453-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasome deficiency alters microglial cytokine response and improves cognitive deficits in Alzheimer's disease-like APPPS1 mice</span></div><div class="casAuthors">Wagner, Lisa K.; Gilling, Kate E.; Schormann, Eileen; Kloetzel, Peter M.; Heppner, Frank L.; Krueger, Elke; Prokop, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neuropathologica Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">52/1-52/16</span>CODEN:
                <span class="NLM_cas:coden">ANCCC9</span>;
        ISSN:<span class="NLM_cas:issn">2051-5960</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The immunoproteasome (iP) represents a specialized type of proteasomes, which plays an important role in the clearance of oxidant-damaged proteins under inflammatory and pathol. conditions detg. the outcome of various diseases.  In Alzheimer's disease (AD)-like APPPS1 mice Aβ-deposition is paralleled by iP upregulation,most likely mediated through type I interferon induction.  To define the impact of increased iP expression we crossed APPPS1 mice with mice deficient in the iP subunit LMP7 resulting in impaired iP function.  While LMP7 deficient APPPS1 mice showed no major change in cerebral Aβ-pathol., we obsd. an altered cytokine response in microglia isolated from LMP7 deficient APPPS1 mice compared to LMP7 expressing APPPS1 control mice.  The altered microglial cytokine profile upon iP deficiency in the presence of extracellular Aβ-pathol. was assocd. with an improvement of Aβ-assocd. cognitive deficits typically present in APPPS1 mice.  Our findings suggest a role for iP in the regulation of the innate immune response towards extracellular Aβ-pathol. and indicate that inhibition of iP function can modulate the cognitive phenotype upon overexpression of Aβ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9-Es2yxPY3LVg90H21EOLACvtfcHk0lh-dM0JUpp3QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvF2qt7vI&md5=4de0d34ef2bf87269cf1c26d6ec11052</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1186%2Fs40478-017-0453-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40478-017-0453-5%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DL.%2BK.%26aulast%3DGilling%26aufirst%3DK.%2BE.%26aulast%3DSchormann%26aufirst%3DE.%26aulast%3DKloetzel%26aufirst%3DP.%2BM.%26aulast%3DHeppner%26aufirst%3DF.%2BL.%26aulast%3DKruger%26aufirst%3DE.%26aulast%3DProkop%26aufirst%3DS.%26atitle%3DImmunoproteasome%2520deficiency%2520alters%2520microglial%2520cytokine%2520response%2520and%2520improves%2520cognitive%2520deficits%2520in%2520Alzheimer%25E2%2580%2599s%2520disease-like%2520APPPS1%2520mice%26jtitle%3DActa%2520Neuropathol.%2520Commun.%26date%3D2017%26volume%3D5%26doi%3D10.1186%2Fs40478-017-0453-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abera, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viollet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yauger, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukumar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgard, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, B. G.</span></span> <span> </span><span class="NLM_article-title">The role of the immunoproteasome in interferon-gamma-mediated microglial activation</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">9365</span> <span class="refDoi"> DOI: 10.1038/s41598-017-09715-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1038%2Fs41598-017-09715-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=28839214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BC1cbhsVOjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&author=K.+E.+Moritzauthor=N.+M.+McCormackauthor=M.+B.+Aberaauthor=C.+Violletauthor=Y.+J.+Yaugerauthor=G.+Sukumarauthor=C.+L.+Dalgardauthor=B.+G.+Burnett&title=The+role+of+the+immunoproteasome+in+interferon-gamma-mediated+microglial+activation&doi=10.1038%2Fs41598-017-09715-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the immunoproteasome in interferon-γ-mediated microglial activation</span></div><div class="casAuthors">Moritz Kasey E; McCormack Nikki M; Yauger Young J; Dalgard Clifton L; Burnett Barrington G; Abera Mahlet B; Dalgard Clifton L; Burnett Barrington G; Viollet Coralie; Sukumar Gauthaman; Dalgard Clifton L; Dalgard Clifton L</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9365</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Microglia regulate the brain microenvironment by sensing damage and neutralizing potentially harmful insults.  Disruption of central nervous system (CNS) homeostasis results in transition of microglia to a reactive state characterized by morphological changes and production of cytokines to prevent further damage to CNS tissue.  Immunoproteasome levels are elevated in activated microglia in models of stroke, infection and traumatic brain injury, though the exact role of the immunoproteasome in neuropathology remains poorly defined.  Using gene expression analysis and native gel electrophoresis we characterize the expression and assembly of the immunoproteasome in microglia following interferon-gamma exposure.  Transcriptome analysis suggests that the immunoproteasome regulates multiple features of microglial activation including nitric oxide production and phagocytosis.  We show that inhibiting the immunoproteasome attenuates expression of pro-inflammatory cytokines and suppresses interferon-gamma-dependent priming of microglia.  These results imply that targeting immunoproteasome function following CNS injury may attenuate select microglial activity to improve the pathophysiology of neurodegenerative conditions or the progress of inflammation-mediated secondary injury following neurotrauma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxLyW0tp5b8BFwe7cAcrfPfW6udTcc2eYi0HzWIuG2Hbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbhsVOjuw%253D%253D&md5=b514ee91f5ca276a7cdbad97d458eed5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-09715-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-09715-y%26sid%3Dliteratum%253Aachs%26aulast%3DMoritz%26aufirst%3DK.%2BE.%26aulast%3DMcCormack%26aufirst%3DN.%2BM.%26aulast%3DAbera%26aufirst%3DM.%2BB.%26aulast%3DViollet%26aufirst%3DC.%26aulast%3DYauger%26aufirst%3DY.%2BJ.%26aulast%3DSukumar%26aufirst%3DG.%26aulast%3DDalgard%26aufirst%3DC.%2BL.%26aulast%3DBurnett%26aufirst%3DB.%2BG.%26atitle%3DThe%2520role%2520of%2520the%2520immunoproteasome%2520in%2520interferon-gamma-mediated%2520microglial%2520activation%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26doi%3D10.1038%2Fs41598-017-09715-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer’s disease</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">18393</span> <span class="refDoi"> DOI: 10.1038/s41598-019-54846-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1038%2Fs41598-019-54846-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=31804556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGhsrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&author=I.+J.+Yeoauthor=M.+J.+Leeauthor=A.+Baekauthor=Z.+Millerauthor=D.+Bhattaraiauthor=Y.+M.+Baekauthor=H.+J.+Jeongauthor=Y.+K.+Kimauthor=D.+E.+Kimauthor=J.+T.+Hongauthor=K.+B.+Kim&title=A+dual+inhibitor+of+the+proteasome+catalytic+subunits+LMP2+and+Y+attenuates+disease+progression+in+mouse+models+of+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fs41598-019-54846-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer's disease</span></div><div class="casAuthors">Yeo, In Jun; Lee, Min Jae; Baek, Ahruem; Miller, Zachary; Bhattarai, Deepak; Baek, Yu Mi; Jeong, Hyun Jung; Kim, Yun Kyung; Kim, Dong-Eun; Hong, Jin Tae; Kim, Kyung Bo</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18393</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The immunoproteasome (iP) is a variant of the constitutive proteasome (cP) that is abundantly expressed in immune cells which can also be induced in somatic cells by cytokines such as TNF-a or IFN-κ.  Accumulating evidence support that the iP is closely linked to multiple facets of inflammatory response, eventually leading to the development of several iP inhibitors as potential therapeutic agents for autoimmune diseases.  Recent studies also found that the iP is upregulated in reactive glial cells surrounding amyloid β (Aβ) deposits in brains of Alzheimer's disease (AD) patients, but the role it plays in the pathogenesis of AD remains unclear.  In this study, we investigated the effects of several proteasome inhibitors on cognitive function in AD mouse models and found that YU102, a dual inhibitor of the iP catalytic subunit LMP2 and the cP catalytic subunit Y, ameliorates cognitive impairments in AD mouse models without affecting Aβ deposition.  The data obtained from our investigation revealed that YU102 suppresses the secretion of inflammatory cytokines from microglial cells.  Overall, this study indicates that there may exist a potential link between LMP2/Y and microglia-mediated neuroinflammation and that inhibition of these subunits may offer a new therapeutic strategy for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQXqRAKDBNL7Vg90H21EOLACvtfcHk0li2oiqM2SLiVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGhsrvM&md5=67f2deacfc69d76c76ca9334f70d1a75</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-54846-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-54846-z%26sid%3Dliteratum%253Aachs%26aulast%3DYeo%26aufirst%3DI.%2BJ.%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DBaek%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DZ.%26aulast%3DBhattarai%26aufirst%3DD.%26aulast%3DBaek%26aufirst%3DY.%2BM.%26aulast%3DJeong%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DY.%2BK.%26aulast%3DKim%26aufirst%3DD.%2BE.%26aulast%3DHong%26aufirst%3DJ.%2BT.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DA%2520dual%2520inhibitor%2520of%2520the%2520proteasome%2520catalytic%2520subunits%2520LMP2%2520and%2520Y%2520attenuates%2520disease%2520progression%2520in%2520mouse%2520models%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26doi%3D10.1038%2Fs41598-019-54846-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">LMP2 inhibitors as a potential treatment for Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3763</span>– <span class="NLM_lpage">3783</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00416</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00416" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlt1Cktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3763-3783&author=D.+Bhattaraiauthor=M.+J.+Leeauthor=A.+Baekauthor=I.+J.+Yeoauthor=Z.+Millerauthor=Y.+M.+Baekauthor=S.+Leeauthor=D.+E.+Kimauthor=J.+T.+Hongauthor=K.+B.+Kim&title=LMP2+inhibitors+as+a+potential+treatment+for+Alzheimer%E2%80%99s+disease&doi=10.1021%2Facs.jmedchem.0c00416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">LMP2 Inhibitors as a Potential Treatment for Alzheimer's Disease</span></div><div class="casAuthors">Bhattarai, Deepak; Lee, Min Jae; Baek, Ahruem; Yeo, In Jun; Miller, Zachary; Baek, Yu Mi; Lee, Sukyeong; Kim, Dong-Eun; Hong, Jin Tae; Kim, Kyung Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3763-3783</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The immunoproteasome (iP), an inducible proteasome variant harboring three immunosubunits, low mol. mass polypeptide-2 (LMP2), multicatalytic endopeptidase complex subunit-1, and low mol. mass polypeptide-7 (LMP7), is involved in multiple facets of inflammatory responses.  We recently reported that YU102, a dual inhibitor of the iP subunit LMP2 and the constitutive proteasome catalytic subunit β1, ameliorates cognitive impairments in mouse models of Alzheimer's disease (AD) independently of amyloid deposits.  To investigate whether inhibition of LMP2 is sufficient to improve the cognitive functions of AD mice, here we prepd. 37 YU102 analogs and identified a potent LMP2 inhibitor DB-310 (28) (IC50: 80.6 nM) with improved selectivity and permeability in cells overexpressing ABCB1 transporters.  We show that DB-310 induces suppression of IL-1α prodn. in microglia cells and improves cognitive functions in the Tg2576 transgenic mouse model of AD.  This study supports that inhibition of LMP2 is a promising therapeutic strategy for treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWVF7Wt9HxE7Vg90H21EOLACvtfcHk0li2oiqM2SLiVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlt1Cktb8%253D&md5=6b2ae19d692a78b2a7654a0ef713431a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00416%26sid%3Dliteratum%253Aachs%26aulast%3DBhattarai%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DBaek%26aufirst%3DA.%26aulast%3DYeo%26aufirst%3DI.%2BJ.%26aulast%3DMiller%26aufirst%3DZ.%26aulast%3DBaek%26aufirst%3DY.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DD.%2BE.%26aulast%3DHong%26aufirst%3DJ.%2BT.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DLMP2%2520inhibitors%2520as%2520a%2520potential%2520treatment%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D3763%26epage%3D3783%26doi%3D10.1021%2Facs.jmedchem.0c00416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leng, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span> <span> </span><span class="NLM_article-title">Amyloid beta deposition related retinal pigment epithelium cell impairment and subretinal microglia activation in aged APPswePS1 transgenic mice</span>. <i>Int. J. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">747</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.18240/ijo.2018.05.06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.18240%2Fijo.2018.05.06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=29862171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BC1MbjtlSmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=747-755&author=Z.+Z.+Dongauthor=J.+Liauthor=Y.+F.+Ganauthor=X.+R.+Sunauthor=Y.+X.+Lengauthor=J.+Ge&title=Amyloid+beta+deposition+related+retinal+pigment+epithelium+cell+impairment+and+subretinal+microglia+activation+in+aged+APPswePS1+transgenic+mice&doi=10.18240%2Fijo.2018.05.06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid beta deposition related retinal pigment epithelium cell impairment and subretinal microglia activation in aged APPswePS1 transgenic mice</span></div><div class="casAuthors">Dong Zhi-Zhang; Gan Yi-Feng; Li Juan; Sun Xue-Rong; Leng Yun-Xia; Ge Jian</div><div class="citationInfo"><span class="NLM_cas:title">International journal of ophthalmology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">747-755</span>
        ISSN:<span class="NLM_cas:issn">2222-3959</span>.
    </div><div class="casAbstract">AIM:  To identify the pathological role of amyloid beta (Aβ) deposition in retinal degeneration, and explore Aβ deposition on the retinal pigment epithelium cells (RPE) layer and the associated structural and functional changes in Alzheimer's disease transgenic mice.  METHODS:  RPE changes in the eyes of APPswe/PS1 transgenic and none transgenic (NTG) mice over 20 months old were examined.  Histological changes were investigated via hematoxylin and eosin (H&E) staining and transmission electron microscopy (TEM) examination, whereas the expression of amyloid precursor protein (APP), Aβ, Zonula occludens-1 (ZO-1) and Ionized calcium binding adaptor molecule-1 (IBA-1) were investigated using immunohistochemistry and immunofluorescence techniques.  All of the obtained results were quantitatively and statistically analyzed.  RESULTS:  In aged transgenic mice, an APP-positive immunoreaction and Aβ deposition were detected on the RPE layer but were undetectable in NTG mice.  The RPE demonstrated some vacuole changes, shortened basal infoldings and basal deposition in histopathological examination and TEM tests, wherein irregular shapes were indicated by ZO-1 disorganization through fluorescence.  Furthermore, IBA-1 positive cells were observed to have accumulated and infiltrated into the RPE layer and localized beneath the RPE/Bruch's membrane (BrM) complex, which was accompanied by an increase in BrM thickness in aged transgenic mice in comparison to NTG mice.  The IBA-1 positive cells were found to be co-stained with Aβ deposition on the RPE flat mounts.  CONCLUSION:  The observed Aβ deposition in the RPE layer may cause RPE dysfunction, which is associated with microglia cells infiltration into the retina of aged transgenic mice, suggesting that Aβ deposition probably plays a significant role in RPE-related degenerative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxwXYefhgNVMRAV4D_Ins_fW6udTcc2eaiFMsZUm2US7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbjtlSmsA%253D%253D&md5=34e785ee9252caa8648c2d4e901a0a3b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.18240%2Fijo.2018.05.06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18240%252Fijo.2018.05.06%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DZ.%2BZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGan%26aufirst%3DY.%2BF.%26aulast%3DSun%26aufirst%3DX.%2BR.%26aulast%3DLeng%26aufirst%3DY.%2BX.%26aulast%3DGe%26aufirst%3DJ.%26atitle%3DAmyloid%2520beta%2520deposition%2520related%2520retinal%2520pigment%2520epithelium%2520cell%2520impairment%2520and%2520subretinal%2520microglia%2520activation%2520in%2520aged%2520APPswePS1%2520transgenic%2520mice%26jtitle%3DInt.%2520J.%2520Ophthalmol.%26date%3D2018%26volume%3D11%26spage%3D747%26epage%3D755%26doi%3D10.18240%2Fijo.2018.05.06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumayag, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mufson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span> <span> </span><span class="NLM_article-title">Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer’s disease</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">800</span>, <span class="refDoi"> DOI: 10.1167/iovs.08-2384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1167%2Fiovs.08-2384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=18791173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252Fps1Ggsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=793-800&author=S.+E.+Perezauthor=S.+Lumayagauthor=B.+Kovacsauthor=E.+J.+Mufsonauthor=S.+Xu&title=Beta-amyloid+deposition+and+functional+impairment+in+the+retina+of+the+APPswe%2FPS1DeltaE9+transgenic+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.1167%2Fiovs.08-2384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer's disease</span></div><div class="casAuthors">Perez Sylvia E; Lumayag Stephen; Kovacs Beatrix; Mufson Elliott J; Xu Shunbin</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">793-800</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  To determine whether beta-amyloid (Abeta) deposition affects the structure and function of the retina of the APPswe/PS1DeltaE9 transgenic (tg) mouse model of Alzheimer's disease.  METHODS:  Retinas from 12- to 19-month old APPswe/PS1DeltaE9 tg and age-matched non-transgenic (ntg) littermates were single or double stained with thioflavine-S and antibodies against Abeta, glial fibrillar acidic protein (GFAP), microglial marker F4/80, choline acetyltransferase (ChAT), and syntaxin 1.  Quantification of thioflavine-S positive plaques and retinal layer thickness was analyzed semi-quantitatively, whereas microglial cell size and levels of F4/80 immunoreactivity were evaluated using a densitometry program.  Scotopic electroretinogram (ERG) recording was used to investigate retinal physiology in these mice.  RESULTS:  Thioflavine-S positive plaques appeared at 12 months in the retinas of APPswe/PS1DeltaE9 tg mice with the majority of plaques in the outer and inner plexiform layers.  Plaques were embedded in the inner plexiform layer strata displaying syntaxin 1 and ChAT.  The number and size of the plaques in the retina increased with age.  Plaques appeared earlier and in greater numbers in females than in male tg littermate mice.  Microglial activity was significantly increased in the retinas of APPswe/PS1DeltaE9 tg mice.  Although we did not detect neuronal degeneration in the retina, ERG recordings revealed a significant reduction in the amplitudes of a- and b-waves in aged APPswe/PS1DeltaE9 tg compared to ntg littermates.  CONCLUSIONS:  The present findings suggest that Abeta deposition disrupts retinal structure and may contribute to the visual deficits seen in aged APPswe/PS1DeltaE9 tg mice.  Whether Abeta is involved in other forms of age-related retinal dysfunction is unclear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTzVOs-3djhcDDnmmyUf5qOfW6udTcc2ebwXZF7u11Zvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252Fps1Ggsw%253D%253D&md5=bbfd261e70fcc3d4b9dd42a4765510d7</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1167%2Fiovs.08-2384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.08-2384%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DS.%2BE.%26aulast%3DLumayag%26aufirst%3DS.%26aulast%3DKovacs%26aufirst%3DB.%26aulast%3DMufson%26aufirst%3DE.%2BJ.%26aulast%3DXu%26aufirst%3DS.%26atitle%3DBeta-amyloid%2520deposition%2520and%2520functional%2520impairment%2520in%2520the%2520retina%2520of%2520the%2520APPswe%252FPS1DeltaE9%2520transgenic%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2009%26volume%3D50%26spage%3D793%26epage%3D800%26doi%3D10.1167%2Fiovs.08-2384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanke, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marron, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seligmann, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garland, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, A. F.</span></span> <span> </span><span class="NLM_article-title">Characterization of carfilzomib-resistant non-small cell lung cancer cell lines</span>. <i>J. Cancer Res. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">1317</span>– <span class="NLM_lpage">1327</span>, <span class="refDoi"> DOI: 10.1007/s00432-018-2662-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1007%2Fs00432-018-2662-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=29766327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsFCgt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2018&pages=1317-1327&author=N.+T.+Hankeauthor=E.+Imlerauthor=M.+T.+Marronauthor=B.+E.+Seligmannauthor=L.+L.+Garlandauthor=A.+F.+Baker&title=Characterization+of+carfilzomib-resistant+non-small+cell+lung+cancer+cell+lines&doi=10.1007%2Fs00432-018-2662-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of carfilzomib-resistant non-small cell lung cancer cell lines</span></div><div class="casAuthors">Hanke, Neale T.; Imler, Elliot; Marron, Marilyn T.; Seligmann, Bruce E.; Garland, Linda L.; Baker, Amanda F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer Research and Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1317-1327</span>CODEN:
                <span class="NLM_cas:coden">JCROD7</span>;
        ISSN:<span class="NLM_cas:issn">0171-5216</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: We previously showed that carfilzomib (CFZ) has potent anti-proliferative and cytotoxic activity in a broad range of lung cancer cell lines.  Here we investigate possible mechanisms of CFZ acquired resistance in lung cancer cell lines.  Methods: CFZ-resistant non-small cell lung cancer (NSCLC) cell lines were developed by exposing A549 and H520 cells to stepwise increasing concns. of CFZ.  Resistance to CFZ and cross-resistance to bortezomib and other chemotherapy drugs was measured using the MTT assay.  Cytotoxicity to CFZ was detd. using a CytoTox assay.  Western blot was used to measure apoptosis, autophagy, and drug efflux transporter-related proteins.  Quant. targeted whole transcriptome sequencing and quant. RT-PCR was used to measure gene expression.  Flow cytometry was used to analyze intracellular accumulation of doxorubicin.  Results: The CFZ IC50 value of the resistant cells increased vs. parental lines (2.5-fold for A549, 122-fold for H520).  Resistant lines showed reduced expression of apoptosis and autophagy markers and reduced death vs. parental lines following CFZ treatment.  Both resistant lines exhibited higher P-glycoprotein (Pgp) gene (TempO-Seq anal., increased 1.2-fold in A549, > 9000-fold in H520) and protein expression levels vs. parental lines.  TempO-Seq anal. indicated other drug resistance pathways were upregulated.  The resistant cell lines demonstrated less accumulation of intracellular doxorubicin, and were cross-resistant to other Pgp client drugs: bortezomib, doxorubicin, and paclitaxel, but not cisplatin.  Conclusions: Upregulation of Pgp appears to be an important, but not the only, mechanism of CFZ resistance in NSCLC cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7UAttywNQ0LVg90H21EOLACvtfcHk0lh0J-ESkTjZZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsFCgt7k%253D&md5=a67a0ddeb3793a04efc3e9daf34ef7e9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2Fs00432-018-2662-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00432-018-2662-0%26sid%3Dliteratum%253Aachs%26aulast%3DHanke%26aufirst%3DN.%2BT.%26aulast%3DImler%26aufirst%3DE.%26aulast%3DMarron%26aufirst%3DM.%2BT.%26aulast%3DSeligmann%26aufirst%3DB.%2BE.%26aulast%3DGarland%26aufirst%3DL.%2BL.%26aulast%3DBaker%26aufirst%3DA.%2BF.%26atitle%3DCharacterization%2520of%2520carfilzomib-resistant%2520non-small%2520cell%2520lung%2520cancer%2520cell%2520lines%26jtitle%3DJ.%2520Cancer%2520Res.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D144%26spage%3D1317%26epage%3D1327%26doi%3D10.1007%2Fs00432-018-2662-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, H. W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderl, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arastu-Kapur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of highly selective inhibitors of the immunoproteasome low molecular mass polypeptide 2 (LMP2) subunit</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">417</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00496</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00496" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktVahtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=413-417&author=H.+W.+B.+Johnsonauthor=J.+L.+Anderlauthor=E.+K.+Bradleyauthor=J.+Buiauthor=J.+Jonesauthor=S.+Arastu-Kapurauthor=L.+M.+Kellyauthor=E.+Loweauthor=D.+C.+Moebiusauthor=T.+Muchamuelauthor=C.+Kirkauthor=Z.+Wangauthor=D.+McMinn&title=Discovery+of+highly+selective+inhibitors+of+the+immunoproteasome+low+molecular+mass+polypeptide+2+%28LMP2%29+subunit&doi=10.1021%2Facsmedchemlett.6b00496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit</span></div><div class="casAuthors">Johnson, Henry W. B.; Anderl, Janet L.; Bradley, Erin K.; Bui, John; Jones, Jeffrey; Arastu-Kapur, Shirin; Kelly, Lisa M.; Lowe, Eric; Moebius, David C.; Muchamuel, Tony; Kirk, Christopher; Wang, Zhengping; McMinn, Dustin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">413-417</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Building upon the success of bortezomib (VELCADE) and carfilzomib (KYPROLIS), the design of a next generation of inhibitors targeting specific subunits within the immunoproteasome is of interest for the treatment of autoimmune disease.  There are three catalytic subunits within the immunoproteasome (low mol. mass polypeptide-7, -2, and multicatalytic endopeptidase complex subunit-1; LMP7, LMP2, and MECL-1), and a campaign was undertaken to design a potent and selective LMP2 inhibitor with sufficient properties to allow for sustained inhibition in vivo.  Screening a focused library of epoxyketones revealed a series of potent dipeptides that were optimized to provide the highly selective inhibitor KZR-504 (12).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL-9Mx7yA1VLVg90H21EOLACvtfcHk0lh0J-ESkTjZZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktVahtLs%253D&md5=5abf3912c1dbcc6f77d271235c75b17c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00496%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DH.%2BW.%2BB.%26aulast%3DAnderl%26aufirst%3DJ.%2BL.%26aulast%3DBradley%26aufirst%3DE.%2BK.%26aulast%3DBui%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DArastu-Kapur%26aufirst%3DS.%26aulast%3DKelly%26aufirst%3DL.%2BM.%26aulast%3DLowe%26aufirst%3DE.%26aulast%3DMoebius%26aufirst%3DD.%2BC.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DKirk%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DMcMinn%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520highly%2520selective%2520inhibitors%2520of%2520the%2520immunoproteasome%2520low%2520molecular%2520mass%2520polypeptide%25202%2520%2528LMP2%2529%2520subunit%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D413%26epage%3D417%26doi%3D10.1021%2Facsmedchemlett.6b00496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elghoul, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, Q. P.</span></span> <span> </span><span class="NLM_article-title">P-Glycoprotein inhibition sensitizes human breast cancer cells to proteasome inhibitors</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">1239</span>– <span class="NLM_lpage">1248</span>, <span class="refDoi"> DOI: 10.1002/jcb.25783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1002%2Fjcb.25783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=27813130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmslertw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2017&pages=1239-1248&author=R.+R.+Deshmukhauthor=S.+Kimauthor=Y.+Elghoulauthor=Q.+P.+Dou&title=P-Glycoprotein+inhibition+sensitizes+human+breast+cancer+cells+to+proteasome+inhibitors&doi=10.1002%2Fjcb.25783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors</span></div><div class="casAuthors">Deshmukh, Rahul R.; Kim, Seongho; Elghoul, Yasmine; Dou, Q. Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1239-1248</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Although effective for the treatment of hematol. malignancies, the FDA approved proteasome inhibitors bortezomib and carfilzomib have limited efficacy in solid tumors including triple neg. breast cancer (TNBC).  Chemotherapy is the only option for treating TNBC due to the absence of specific therapeutic targets.  Therefore, development of new TNBC therapeutic strategies has been warranted.  We studied whether P-glycoprotein (P-gp) inhibition could sensitize TNBC cells to proteasome inhibitors.  When verapamil, a P-gp inhibitor, was combined with the proteasome inhibitor MG132, bortezomib, or carfilzomib, the cytotoxic effects and apoptosis in TNBC MDA-MB-231 cells were enhanced, compared to each treatment alone.  Furthermore, addn. of verapamil improved proteasome-inhibitory properties of MG132, bortezomib, or carfilzomib in MDA-MB-231 cells, as shown by the increased accumulation of ubiquitinated proteins and proteasome substrates such as IκBα and p27kip1.  Addnl., when nicardipine, another P-gp inhibitor, was combined with bortezomib or carfilzomib, enhanced inhibition of MDA-MB-231 cell proliferation was obsd.  These findings indicate that P-gp inhibitors could sensitize TNBC cells to structurally and functionally diverse proteasome inhibitors and might provide new treatment strategy for TNBC.  J. Cell. Biochem. 9999: 1-10, 2016. cpr 2016 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonNLKDRZBk2LVg90H21EOLACvtfcHk0ljh1fAFksfMPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmslertw%253D%253D&md5=f0bf11f094c669c7446118a062e55d7b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fjcb.25783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.25783%26sid%3Dliteratum%253Aachs%26aulast%3DDeshmukh%26aufirst%3DR.%2BR.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DElghoul%26aufirst%3DY.%26aulast%3DDou%26aufirst%3DQ.%2BP.%26atitle%3DP-Glycoprotein%2520inhibition%2520sensitizes%2520human%2520breast%2520cancer%2520cells%2520to%2520proteasome%2520inhibitors%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2017%26volume%3D118%26spage%3D1239%26epage%3D1248%26doi%3D10.1002%2Fjcb.25783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verbrugge, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaraf, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dijkmans, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Uyl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oerlemans, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Heijden, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Gruijl, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheper, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, G.</span></span> <span> </span><span class="NLM_article-title">Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">174</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.187542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1124%2Fjpet.111.187542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=22235146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVagtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=174-182&author=S.+E.+Verbruggeauthor=Y.+G.+Assarafauthor=B.+A.+Dijkmansauthor=G.+L.+Schefferauthor=M.+Alauthor=D.+den+Uylauthor=R.+Oerlemansauthor=E.+T.+Chanauthor=C.+J.+Kirkauthor=G.+J.+Petersauthor=J.+W.+van+der+Heijdenauthor=T.+D.+de+Gruijlauthor=R.+J.+Scheperauthor=G.+Jansen&title=Inactivating+PSMB5+mutations+and+P-glycoprotein+%28multidrug+resistance-associated+protein%2FATP-binding+cassette+B1%29+mediate+resistance+to+proteasome+inhibitors%3A+ex+vivo+efficacy+of+%28immuno%29proteasome+inhibitors+in+mononuclear+blood+cells+from+patients+with+rheumatoid+arthritis&doi=10.1124%2Fjpet.111.187542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis</span></div><div class="casAuthors">Verbrugge, Sue Ellen; Assaraf, Yehuda G.; Dijkmans, Ben A. C.; Scheffer, George L.; Al, Marjon; den Uyl, Debby; Oerlemans, Ruud; Chan, Elena T.; Kirk, Christopher J.; Peters, Godefridus J.; van der Heijden, Joost W.; de Gruijl, Tanja D.; Scheper, Rik J.; Jansen, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">174-182</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bortezomib (BTZ), a registered proteasome inhibitor (PI) for multiple myeloma, has also been proposed as a potential antirheumatic agent.  Its reported side effects, however, make it unappealing for long-term administration, and resistance may also develop.  To overcome this, second-generation PIs became available.  Here, we investigated whether a novel class of peptide epoxyketone-based PIs, including carfilzomib, N-((S)-3-methoxy-1-(((S)-3-methoxy-1-(((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide (ONX0912), and (S)-3-(4-methoxyphenyl)-N-((S)-1-((S)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide (ONX0914), might escape two established BTZ-resistance mechanisms: (1) mutations in the proteasome β5 subunit (PSMB5) targeted by these PIs, and (2) drug efflux mediated by ATP-binding cassette transporters.  THP1 myeloid sublines with acquired resistance to BTZ (54- to 235-fold) caused by mutations in the PSMB5 gene displayed marked cross-resistance but less pronounced cross-resistance to carfilzomib (9- to 32-fold), ONX0912 (39- to 62-fold), and ONX0914 (27- to 97-fold).  As for ATP-binding cassette transporter-mediated efflux, lymphoid CEM/VLB cells with P-glycoprotein (Pgp)/multidrug resistance 1 overexpression exhibited substantial resistance to carfilzomib (114-fold), ONX0912 (23-fold), and ONX0914 (162-fold), whereas less resistance to BTZ (4.5-fold) was obsd.  Consistently, β5 subunit-assocd. chymotrypsin-like proteasome activity was significantly less inhibited in these CEM/VLB cells.  Ex vivo anal. of peripheral blood mononuclear cells from therapy-naive patients with rheumatoid arthritis revealed that, although basal Pgp levels were low, P-glycoprotein expression compromised the inhibitory effect of carfilzomib and ONX0914.  However, the use of P121 (reversin 121), a Pgp transport inhibitor, restored parental cell inhibitory levels in both CEM/VLB cells and peripheral blood mononuclear cells.  These results indicate that the pharmacol. activity of these PIs may be hindered by drug resistance mechanisms involving PSMBS mutations and PI extrusion via Pgp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLjyDKKBsD_7Vg90H21EOLACvtfcHk0ljh1fAFksfMPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVagtr8%253D&md5=5b87626879dfdca4f1003e35833af2e0</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187542%26sid%3Dliteratum%253Aachs%26aulast%3DVerbrugge%26aufirst%3DS.%2BE.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DDijkmans%26aufirst%3DB.%2BA.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DAl%26aufirst%3DM.%26aulast%3Dden%2BUyl%26aufirst%3DD.%26aulast%3DOerlemans%26aufirst%3DR.%26aulast%3DChan%26aufirst%3DE.%2BT.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3Dvan%2Bder%2BHeijden%26aufirst%3DJ.%2BW.%26aulast%3Dde%2BGruijl%26aufirst%3DT.%2BD.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26aulast%3DJansen%26aufirst%3DG.%26atitle%3DInactivating%2520PSMB5%2520mutations%2520and%2520P-glycoprotein%2520%2528multidrug%2520resistance-associated%2520protein%252FATP-binding%2520cassette%2520B1%2529%2520mediate%2520resistance%2520to%2520proteasome%2520inhibitors%253A%2520ex%2520vivo%2520efficacy%2520of%2520%2528immuno%2529proteasome%2520inhibitors%2520in%2520mononuclear%2520blood%2520cells%2520from%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D174%26epage%3D182%26doi%3D10.1124%2Fjpet.111.187542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">Development of novel epoxyketone-based proteasome inhibitors as a strategy to overcome cancer resistance to carfilzomib and bortezomib</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4444</span>– <span class="NLM_lpage">4455</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01943</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01943" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntFaqsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4444-4455&author=M.+J.+Leeauthor=D.+Bhattaraiauthor=J.+Yooauthor=Z.+Millerauthor=J.+E.+Parkauthor=S.+Leeauthor=W.+Leeauthor=J.+J.+Driscollauthor=K.+B.+Kim&title=Development+of+novel+epoxyketone-based+proteasome+inhibitors+as+a+strategy+to+overcome+cancer+resistance+to+carfilzomib+and+bortezomib&doi=10.1021%2Facs.jmedchem.8b01943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib</span></div><div class="casAuthors">Lee, Min Jae; Bhattarai, Deepak; Yoo, Jisu; Miller, Zach; Park, Ji Eun; Lee, Sukyeong; Lee, Wooin; Driscoll, James J.; Kim, Kyung Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4444-4455</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Over the past 15 years, proteasome inhibitors (PIs), namely bortezomib, carfilzomib (Cfz) and ixazomib, have significantly improved the overall survival and quality-of-life for multiple myeloma (MM) patients.  However, a significant portion of MM patients do not respond to PI therapies.  Drug resistance is present either de novo or acquired after prolonged therapy through mechanisms that remain poorly defined.  The lack of a clear understanding of clin. PI resistance has hampered the development of next-generation PI drugs to treat MM patients who no longer respond to currently available therapies.  Here, the authors designed and synthesized novel epoxyketone-based PIs by structural modifications at the P1' site.  The authors show that a Cfz analog, harboring a hydroxyl substituent at its P1' position was highly cytotoxic against cancer cell lines displaying de novo or acquired resistance to Cfz.  These results suggest that peptide epoxyketones incorporating P1'-targeting moieties may have the potential to bypass resistance mechanisms assocd. with Cfz and to provide addnl. clin. options for patients resistant to Cfz.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6IBXmFPMA87Vg90H21EOLACvtfcHk0licVeO7pQ43Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntFaqsbY%253D&md5=65447e8e68a7d1b6d8435b99138f5803</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01943%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DBhattarai%26aufirst%3DD.%26aulast%3DYoo%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DZ.%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DDriscoll%26aufirst%3DJ.%2BJ.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DDevelopment%2520of%2520novel%2520epoxyketone-based%2520proteasome%2520inhibitors%2520as%2520a%2520strategy%2520to%2520overcome%2520cancer%2520resistance%2520to%2520carfilzomib%2520and%2520bortezomib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4444%26epage%3D4455%26doi%3D10.1021%2Facs.jmedchem.8b01943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">Next-generation proteasome inhibitors for cancer therapy</span>. <i>Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>198</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.trsl.2018.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2Fj.trsl.2018.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=29654740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsVeht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2018&pages=1-16&author=J.+E.+Parkauthor=Z.+Millerauthor=Y.+Junauthor=W.+Leeauthor=K.+B.+Kim&title=Next-generation+proteasome+inhibitors+for+cancer+therapy&doi=10.1016%2Fj.trsl.2018.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Next-generation proteasome inhibitors for cancer therapy</span></div><div class="casAuthors">Park, Ji Eun; Miller, Zachary; Jun, Yearin; Lee, Wooin; Kim, Kyung Bo</div><div class="citationInfo"><span class="NLM_cas:title">Translational Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-16</span>CODEN:
                <span class="NLM_cas:coden">TRRECL</span>;
        ISSN:<span class="NLM_cas:issn">1878-1810</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Over 2 decades ago, the proteasome was considered a risky or even untenable therapeutic target.  Today, proteasome inhibitors are a mainstay in the treatment of multiple myeloma (MM) and have sales in excess of 3 billion US dollars annually.  More importantly, the availability of proteasome inhibitors has greatly improved the survival and quality of life for patients with MM.  Despite the remarkable success of proteasome inhibitor therapies to date, the potential for improvement remains, and the development and optimal use of proteasome inhibitors as anticancer agents continues to be an active area of research.  In this review, we briefly discuss the features and limitations of the 3 proteasome inhibitor drugs currently used in the clinic and provide an update on current efforts to develop next-generation proteasome inhibitors with the potential to overcome the limitations of existing proteasome inhibitor drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ5nMmurd6-7Vg90H21EOLACvtfcHk0licVeO7pQ43Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsVeht7o%253D&md5=25d9295ddb58861676c56ed4b72af110</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.trsl.2018.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trsl.2018.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DMiller%26aufirst%3DZ.%26aulast%3DJun%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DNext-generation%2520proteasome%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DTransl.%2520Res.%26date%3D2018%26volume%3D198%26spage%3D1%26epage%3D16%26doi%3D10.1016%2Fj.trsl.2018.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marsault, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, M. L.</span></span> <span> </span><span class="NLM_article-title">Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1961</span>– <span class="NLM_lpage">2004</span>, <span class="refDoi"> DOI: 10.1021/jm1012374</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1012374" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVSjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1961-2004&author=E.+Marsaultauthor=M.+L.+Peterson&title=Macrocycles+are+great+cycles%3A+applications%2C+opportunities%2C+and+challenges+of+synthetic+macrocycles+in+drug+discovery&doi=10.1021%2Fjm1012374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocycles Are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocycles in Drug Discovery</span></div><div class="casAuthors">Marsault, Eric; Peterson, Mark L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1961-2004</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Macrocycles occupy a unique segment of chem. space.  In the past decade, their chem. diversity expanded significantly, supported by advances in bioinformatics and synthetic methodol.  As a consequence, this structural type has now been successfully tested on most biol. target classes.  The goal of this article is to put into perspective the current applications, opportunities, and challenges assocd. with synthetic macrocycles in drug discovery.  Accordingly, the first part of this article is dedicated to the drug discovery aspects of macrocycles and highlights salient features of their medicinal chem.  This section is organized by target class, a choice aimed at providing the reader an appreciation of the structural diversity generated for each class.  To give the reader an appreciation of the tools available to construct macrocyclic scaffolds, the site and method of the pivotal macrocyclization step are indicated in the figures.  Readers are referred to the source articles for further details.  In the second part, the technologies and synthetic approaches that already have demonstrated utility or possess a high potential for macrocycle-based drug discovery are discussed.  Finally, a perspective on the future of synthetic macrocycles in medicinal chem. is offered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrygQLE6JraHrVg90H21EOLACvtfcHk0licVeO7pQ43Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVSjtbo%253D&md5=97c1120896e90a85790a9ac1274259f3</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm1012374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1012374%26sid%3Dliteratum%253Aachs%26aulast%3DMarsault%26aufirst%3DE.%26aulast%3DPeterson%26aufirst%3DM.%2BL.%26atitle%3DMacrocycles%2520are%2520great%2520cycles%253A%2520applications%252C%2520opportunities%252C%2520and%2520challenges%2520of%2520synthetic%2520macrocycles%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1961%26epage%3D2004%26doi%3D10.1021%2Fjm1012374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Driggers, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrett, N. K.</span></span> <span> </span><span class="NLM_article-title">The exploration of macrocycles for drug discovery--an underexploited structural class</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">608</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1038/nrd2590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1038%2Fnrd2590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=18591981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvFShsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=608-624&author=E.+M.+Driggersauthor=S.+P.+Haleauthor=J.+Leeauthor=N.+K.+Terrett&title=The+exploration+of+macrocycles+for+drug+discovery%2D%2Dan+underexploited+structural+class&doi=10.1038%2Fnrd2590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The exploration of macrocycles for drug discovery - an underexploited structural class</span></div><div class="casAuthors">Driggers, Edward M.; Hale, Stephen P.; Lee, Jinbo; Terrett, Nicholas K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">608-624</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Natural products comprised of a macrocycle ring structure have proven their therapeutic applications as antibiotics, immunosuppressants as well as anticancer agents.  Despite this, macrocyclic compds. remain under-explored.  Terrett and colleagues review the properties and features of current macrocycle drugs, emphasizing the vast potential of synthetic macrocycles in drug discovery.  Macrocyclic natural products have evolved to fulfil numerous biochem. functions, and their profound pharmacol. properties have led to their development as drugs.  A macrocycle provides diverse functionality and stereochem. complexity in a conformationally pre-organized ring structure.  This can result in high affinity and selectivity for protein targets, while preserving sufficient bioavailability to reach intracellular locations.  Despite these valuable characteristics, and the proven success of more than 100 marketed macrocycle drugs derived from natural products, this structural class has been poorly explored within drug discovery.  This is in part due to concerns about synthetic intractability and non-drug-like properties.  This Review describes the growing body of data in favor of macrocyclic therapeutics, and demonstrates that this class of compds. can be both fully drug-like in its properties and readily prepd. owing to recent advances in synthetic medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDtW8LpE4ru7Vg90H21EOLACvtfcHk0lieIAnEIWEbVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvFShsbc%253D&md5=16e091818053e5b163b81078a8d03094</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrd2590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2590%26sid%3Dliteratum%253Aachs%26aulast%3DDriggers%26aufirst%3DE.%2BM.%26aulast%3DHale%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DTerrett%26aufirst%3DN.%2BK.%26atitle%3DThe%2520exploration%2520of%2520macrocycles%2520for%2520drug%2520discovery--an%2520underexploited%2520structural%2520class%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D608%26epage%3D624%26doi%3D10.1038%2Fnrd2590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, J. J.</span></span> <span> </span><span class="NLM_article-title">Lead discovery and optimization strategies for peptide macrocycles</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">471</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.07.083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2Fj.ejmech.2014.07.083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=25109255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GktrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2015&pages=471-479&author=A.+Bhatauthor=L.+R.+Robertsauthor=J.+J.+Dwyer&title=Lead+discovery+and+optimization+strategies+for+peptide+macrocycles&doi=10.1016%2Fj.ejmech.2014.07.083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Lead discovery and optimization strategies for peptide macrocycles</span></div><div class="casAuthors">Bhat, Abhijit; Roberts, Lee R.; Dwyer, John J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">471-479</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Peptide macrocycles represent a chem. space where the best of biol. tools can synergize with the best of chem. approaches in the quest for leads against undruggable targets.  Peptide macrocycles offer some key advantages in both lead discovery and lead optimization phases of drug discovery when compared to natural product and synthetic macrocycles.  In addn., they are uniquely positioned to capitalize on the therapeutic potential of peptides because cyclization can help drive selectivity, potency and overcome the common limitations of metabolic instability of peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrYEBhURBm07Vg90H21EOLACvtfcHk0lieIAnEIWEbVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GktrrM&md5=2e12788610c87e9c774dcf3804855cf4</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.07.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.07.083%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DL.%2BR.%26aulast%3DDwyer%26aufirst%3DJ.%2BJ.%26atitle%3DLead%2520discovery%2520and%2520optimization%2520strategies%2520for%2520peptide%2520macrocycles%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D94%26spage%3D471%26epage%3D479%26doi%3D10.1016%2Fj.ejmech.2014.07.083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, D. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of peptide macrocycles</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1151</span>– <span class="NLM_lpage">1163</span>, <span class="refDoi"> DOI: 10.1080/17460441.2016.1245720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1080%2F17460441.2016.1245720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=27718641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSqs7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1151-1163&author=A.+M.+Whiteauthor=D.+J.+Craik&title=Discovery+and+optimization+of+peptide+macrocycles&doi=10.1080%2F17460441.2016.1245720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of peptide macrocycles</span></div><div class="casAuthors">White, Andrew M.; Craik, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1151-1163</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Macrocyclic peptides are generally more resistant to proteolysis and often have higher potency than linear peptides and so they are excellent leads in drug design.  Their study is significant because they offer potential as a new generation of drugs that are potent and specific, and thus might have fewer side effects than traditional small mol. drugs.  This article covers macrocyclic drug leads based on nature-derived cyclic peptides as well as synthetic cyclic peptides and close derivs.  The natural peptides include cyclotides, sunflower-derived peptides, theta-defensins and orbitides.  Technologies to make engineered cyclic peptides covered here include cyclization via amino acid linkers, CLIPS, templates, and stapled peptides.  Macrocyclic peptides are promising drug leads and several are in clin. trials.  The authors believe they offer key advantages over traditional small mol. drugs, as well as some advantages over protein-based 'biologics' such as antibodies or growth factors.  These include the ability to penetrate cells and attack intracellular targets such as protein-protein interactions as well as to hit extracellular targets.  Some macrocyclic peptides such as cyclotides offer the potential for prodn. in plants, thus reducing manuf. costs and potentially increasing opportunities for their distribution to developing countries at low cost.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_0bCIvweBD7Vg90H21EOLACvtfcHk0lieIAnEIWEbVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSqs7jP&md5=fb6f9faf28fed8e2a5533623fc5e2a19</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1245720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1245720%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DA.%2BM.%26aulast%3DCraik%26aufirst%3DD.%2BJ.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520peptide%2520macrocycles%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26spage%3D1151%26epage%3D1163%26doi%3D10.1080%2F17460441.2016.1245720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cacciatore, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornasari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Stefano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerasa, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aydin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moretto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesce, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">di Giacomo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costantini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Giovanni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speranza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felaco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patruno, A.</span></span> <span> </span><span class="NLM_article-title">Development of glycine-alpha-methyl-proline-containing tripeptides with neuroprotective properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">563</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2Fj.ejmech.2015.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=26717205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1yiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=553-563&author=I.+Cacciatoreauthor=E.+Fornasariauthor=A.+Di+Stefanoauthor=L.+Marinelliauthor=L.+S.+Cerasaauthor=H.+Turkezauthor=E.+Aydinauthor=A.+Morettoauthor=A.+Ferroneauthor=M.+Pesceauthor=V.+di+Giacomoauthor=M.+Realeauthor=E.+Costantiniauthor=P.+Di+Giovanniauthor=L.+Speranzaauthor=M.+Felacoauthor=A.+Patruno&title=Development+of+glycine-alpha-methyl-proline-containing+tripeptides+with+neuroprotective+properties&doi=10.1016%2Fj.ejmech.2015.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Development of glycine-α-methyl-proline-containing tripeptides with neuroprotective properties</span></div><div class="casAuthors">Cacciatore, Ivana; Fornasari, Erika; Di Stefano, Antonio; Marinelli, Lisa; Cerasa, Laura Serafina; Turkez, Hasan; Aydin, Elanur; Moretto, Alessandro; Ferrone, Alessio; Pesce, Mirko; di Giacomo, Viviana; Reale, Marcella; Costantini, Erica; Di Giovanni, Pamela; Speranza, Lorenza; Felaco, Mario; Patruno, Antonia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">553-563</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Herein is described the synthesis of novel glycine-α-methyl-proline-contg. tripeptides with the aim of obtaining derivs. highly stable in human plasma and able to counteract neuroinflammatory processes that are distinctive of neurodegenerative pathologies.  The syntheses of glycine-α-methyl-proline-contg. tripeptides were all achieved both by introducing the methylproline residue into the Gly-Pro-Arg (GPR) sequence in place of the native Pro in P2 position and replacing the basic amino acid Arg in P3 position by Lys or His.  Results showed that all novel tripeptides are stable in human plasma (t1/2 > 51 h) and that glycinyl-α-methyl-prolinyl-histidine- generating stable intramol. H-bond in a C11-turn by interaction of His imidazole ring and Gly carbonyl group - restored physiol. levels of nitric oxide deriving from neuronal NOS (nNOS) activity, thus preventing the inflammatory response by suppression of the NF-kB activity and, consequently, the expression of inflammatory genes such as inducibile NOS (iNOS).  Therefore, glycinyl-α-methyl-prolinyl-histidine could be a lead compd. for further development of peptidomimetics able to contrast neuroinflammatory processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphRkGI_EPT5bVg90H21EOLACvtfcHk0lhv-avvMzGzFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1yiug%253D%253D&md5=36458c81a6d1c59c627f1e659d0ba993</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DCacciatore%26aufirst%3DI.%26aulast%3DFornasari%26aufirst%3DE.%26aulast%3DDi%2BStefano%26aufirst%3DA.%26aulast%3DMarinelli%26aufirst%3DL.%26aulast%3DCerasa%26aufirst%3DL.%2BS.%26aulast%3DTurkez%26aufirst%3DH.%26aulast%3DAydin%26aufirst%3DE.%26aulast%3DMoretto%26aufirst%3DA.%26aulast%3DFerrone%26aufirst%3DA.%26aulast%3DPesce%26aufirst%3DM.%26aulast%3Ddi%2BGiacomo%26aufirst%3DV.%26aulast%3DReale%26aufirst%3DM.%26aulast%3DCostantini%26aufirst%3DE.%26aulast%3DDi%2BGiovanni%26aufirst%3DP.%26aulast%3DSperanza%26aufirst%3DL.%26aulast%3DFelaco%26aufirst%3DM.%26aulast%3DPatruno%26aufirst%3DA.%26atitle%3DDevelopment%2520of%2520glycine-alpha-methyl-proline-containing%2520tripeptides%2520with%2520neuroprotective%2520properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D108%26spage%3D553%26epage%3D563%26doi%3D10.1016%2Fj.ejmech.2015.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eildal, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuhr-Hansen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeskamp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottschalk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristensen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stromgaard, K.</span></span> <span> </span><span class="NLM_article-title">Cell-permeable and plasma-stable peptidomimetic inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1333</span>– <span class="NLM_lpage">1346</span>, <span class="refDoi"> DOI: 10.1021/jm1013924</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013924" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1333-1346&author=A.+Bachauthor=J.+N.+Eildalauthor=N.+Stuhr-Hansenauthor=R.+Deeskampauthor=M.+Gottschalkauthor=S.+W.+Pedersenauthor=A.+S.+Kristensenauthor=K.+Stromgaard&title=Cell-permeable+and+plasma-stable+peptidomimetic+inhibitors+of+the+postsynaptic+density-95%2FN-methyl-D-aspartate+receptor+interaction&doi=10.1021%2Fjm1013924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-Permeable and Plasma-Stable Peptidomimetic Inhibitors of the Postsynaptic Density-95/N-Methyl-d-Aspartate Receptor Interaction</span></div><div class="casAuthors">Bach, Anders; Eildal, Jonas N. N.; Stuhr-Hansen, Nicolai; Deeskamp, Rasmus; Gottschalk, Marie; Pedersen, Soren W.; Kristensen, Anders S.; Stromgaard, Kristian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1333-1346</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The protein-protein interaction between the NMDA receptor and its intracellular scaffolding protein, PSD-95, is a potential target for treating ischemic brain diseases, neuropathic pain, and Alzheimer's disease.  We have previously demonstrated that N-alkylated tetrapeptides are potent inhibitors of this interaction, and here, this template is exploited for the development of blood plasma-stable and cell-permeable inhibitors.  Initially, we explored both the amino acid sequence of the tetrapeptide and the nature of the N-alkyl groups, which consolidated N-cyclohexylethyl-ETAV (1) as the most potent and selective compd.  Next, the amide moieties of N-methylated ETAV were systematically replaced with thioamides, demonstrating that one of three amide bonds could be replaced without compromising the affinity.  Subsequent optimization of the N-alkyl groups and evaluation of cell permeability led to identification of N-cyclohexylethyl-ETASV (54) as the most potent, plasma-stable and cell-permeable inhibitor, which is a promising tool in unraveling the therapeutic potential of the PSD-95/NMDA receptor interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxlYJ9ewixrrVg90H21EOLACvtfcHk0lhv-avvMzGzFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFeitrw%253D&md5=e4517970b5bcd0b2790181619bec9a41</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm1013924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013924%26sid%3Dliteratum%253Aachs%26aulast%3DBach%26aufirst%3DA.%26aulast%3DEildal%26aufirst%3DJ.%2BN.%26aulast%3DStuhr-Hansen%26aufirst%3DN.%26aulast%3DDeeskamp%26aufirst%3DR.%26aulast%3DGottschalk%26aufirst%3DM.%26aulast%3DPedersen%26aufirst%3DS.%2BW.%26aulast%3DKristensen%26aufirst%3DA.%2BS.%26aulast%3DStromgaard%26aufirst%3DK.%26atitle%3DCell-permeable%2520and%2520plasma-stable%2520peptidomimetic%2520inhibitors%2520of%2520the%2520postsynaptic%2520density-95%252FN-methyl-D-aspartate%2520receptor%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1333%26epage%3D1346%26doi%3D10.1021%2Fjm1013924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chua, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hautmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruning, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutschow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, A. D.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic protease inhibitors with reduced peptide character</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7828</span>– <span class="NLM_lpage">7831</span>, <span class="refDoi"> DOI: 10.1002/anie.201404301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1002%2Fanie.201404301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptlOju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=7828-7831&author=K.+C.+Chuaauthor=M.+Pietschauthor=X.+Zhangauthor=S.+Hautmannauthor=H.+Y.+Chanauthor=J.+B.+Bruningauthor=M.+Gutschowauthor=A.+D.+Abell&title=Macrocyclic+protease+inhibitors+with+reduced+peptide+character&doi=10.1002%2Fanie.201404301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic Protease Inhibitors with Reduced Peptide Character</span></div><div class="casAuthors">Chua, Krystle C. H.; Pietsch, Markus; Zhang, Xiaozhou; Hautmann, Stephanie; Chan, Hon Y.; Bruning, John B.; Guetschow, Michael; Abell, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">7828-7831</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">There is a real need for simple structures that define a β-strand conformation, a secondary structure that is central to peptide-protein interactions.  For example, protease substrates and inhibitors almost universally adopt this geometry upon active site binding.  A planar pyrrole is used to replace two amino acids of a peptide backbone to generate a simple macrocycle that retains the required geometry for active site binding.  The resulting β-strand templates have reduced peptide character and provide potent protease inhibitors with the attachment of an appropriate amino aldehyde to the C-terminus.  Picomolar inhibitors of cathepsin L and S are reported and the mode of binding of one example to the model protease chymotrypsin is defined by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLoSjiRph32bVg90H21EOLACvtfcHk0lhv-avvMzGzFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptlOju7g%253D&md5=f195f61bf6c368ce1bdaf71f347372db</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fanie.201404301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201404301%26sid%3Dliteratum%253Aachs%26aulast%3DChua%26aufirst%3DK.%2BC.%26aulast%3DPietsch%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHautmann%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DH.%2BY.%26aulast%3DBruning%26aufirst%3DJ.%2BB.%26aulast%3DGutschow%26aufirst%3DM.%26aulast%3DAbell%26aufirst%3DA.%2BD.%26atitle%3DMacrocyclic%2520protease%2520inhibitors%2520with%2520reduced%2520peptide%2520character%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D7828%26epage%3D7831%26doi%3D10.1002%2Fanie.201404301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Besse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolze, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasche, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinhold, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span> <span> </span><span class="NLM_article-title">Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1038%2Fleu.2017.212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=28676669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1eqt77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=391-401&author=A.+Besseauthor=S.+C.+Stolzeauthor=L.+Rascheauthor=N.+Weinholdauthor=G.+J.+Morganauthor=M.+Krausauthor=J.+Baderauthor=H.+S.+Overkleeftauthor=L.+Besseauthor=C.+Driessen&title=Carfilzomib+resistance+due+to+ABCB1%2FMDR1+overexpression+is+overcome+by+nelfinavir+and+lopinavir+in+multiple+myeloma&doi=10.1038%2Fleu.2017.212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma</span></div><div class="casAuthors">Besse, A.; Stolze, S. C.; Rasche, L.; Weinhold, N.; Morgan, G. J.; Kraus, M.; Bader, J.; Overkleeft, H. S.; Besse, L.; Driessen, C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">391-401</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Proteasome inhibitor (PI) carfilzomib (CFZ) has activity superior to bortezomib (BTZ) and is increasingly incorporated in multiple myeloma (MM) frontline therapy and relapsed settings.  Most MM patients ultimately experience PI-refractory disease, an unmet medical need with poorly understood biol. and dismal outcome.  Pharmacol. targeting of ABCB1 improved patient outcomes, including MM, but suffered from adverse drug effects and insufficient plasma concns.  Proteomics anal. identified ABCB1 overexpression as the most significant change in CFZ-resistant MM cells.  We addressed the functional role of ABCB1 overexpression in MM and obsd. significantly upregulated ABCB1 in peripheral blood malignant plasma cells (PCs) vs untreated patients' bone marrow PC.  ABCB1 overexpression reduces the proteasome-inhibiting activity of CFZ due to drug efflux, in contrast to BTZ.  Likewise, the cytotoxicity of established anti-MM drugs was significantly reduced in ABCB1-expressing MM cells.  In search for potential drugs targeting ABCB1 in clin. trials, we identified the HIV protease inhibitors nelfinavir (NFV) and lopinavir (LPV) as potent functional modulators of ABCB1-mediated drug export, most likely via modulation of mitochondria permeability transition pore.  NFV and LPV restored CFZ activity at therapeutically relevant drug levels and thus represent ready-to-use drugs to be tested in clin. trials to target ABCB1 and to re-sensitize PC to established myeloma drugs, in particular CFZ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmgYUIhFu_qLVg90H21EOLACvtfcHk0livfQe0m0ahuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1eqt77L&md5=8e100e4a939f21362c4eb75a3da81e37</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.212%26sid%3Dliteratum%253Aachs%26aulast%3DBesse%26aufirst%3DA.%26aulast%3DStolze%26aufirst%3DS.%2BC.%26aulast%3DRasche%26aufirst%3DL.%26aulast%3DWeinhold%26aufirst%3DN.%26aulast%3DMorgan%26aufirst%3DG.%2BJ.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DBader%26aufirst%3DJ.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DBesse%26aufirst%3DL.%26aulast%3DDriessen%26aufirst%3DC.%26atitle%3DCarfilzomib%2520resistance%2520due%2520to%2520ABCB1%252FMDR1%2520overexpression%2520is%2520overcome%2520by%2520nelfinavir%2520and%2520lopinavir%2520in%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D391%26epage%3D401%26doi%3D10.1038%2Fleu.2017.212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span> <span> </span><span class="NLM_article-title">Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2197</span>– <span class="NLM_lpage">2205</span>, <span class="refDoi"> DOI: 10.1021/mp300044b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300044b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC38XptFCju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=2197-2205&author=L.+Aoauthor=Y.+Wuauthor=D.+Kimauthor=E.+R.+Jangauthor=K.+Kimauthor=D.+M.+Leeauthor=K.+B.+Kimauthor=W.+Lee&title=Development+of+peptide-based+reversing+agents+for+p-glycoprotein-mediated+resistance+to+carfilzomib&doi=10.1021%2Fmp300044b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carfilzomib</span></div><div class="casAuthors">Ao, Lin; Wu, Ying; Kim, Donghern; Jang, Eun Ryoung; Kim, Kyunghwa; Lee, Do-min; Kim, Kyung Bo; Lee, Wooin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2197-2205</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Carfilzomib is a novel class of peptidyl epoxyketone proteasome inhibitor and has demonstrated promising activity in multiple clin. trials to treat patients with multiple myeloma and other types of cancers.  Here, we investigated mol. mechanisms underlying acquired resistance to carfilzomib and a potential strategy to restore cellular sensitivity to carfilzomib.  H23 and DLD-1 cells (human lung and colon adenocarcinoma cell lines) with acquired resistance to carfilzomib displayed marked cross-resistance to YU-101, a closely related proteasome inhibitor, and paclitaxel, a known substrate of Pgp.  However, carfilzomib-resistant cells remained sensitive to bortezomib, a clin. used dipeptide with boronic acid pharmacophore.  In accordance with these observations, carfilzomib-resistant H23 and DLD-1 cells showed marked upregulation of P-glycoprotein (Pgp) as compared to their parental controls, and coincubation with verapamil, a Pgp inhibitor, led to an almost complete restoration of cellular sensitivity to carfilzomib.  These results indicate that Pgp upregulation plays a major role in the development of carfilzomib resistance in these cell lines.  In developing a potential strategy to overcome carfilzomib resistance, we as a proof of concept prepd. a small library of peptide analogs derived from the peptide backbone of carfilzomib and screened these mols. for their activity to restore carfilzomib sensitivity when cotreated with carfilzomib.  We found that compds. as small as dipeptides are sufficient in restoring carfilzomib sensitivity.  Taken together, we found that Pgp upregulation plays a major role in the development of resistance to carfilzomib in lung and colon adenocarcinoma cell lines and that small peptide analogs lacking the pharmacophore can be used as agents to reverse acquired carfilzomib resistance.  Our findings may provide important information in developing a potential strategy to overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrslgMOfDD53rVg90H21EOLACvtfcHk0livfQe0m0ahuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptFCju7c%253D&md5=ba90f3b18f9e4cc80cf1fc72d523fb5c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fmp300044b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300044b%26sid%3Dliteratum%253Aachs%26aulast%3DAo%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DJang%26aufirst%3DE.%2BR.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DD.%2BM.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DLee%26aufirst%3DW.%26atitle%3DDevelopment%2520of%2520peptide-based%2520reversing%2520agents%2520for%2520p-glycoprotein-mediated%2520resistance%2520to%2520carfilzomib%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D2197%26epage%3D2205%26doi%3D10.1021%2Fmp300044b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S. J.</span></span> <span> </span><span class="NLM_article-title">Suppression of canine ATP binding cassette ABCB1 in Madin-Darby canine kidney type II cells unmasks human ABCG2-mediated efflux of olaparib</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1124/jpet.118.250225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1124%2Fjpet.118.250225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=30396915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktFGjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2019&pages=79-87&author=Y.+K.+Songauthor=J.+E.+Parkauthor=Y.+Ohauthor=S.+Hyungauthor=Y.+S.+Jeongauthor=M.+S.+Kimauthor=W.+Leeauthor=S.+J.+Chung&title=Suppression+of+canine+ATP+binding+cassette+ABCB1+in+Madin-Darby+canine+kidney+type+II+cells+unmasks+human+ABCG2-mediated+efflux+of+olaparib&doi=10.1124%2Fjpet.118.250225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of canine ATP binding cassette ABCB1 in madin-darby canine kidney type II cells unmasks human ABCG2-mediated efflux of olaparibs</span></div><div class="casAuthors">Song, Yoo-Kyung; Park, Ji Eun; Oh, Yunseok; Hyung, Sungwoo; Jeong, Yoo-Seong; Kim, Min-Soo; Lee, Wooin; Chung, Suk-Jae</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-87, S1-S8</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Endogenous canine ATP binding cassette B1 (cABCB1) is expressed abundantly in Madin-Darby canine kidney type II (MDCKII) cells, and its presence often complicates phenotyping of the transport process.  Errors in estg. the cor. efflux ratio (cER), as a result of the variable expression of cABCB1, were examd. for the dual substrates of ABCB1 and ABCG2 in MDCKII cells expressing human ABCG2 (hABCG2). cABCB1 mRNA and protein expression was 60% and 55% lower, resp., inMDCKII cells expressing hABCG2 comparedwith the wild type, suggesting that the expression of endogenous cABCB1 became variable after the expression of hABCG2.  To minimize the contribution of endogenous efflux, cABCB1 was suppressed kinetically (using verapamil as a selective inhibitor) or biochem. (transfecting short-hairpin RNA against cABCB1).  Under these suppression conditions, cER values for irinotecan and topotecan (dual substrates of ABCB1 and ABCG2) were elevated by more than 4-fold and 2-fold, resp., compared with cER values without the suppression.  The cER of olaparib was similarly increased to 3- and 5-fold in MDCKII cells under the kinetic and biochem. suppression of cABCB1, resp., suggesting that hABCG2-mediated efflux cannot be ruled out for olaparib.  Since the substrate selectivity for ABCB1 and ABCG2 overlapped considerably, the possibility of an inaccurate estn. of cER must be considered for dual substrates in the case of the variable expression of cABCB1 in MDCKII cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc02WPiUzhv7Vg90H21EOLACvtfcHk0livfQe0m0ahuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktFGjs74%253D&md5=e5e721b1643376cde1fd768868546a83</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1124%2Fjpet.118.250225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.118.250225%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DY.%2BK.%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DOh%26aufirst%3DY.%26aulast%3DHyung%26aufirst%3DS.%26aulast%3DJeong%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DChung%26aufirst%3DS.%2BJ.%26atitle%3DSuppression%2520of%2520canine%2520ATP%2520binding%2520cassette%2520ABCB1%2520in%2520Madin-Darby%2520canine%2520kidney%2520type%2520II%2520cells%2520unmasks%2520human%2520ABCG2-mediated%2520efflux%2520of%2520olaparib%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2019%26volume%3D368%26spage%3D79%26epage%3D87%26doi%3D10.1124%2Fjpet.118.250225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abuznait, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaddoumi, A.</span></span> <span> </span><span class="NLM_article-title">Role of ABC transporters in the pathogenesis of Alzheimer’s disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">820</span>– <span class="NLM_lpage">831</span>, <span class="refDoi"> DOI: 10.1021/cn300077c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn300077c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVylu73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=820-831&author=A.+H.+Abuznaitauthor=A.+Kaddoumi&title=Role+of+ABC+transporters+in+the+pathogenesis+of+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fcn300077c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Role of ABC Transporters in the Pathogenesis of Alzheimer's Disease</span></div><div class="casAuthors">Abuznait, Alaa H.; Kaddoumi, Amal</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">820-831</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common form of age-related dementia that begins with memory loss and progresses to include severe cognitive impairment.  A major pathol. hallmark of AD is the accumulation of beta amyloid peptide (Aβ) in senile plaques in the brain of AD patients.  The exact mechanism by which AD takes place remains unknown.  However, an increasing no. of studies suggests that ATP-binding cassette (ABC) transporters, which are localized on the surface of brain endothelial cells of the blood-brain barrier (BBB) and brain parenchyma, may contribute to the pathogenesis of AD.  Recent studies have unraveled important roles of ABC transporters including ABCB1 (P-glycoprotein, P-gp), ABCG2 (breast cancer resistant protein, BCRP), ABCC1 (multidrug resistance protein 1, MRP1), and the cholesterol transporter ABCA1 in the pathogenesis of AD and Aβ peptides deposition inside the brain.  Therefore, understanding the mechanisms by which these transporters contribute to Aβ deposition in the brain is important for the development of new therapeutic strategies against AD.  This review summarizes and highlights the accumulating evidence in the literature which describe the role of altered function of various ABC transporters in the pathogenesis and progression of AD and the implications of modulating their functions for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdBjHwrzdoO7Vg90H21EOLACvtfcHk0lgnu3UvXZL0-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVylu73N&md5=608c06826463e2b58ed23bf93feb92e0</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fcn300077c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn300077c%26sid%3Dliteratum%253Aachs%26aulast%3DAbuznait%26aufirst%3DA.%2BH.%26aulast%3DKaddoumi%26aufirst%3DA.%26atitle%3DRole%2520of%2520ABC%2520transporters%2520in%2520the%2520pathogenesis%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D820%26epage%3D831%26doi%3D10.1021%2Fcn300077c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farsiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groelle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mace, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamison, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrabi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollini, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dilley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowes Rickman, C.</span></span> <span> </span><span class="NLM_article-title">Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">E279</span>– <span class="NLM_lpage">E287</span>, <span class="refDoi"> DOI: 10.1073/pnas.1100901108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1073%2Fpnas.1100901108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=21690377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpt12qtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=E279-E287&author=J.+D.+Dingauthor=L.+V.+Johnsonauthor=R.+Herrmannauthor=S.+Farsiuauthor=S.+G.+Smithauthor=M.+Groelleauthor=B.+E.+Maceauthor=P.+Sullivanauthor=J.+A.+Jamisonauthor=U.+Kellyauthor=O.+Harrabiauthor=S.+S.+Bolliniauthor=J.+Dilleyauthor=D.+Kobayashiauthor=B.+Kuangauthor=W.+Liauthor=J.+Ponsauthor=J.+C.+Linauthor=C.+Bowes+Rickman&title=Anti-amyloid+therapy+protects+against+retinal+pigmented+epithelium+damage+and+vision+loss+in+a+model+of+age-related+macular+degeneration&doi=10.1073%2Fpnas.1100901108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration</span></div><div class="casAuthors">Ding, Jin-Dong; Johnson, Lincoln V.; Herrmann, Rolf; Farsiu, Sina; Smith, Stephanie G.; Groelle, Marybeth; Mace, Brian E.; Sullivan, Patrick; Jamison, Jeffrey A.; Kelly, Una; Harrabi, Ons; Bollini, Sangeetha Subbarao; Dilley, Jeanette; Kobayashi, Dione; Kuang, Bing; Li, Wenlin; Pons, Jaume; Lin, John C.; Rickman, Catherine Bowes</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">E279-E287, SE279/1-SE279/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Age-related macular degeneration (AMD) is a leading cause of visual dysfunction worldwide.  Amyloid β (Aβ) peptides, Aβ1-40 (Aβ40) and Aβ1-42 (Aβ42), have been implicated previously in the AMD disease process.  Consistent with a pathogenic role for Aβ, we show here that a mouse model of AMD that invokes multiple factors that are known to modify AMD risk (aged human apolipoprotein E 4 targeted replacement mice on a high-fat, cholesterol-enriched diet) presents with Aβ-contg. deposits basal to the retinal pigmented epithelium (RPE), histopathol. changes in the RPE, and a deficit in scotopic electroretinog. response, which is reflective of impaired visual function.  Strikingly, these electroretinog. deficits are abrogated in a dose-dependent manner by systemic administration of an antibody targeting the C termini of Aβ40 and Aβ42.  Concomitant redn. in the levels of Aβ and activated complement components in sub-RPE deposits and structural preservation of the RPE are assocd. with anti-Aβ40/42 antibody immunotherapy and visual protection.  These observations are consistent with the redn. in amyloid plaques and improvement of cognitive function in mouse models of Alzheimer's disease treated with anti-Aβ antibodies.  They also implicate Aβ in the pathogenesis of AMD and identify Aβ as a viable therapeutic target for its treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooGlkfZz8fUrVg90H21EOLACvtfcHk0lgnu3UvXZL0-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpt12qtrg%253D&md5=2961014310520880e0f400f367952057</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1100901108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1100901108%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DJ.%2BD.%26aulast%3DJohnson%26aufirst%3DL.%2BV.%26aulast%3DHerrmann%26aufirst%3DR.%26aulast%3DFarsiu%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DS.%2BG.%26aulast%3DGroelle%26aufirst%3DM.%26aulast%3DMace%26aufirst%3DB.%2BE.%26aulast%3DSullivan%26aufirst%3DP.%26aulast%3DJamison%26aufirst%3DJ.%2BA.%26aulast%3DKelly%26aufirst%3DU.%26aulast%3DHarrabi%26aufirst%3DO.%26aulast%3DBollini%26aufirst%3DS.%2BS.%26aulast%3DDilley%26aufirst%3DJ.%26aulast%3DKobayashi%26aufirst%3DD.%26aulast%3DKuang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DPons%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%2BC.%26aulast%3DBowes%2BRickman%26aufirst%3DC.%26atitle%3DAnti-amyloid%2520therapy%2520protects%2520against%2520retinal%2520pigmented%2520epithelium%2520damage%2520and%2520vision%2520loss%2520in%2520a%2520model%2520of%2520age-related%2520macular%2520degeneration%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3DE279%26epage%3DE287%26doi%3D10.1073%2Fpnas.1100901108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Development of macrocyclic peptides containing epoxyketone with oral availability as proteasome inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9177</span>– <span class="NLM_lpage">9204</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00819</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00819" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVantLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9177-9204&author=D.+Liauthor=X.+Zhangauthor=X.+Maauthor=L.+Xuauthor=J.+Yuauthor=L.+Gaoauthor=X.+Huauthor=J.+Zhangauthor=X.+Dongauthor=J.+Liauthor=T.+Liuauthor=Y.+Zhouauthor=Y.+Hu&title=Development+of+macrocyclic+peptides+containing+epoxyketone+with+oral+availability+as+proteasome+inhibitors&doi=10.1021%2Facs.jmedchem.8b00819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Development of macrocyclic peptides containing epoxyketone with oral availability as proteasome inhibitors</span></div><div class="casAuthors">Li, Daqiang; Zhang, Xiaotuan; Ma, Xiaodong; Xu, Lei; Yu, Jianjun; Gao, Lixin; Hu, Xiaobei; Zhang, Jiankang; Dong, Xiaowu; Li, Jia; Liu, Tao; Zhou, Yubo; Hu, Yongzhou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9177-9204</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Macrocyclization has been frequently utilized for optimizing peptide or peptidomimetic-based compds.  In an attempt to obtain potent, metabolically stable, and orally available proteasome inhibitors, 30 oprozomib-derived macrocyclic peptides with structural diversity in their N-terminus and linker were successively designed and synthesized for structure-activity relationship (SAR) studies.  As a consequence, the macrocyclic peptides with N-methyl-pyrazole, imidazole, and pyrazole as their resp. N-termini exhibited favorable in vitro activity and metabolic stability, which translated into their potent in vivo proteasome inhibitory activity after oral administration.  In particular, pyrazole-contg. compd. (I), as the most distinguished one among this series, displayed excellent chymotrypsin-like (ChT-L, β5) inhibitory potency (IC50 = 16 nM), low nanomolar antiproliferative activity against all three of the tested cell lines, and superior metabolic stability in mouse liver microsome (MLM), as well as favorable inhibition against ChT-L compared to that of oprozomib in BABL/c mice following administration at a comparatively low dose, thereby representing a promising candidate for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYHTTVYr92xrVg90H21EOLACvtfcHk0lgnu3UvXZL0-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVantLzP&md5=958573573fe76d3b80e74fb0d7373c95</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00819%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DDevelopment%2520of%2520macrocyclic%2520peptides%2520containing%2520epoxyketone%2520with%2520oral%2520availability%2520as%2520proteasome%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9177%26epage%3D9204%26doi%3D10.1021%2Facs.jmedchem.8b00819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pogue, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dua, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukiw, W. J.</span></span> <span> </span><span class="NLM_article-title">Progressive inflammatory pathology in the retina of aluminum-fed 5xFAD transgenic mice</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1016/j.jinorgbio.2015.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2Fj.jinorgbio.2015.07.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=26213226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ChsL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2015&pages=206-209&author=A.+I.+Pogueauthor=P.+Duaauthor=J.+M.+Hillauthor=W.+J.+Lukiw&title=Progressive+inflammatory+pathology+in+the+retina+of+aluminum-fed+5xFAD+transgenic+mice&doi=10.1016%2Fj.jinorgbio.2015.07.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Progressive inflammatory pathology in the retina of aluminum-fed 5xFAD transgenic mice</span></div><div class="casAuthors">Pogue, A. I.; Dua, P.; Hill, J. M.; Lukiw, W. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">206-209</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">At least 57 murine transgenic models for Alzheimer's disease (Tg-AD) have been developed to overexpress the 42 amino acid amyloid-beta (Aβ42) peptide in the central nervous system (CNS).  These 'humanized murine Tg-AD models' have greatly expanded our understanding of the contribution of Aβ42 peptide-mediated pro-inflammatory neuropathol. to the AD process.  A no. of independent labs. using different amyloid-overexpressing Tg-AD models have shown that supplementation of murine Tg-AD diets and/or drinking water with aluminum significantly enhances Aβ42 peptide-mediated inflammatory pathol. and AD-type cognitive change compared to animals receiving control diets.  In humans AD-type pathol. appears to originate in the limbic system and progressively spreads into primary processing and sensory regions such as the retina.  In these studies, for the first time, we assess the propagation of Aβ42 and inflammatory signals into the retina of 5xFAD Tg-AD amyloid-overexpressing mice whose diets were supplemented with aluminum.  The two most interesting findings were (1) that similar to other Tg-AD models, there was a significantly accelerated development of Aβ42 and inflammatory pathol. in 5xFAD Tg-AD mice fed aluminum; and (2) in aluminum-supplemented animals, markers for inflammatory pathol. appeared in both the brain and the retina as evidenced by an evolving presence of Aβ42 peptides, and accompanied by inflammatory markers-cyclooxygenase-2 (COX-2) and C-reactive protein (CRP).  The results indicate that in the 5xFAD Tg-AD model aluminum not only enhances an Aβ42-mediated inflammatory degeneration of the brain but also appears to induce AD-type pathol. in an anatomically-linked primary sensory area that involves vision.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyaBfODuNRIbVg90H21EOLACvtfcHk0ljIwpog3vGjjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ChsL7I&md5=fcc91f8161110282e337a698565a5161</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2015.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2015.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DPogue%26aufirst%3DA.%2BI.%26aulast%3DDua%26aufirst%3DP.%26aulast%3DHill%26aufirst%3DJ.%2BM.%26aulast%3DLukiw%26aufirst%3DW.%2BJ.%26atitle%3DProgressive%2520inflammatory%2520pathology%2520in%2520the%2520retina%2520of%2520aluminum-fed%25205xFAD%2520transgenic%2520mice%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2015%26volume%3D152%26spage%3D206%26epage%3D209%26doi%3D10.1016%2Fj.jinorgbio.2015.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljubimov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross-Cisneros, F. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadun, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svendsen, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Ocular changes in TgF344-AD rat model of Alzheimer’s disease</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.1167/iovs.13-12888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1167%2Fiovs.13-12888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=24398104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Gltr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=523-534&author=Y.+Tsaiauthor=B.+Luauthor=A.+V.+Ljubimovauthor=S.+Girmanauthor=F.+N.+Ross-Cisnerosauthor=A.+A.+Sadunauthor=C.+N.+Svendsenauthor=R.+M.+Cohenauthor=S.+Wang&title=Ocular+changes+in+TgF344-AD+rat+model+of+Alzheimer%E2%80%99s+disease&doi=10.1167%2Fiovs.13-12888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Ocular changes in TgF344-AD rat model of Alzheimer's disease</span></div><div class="casAuthors">Tsai, Yuchun; Lu, Bin; Ljubimov, Alexander V.; Girman, Sergey; Ross-Cisneros, Fred N.; Sadun, Alfredo A.; Svendsen, Clive N.; Cohen, Robert M.; Wang, Shaomei</div><div class="citationInfo"><span class="NLM_cas:title">Investigative Ophthalmology & Visual Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">523-534</span>CODEN:
                <span class="NLM_cas:coden">IOVSDA</span>;
        ISSN:<span class="NLM_cas:issn">1552-5783</span>.
    
            (<span class="NLM_cas:orgname">Association for Research in Vision and Ophthalmology</span>)
        </div><div class="casAbstract">Purpose. Alzheimer's disease (AD) is the most common neurodegenerative disorder characterized by progressive decline in learning, memory, and executive functions.  In addn. to cognitive and behavioral deficits, vision disturbances have been reported in early stage of AD, well before the diagnosis is clearly established.  To further investigate ocular abnormalities, a novel AD transgenic rat model was analyzed.  Methods. Transgenic (Tg) rats (TgF344-AD) heterozygous for human mutant APPswe/PS1DE9 and age-matched wild type (WT) rats, as well as 20 human postmortem retinal samples from both AD and healthy donors were used.  Visual function in the rodent was analyzed using the optokinetic response and luminance threshold recording from the superior colliculus.  Immunohistochem. on retinal and brain sections was used to detect various markers including amyloid-β (Aβ) plaques.  Results. As expected, Aβ plaques were detected in the hippocampus, cortex, and retina of Tg rats.  Plaque-like structures were also found in two AD human whole-mount retinas.  The choroidal thickness was significantly reduced in both Tg rat and in AD human eyes when compared with age-matched controls.  Tg rat eyes also showed hypertrophic retinal pigment epithelial cells, inflammatory cells, and upregulation of complement factor C3.  Although visual acuity was lower in Tg than in WT rats, there was no significant difference in the retinal ganglion cell no. and retinal vasculature.  Conclusions. In this study, we obsd. pathol. changes in the choroid and in RPE cells in the TgF344-AD rat model; choroidal thinning was obsd. further in human AD retina.  Along with Aβ deposition, the inflammatory response was manifested by microglial recruitment and complement activation.  Further studies are needed to elucidate the significance and mechanisms of these pathol. changes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozYhkpwg3wIrVg90H21EOLACvtfcHk0ljIwpog3vGjjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Gltr7P&md5=f4c76f60b0aca2d0942b782a955f9789</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1167%2Fiovs.13-12888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.13-12888%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DLjubimov%26aufirst%3DA.%2BV.%26aulast%3DGirman%26aufirst%3DS.%26aulast%3DRoss-Cisneros%26aufirst%3DF.%2BN.%26aulast%3DSadun%26aufirst%3DA.%2BA.%26aulast%3DSvendsen%26aufirst%3DC.%2BN.%26aulast%3DCohen%26aufirst%3DR.%2BM.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DOcular%2520changes%2520in%2520TgF344-AD%2520rat%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2014%26volume%3D55%26spage%3D523%26epage%3D534%26doi%3D10.1167%2Fiovs.13-12888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasool, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glabe, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span> <span> </span><span class="NLM_article-title">Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer’s transgenic mice</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">2099</span>– <span class="NLM_lpage">2110</span>, <span class="refDoi"> DOI: 10.2353/ajpath.2009.090159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.2353%2Fajpath.2009.090159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=19834067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2009&pages=2099-2110&author=B.+Liuauthor=S.+Rasoolauthor=Z.+Yangauthor=C.+G.+Glabeauthor=S.+S.+Schreiberauthor=J.+Geauthor=Z.+Tan&title=Amyloid-peptide+vaccinations+reduce+%7Bbeta%7D-amyloid+plaques+but+exacerbate+vascular+deposition+and+inflammation+in+the+retina+of+Alzheimer%E2%80%99s+transgenic+mice&doi=10.2353%2Fajpath.2009.090159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid-peptide vaccinations reduce β-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice</span></div><div class="casAuthors">Liu, Bingqian; Rasool, Suhail; Yang, Zhikuan; Glabe, Charles G.; Schreiber, Steven S.; Ge, Jian; Tan, Zhiqun</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2099-2110</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is pathol. characterized by accumulation of β-amyloid (Aβ) protein deposits and/or neurofibrillary tangles in assocn. with progressive cognitive deficits.  Although numerous studies have demonstrated a relationship between brain pathol. and AD progression, the Alzheimer's pathol. hallmarks have not been found in the AD retina.  A recent report showed Aβ plaques in the retinas of APPswe/PS1ΔE9 transgenic mice.  We now report the detection of Aβ plaques with increased retinal microvascular deposition of Aβ and neuroinflammation in Tg2576 mouse retinas.  The majority of Aβ-immunoreactive plaques were detected from the ganglion cell layer to the inner plexiform layer, and some plaques were obsd. in the outer nuclear layer, photoreceptor outer segment, and optic nerve.  Hyperphosphorylated tau was labeled in the corresponding areas of the Aβ plaques in adjacent sections.  Although Aβ vaccinations reduced retinal Aβ deposits, there was a marked increase in retinal microvascular Aβ deposition as well as local neuroinflammation manifested by microglial infiltration and astrogliosis linked with disruption of the retinal organization.  These results provide evidence to support further investigation of the use of retinal imaging to diagnose AD and to monitor disease activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWWEOKqgNBzLVg90H21EOLACvtfcHk0ljIwpog3vGjjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSjtbo%253D&md5=b93c29a69c5a842cd61e1ccc694e9a40</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2009.090159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2009.090159%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DRasool%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DGlabe%26aufirst%3DC.%2BG.%26aulast%3DSchreiber%26aufirst%3DS.%2BS.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DZ.%26atitle%3DAmyloid-peptide%2520vaccinations%2520reduce%2520%257Bbeta%257D-amyloid%2520plaques%2520but%2520exacerbate%2520vascular%2520deposition%2520and%2520inflammation%2520in%2520the%2520retina%2520of%2520Alzheimer%25E2%2580%2599s%2520transgenic%2520mice%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2009%26volume%3D175%26spage%3D2099%26epage%3D2110%26doi%3D10.2353%2Fajpath.2009.090159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masuzzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanagh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krantic, S.</span></span> <span> </span><span class="NLM_article-title">Amyloidosis in retinal neurodegenerative diseases</span>. <i>Front. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">127</span> <span class="refDoi"> DOI: 10.3389/fneur.2016.00127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.3389%2Ffneur.2016.00127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=27551275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BC2szjsVarsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&author=A.+Masuzzoauthor=V.+Dinetauthor=C.+Cavanaghauthor=F.+Mascarelliauthor=S.+Krantic&title=Amyloidosis+in+retinal+neurodegenerative+diseases&doi=10.3389%2Ffneur.2016.00127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloidosis in Retinal Neurodegenerative Diseases</span></div><div class="casAuthors">Masuzzo Ambra; Dinet Virginie; Mascarelli Frederic; Krantic Slavica; Cavanagh Chelsea</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neurology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127</span>
        ISSN:<span class="NLM_cas:issn">1664-2295</span>.
    </div><div class="casAbstract">As a part of the central nervous system, the retina may reflect both physiological processes and abnormalities related to pathologies that affect the brain.  Amyloidosis due to the accumulation of amyloid-beta (Aβ) was initially regarded as a specific and exclusive characteristic of neurodegenerative alterations seen in the brain of Alzheimer's disease (AD) patients.  More recently, it was discovered that amyloidosis-related alterations, similar to those seen in the brain of Alzheimer's patients, also occur in the retina.  Remarkably, these alterations were identified not only in primary retinal pathologies, such as age-related macular degeneration (AMD) and glaucoma, but also in the retinas of Alzheimer's patients.  In this review, we first briefly discuss the biogenesis of Aβ, a peptide involved in amyloidosis.  We then discuss some pathological aspects (synaptic dysfunction, mitochondrial failure, glial activation, and vascular abnormalities) related to the neurotoxic effects of Aβ.  We finally highlight common features shared by AD, AMD, and glaucoma in the context of Aβ amyloidosis and further discuss why the retina, due to the transparency of the eye, can be considered as a "window" to the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgVWH_vPmpkd0Q2ypr7jHkfW6udTcc2ebz3XztmPLgubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szjsVarsg%253D%253D&md5=10b9324619c0d85505d60e69989d9ef8</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.3389%2Ffneur.2016.00127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffneur.2016.00127%26sid%3Dliteratum%253Aachs%26aulast%3DMasuzzo%26aufirst%3DA.%26aulast%3DDinet%26aufirst%3DV.%26aulast%3DCavanagh%26aufirst%3DC.%26aulast%3DMascarelli%26aufirst%3DF.%26aulast%3DKrantic%26aufirst%3DS.%26atitle%3DAmyloidosis%2520in%2520retinal%2520neurodegenerative%2520diseases%26jtitle%3DFront.%2520Neurol.%26date%3D2016%26volume%3D7%26doi%3D10.3389%2Ffneur.2016.00127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sivak, J. M.</span></span> <span> </span><span class="NLM_article-title">The aging eye: common degenerative mechanisms between the Alzheimer’s brain and retinal disease</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">871</span>– <span class="NLM_lpage">880</span>, <span class="refDoi"> DOI: 10.1167/iovs.12-10827</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1167%2Fiovs.12-10827" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=23364356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsFGhsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=871-880&author=J.+M.+Sivak&title=The+aging+eye%3A+common+degenerative+mechanisms+between+the+Alzheimer%E2%80%99s+brain+and+retinal+disease&doi=10.1167%2Fiovs.12-10827"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease</span></div><div class="casAuthors">Sivak, Jeremy M.</div><div class="citationInfo"><span class="NLM_cas:title">Investigative Ophthalmology & Visual Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">871-880, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">IOVSDA</span>;
        ISSN:<span class="NLM_cas:issn">1552-5783</span>.
    
            (<span class="NLM_cas:orgname">Association for Research in Vision and Ophthalmology</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a common, incurable, and progressive dementia, characterized by loss of learning and memory and the neuropathol. accumulation of amyloid plaques and neurofibrillary tangles in the brain.  A no. of similarities between AD pathol. and several distinct retinal degenerations have been described, particularly with respect to either glaucoma or age-related macular degeneration (AMD), each a leading cause of vision loss and blindness worldwide.  Although comparisons between these diseases may provide important new insights into their pathogenic mechanisms, glaucoma and AMD result in markedly different degenerations.  Therefore, analyses of the differences and the similarities between these conditions may prove equally productive.  Common mechanisms that appear to underlie all three diseases are explored here, as well as potential use of the retina as a biomarker for AD diagnosis and progression.  Based on this comparison, past and current efforts to transfer therapeutic strategies between diseases are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxGcgyGvaPBbVg90H21EOLACvtfcHk0ljmQTHD7kVIGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsFGhsr8%253D&md5=704d22062819dd71e3de0eb234f9ee1e</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1167%2Fiovs.12-10827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.12-10827%26sid%3Dliteratum%253Aachs%26aulast%3DSivak%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520aging%2520eye%253A%2520common%2520degenerative%2520mechanisms%2520between%2520the%2520Alzheimer%25E2%2580%2599s%2520brain%2520and%2520retinal%2520disease%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2013%26volume%3D54%26spage%3D871%26epage%3D880%26doi%3D10.1167%2Fiovs.12-10827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaarniranta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salminen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haapasalo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soininen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiltunen, M.</span></span> <span> </span><span class="NLM_article-title">Age-related macular degeneration (AMD): Alzheimer’s disease in the eye?</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">631</span>, <span class="refDoi"> DOI: 10.3233/JAD-2011-101908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.3233%2FJAD-2011-101908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=21297256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFyrs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=615-631&author=K.+Kaarnirantaauthor=A.+Salminenauthor=A.+Haapasaloauthor=H.+Soininenauthor=M.+Hiltunen&title=Age-related+macular+degeneration+%28AMD%29%3A+Alzheimer%E2%80%99s+disease+in+the+eye%3F&doi=10.3233%2FJAD-2011-101908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Age-Related Macular Degeneration (AMD): Alzheimer's Disease in the Eye?</span></div><div class="casAuthors">Kaarniranta, Kai; Salminen, Antero; Haapasalo, Annakaisa; Soininen, Hilkka; Hiltunen, Mikko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">615-631</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A review.  Age-related macular degeneration (AMD) is a late-onset, neurodegenerative retinal disease that shares several clin. and pathol. features with Alzheimer's disease (AD), including stress stimuli such as oxidative stress and inflammation.  In both diseases, the detrimental intra- and extracellular deposits have many similarities.  Aging, hypercholesterolemia, hypertension, obesity, arteriosclerosis, and smoking are risk factors to develop AMD and AD.  Cellular aging processes have similar organelle and signaling assocn. in the retina and brain tissues.  However, it seems that these diseases have a different genetic background.  In this review, differences and similarities of AMD and AD are thoroughly discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKjxD56K88lrVg90H21EOLACvtfcHk0ljmQTHD7kVIGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFyrs78%253D&md5=fee8550e40303de5941b33d9d37c1885</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.3233%2FJAD-2011-101908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2011-101908%26sid%3Dliteratum%253Aachs%26aulast%3DKaarniranta%26aufirst%3DK.%26aulast%3DSalminen%26aufirst%3DA.%26aulast%3DHaapasalo%26aufirst%3DA.%26aulast%3DSoininen%26aufirst%3DH.%26aulast%3DHiltunen%26aufirst%3DM.%26atitle%3DAge-related%2520macular%2520degeneration%2520%2528AMD%2529%253A%2520Alzheimer%25E2%2580%2599s%2520disease%2520in%2520the%2520eye%253F%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2011%26volume%3D24%26spage%3D615%26epage%3D631%26doi%3D10.3233%2FJAD-2011-101908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohno-Matsui, K.</span></span> <span> </span><span class="NLM_article-title">Parallel findings in age-related macular degeneration and Alzheimer’s disease</span>. <i>Prog. Retinal Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1016/j.preteyeres.2011.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2Fj.preteyeres.2011.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=21440663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BC3MrptlygtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=217-238&author=K.+Ohno-Matsui&title=Parallel+findings+in+age-related+macular+degeneration+and+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.preteyeres.2011.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Parallel findings in age-related macular degeneration and Alzheimer's disease</span></div><div class="casAuthors">Ohno-Matsui Kyoko</div><div class="citationInfo"><span class="NLM_cas:title">Progress in retinal and eye research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">217-38</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Age is a common risk factor for Alzheimer's disease (AD) and age-related macular degeneration (AMD).  Because of the increasing age of the population, these two age-related diseases have recently received a great deal of attention.  In addition to age as a risk factor, AD and AMD have many characteristics in common.  An important characteristic common to both diseases is the presence of amyloid β (Aβ) in the senile plaques of the AD brain and in the drusen of AMD patients.  We have focused on the role of Aβ as a key regulator of the progression from drusen to AMD, and our results have shown that Aβ causes an imbalance of angiogenesis-related factors in the retinal pigment epithelial (RPE) cells.  Mice that lack the Aβ-degrading enzyme neprilysin develop RPE degeneration, and the sub-RPE deposits that are formed have features similar to those of AMD in humans.  These data suggest that a common pathogenic mechanism might exist between AMD and AD.  Thus, therapeutic approaches that have targeted Aβ in patients with AD can also be applied to AMD.  In this review, we summarise recent findings on the shared characteristics and perspectives between AMD and AD, beginning with the mechanism of Aβ deposition and including a discussion of Aβ-targeted therapeutic approaches for both AD and AMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRA2QyQ5wswajToTC3aBaesfW6udTcc2ebrMTPIt7uk_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrptlygtA%253D%253D&md5=3169ac32125230c40b2d637c21915757</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.preteyeres.2011.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.preteyeres.2011.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DOhno-Matsui%26aufirst%3DK.%26atitle%3DParallel%2520findings%2520in%2520age-related%2520macular%2520degeneration%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DProg.%2520Retinal%2520Eye%2520Res.%26date%3D2011%26volume%3D30%26spage%3D217%26epage%3D238%26doi%3D10.1016%2Fj.preteyeres.2011.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiquita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues-Neves, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baptista, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carecho, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelo-Branco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosio, A. F.</span></span> <span> </span><span class="NLM_article-title">The retina as a window or mirror of the brain changes detected in Alzheimer’s disease: critical aspects to unravel</span>. <i>Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5416</span>– <span class="NLM_lpage">5435</span>, <span class="refDoi"> DOI: 10.1007/s12035-018-1461-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1007%2Fs12035-018-1461-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=30612332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVGjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2019&pages=5416-5435&author=S.+Chiquitaauthor=A.+C.+Rodrigues-Nevesauthor=F.+I.+Baptistaauthor=R.+Carechoauthor=P.+I.+Moreiraauthor=M.+Castelo-Brancoauthor=A.+F.+Ambrosio&title=The+retina+as+a+window+or+mirror+of+the+brain+changes+detected+in+Alzheimer%E2%80%99s+disease%3A+critical+aspects+to+unravel&doi=10.1007%2Fs12035-018-1461-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The Retina as a Window or Mirror of the Brain Changes Detected in Alzheimer's Disease: Critical Aspects to Unravel</span></div><div class="casAuthors">Chiquita, Samuel; Rodrigues-Neves, Ana C.; Baptista, Filipa I.; Carecho, Rafael; Moreira, Paula I.; Castelo-Branco, Miguel; Ambrosio, Antonio F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurobiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">5416-5435</span>CODEN:
                <span class="NLM_cas:coden">MONBEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-7648</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease is the most frequent cause of dementia worldwide, representing a global health challenge, with a massive impact on the quality of life of Alzheimer's disease patients and their relatives.  The diagnosis of Alzheimer's disease constitutes a real challenge, because the symptoms manifest years after the first degenerative changes occurring in the brain and the diagnosis is based on invasive and/or expensive techniques.  Therefore, there is an urgent need to identify new reliable biomarkers to detect Alzheimer's disease at an early stage.  Taking into account the evidence for visual deficits in Alzheimer's disease patients, sometimes even before the appearance of the first disease symptoms, and that the retina is an extension of the brain, the concept of the retina as a window to look into the brain or a mirror of the brain has received increasing interest in recent years.  However, only a few studies have assessed the changes occurring in the retina and the brain at the same time points.  Unlike previous reviews on this subject, which are mainly focused on brain changes, we organized this review by comprehensively summarizing findings related with structural, functional, cellular, and mol. parameters in the retina reported in both Alzheimer's disease patients and animal models.  Moreover, we sepd. the studies that assessed only the retina, and those that assessed both the retina and brain, which are few but allow establishing correlations between the retina and brain.  This review also highlights some inconsistent results in the literature as well as relevant missing gaps in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozpdva0-jg97Vg90H21EOLACvtfcHk0lhhm6wvu_tg0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVGjsb0%253D&md5=0ebea22232c4bbedc69172a357757766</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1007%2Fs12035-018-1461-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12035-018-1461-6%26sid%3Dliteratum%253Aachs%26aulast%3DChiquita%26aufirst%3DS.%26aulast%3DRodrigues-Neves%26aufirst%3DA.%2BC.%26aulast%3DBaptista%26aufirst%3DF.%2BI.%26aulast%3DCarecho%26aufirst%3DR.%26aulast%3DMoreira%26aufirst%3DP.%2BI.%26aulast%3DCastelo-Branco%26aufirst%3DM.%26aulast%3DAmbrosio%26aufirst%3DA.%2BF.%26atitle%3DThe%2520retina%2520as%2520a%2520window%2520or%2520mirror%2520of%2520the%2520brain%2520changes%2520detected%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520critical%2520aspects%2520to%2520unravel%26jtitle%3DMol.%2520Neurobiol.%26date%3D2019%26volume%3D56%26spage%3D5416%26epage%3D5435%26doi%3D10.1007%2Fs12035-018-1461-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00291&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Previously reported linear peptide epoxyketones targeting the immunoproteasome (iP) catalytic subunits LMP7 (a) and LMP2 (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00291&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure-aided design strategy for macrocyclic peptide epoxyketones. (a) Predicted docking model of DB-310 bound to LMP2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNF">3UNF</a>) from the mouse 20S immunoproteasome. (b) Proposed macrocyclization strategy between the P2 and P3/P4 residues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00291&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Strategy for Macrocyclic Analogues of DB-310<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00291&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: a: (a) HN(CH<sub>3</sub>)OCH<sub>3</sub>, HOBt, EDCI·HCl, DIPEA, DCM, rt, 12 h; (b) isopropenylmagnesium bromide, THF, −78 °C, 12 h; (c) (i) benzonitrile, H<sub>2</sub>O<sub>2</sub>, DIPEA, methanol, 0 °C to rt, 2 h; (ii) TFA, DCM, rt, 1 h, then evaporated and vacuum-dried. b: (a) HBTU, HOBt, DIPEA, DCM, rt, 18 h; (b) potassium carbonate, 4-bromo-1-butane, DMF, rt, 6 h; (c) allyl methyl carbonate, Pd(PPh<sub>3</sub>)<sub>4</sub>, THF, 60 °C, 3 h; (d) (i) TFA, DCM, rt, 1 h, then evaporated and dried; (ii) <i>N</i>-Boc-glycine (for compound <b>13</b>) or alkenyl carboxylic acid, HBTU, HOBt, DIPEA, DCM, rt, 18 h; (e) (i) Grubb’s second-generation catalyst, toluene, 90 °C, 1 h, purified by flash column chromatography; (ii) H<sub>2</sub>, Pd/C, methanol, rt, 1 h; (f) amine-deprotected epoxyketone (<b>4a</b>, <b>4b</b> or <b>4c</b>), HBTU, HOBt, DIPEA, DCM, rt, 18 h.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Macrocyclic Analogues of DB-310 with P3-Proline Substitutions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00291&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) allyl methyl carbonate, Pd(PPh<sub>3</sub>)<sub>4</sub>, THF, 60 °C, 3 h; (b) TFA, DCM, rt, 1 h, then evaporated and dried, <i>N</i>-Boc-proline derivative, HBTU, HOBt, DIPEA, DCM, rt, 18 h; (c) (1) TFA, DCM, rt, 1 h, then evaporated and dried; (2) alkenyl carboxylic acid, HBTU, HOBt, DIPEA, DCM, rt, 18 h; (d) (1) Grubb’s second-generation catalyst, toluene, 90 °C, 1 h, purified by flash column chromatography; (2) H<sub>2</sub>, Pd/C, methanol, rt, 1 h; (e) amine-deprotected epoxyketone (<b>4a</b>), HBTU, HOBt, DIPEA, DCM, rt, 18 h.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) LMP2 inhibitory activity of DB-60 (<b>20</b>) and other compounds in ABCB1-overexpressing RPMI-8226 cells. ABCB1-overexpressing RPMI-8226 cells or the parental RPMI-8226 cells were incubated with varying concentrations of respective compounds (<i>n</i> = 3 replicates per concentration). After 72 h, cell lysates were prepared to measure proteasome catalytic subunit activities (LMP2 and LMP7). Curve fitting analysis was performed to calculate IC<sub>50</sub> values reported as the mean ± SD. *Due to carfilzomib’s cytotoxic effect (a dual inhibitor of cP and iP), cells were incubated for 3 h, followed by the measurement of chymotrypsin-like (CT-L) activity. (b) Lack of interactions between DB-60 (<b>20</b>) and ABCG2. The inhibitory interactions with ABCG2 were assessed by measuring the changes in the cellular accumulation of pheophorbide A (PhA, a fluorescent ABCG2 substrate) using MDCKII cells stably expressing ABCG2 (established in our previous study41) and parental cells. The known ABCG2 inhibitor Ko143 was used as a positive control. After cells were preincubated in the complete medium containing PhA (1 μM) with Ko143 (0.2 μM) or DB-60 (<b>20</b>) (2 or 5 μM) at 37 °C for 30 min, cells were then washed with ice-cold medium and incubated again with Ko143 or DB-60 (<b>20</b>) for 45 min at 37 °C. Subsequently, the fluorescent signal was measured via flow cytometry using the excitation and emission wavelengths of 635 and 670 nm, respectively. Colored lines represent the following groups: gray, PhA only; orange, PhA in the presence of <b>20</b> (2 μM); red, PhA in the presence of <b>20</b> (5 μM); purple, PhA in the presence of Ko143 (0.2 μM) (<i>n</i> = 2 per group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00291&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) <i>In vitro</i> metabolic stability of DB-60 (<b>20</b>) in the whole blood or liver homogenates from mice. The whole blood and the liver were collected from ICR mice and incubated with the test compounds for the indicated time. The remaining drug levels were quantified (details provided in the Methods). <i>P</i> values were calculated using Student’s <i>t</i>-test (GraphPad Prism, v.8.4.1). (b) Effects of DB-60 (<b>20</b>) on LMP2 inhibition and IL-1α release in microglial BV-2 cells stimulated with lipopolysaccharide (LPS) (1 μg/mL). Error bars indicate standard deviation derived from three technical replicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00291&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) DB-60 (<b>20</b>) improves cognitive function in Tg2576 mice. The Morris water maze test was performed to measure cognitive function: escape distance (upper) and escape latency time (lower). Statistical analyses were performed using two-way ANOVA. *Difference in days 4–5 between control and DB-60 (<b>20</b>)-treated mice was statistically significant (<i>p</i>-value < 0.05, <i>n</i> = 12 for control and <i>n</i> = 5 for DB-60 (<b>20</b>)-treated mice). (b) Probe trial (on day 6, upper panel) and the passive avoidance test (on days 7 and 8, lower panel) were performed following the Morris water maze test on days 1–5. Student’s <i>t</i>-test was used for statistical analyses of probe trials and passive avoidance. Differences in time spent in the target quadrant or step-through latency between control and DB-60 (<b>20</b>)-treated mice were statistically significant (<i>p</i>-value < 0.05, <i>n</i> = 5). (c) Serum samples collected from mice treated with vehicle or DB-60 (<b>20</b>) were used to quantify IL-1α levels via ELISA (<i>p</i>-value < 0.05, <i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00291&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/medium/jm1c00291_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Protection of Tg2576 mice from retinal pigment epithelium (RPE) destruction by DB-60 (<b>20</b>). Upon completing behavior tests for Tg2576 mice treated with DB-60 (<b>20</b>), RPE samples were collected and immunostained using an anti-β-catenin antibody for visualization. A parallel experiment was also performed using age-matched nontransgenic ICR mice. The images are representative of three independent replicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00291/20210726/images/large/jm1c00291_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00291&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i88">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81367" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81367" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 52 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yiannopoulou, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasiou, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachariou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelidou, S. H.</span></span> <span> </span><span class="NLM_article-title">Reasons for failed trials of disease-modifying treatments for Alzheimer disease and their contribution in recent research</span>. <i>Biomedicines</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">97</span> <span class="refDoi"> DOI: 10.3390/biomedicines7040097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.3390%2Fbiomedicines7040097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1SitLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&author=K.+G.+Yiannopoulouauthor=A.+I.+Anastasiouauthor=V.+Zachariouauthor=S.+H.+Pelidou&title=Reasons+for+failed+trials+of+disease-modifying+treatments+for+Alzheimer+disease+and+their+contribution+in+recent+research&doi=10.3390%2Fbiomedicines7040097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Reasons for failed trials of disease-modifying treatments for Alzheimer disease and their contribution in recent research</span></div><div class="casAuthors">Yiannopoulou, Konstantina G.; Anastasiou, Aikaterini I.; Zachariou, Venetia; Pelou, Sygkliti-Henrietta</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicines</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">97</span>CODEN:
                <span class="NLM_cas:coden">BIOMID</span>;
        ISSN:<span class="NLM_cas:issn">2227-9059</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The most probable explanations for failures of disease-modifying treatments (DMTs) for AD may include late initiation of treatments during the course of AD development, inappropriate drug dosages, erroneous selection of treatment targets, and mainly an inadequate understanding of the complex pathophysiol. of AD, which may necessitate combination treatments rather than monotherapy.  Drug-development research for AD is aimed to overcome these drawbacks.  Preclin. and prodromal AD populations, as well as traditionally investigated populations representing all the clin. stages of AD, are included in recent trials.  The application of amyloid, tau, and neurodegeneration biomarkers, including new biomarkers-such as Tau positron emission tomog., neurofilament light chain (blood and Cerebrospinal fluid (CSF) biomarker of axonal degeneration) and neurogranin (CSF biomarker of synaptic functioning)-to clin. trials allows more precise staging of AD.  Addnl., use of Bayesian statistics, modifiable clin. trial designs, and clin. trial simulators enrich the trial methodol.  Besides, combination therapy regimens are assessed in clin. trials.  The above-mentioned diagnostic and statistical advances, which have been recently integrated in clin. trials, are relevant to the recent failures of studies of disease-modifying treatments.  Their experiential rather than theor. origins may better equip potentially successful drug-development strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLyhykjjZkYrVg90H21EOLACvtfcHk0lgQOqUxHaT03w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1SitLbJ&md5=33a9c1d07f4ec3584a5dab2548c6448f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3390%2Fbiomedicines7040097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiomedicines7040097%26sid%3Dliteratum%253Aachs%26aulast%3DYiannopoulou%26aufirst%3DK.%2BG.%26aulast%3DAnastasiou%26aufirst%3DA.%2BI.%26aulast%3DZachariou%26aufirst%3DV.%26aulast%3DPelidou%26aufirst%3DS.%2BH.%26atitle%3DReasons%2520for%2520failed%2520trials%2520of%2520disease-modifying%2520treatments%2520for%2520Alzheimer%2520disease%2520and%2520their%2520contribution%2520in%2520recent%2520research%26jtitle%3DBiomedicines%26date%3D2019%26volume%3D7%26doi%3D10.3390%2Fbiomedicines7040097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtzman, D. M.</span></span> <span> </span><span class="NLM_article-title">Alzheimer disease: an update on pathobiology and treatment strategies</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2Fj.cell.2019.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=31564456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVylsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2019&pages=312-339&author=J.+M.+Longauthor=D.+M.+Holtzman&title=Alzheimer+disease%3A+an+update+on+pathobiology+and+treatment+strategies&doi=10.1016%2Fj.cell.2019.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer Disease: An Update on Pathobiology and Treatment Strategies</span></div><div class="casAuthors">Long, Justin M.; Holtzman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">312-339</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Alzheimer disease (AD) is a heterogeneous disease with a complex pathobiol.  The presence of extracellular β-amyloid deposition as neuritic plaques and intracellular accumulation of hyperphosphorylated tau as neurofibrillary tangles remains the primary neuropathol. criteria for AD diagnosis.  However, a no. of recent fundamental discoveries highlight important pathol. roles for other crit. cellular and mol. processes.  Despite this, no disease-modifying treatment currently exists, and numerous phase 3 clin. trials have failed to demonstrate benefits.  Here, we review recent advances in our understanding of AD pathobiol. and discuss current treatment strategies, highlighting recent clin. trials and opportunities for developing future disease-modifying therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIdXAv0NNRFbVg90H21EOLACvtfcHk0lgFS46JRoyrWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVylsbrN&md5=b68edceb2c7ebe4515efded93c9281c3</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DJ.%2BM.%26aulast%3DHoltzman%26aufirst%3DD.%2BM.%26atitle%3DAlzheimer%2520disease%253A%2520an%2520update%2520on%2520pathobiology%2520and%2520treatment%2520strategies%26jtitle%3DCell%26date%3D2019%26volume%3D179%26spage%3D312%26epage%3D339%26doi%3D10.1016%2Fj.cell.2019.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blennow, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bateman, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinuevo, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touchon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellas, B.</span></span> <span> </span><span class="NLM_article-title">Anti-Tau trials for Alzheimer’s disease: a report from the EU/US/CTAD task force</span>. <i>J. Prev. Alzheimers Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.14283/jpad.2019.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.14283%2Fjpad.2019.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=31062825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BB3M7jtF2hsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=157-163&author=J.+Cummingsauthor=K.+Blennowauthor=K.+Johnsonauthor=M.+Keeleyauthor=R.+J.+Batemanauthor=J.+L.+Molinuevoauthor=J.+Touchonauthor=P.+Aisenauthor=B.+Vellas&title=Anti-Tau+trials+for+Alzheimer%E2%80%99s+disease%3A+a+report+from+the+EU%2FUS%2FCTAD+task+force&doi=10.14283%2Fjpad.2019.14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force</span></div><div class="casAuthors">Cummings J; Blennow K; Johnson K; Keeley M; Bateman R J; Molinuevo J L; Touchon J; Aisen P; Vellas B</div><div class="citationInfo"><span class="NLM_cas:title">The journal of prevention of Alzheimer's disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">157-163</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Efforts to develop effective disease-modifying treatments for Alzheimer's disease (AD) have mostly targeted the amyloid β (Aβ) protein; however, there has recently been increased interest in other targets including phosphorylated tau and other forms of tau.  Aggregated tau appears to spread in a characteristic pattern throughout the brain and is thought to drive neurodegeneration.  Both neuropathological and imaging studies indicate that tau first appears in the entorhinal cortex and then spreads to the neocortex.  Anti-tau therapies currently in Phase 1 or 2 trials include passive and active immunotherapies designed to prevent aggregation, seeding, and spreading, as well as small molecules that modulate tau metabolism and function.  EU/US/CTAD Task Force members support advancing the development of anti-tau therapies, which will require novel imaging agents and biomarkers, a deeper understanding of tau biology and the dynamic interaction of tau and Aβ protein, and development of multiple targets and candidate agents addressing the tauopathy of AD.  Incorporating tau biomarkers in AD clinical trials will provide additional knowledge about the potential to treat AD by targeting tau.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZi0VtAauolAMthz5_Rx5rfW6udTcc2eYPdT2ghrN097ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7jtF2hsw%253D%253D&md5=47291042d489a89979f46cae42d06179</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.14283%2Fjpad.2019.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14283%252Fjpad.2019.14%26sid%3Dliteratum%253Aachs%26aulast%3DCummings%26aufirst%3DJ.%26aulast%3DBlennow%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DKeeley%26aufirst%3DM.%26aulast%3DBateman%26aufirst%3DR.%2BJ.%26aulast%3DMolinuevo%26aufirst%3DJ.%2BL.%26aulast%3DTouchon%26aufirst%3DJ.%26aulast%3DAisen%26aufirst%3DP.%26aulast%3DVellas%26aufirst%3DB.%26atitle%3DAnti-Tau%2520trials%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520a%2520report%2520from%2520the%2520EU%252FUS%252FCTAD%2520task%2520force%26jtitle%3DJ.%2520Prev.%2520Alzheimers%2520Dis.%26date%3D2019%26volume%3D6%26spage%3D157%26epage%3D163%26doi%3D10.14283%2Fjpad.2019.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Congdon, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigurdsson, E. M.</span></span> <span> </span><span class="NLM_article-title">Tau-targeting therapies for Alzheimer’s disease</span>. <i>Nat. Rev. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">399</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.1038/s41582-018-0013-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1038%2Fs41582-018-0013-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=29895964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFaks73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=399-415&author=E.+E.+Congdonauthor=E.+M.+Sigurdsson&title=Tau-targeting+therapies+for+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fs41582-018-0013-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Tau-targeting therapies for Alzheimer disease</span></div><div class="casAuthors">Congdon, Erin E.; Sigurdsson, Einar M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neurology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">399-415</span>CODEN:
                <span class="NLM_cas:coden">NRNACP</span>;
        ISSN:<span class="NLM_cas:issn">1759-4758</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Alzheimer disease (AD) is the most common form of dementia.  Pathol., AD is characterized by amyloid plaques and neurofibrillary tangles in the brain, with assocd. loss of synapses and neurons, resulting in cognitive deficits and eventually dementia.  Amyloid-β (Aβ) peptide and tau protein are the primary components of the plaques and tangles, resp.  In the decades since Aβ and tau were identified, development of therapies for AD has primarily focused on Aβ, but tau has received more attention in recent years, in part because of the failure of various Aβ-targeting treatments in clin. trials.  In this article, we review the current status of tau-targeting therapies for AD.  Initially, potential anti-tau therapies were based mainly on inhibition of kinases or tau aggregation, or on stabilization of microtubules, but most of these approaches have been discontinued because of toxicity and/or lack of efficacy.  Currently, the majority of tau-targeting therapies in clin. trials are immunotherapies, which have shown promise in numerous preclin. studies.  Given that tau pathol. correlates better with cognitive impairments than do Aβ lesions, targeting of tau is expected to be more effective than Aβ clearance once the clin. symptoms are evident.  With future improvements in diagnostics, these two hallmarks of the disease might be targeted prophylactically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT0IYIr5ElmbVg90H21EOLACvtfcHk0lgFS46JRoyrWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFaks73M&md5=d26350964814206ce4860b7256c9d6a0</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fs41582-018-0013-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41582-018-0013-z%26sid%3Dliteratum%253Aachs%26aulast%3DCongdon%26aufirst%3DE.%2BE.%26aulast%3DSigurdsson%26aufirst%3DE.%2BM.%26atitle%3DTau-targeting%2520therapies%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2018%26volume%3D14%26spage%3D399%26epage%3D415%26doi%3D10.1038%2Fs41582-018-0013-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGeer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGeer, E. G.</span></span> <span> </span><span class="NLM_article-title">Inflammation, anti-inflammatory agents, and Alzheimer’s disease: the last 22 years</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">853</span>– <span class="NLM_lpage">857</span>, <span class="refDoi"> DOI: 10.3233/JAD-160488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.3233%2FJAD-160488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=27716676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BC2svotFGisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2016&pages=853-857&author=P.+L.+McGeerauthor=J.+Rogersauthor=E.+G.+McGeer&title=Inflammation%2C+anti-inflammatory+agents%2C+and+Alzheimer%E2%80%99s+disease%3A+the+last+22+years&doi=10.3233%2FJAD-160488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation, Antiinflammatory Agents, and Alzheimer's Disease: The Last 22 Years</span></div><div class="casAuthors">McGeer Patrick L; McGeer Edith G; Rogers Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's disease : JAD</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">853-857</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Two basic discoveries spurred research into inflammation as a driving force in the pathogenesis of Alzheimer's disease (AD).  The first was the identification of activated microglia in association with the lesions.  The second was the discovery that rheumatoid arthritics, who regularly consume anti-inflammatory agents, were relatively spared from the disease.  These findings led to an exploration of the inflammatory pathways that were involved in AD pathogenesis.  A pivotal advance was the discovery that amyloid-β protein (Aβ) activated the complement system.  This focused attention on anti-inflammatories as blockers of complement activation.  More than 15 epidemiological studies have since showed a sparing effect of non-steroidal anti-inflammatory drugs (NSAIDs) in AD.  A consistent finding has been that the longer the NSAIDs were used prior to clinical diagnosis, the greater the sparing effect.  The reason has since emerged from studies of biomarkers such as amyloid-β (Aβ) levels in the cerebrospinal fluid and Aβ deposits in brain.  They have established that the onset of AD commences at least a decade before cognitive decline permits clinical diagnosis.  Such biomarker studies have revealed that a huge window of opportunity exists when application of NSAIDs, other anti-inflammatory agents, or complement activation blockers, could arrest further progress of AD, thus eliminating its manifestation.  It can be anticipated that this principle will apply to many other chronic neurodegenerative diseases.  Neuroinflammation, discovered in AD more than 30 years ago, has now become a major field of brain research today.  Inhibiting it may be the key to successful treatment of many chronic neurological disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSzdOKynCN-UwlCcfExbvbfW6udTcc2eajxxjANV5Nlrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svotFGisg%253D%253D&md5=19d0eb6e39ba2b52a35e93e6e92bdee3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.3233%2FJAD-160488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-160488%26sid%3Dliteratum%253Aachs%26aulast%3DMcGeer%26aufirst%3DP.%2BL.%26aulast%3DRogers%26aufirst%3DJ.%26aulast%3DMcGeer%26aufirst%3DE.%2BG.%26atitle%3DInflammation%252C%2520anti-inflammatory%2520agents%252C%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520the%2520last%252022%2520years%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2016%26volume%3D54%26spage%3D853%26epage%3D857%26doi%3D10.3233%2FJAD-160488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellmann-Regen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costantini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reale, M.</span></span> <span> </span><span class="NLM_article-title">Neuroinflammation and Alzheimer’s disease: implications for microglial activation</span>. <i>Curr. Alzheimer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1140</span>– <span class="NLM_lpage">1148</span>, <span class="refDoi"> DOI: 10.2174/1567205014666170203141717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.2174%2F1567205014666170203141717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=28164764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BC1c3jsVKmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=1140-1148&author=F.+Regenauthor=J.+Hellmann-Regenauthor=E.+Costantiniauthor=M.+Reale&title=Neuroinflammation+and+Alzheimer%E2%80%99s+disease%3A+implications+for+microglial+activation&doi=10.2174%2F1567205014666170203141717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroinflammation and Alzheimer's Disease: Implications for Microglial Activation</span></div><div class="casAuthors">Regen Francesca; Hellmann-Regen Julian; Costantini Erica; Reale Marcella</div><div class="citationInfo"><span class="NLM_cas:title">Current Alzheimer research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1140-1148</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Microglial activation is a hallmark of neuroinflammation, seen in most acute and chronic neuropsychiatric conditions.  With growing knowledge about microglia functions in surveying the brain for alterations, microglial activation is increasingly discussed in the context of disease progression and pathogenesis of Alzheimer's disease (AD).  Underlying molecular mechanisms, however, remain largely unclear.  While proper microglial function is essentially required for its scavenging duties, local activation of the brain's innate immune cells also brings about many less advantageous changes, such as reactive oxygen species (ROS) production, secretion of proinflammatory cytokines or degradation of neuroprotective retinoids, and may thus unnecessarily put surrounding healthy neurons in danger.  In view of this dilemma, it is little surprising that both, AD vaccination trials, and also immunosuppressive strategies have consistently failed in AD patients.  Nevertheless, epidemiological evidence has suggested a protective effect for anti-inflammatory agents, supporting the hypothesis that key processes involved in the pathogenesis of AD may take place rather early in the time course of the disorder, likely long before memory impairment becomes clinically evident.  Activation of microglia results in a severely altered microenvironment.  This is not only caused by the plethora of secreted cytokines, chemokines or ROS, but may also involve increased turnover of neuroprotective endogenous substances such as retinoic acid (RA), as recently shown in vitro.  RESULTS:  We discuss findings linking microglial activation and AD and speculate that microglial malfunction, which brings about changes in local RA concentrations in vitro, may underlie AD pathogenesis and precede or facilitate the onset of AD.  Thus, chronic, "innate neuroinflammation" may provide a valuable target for preventive and therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR4-i3dKE7hx11C8OJBvdfbfW6udTcc2eajxxjANV5Nlrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3jsVKmsg%253D%253D&md5=0d790b9dfcb91be9eaa10ea0d31ce020</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2174%2F1567205014666170203141717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1567205014666170203141717%26sid%3Dliteratum%253Aachs%26aulast%3DRegen%26aufirst%3DF.%26aulast%3DHellmann-Regen%26aufirst%3DJ.%26aulast%3DCostantini%26aufirst%3DE.%26aulast%3DReale%26aufirst%3DM.%26atitle%3DNeuroinflammation%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520implications%2520for%2520microglial%2520activation%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2017%26volume%3D14%26spage%3D1140%26epage%3D1148%26doi%3D10.2174%2F1567205014666170203141717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liddelow, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guttenplan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirmer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munch, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilton, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frouin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napier, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panicker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckwalter, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowitch, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barres, B. A.</span></span> <span> </span><span class="NLM_article-title">Neurotoxic reactive astrocytes are induced by activated microglia</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>541</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1038/nature21029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1038%2Fnature21029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=28099414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Olt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=541&publication_year=2017&pages=481-487&author=S.+A.+Liddelowauthor=K.+A.+Guttenplanauthor=L.+E.+Clarkeauthor=F.+C.+Bennettauthor=C.+J.+Bohlenauthor=L.+Schirmerauthor=M.+L.+Bennettauthor=A.+E.+Munchauthor=W.+S.+Chungauthor=T.+C.+Petersonauthor=D.+K.+Wiltonauthor=A.+Frouinauthor=B.+A.+Napierauthor=N.+Panickerauthor=M.+Kumarauthor=M.+S.+Buckwalterauthor=D.+H.+Rowitchauthor=V.+L.+Dawsonauthor=T.+M.+Dawsonauthor=B.+Stevensauthor=B.+A.+Barres&title=Neurotoxic+reactive+astrocytes+are+induced+by+activated+microglia&doi=10.1038%2Fnature21029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotoxic reactive astrocytes are induced by activated microglia</span></div><div class="casAuthors">Liddelow, Shane A.; Guttenplan, Kevin A.; Clarke, Laura E.; Bennett, Frederick C.; Bohlen, Christopher J.; Schirmer, Lucas; Bennett, Mariko L.; Munch, Alexandra E.; Chung, Won-Suk; Peterson, Todd C.; Wilton, Daniel K.; Frouin, Arnaud; Napier, Brooke A.; Panicker, Nikhil; Kumar, Manoj; Buckwalter, Marion S.; Rowitch, David H.; Dawson, Valina L.; Dawson, Ted M.; Stevens, Beth; Barres, Ben A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">541</span>
        (<span class="NLM_cas:issue">7638</span>),
    <span class="NLM_cas:pages">481-487</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reactive astrocytes are strongly induced by central nervous system (CNS) injury and disease, but their role is poorly understood.  Here we show that a subtype of reactive astrocytes, which we termed A1, is induced by classically activated neuroinflammatory microglia.  We show that activated microglia induce A1 astrocytes by secreting Il-1α, TNF and C1q, and that these cytokines together are necessary and sufficient to induce A1 astrocytes.  A1 astrocytes lose the ability to promote neuronal survival, outgrowth, synaptogenesis and phagocytosis, and induce the death of neurons and oligodendrocytes.  Death of axotomized CNS neurons in vivo is prevented when the formation of A1 astrocytes is blocked.  Finally, we show that A1 astrocytes are abundant in various human neurodegenerative diseases including Alzheimer's, Huntington's and Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis.  Taken together these findings help to explain why CNS neurons die after axotomy, strongly suggest that A1 astrocytes contribute to the death of neurons and oligodendrocytes in neurodegenerative disorders, and provide opportunities for the development of new treatments for these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh7e-6d68IirVg90H21EOLACvtfcHk0li-0nnGepNZuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Olt74%253D&md5=bec380f741ffc971ec2072b6acaa301b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature21029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature21029%26sid%3Dliteratum%253Aachs%26aulast%3DLiddelow%26aufirst%3DS.%2BA.%26aulast%3DGuttenplan%26aufirst%3DK.%2BA.%26aulast%3DClarke%26aufirst%3DL.%2BE.%26aulast%3DBennett%26aufirst%3DF.%2BC.%26aulast%3DBohlen%26aufirst%3DC.%2BJ.%26aulast%3DSchirmer%26aufirst%3DL.%26aulast%3DBennett%26aufirst%3DM.%2BL.%26aulast%3DMunch%26aufirst%3DA.%2BE.%26aulast%3DChung%26aufirst%3DW.%2BS.%26aulast%3DPeterson%26aufirst%3DT.%2BC.%26aulast%3DWilton%26aufirst%3DD.%2BK.%26aulast%3DFrouin%26aufirst%3DA.%26aulast%3DNapier%26aufirst%3DB.%2BA.%26aulast%3DPanicker%26aufirst%3DN.%26aulast%3DKumar%26aufirst%3DM.%26aulast%3DBuckwalter%26aufirst%3DM.%2BS.%26aulast%3DRowitch%26aufirst%3DD.%2BH.%26aulast%3DDawson%26aufirst%3DV.%2BL.%26aulast%3DDawson%26aufirst%3DT.%2BM.%26aulast%3DStevens%26aufirst%3DB.%26aulast%3DBarres%26aufirst%3DB.%2BA.%26atitle%3DNeurotoxic%2520reactive%2520astrocytes%2520are%2520induced%2520by%2520activated%2520microglia%26jtitle%3DNature%26date%3D2017%26volume%3D541%26spage%3D481%26epage%3D487%26doi%3D10.1038%2Fnature21029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ising, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venegas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiblich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieira-Saecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albasset, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McManus, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tejera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griep, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosseron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stunden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golenbock, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heneka, M. T.</span></span> <span> </span><span class="NLM_article-title">NLRP3 inflammasome activation drives tau pathology</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>575</i></span>,  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1038/s41586-019-1769-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1038%2Fs41586-019-1769-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=31748742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitF2qt7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=575&publication_year=2019&pages=669-673&author=C.+Isingauthor=C.+Venegasauthor=S.+Zhangauthor=H.+Scheiblichauthor=S.+V.+Schmidtauthor=A.+Vieira-Saeckerauthor=S.+Schwartzauthor=S.+Albassetauthor=R.+M.+McManusauthor=D.+Tejeraauthor=A.+Griepauthor=F.+Santarelliauthor=F.+Brosseronauthor=S.+Opitzauthor=J.+Stundenauthor=M.+Mertenauthor=R.+Kayedauthor=D.+T.+Golenbockauthor=D.+Blumauthor=E.+Latzauthor=L.+Bueeauthor=M.+T.+Heneka&title=NLRP3+inflammasome+activation+drives+tau+pathology&doi=10.1038%2Fs41586-019-1769-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">NLRP3 inflammasome activation drives tau pathology</span></div><div class="casAuthors">Ising, Christina; Venegas, Carmen; Zhang, Shuangshuang; Scheiblich, Hannah; Schmidt, Susanne V.; Vieira-Saecker, Ana; Schwartz, Stephanie; Albasset, Shadi; McManus, Roisin M.; Tejera, Dario; Griep, Angelika; Santarelli, Francesco; Brosseron, Frederic; Opitz, Sabine; Stunden, James; Merten, Maximilian; Kayed, Rakez; Golenbock, Douglas T.; Blum, David; Latz, Eicke; Buee, Luc; Heneka, Michael T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">575</span>
        (<span class="NLM_cas:issue">7784</span>),
    <span class="NLM_cas:pages">669-673</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Alzheimer's disease is characterized by the accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together resulting in neurodegeneration and cognitive decline1.  The inflammasome inflammasome assembles inside of microglia on activation, leading to increased cleavage and activity of caspase-1 and downstream interleukin-1β release2.  Although the NLRP3 inflammasome has been shown to be essential for the development and progression of amyloid-beta pathol. in mice3, the precise effect on tau pathol. remains unknown.  Here we show that loss of NLRP3 inflammasome function reduced tau hyperphosphorylation and aggregation by regulating tau kinases and phosphatases.  Tau activated the NLRP3 inflammasome and intracerebral injection of fibrillar amyloid-beta-contg. brain homogenates induced tau pathol. in an NLRP3-dependent manner.  These data identify an important role of microglia and NLRP3 inflammasome activation in the pathogenesis of tauopathies and support the amyloid-cascade hypothesis in Alzheimer's disease, demonstrating that neurofibrillary tangles develop downstream of amyloid-beta-induced microglial activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCaPXz72o9VrVg90H21EOLACvtfcHk0ljlO-PAWy6wqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitF2qt7nE&md5=efd69ac9ce47699e362679c7c39265cc</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1769-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1769-z%26sid%3Dliteratum%253Aachs%26aulast%3DIsing%26aufirst%3DC.%26aulast%3DVenegas%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DScheiblich%26aufirst%3DH.%26aulast%3DSchmidt%26aufirst%3DS.%2BV.%26aulast%3DVieira-Saecker%26aufirst%3DA.%26aulast%3DSchwartz%26aufirst%3DS.%26aulast%3DAlbasset%26aufirst%3DS.%26aulast%3DMcManus%26aufirst%3DR.%2BM.%26aulast%3DTejera%26aufirst%3DD.%26aulast%3DGriep%26aufirst%3DA.%26aulast%3DSantarelli%26aufirst%3DF.%26aulast%3DBrosseron%26aufirst%3DF.%26aulast%3DOpitz%26aufirst%3DS.%26aulast%3DStunden%26aufirst%3DJ.%26aulast%3DMerten%26aufirst%3DM.%26aulast%3DKayed%26aufirst%3DR.%26aulast%3DGolenbock%26aufirst%3DD.%2BT.%26aulast%3DBlum%26aufirst%3DD.%26aulast%3DLatz%26aufirst%3DE.%26aulast%3DBuee%26aufirst%3DL.%26aulast%3DHeneka%26aufirst%3DM.%2BT.%26atitle%3DNLRP3%2520inflammasome%2520activation%2520drives%2520tau%2520pathology%26jtitle%3DNature%26date%3D2019%26volume%3D575%26spage%3D669%26epage%3D673%26doi%3D10.1038%2Fs41586-019-1769-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrivastav, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span> <span> </span><span class="NLM_article-title">Role of traditional nonsteroidal anti-inflammatory drugs in Alzheimer’s disease: a meta-analysis of randomized clinical trials</span>. <i>Am. J. Alzheimer’s Dis. Other Demen.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1177/1533317514542644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1177%2F1533317514542644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=25024454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BC2cbitFCrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2015&pages=178-182&author=P.+P.+Guptaauthor=R.+D.+Pandeyauthor=D.+Jhaauthor=V.+Shrivastavauthor=S.+Kumar&title=Role+of+traditional+nonsteroidal+anti-inflammatory+drugs+in+Alzheimer%E2%80%99s+disease%3A+a+meta-analysis+of+randomized+clinical+trials&doi=10.1177%2F1533317514542644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Role of traditional nonsteroidal anti-inflammatory drugs in Alzheimer's disease: a meta-analysis of randomized clinical trials</span></div><div class="casAuthors">Gupta Prem Prakash; Pandey Rishabh Dev; Jha Diwakar; Kumar Sandeep; Shrivastav Vikesh</div><div class="citationInfo"><span class="NLM_cas:title">American journal of Alzheimer's disease and other dementias</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The role of nonsteroidal anti-inflammatory drugs (NSAIDs) in prevention of Alzheimer's disease (AD) has been evaluated in many studies.  We performed a meta-analysis to summarize the existing evidence on the relation between use of classical NSAIDs and AD.  Randomized controlled trials (RCTs) evaluating the role of classical NSAIDs in AD was searched using different search engines.  The RCTs in patients who had the degree of AD measured on Mini-Mental State Examination (MMSE) or AD Assessment Scale-Cognitive subscale (ADAS-cog) were included in the study.  The RCTs and data (AD scores) were independently assessed by 2 reviewers, and data were included in meta-analysis only after a common consensus was reached.  The pooled results from the ADAS-cog and MMSE scores failed to show any difference between the treatment and the placebo groups as opposed to findings from some observational studies.  However, in view of heterogeneity of results, there is a need to conduct more RCTs to arrive at confirmatory findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR1kKqxjE0_lkNoizSOkG_FfW6udTcc2eaUWtmsJGsws7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbitFCrtg%253D%253D&md5=3e43f088e91631b405437d6aa737c0a9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1177%2F1533317514542644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1533317514542644%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DP.%2BP.%26aulast%3DPandey%26aufirst%3DR.%2BD.%26aulast%3DJha%26aufirst%3DD.%26aulast%3DShrivastav%26aufirst%3DV.%26aulast%3DKumar%26aufirst%3DS.%26atitle%3DRole%2520of%2520traditional%2520nonsteroidal%2520anti-inflammatory%2520drugs%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520a%2520meta-analysis%2520of%2520randomized%2520clinical%2520trials%26jtitle%3DAm.%2520J.%2520Alzheimer%25E2%2580%2599s%2520Dis.%2520Other%2520Demen.%26date%3D2015%26volume%3D30%26spage%3D178%26epage%3D182%26doi%3D10.1177%2F1533317514542644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chou, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghimire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gui, J.</span></span> <span> </span><span class="NLM_article-title">Treatment for rheumatoid arthritis and risk of Alzheimer’s disease: a nested case-control analysis</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1111</span>– <span class="NLM_lpage">1120</span>, <span class="refDoi"> DOI: 10.1007/s40263-016-0374-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1007%2Fs40263-016-0374-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=27470609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlWgur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=1111-1120&author=R.+C.+Chouauthor=M.+Kaneauthor=S.+Ghimireauthor=S.+Gautamauthor=J.+Gui&title=Treatment+for+rheumatoid+arthritis+and+risk+of+Alzheimer%E2%80%99s+disease%3A+a+nested+case-control+analysis&doi=10.1007%2Fs40263-016-0374-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment for Rheumatoid Arthritis and Risk of Alzheimer's Disease: A Nested Case-Control Analysis</span></div><div class="casAuthors">Chou, Richard C.; Kane, Michael; Ghimire, Sanjay; Gautam, Shiva; Gui, Jiang</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1111-1120</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Introduction: It is increasingly becoming accepted that inflammation may play an important role in the pathogenesis of Alzheimer's disease (AD), as several immune-related genes have been assocd. with AD.  Among these is tumor necrosis factor (TNF)-α, a proinflammatory cytokine known to play an important role in autoimmune disorders, including rheumatoid arthritis (RA).  Although AD and RA appear to involve similar pathol. mechanisms through the prodn. of TNF-α, the relationship between AD and RA remains unknown.  Objective: To det. the relative risk of AD among RA patients and non-RA patients, and whether anti-TNF therapy for RA was assocd. with a lower risk of AD in RA patients.  Methods: We performed a nested case-control study of more than 8.5 million com. insured adults (aged ≥18 years) in all 50 US states, Puerto Rico, and US Virgin Islands in the Verisk Health claims database.  We derived a sub-cohort of subjects with a diagnosis of RA (controls), or RA and AD (cases), matching cases and controls based on age, sex, exposure assessment period, and methotrexate treatment.  We also assessed relative risk of AD following exposure to std. RA therapies, including anti-TNF agents (infliximab, adalimumab, etanercept), methotrexate, prednisone, sulfasalazine, and rituximab.  Odds ratios were adjusted for comorbidities, including coronary artery disease, diabetes mellitus, and peripheral vascular disease.  Results: AD was more prevalent (p < 0.0001) among RA patients (0.79 %) than among those without RA (0.11 %).  Chronic conditions such as coronary artery disease (odds ratio [OR] 1.48; 95 % confidence interval [CI] 1.04-2.05; p = 0.03), diabetes (OR 1.86; 95 % CI 1.32-2.62; p = 0.0004), and peripheral vascular disease (OR 1.61; 95 % CI 1.06-2.43; p = 0.02) significantly increased the relative risk of AD among RA patients.  Exposure to anti-TNF agents as a class, but not other immunosuppressive drugs studied, was assocd. with lowered risk of AD among RA patients (unadjusted OR 0.44; 95 % CI 0.22-0.87; p = 0.02; adjusted OR 0.45; 95 % CI 0.23-0.90; p = 0.02).  Sub-group anal. demonstrated that of the three anti-TNF agents studied, only etanercept (unadjusted OR, 0.33; 95 % CI 0.08-0.94; p = 0.03; adjusted OR 0.30; 95 % CI 0.08-0.89; p = 0.02) was assocd. with a decreased risk of AD in RA patients.  Conclusion: There is an increased risk of AD in the studied RA population.  The relative risk of AD among RA subjects was lowered in those exposed to etanercept.  Anti-TNF therapy with etanercept shows promise as a potential treatment for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-UEOUpHXZ87Vg90H21EOLACvtfcHk0lgdz1qq9F4B4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlWgur7J&md5=7497cb4bf98a3725cf5a2b7e6da9264f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs40263-016-0374-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-016-0374-z%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DR.%2BC.%26aulast%3DKane%26aufirst%3DM.%26aulast%3DGhimire%26aufirst%3DS.%26aulast%3DGautam%26aufirst%3DS.%26aulast%3DGui%26aufirst%3DJ.%26atitle%3DTreatment%2520for%2520rheumatoid%2520arthritis%2520and%2520risk%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520a%2520nested%2520case-control%2520analysis%26jtitle%3DCNS%2520Drugs%26date%3D2016%26volume%3D30%26spage%3D1111%26epage%3D1120%26doi%3D10.1007%2Fs40263-016-0374-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Group, A. D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellwood, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hills, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crome, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raftery, J.</span></span> <span> </span><span class="NLM_article-title">Aspirin in Alzheimer’s disease (AD2000): a randomised open-label trial</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(07)70293-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2FS1474-4422%2807%2970293-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=18068522" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=41-49&author=A.+D.+C.+Groupauthor=P.+Benthamauthor=R.+Grayauthor=E.+Sellwoodauthor=R.+Hillsauthor=P.+Cromeauthor=J.+Raftery&title=Aspirin+in+Alzheimer%E2%80%99s+disease+%28AD2000%29%3A+a+randomised+open-label+trial&doi=10.1016%2FS1474-4422%2807%2970293-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2807%2970293-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252807%252970293-4%26sid%3Dliteratum%253Aachs%26aulast%3DGroup%26aufirst%3DA.%2BD.%2BC.%26aulast%3DBentham%26aufirst%3DP.%26aulast%3DGray%26aufirst%3DR.%26aulast%3DSellwood%26aufirst%3DE.%26aulast%3DHills%26aufirst%3DR.%26aulast%3DCrome%26aufirst%3DP.%26aulast%3DRaftery%26aufirst%3DJ.%26atitle%3DAspirin%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520%2528AD2000%2529%253A%2520a%2520randomised%2520open-label%2520trial%26jtitle%3DLancet%2520Neurol.%26date%3D2008%26volume%3D7%26spage%3D41%26epage%3D49%26doi%3D10.1016%2FS1474-4422%2807%2970293-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">The
Alzheimer’s Disease Anti-inflammatory Prevention Trial Research
Group</span> <span> </span><span class="NLM_article-title">Results of a follow-up
study to the randomized Alzheimer’s disease anti-inflammatory
prevention trial (ADAPT)</span>. <i>Alzheimer’s
Dementia</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">714</span>– <span class="NLM_lpage">723</span>, <span class="refDoi"> DOI: 10.1016/j.jalz.2012.11.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2Fj.jalz.2012.11.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=23562431" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=714-723&author=The%0AAlzheimer%E2%80%99s+Disease+Anti-inflammatory+Prevention+Trial+Research%0AGroup&title=Results+of+a+follow-up%0Astudy+to+the+randomized+Alzheimer%E2%80%99s+disease+anti-inflammatory%0Aprevention+trial+%28ADAPT%29&doi=10.1016%2Fj.jalz.2012.11.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2012.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2012.11.012%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DResults%2520of%2520a%2520follow-up%250Astudy%2520to%2520the%2520randomized%2520Alzheimer%25E2%2580%2599s%2520disease%2520anti-inflammatory%250Aprevention%2520trial%2520%2528ADAPT%2529%26jtitle%3DAlzheimer%25E2%2580%2599s%250ADementia%26date%3D2013%26volume%3D9%26spage%3D714%26epage%3D723%26doi%3D10.1016%2Fj.jalz.2012.11.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the immunoproteasome: current status and future directions</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4140</span>– <span class="NLM_lpage">4151</span>, <span class="refDoi"> DOI: 10.2174/1381612811319220018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.2174%2F1381612811319220018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=23181576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslyrtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4140-4151&author=Z.+Millerauthor=L.+Aoauthor=K.+B.+Kimauthor=W.+Lee&title=Inhibitors+of+the+immunoproteasome%3A+current+status+and+future+directions&doi=10.2174%2F1381612811319220018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the immunoproteasome: current status and future directions</span></div><div class="casAuthors">Miller, Zachary; Ao, Lin; Kim, Kyung Bo; Lee, Wooin</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4140-4151</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome system (UPS) plays a vital role in maintaining protein homeostasis and regulating numerous cellular processes.  The proteasome, a multi-protease complex, is the key component of the UPS and has been validated as a therapeutic target by the FDA's approval of bortezomib and carfilzomib.  These proteasome inhibitor drugs have substantially improved outcomes in patients with hematol. malignancies and are currently being investigated for other types of cancer as well as several other diseases.  These approved proteasome inhibitors target the catalytic activity of both the constitutive proteasome and the immunoproteasome indiscriminately, and their inhibitory effects on the constitutive proteasome in normal cells are believed to contribute to unwanted side effects.  In addn., selective immunoproteasome inhibition has been proposed to have unique effects on other diseases, including those involving aberrant immune function.  Initially recognized for its role in the adaptive immune response, the immunoproteasome is often upregulated in disease states such as inflammatory diseases and cancer, suggesting functions beyond antigen presentation.  In an effort to explore the immunoproteasome as a potential therapeutic target in these diseases, the development of immunoproteasome-specific inhibitors has become the focus of recent studies.  Owing to considerable efforts by both academic and industry groups, immunoproteasome-selective inhibitors have now been identified and tested against several disease models.  These inhibitors also provide a valuable set of chem. tools for investigating the biol. function of the immunoproteasome.  In this review, we will focus on the recent efforts towards the development of immunoproteasome-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiaZ1chVK_KrVg90H21EOLACvtfcHk0liBznhVcjL32Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslyrtrc%253D&md5=597fa7cdfee60647d64bad55a2bb0672</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F1381612811319220018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612811319220018%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DZ.%26aulast%3DAo%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DLee%26aufirst%3DW.%26atitle%3DInhibitors%2520of%2520the%2520immunoproteasome%253A%2520current%2520status%2520and%2520future%2520directions%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26spage%3D4140%26epage%3D4151%26doi%3D10.2174%2F1381612811319220018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">The immunoproteasome: a novel drug target for autoimmune diseases</span>. <i>Clin. Exp. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">S74</span>– <span class="NLM_lpage">S79</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=26458097" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=S74-S79&author=M.+Baslerauthor=S.+Mundtauthor=A.+Bitzerauthor=C.+Schmidtauthor=M.+Groettrup&title=The+immunoproteasome%3A+a+novel+drug+target+for+autoimmune+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DMundt%26aufirst%3DS.%26aulast%3DBitzer%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DC.%26aulast%3DGroettrup%26aufirst%3DM.%26atitle%3DThe%2520immunoproteasome%253A%2520a%2520novel%2520drug%2520target%2520for%2520autoimmune%2520diseases%26jtitle%3DClin.%2520Exp.%2520Rheumatol.%26date%3D2015%26volume%3D33%26spage%3DS74%26epage%3DS79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogorevc, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffrer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobec, S.</span></span> <span> </span><span class="NLM_article-title">A patent review of immunoproteasome inhibitors</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1080/13543776.2018.1484904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1080%2F13543776.2018.1484904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=29865878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFelsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=517-540&author=E.+Ogorevcauthor=E.+S.+Schiffrerauthor=I.+Sosicauthor=S.+Gobec&title=A+patent+review+of+immunoproteasome+inhibitors&doi=10.1080%2F13543776.2018.1484904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A patent review of immunoproteasome inhibitors</span></div><div class="casAuthors">Ogorevc, Eva; Schiffrer, Eva Shannon; Sosic, Izidor; Gobec, Stanislav</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">517-540</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome system is responsible for maintaining protein homeostasis and regulating a variety of cellular processes.  The constitutive proteasome is expressed in all cells while the immunoproteasome (IP) is predominantly found in cells of hematopoietic origin.  In other cells, the expression of IP can be induced under the influence of cytokines released by T cells during acute immune and stress responses.  Inhibitors of IP are of significant interest, because it is expected that selective inhibition of the IP would cause fewer adverse effects.  There is a considerable interest on patenting IP-specific inhibitors.  We also briefly report on the biochem. methods used in the patents to profile the characteristics of IP inhibitors.  Several selective inhibitors of IP with a promising ability to address autoimmune and inflammatory diseases are being developed.  Peptidic compds. are prevalent and the most advanced IP-selective compds. to date, ONX-0914 and KZR-616, are tripeptide epoxyketone-based mols.  However, some patents disclose that IP-selective inhibition is possible with compds. possessing non-peptidic scaffolds indicating countless possibilities to address inhibition of IP in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0dJE7LZsDw7Vg90H21EOLACvtfcHk0liBznhVcjL32Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFelsLnL&md5=1cbc997fb71e37c456548601b977e15f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1080%2F13543776.2018.1484904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2018.1484904%26sid%3Dliteratum%253Aachs%26aulast%3DOgorevc%26aufirst%3DE.%26aulast%3DSchiffrer%26aufirst%3DE.%2BS.%26aulast%3DSosic%26aufirst%3DI.%26aulast%3DGobec%26aufirst%3DS.%26atitle%3DA%2520patent%2520review%2520of%2520immunoproteasome%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2018%26volume%3D28%26spage%3D517%26epage%3D540%26doi%3D10.1080%2F13543776.2018.1484904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, H. W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderl, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D. L.</span></span> <span> </span><span class="NLM_article-title">A required immunoproteasome subunit inhibition profile for anti-inflammatory efficacy and clinical candidate KZR-616 ((2S,3R)-N-((S)-3-(cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2 -yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)pr openamide)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">11127</span>– <span class="NLM_lpage">11143</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVKltLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=11127-11143&author=H.+W.+B.+Johnsonauthor=E.+Loweauthor=J.+L.+Anderlauthor=A.+Fanauthor=T.+Muchamuelauthor=S.+Bowersauthor=D.+Moebiusauthor=C.+Kirkauthor=D.+L.+McMinn&title=A+required+immunoproteasome+subunit+inhibition+profile+for+anti-inflammatory+efficacy+and+clinical+candidate+KZR-616+%28%282S%2C3R%29-N-%28%28S%29-3-%28cyclopent-1-en-1-yl%29-1-%28%28R%29-2-methyloxiran-2-yl%29-1-oxopropan-2+-yl%29-3-hydroxy-3-%284-methoxyphenyl%29-2-%28%28S%29-2-%282-morpholinoacetamido%29propanamido%29pr+openamide%29&doi=10.1021%2Facs.jmedchem.8b01201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)</span></div><div class="casAuthors">Johnson, Henry W. B.; Lowe, Eric; Anderl, Janet L.; Fan, Andrea; Muchamuel, Tony; Bowers, Simeon; Moebius, David C.; Kirk, Christopher; McMinn, Dustin L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11127-11143</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective immunoproteasome inhibition is a promising approach for treating autoimmune disorders, but optimal proteolytic active site subunit inhibition profiles remain unknown.  We reveal here our design of peptide epoxyketone-based selective low mol. mass polypeptide-7 (LMP7) and multicatalytic endopeptidase complex subunit-1 (MECL-1) subunit inhibitors.  Utilizing these and our previously disclosed low mol. mass polypeptide-2 (LMP2) inhibitor, we demonstrate a requirement of dual LMP7/LMP2 or LMP7/MECL-1 subunit inhibition profiles for potent cytokine expression inhibition and in vivo efficacy in an inflammatory disease model.  These and addnl. findings toward optimized soly. led the design and selection of KZR-616 disclosed here and presently in clin. trials for treatment of rheumatic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNq1pg3kpVXrVg90H21EOLACvtfcHk0lia2Sj7sdOFMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVKltLfF&md5=70170b636fbb858edda5f571af45ca7f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01201%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DH.%2BW.%2BB.%26aulast%3DLowe%26aufirst%3DE.%26aulast%3DAnderl%26aufirst%3DJ.%2BL.%26aulast%3DFan%26aufirst%3DA.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DBowers%26aufirst%3DS.%26aulast%3DMoebius%26aufirst%3DD.%26aulast%3DKirk%26aufirst%3DC.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26atitle%3DA%2520required%2520immunoproteasome%2520subunit%2520inhibition%2520profile%2520for%2520anti-inflammatory%2520efficacy%2520and%2520clinical%2520candidate%2520KZR-616%2520%2528%25282S%252C3R%2529-N-%2528%2528S%2529-3-%2528cyclopent-1-en-1-yl%2529-1-%2528%2528R%2529-2-methyloxiran-2-yl%2529-1-oxopropan-2%2520-yl%2529-3-hydroxy-3-%25284-methoxyphenyl%2529-2-%2528%2528S%2529-2-%25282-morpholinoacetamido%2529propanamido%2529pr%2520openamide%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D11127%26epage%3D11143%26doi%3D10.1021%2Facs.jmedchem.8b01201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamphuis, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooves, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kooijman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimayuga Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hol, E. M.</span></span> <span> </span><span class="NLM_article-title">Reactive glia show increased immunoproteasome activity in Alzheimer’s disease</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">1415</span>– <span class="NLM_lpage">1431</span>, <span class="refDoi"> DOI: 10.1093/brain/awt083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1093%2Fbrain%2Fawt083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=23604491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BC3srmvFaisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2013&pages=1415-1431&author=M.+Orreauthor=W.+Kamphuisauthor=S.+Doovesauthor=L.+Kooijmanauthor=E.+T.+Chanauthor=C.+J.+Kirkauthor=V.+Dimayuga+Smithauthor=S.+Kootauthor=C.+Mamberauthor=A.+H.+Jansenauthor=H.+Ovaaauthor=E.+M.+Hol&title=Reactive+glia+show+increased+immunoproteasome+activity+in+Alzheimer%E2%80%99s+disease&doi=10.1093%2Fbrain%2Fawt083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive glia show increased immunoproteasome activity in Alzheimer's disease</span></div><div class="casAuthors">Orre Marie; Kamphuis Willem; Dooves Stephanie; Kooijman Lieneke; Chan Elena T; Kirk Christopher J; Dimayuga Smith Vanessa; Koot Sanne; Mamber Carlyn; Jansen Anne H; Ovaa Huib; Hol Elly M</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">Pt 5</span>),
    <span class="NLM_cas:pages">1415-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The proteasome is the major protein degradation system within the cell, comprised of different proteolytic subunits; amyloid-β is thought to impair its activity in Alzheimer's disease.  Neuroinflammation is a prominent hallmark of Alzheimer's disease, which may implicate an activation of the immunoproteasome, a specific proteasome variant induced by immune signalling that holds slightly different proteolytic properties than the constitutive proteasome.  Using a novel cell-permeable proteasome activity probe, we found that amyloid-β enhances proteasome activity in glial and neuronal cultures.  Additionally, using a subunit-specific proteasome activity assay we showed that in the cortex of the APPswePS1dE9 plaque pathology mouse model, immunoproteasome activities were strongly increased together with increased messenger RNA and protein expression in reactive glia surrounding plaques.  Importantly, this elevated activity was confirmed in human post-mortem tissue from donors with Alzheimer's disease.  These findings are in contrast with earlier studies, which reported impairment of proteasome activity in human Alzheimer's disease tissue and mouse models.  Targeting the increased immunoproteasome activity with a specific inhibitor resulted in a decreased expression of inflammatory markers in ex vivo microglia.  This may serve as a potential novel approach to modulate sustained neuroinflammation and glial dysfunction associated with Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtUv1o7ovLKYYPsCkJIw00fW6udTcc2eZijtjbMEAy-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srmvFaisg%253D%253D&md5=8ae273c3ca26fd107d41a141afa4e0ef</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawt083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawt083%26sid%3Dliteratum%253Aachs%26aulast%3DOrre%26aufirst%3DM.%26aulast%3DKamphuis%26aufirst%3DW.%26aulast%3DDooves%26aufirst%3DS.%26aulast%3DKooijman%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DE.%2BT.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DDimayuga%2BSmith%26aufirst%3DV.%26aulast%3DKoot%26aufirst%3DS.%26aulast%3DMamber%26aufirst%3DC.%26aulast%3DJansen%26aufirst%3DA.%2BH.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DHol%26aufirst%3DE.%2BM.%26atitle%3DReactive%2520glia%2520show%2520increased%2520immunoproteasome%2520activity%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBrain%26date%3D2013%26volume%3D136%26spage%3D1415%26epage%3D1431%26doi%3D10.1093%2Fbrain%2Fawt083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mishto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellavista, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolzing, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligorio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacmias, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spazzafumo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiappelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licastro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorbi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pession, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grune, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, C.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome and LMP2 polymorphism in aged and Alzheimer’s disease brains</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2004.12.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2Fj.neurobiolaging.2004.12.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=16298241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1egsr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=54-66&author=M.+Mishtoauthor=E.+Bellavistaauthor=A.+Santoroauthor=A.+Stolzingauthor=C.+Ligorioauthor=B.+Nacmiasauthor=L.+Spazzafumoauthor=M.+Chiappelliauthor=F.+Licastroauthor=S.+Sorbiauthor=A.+Pessionauthor=T.+Ohmauthor=T.+Gruneauthor=C.+Franceschi&title=Immunoproteasome+and+LMP2+polymorphism+in+aged+and+Alzheimer%E2%80%99s+disease+brains&doi=10.1016%2Fj.neurobiolaging.2004.12.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains</span></div><div class="casAuthors">Mishto, Michele; Bellavista, Elena; Santoro, Aurelia; Stolzing, Alexandra; Ligorio, Claudia; Nacmias, Benedetta; Spazzafumo, Liana; Chiappelli, Martina; Licastro, Federico; Sorbi, Sandro; Pession, Annalisa; Ohm, Thomas; Grune, Tilman; Franceschi, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-66</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In this study, we investigated the presence and role of immunoproteasome and its LMP2 subunit polymorphism at codon 60 in Alzheimer's disease (AD).  Immunoproteasome was present in brain areas such as hippocampus and cerebellum and localized in neurons, astrocytes and endothelial cells.  A higher expression of immunoproteasome was found in brain of AD patients than in brain of non-demented elderly, being its expression in young brain negligible or absent.  Furthermore, AD affected regions showed a partial decrease in proteasome trypsin-like activity.  The study of LMP2 polymorphism (R/H) showed that it does not influence LMP2 expression (neither the mRNA nor mature protein) in brain tissue.  However, control brain areas of AD patients carrying the RR genotype showed an increased proteasome activity in comparison with RH carriers.  To test whether this effect of the genotype might be related to AD onset we performed a genetic study, which allowed us to exclude an assocn. of LMP2 codon 60 polymorphism with AD onset, despite its influence on the proteasome activity in human brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBR5TJqY4-frVg90H21EOLACvtfcHk0lia2Sj7sdOFMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1egsr3E&md5=cb7aeff396023f3fcfd6664e775b2c06</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2004.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2004.12.004%26sid%3Dliteratum%253Aachs%26aulast%3DMishto%26aufirst%3DM.%26aulast%3DBellavista%26aufirst%3DE.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DStolzing%26aufirst%3DA.%26aulast%3DLigorio%26aufirst%3DC.%26aulast%3DNacmias%26aufirst%3DB.%26aulast%3DSpazzafumo%26aufirst%3DL.%26aulast%3DChiappelli%26aufirst%3DM.%26aulast%3DLicastro%26aufirst%3DF.%26aulast%3DSorbi%26aufirst%3DS.%26aulast%3DPession%26aufirst%3DA.%26aulast%3DOhm%26aufirst%3DT.%26aulast%3DGrune%26aufirst%3DT.%26aulast%3DFranceschi%26aufirst%3DC.%26atitle%3DImmunoproteasome%2520and%2520LMP2%2520polymorphism%2520in%2520aged%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%2520brains%26jtitle%3DNeurobiol.%2520Aging%26date%3D2006%26volume%3D27%26spage%3D54%26epage%3D66%26doi%3D10.1016%2Fj.neurobiolaging.2004.12.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mishto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonafe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvioli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, C.</span></span> <span> </span><span class="NLM_article-title">Age dependent impact of LMP polymorphisms on TNF-alpha-induced apoptosis in human peripheral blood mononuclear cells</span>. <i>Exp. Gerontol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1016/S0531-5565(01)00196-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2FS0531-5565%2801%2900196-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=11772516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BD38XitlGn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2002&pages=301-308&author=M.+Mishtoauthor=M.+Bonafeauthor=S.+Salvioliauthor=F.+Olivieriauthor=C.+Franceschi&title=Age+dependent+impact+of+LMP+polymorphisms+on+TNF-alpha-induced+apoptosis+in+human+peripheral+blood+mononuclear+cells&doi=10.1016%2FS0531-5565%2801%2900196-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Age dependent impact of LMP polymorphisms on TNFα-induced apoptosis in human peripheral blood mononuclear cells</span></div><div class="casAuthors">Mishto, M.; Bonafe, M.; Salvioli, S.; Olivieri, F.; Franceschi, C.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Gerontology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">301-308</span>CODEN:
                <span class="NLM_cas:coden">EXGEAB</span>;
        ISSN:<span class="NLM_cas:issn">0531-5565</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">As a consequence of inflammatory stimuli (such as TNFα and IFNγ), some constitutive subunits of the proteasome, the principal mediator of nonlysosomal protein degrdn., are replaced with other subunits, the large multifunctional proteases LMP2 and LMP7, thus originating the immunoproteasome.  An age-related alteration of proteasome activity and susceptibility to TNFα-induced apoptosis, in which LMP2 and the nuclear factor (NF)-κB activation play an important role has been recently reported.  In this paper, we investigated the possible influence of two LMP2 and LMP7 polymorphisms on susceptibility to TNFα-induced apoptosis.  Our data show that an increase in susceptibility to TNFα-induced apoptosis is evident in long-lived people (aged >88 yr) in comparison to young individuals.  Moreover, the modulation of LMP2 codon 60 polymorphism on TNFα-induced apoptosis is evident in long-lived subjects.  Genotyping of 311 young people and 157 nonagenarians and centenarians revealed no changes in LMP2 codon 60 genotype frequency distribution.  No correlation with TNFα-induced apoptosis and no difference in frequency between young people and nonagenarians/centenarians was obsd. when the LMP7 nucleotide 145 polymorphism was studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryPeO3AGCLR7Vg90H21EOLACvtfcHk0lhTIJwK8sG30w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitlGn&md5=f4fbae49fa294f53b0cf204f2bf9d2e7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0531-5565%2801%2900196-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0531-5565%252801%252900196-6%26sid%3Dliteratum%253Aachs%26aulast%3DMishto%26aufirst%3DM.%26aulast%3DBonafe%26aufirst%3DM.%26aulast%3DSalvioli%26aufirst%3DS.%26aulast%3DOlivieri%26aufirst%3DF.%26aulast%3DFranceschi%26aufirst%3DC.%26atitle%3DAge%2520dependent%2520impact%2520of%2520LMP%2520polymorphisms%2520on%2520TNF-alpha-induced%2520apoptosis%2520in%2520human%2520peripheral%2520blood%2520mononuclear%2520cells%26jtitle%3DExp.%2520Gerontol.%26date%3D2002%26volume%3D37%26spage%3D301%26epage%3D308%26doi%3D10.1016%2FS0531-5565%2801%2900196-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilling, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schormann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloetzel, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prokop, S.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome deficiency alters microglial cytokine response and improves cognitive deficits in Alzheimer’s disease-like APPPS1 mice</span>. <i>Acta Neuropathol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">52</span> <span class="refDoi"> DOI: 10.1186/s40478-017-0453-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1186%2Fs40478-017-0453-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=28646899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvF2qt7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&author=L.+K.+Wagnerauthor=K.+E.+Gillingauthor=E.+Schormannauthor=P.+M.+Kloetzelauthor=F.+L.+Heppnerauthor=E.+Krugerauthor=S.+Prokop&title=Immunoproteasome+deficiency+alters+microglial+cytokine+response+and+improves+cognitive+deficits+in+Alzheimer%E2%80%99s+disease-like+APPPS1+mice&doi=10.1186%2Fs40478-017-0453-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasome deficiency alters microglial cytokine response and improves cognitive deficits in Alzheimer's disease-like APPPS1 mice</span></div><div class="casAuthors">Wagner, Lisa K.; Gilling, Kate E.; Schormann, Eileen; Kloetzel, Peter M.; Heppner, Frank L.; Krueger, Elke; Prokop, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neuropathologica Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">52/1-52/16</span>CODEN:
                <span class="NLM_cas:coden">ANCCC9</span>;
        ISSN:<span class="NLM_cas:issn">2051-5960</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The immunoproteasome (iP) represents a specialized type of proteasomes, which plays an important role in the clearance of oxidant-damaged proteins under inflammatory and pathol. conditions detg. the outcome of various diseases.  In Alzheimer's disease (AD)-like APPPS1 mice Aβ-deposition is paralleled by iP upregulation,most likely mediated through type I interferon induction.  To define the impact of increased iP expression we crossed APPPS1 mice with mice deficient in the iP subunit LMP7 resulting in impaired iP function.  While LMP7 deficient APPPS1 mice showed no major change in cerebral Aβ-pathol., we obsd. an altered cytokine response in microglia isolated from LMP7 deficient APPPS1 mice compared to LMP7 expressing APPPS1 control mice.  The altered microglial cytokine profile upon iP deficiency in the presence of extracellular Aβ-pathol. was assocd. with an improvement of Aβ-assocd. cognitive deficits typically present in APPPS1 mice.  Our findings suggest a role for iP in the regulation of the innate immune response towards extracellular Aβ-pathol. and indicate that inhibition of iP function can modulate the cognitive phenotype upon overexpression of Aβ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9-Es2yxPY3LVg90H21EOLACvtfcHk0lhTIJwK8sG30w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvF2qt7vI&md5=4de0d34ef2bf87269cf1c26d6ec11052</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1186%2Fs40478-017-0453-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40478-017-0453-5%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DL.%2BK.%26aulast%3DGilling%26aufirst%3DK.%2BE.%26aulast%3DSchormann%26aufirst%3DE.%26aulast%3DKloetzel%26aufirst%3DP.%2BM.%26aulast%3DHeppner%26aufirst%3DF.%2BL.%26aulast%3DKruger%26aufirst%3DE.%26aulast%3DProkop%26aufirst%3DS.%26atitle%3DImmunoproteasome%2520deficiency%2520alters%2520microglial%2520cytokine%2520response%2520and%2520improves%2520cognitive%2520deficits%2520in%2520Alzheimer%25E2%2580%2599s%2520disease-like%2520APPPS1%2520mice%26jtitle%3DActa%2520Neuropathol.%2520Commun.%26date%3D2017%26volume%3D5%26doi%3D10.1186%2Fs40478-017-0453-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abera, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viollet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yauger, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukumar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgard, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, B. G.</span></span> <span> </span><span class="NLM_article-title">The role of the immunoproteasome in interferon-gamma-mediated microglial activation</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">9365</span> <span class="refDoi"> DOI: 10.1038/s41598-017-09715-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1038%2Fs41598-017-09715-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=28839214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BC1cbhsVOjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&author=K.+E.+Moritzauthor=N.+M.+McCormackauthor=M.+B.+Aberaauthor=C.+Violletauthor=Y.+J.+Yaugerauthor=G.+Sukumarauthor=C.+L.+Dalgardauthor=B.+G.+Burnett&title=The+role+of+the+immunoproteasome+in+interferon-gamma-mediated+microglial+activation&doi=10.1038%2Fs41598-017-09715-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the immunoproteasome in interferon-γ-mediated microglial activation</span></div><div class="casAuthors">Moritz Kasey E; McCormack Nikki M; Yauger Young J; Dalgard Clifton L; Burnett Barrington G; Abera Mahlet B; Dalgard Clifton L; Burnett Barrington G; Viollet Coralie; Sukumar Gauthaman; Dalgard Clifton L; Dalgard Clifton L</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9365</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Microglia regulate the brain microenvironment by sensing damage and neutralizing potentially harmful insults.  Disruption of central nervous system (CNS) homeostasis results in transition of microglia to a reactive state characterized by morphological changes and production of cytokines to prevent further damage to CNS tissue.  Immunoproteasome levels are elevated in activated microglia in models of stroke, infection and traumatic brain injury, though the exact role of the immunoproteasome in neuropathology remains poorly defined.  Using gene expression analysis and native gel electrophoresis we characterize the expression and assembly of the immunoproteasome in microglia following interferon-gamma exposure.  Transcriptome analysis suggests that the immunoproteasome regulates multiple features of microglial activation including nitric oxide production and phagocytosis.  We show that inhibiting the immunoproteasome attenuates expression of pro-inflammatory cytokines and suppresses interferon-gamma-dependent priming of microglia.  These results imply that targeting immunoproteasome function following CNS injury may attenuate select microglial activity to improve the pathophysiology of neurodegenerative conditions or the progress of inflammation-mediated secondary injury following neurotrauma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxLyW0tp5b8BFwe7cAcrfPfW6udTcc2eb-x6d3VRHQa7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbhsVOjuw%253D%253D&md5=b514ee91f5ca276a7cdbad97d458eed5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-09715-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-09715-y%26sid%3Dliteratum%253Aachs%26aulast%3DMoritz%26aufirst%3DK.%2BE.%26aulast%3DMcCormack%26aufirst%3DN.%2BM.%26aulast%3DAbera%26aufirst%3DM.%2BB.%26aulast%3DViollet%26aufirst%3DC.%26aulast%3DYauger%26aufirst%3DY.%2BJ.%26aulast%3DSukumar%26aufirst%3DG.%26aulast%3DDalgard%26aufirst%3DC.%2BL.%26aulast%3DBurnett%26aufirst%3DB.%2BG.%26atitle%3DThe%2520role%2520of%2520the%2520immunoproteasome%2520in%2520interferon-gamma-mediated%2520microglial%2520activation%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26doi%3D10.1038%2Fs41598-017-09715-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer’s disease</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">18393</span> <span class="refDoi"> DOI: 10.1038/s41598-019-54846-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1038%2Fs41598-019-54846-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=31804556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGhsrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&author=I.+J.+Yeoauthor=M.+J.+Leeauthor=A.+Baekauthor=Z.+Millerauthor=D.+Bhattaraiauthor=Y.+M.+Baekauthor=H.+J.+Jeongauthor=Y.+K.+Kimauthor=D.+E.+Kimauthor=J.+T.+Hongauthor=K.+B.+Kim&title=A+dual+inhibitor+of+the+proteasome+catalytic+subunits+LMP2+and+Y+attenuates+disease+progression+in+mouse+models+of+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fs41598-019-54846-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer's disease</span></div><div class="casAuthors">Yeo, In Jun; Lee, Min Jae; Baek, Ahruem; Miller, Zachary; Bhattarai, Deepak; Baek, Yu Mi; Jeong, Hyun Jung; Kim, Yun Kyung; Kim, Dong-Eun; Hong, Jin Tae; Kim, Kyung Bo</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18393</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The immunoproteasome (iP) is a variant of the constitutive proteasome (cP) that is abundantly expressed in immune cells which can also be induced in somatic cells by cytokines such as TNF-a or IFN-κ.  Accumulating evidence support that the iP is closely linked to multiple facets of inflammatory response, eventually leading to the development of several iP inhibitors as potential therapeutic agents for autoimmune diseases.  Recent studies also found that the iP is upregulated in reactive glial cells surrounding amyloid β (Aβ) deposits in brains of Alzheimer's disease (AD) patients, but the role it plays in the pathogenesis of AD remains unclear.  In this study, we investigated the effects of several proteasome inhibitors on cognitive function in AD mouse models and found that YU102, a dual inhibitor of the iP catalytic subunit LMP2 and the cP catalytic subunit Y, ameliorates cognitive impairments in AD mouse models without affecting Aβ deposition.  The data obtained from our investigation revealed that YU102 suppresses the secretion of inflammatory cytokines from microglial cells.  Overall, this study indicates that there may exist a potential link between LMP2/Y and microglia-mediated neuroinflammation and that inhibition of these subunits may offer a new therapeutic strategy for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQXqRAKDBNL7Vg90H21EOLACvtfcHk0lizNLmmW9nVNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGhsrvM&md5=67f2deacfc69d76c76ca9334f70d1a75</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-54846-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-54846-z%26sid%3Dliteratum%253Aachs%26aulast%3DYeo%26aufirst%3DI.%2BJ.%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DBaek%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DZ.%26aulast%3DBhattarai%26aufirst%3DD.%26aulast%3DBaek%26aufirst%3DY.%2BM.%26aulast%3DJeong%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DY.%2BK.%26aulast%3DKim%26aufirst%3DD.%2BE.%26aulast%3DHong%26aufirst%3DJ.%2BT.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DA%2520dual%2520inhibitor%2520of%2520the%2520proteasome%2520catalytic%2520subunits%2520LMP2%2520and%2520Y%2520attenuates%2520disease%2520progression%2520in%2520mouse%2520models%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26doi%3D10.1038%2Fs41598-019-54846-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">LMP2 inhibitors as a potential treatment for Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3763</span>– <span class="NLM_lpage">3783</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00416</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00416" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlt1Cktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3763-3783&author=D.+Bhattaraiauthor=M.+J.+Leeauthor=A.+Baekauthor=I.+J.+Yeoauthor=Z.+Millerauthor=Y.+M.+Baekauthor=S.+Leeauthor=D.+E.+Kimauthor=J.+T.+Hongauthor=K.+B.+Kim&title=LMP2+inhibitors+as+a+potential+treatment+for+Alzheimer%E2%80%99s+disease&doi=10.1021%2Facs.jmedchem.0c00416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">LMP2 Inhibitors as a Potential Treatment for Alzheimer's Disease</span></div><div class="casAuthors">Bhattarai, Deepak; Lee, Min Jae; Baek, Ahruem; Yeo, In Jun; Miller, Zachary; Baek, Yu Mi; Lee, Sukyeong; Kim, Dong-Eun; Hong, Jin Tae; Kim, Kyung Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3763-3783</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The immunoproteasome (iP), an inducible proteasome variant harboring three immunosubunits, low mol. mass polypeptide-2 (LMP2), multicatalytic endopeptidase complex subunit-1, and low mol. mass polypeptide-7 (LMP7), is involved in multiple facets of inflammatory responses.  We recently reported that YU102, a dual inhibitor of the iP subunit LMP2 and the constitutive proteasome catalytic subunit β1, ameliorates cognitive impairments in mouse models of Alzheimer's disease (AD) independently of amyloid deposits.  To investigate whether inhibition of LMP2 is sufficient to improve the cognitive functions of AD mice, here we prepd. 37 YU102 analogs and identified a potent LMP2 inhibitor DB-310 (28) (IC50: 80.6 nM) with improved selectivity and permeability in cells overexpressing ABCB1 transporters.  We show that DB-310 induces suppression of IL-1α prodn. in microglia cells and improves cognitive functions in the Tg2576 transgenic mouse model of AD.  This study supports that inhibition of LMP2 is a promising therapeutic strategy for treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWVF7Wt9HxE7Vg90H21EOLACvtfcHk0lizNLmmW9nVNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlt1Cktb8%253D&md5=6b2ae19d692a78b2a7654a0ef713431a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00416%26sid%3Dliteratum%253Aachs%26aulast%3DBhattarai%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DBaek%26aufirst%3DA.%26aulast%3DYeo%26aufirst%3DI.%2BJ.%26aulast%3DMiller%26aufirst%3DZ.%26aulast%3DBaek%26aufirst%3DY.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DD.%2BE.%26aulast%3DHong%26aufirst%3DJ.%2BT.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DLMP2%2520inhibitors%2520as%2520a%2520potential%2520treatment%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D3763%26epage%3D3783%26doi%3D10.1021%2Facs.jmedchem.0c00416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leng, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span> <span> </span><span class="NLM_article-title">Amyloid beta deposition related retinal pigment epithelium cell impairment and subretinal microglia activation in aged APPswePS1 transgenic mice</span>. <i>Int. J. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">747</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.18240/ijo.2018.05.06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.18240%2Fijo.2018.05.06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=29862171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BC1MbjtlSmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=747-755&author=Z.+Z.+Dongauthor=J.+Liauthor=Y.+F.+Ganauthor=X.+R.+Sunauthor=Y.+X.+Lengauthor=J.+Ge&title=Amyloid+beta+deposition+related+retinal+pigment+epithelium+cell+impairment+and+subretinal+microglia+activation+in+aged+APPswePS1+transgenic+mice&doi=10.18240%2Fijo.2018.05.06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid beta deposition related retinal pigment epithelium cell impairment and subretinal microglia activation in aged APPswePS1 transgenic mice</span></div><div class="casAuthors">Dong Zhi-Zhang; Gan Yi-Feng; Li Juan; Sun Xue-Rong; Leng Yun-Xia; Ge Jian</div><div class="citationInfo"><span class="NLM_cas:title">International journal of ophthalmology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">747-755</span>
        ISSN:<span class="NLM_cas:issn">2222-3959</span>.
    </div><div class="casAbstract">AIM:  To identify the pathological role of amyloid beta (Aβ) deposition in retinal degeneration, and explore Aβ deposition on the retinal pigment epithelium cells (RPE) layer and the associated structural and functional changes in Alzheimer's disease transgenic mice.  METHODS:  RPE changes in the eyes of APPswe/PS1 transgenic and none transgenic (NTG) mice over 20 months old were examined.  Histological changes were investigated via hematoxylin and eosin (H&E) staining and transmission electron microscopy (TEM) examination, whereas the expression of amyloid precursor protein (APP), Aβ, Zonula occludens-1 (ZO-1) and Ionized calcium binding adaptor molecule-1 (IBA-1) were investigated using immunohistochemistry and immunofluorescence techniques.  All of the obtained results were quantitatively and statistically analyzed.  RESULTS:  In aged transgenic mice, an APP-positive immunoreaction and Aβ deposition were detected on the RPE layer but were undetectable in NTG mice.  The RPE demonstrated some vacuole changes, shortened basal infoldings and basal deposition in histopathological examination and TEM tests, wherein irregular shapes were indicated by ZO-1 disorganization through fluorescence.  Furthermore, IBA-1 positive cells were observed to have accumulated and infiltrated into the RPE layer and localized beneath the RPE/Bruch's membrane (BrM) complex, which was accompanied by an increase in BrM thickness in aged transgenic mice in comparison to NTG mice.  The IBA-1 positive cells were found to be co-stained with Aβ deposition on the RPE flat mounts.  CONCLUSION:  The observed Aβ deposition in the RPE layer may cause RPE dysfunction, which is associated with microglia cells infiltration into the retina of aged transgenic mice, suggesting that Aβ deposition probably plays a significant role in RPE-related degenerative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxwXYefhgNVMRAV4D_Ins_fW6udTcc2eZ95KkiD8JMuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbjtlSmsA%253D%253D&md5=34e785ee9252caa8648c2d4e901a0a3b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.18240%2Fijo.2018.05.06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18240%252Fijo.2018.05.06%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DZ.%2BZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGan%26aufirst%3DY.%2BF.%26aulast%3DSun%26aufirst%3DX.%2BR.%26aulast%3DLeng%26aufirst%3DY.%2BX.%26aulast%3DGe%26aufirst%3DJ.%26atitle%3DAmyloid%2520beta%2520deposition%2520related%2520retinal%2520pigment%2520epithelium%2520cell%2520impairment%2520and%2520subretinal%2520microglia%2520activation%2520in%2520aged%2520APPswePS1%2520transgenic%2520mice%26jtitle%3DInt.%2520J.%2520Ophthalmol.%26date%3D2018%26volume%3D11%26spage%3D747%26epage%3D755%26doi%3D10.18240%2Fijo.2018.05.06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumayag, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mufson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span> <span> </span><span class="NLM_article-title">Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer’s disease</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">800</span>, <span class="refDoi"> DOI: 10.1167/iovs.08-2384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1167%2Fiovs.08-2384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=18791173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252Fps1Ggsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=793-800&author=S.+E.+Perezauthor=S.+Lumayagauthor=B.+Kovacsauthor=E.+J.+Mufsonauthor=S.+Xu&title=Beta-amyloid+deposition+and+functional+impairment+in+the+retina+of+the+APPswe%2FPS1DeltaE9+transgenic+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.1167%2Fiovs.08-2384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer's disease</span></div><div class="casAuthors">Perez Sylvia E; Lumayag Stephen; Kovacs Beatrix; Mufson Elliott J; Xu Shunbin</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">793-800</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  To determine whether beta-amyloid (Abeta) deposition affects the structure and function of the retina of the APPswe/PS1DeltaE9 transgenic (tg) mouse model of Alzheimer's disease.  METHODS:  Retinas from 12- to 19-month old APPswe/PS1DeltaE9 tg and age-matched non-transgenic (ntg) littermates were single or double stained with thioflavine-S and antibodies against Abeta, glial fibrillar acidic protein (GFAP), microglial marker F4/80, choline acetyltransferase (ChAT), and syntaxin 1.  Quantification of thioflavine-S positive plaques and retinal layer thickness was analyzed semi-quantitatively, whereas microglial cell size and levels of F4/80 immunoreactivity were evaluated using a densitometry program.  Scotopic electroretinogram (ERG) recording was used to investigate retinal physiology in these mice.  RESULTS:  Thioflavine-S positive plaques appeared at 12 months in the retinas of APPswe/PS1DeltaE9 tg mice with the majority of plaques in the outer and inner plexiform layers.  Plaques were embedded in the inner plexiform layer strata displaying syntaxin 1 and ChAT.  The number and size of the plaques in the retina increased with age.  Plaques appeared earlier and in greater numbers in females than in male tg littermate mice.  Microglial activity was significantly increased in the retinas of APPswe/PS1DeltaE9 tg mice.  Although we did not detect neuronal degeneration in the retina, ERG recordings revealed a significant reduction in the amplitudes of a- and b-waves in aged APPswe/PS1DeltaE9 tg compared to ntg littermates.  CONCLUSIONS:  The present findings suggest that Abeta deposition disrupts retinal structure and may contribute to the visual deficits seen in aged APPswe/PS1DeltaE9 tg mice.  Whether Abeta is involved in other forms of age-related retinal dysfunction is unclear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTzVOs-3djhcDDnmmyUf5qOfW6udTcc2eZ95KkiD8JMuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252Fps1Ggsw%253D%253D&md5=bbfd261e70fcc3d4b9dd42a4765510d7</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1167%2Fiovs.08-2384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.08-2384%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DS.%2BE.%26aulast%3DLumayag%26aufirst%3DS.%26aulast%3DKovacs%26aufirst%3DB.%26aulast%3DMufson%26aufirst%3DE.%2BJ.%26aulast%3DXu%26aufirst%3DS.%26atitle%3DBeta-amyloid%2520deposition%2520and%2520functional%2520impairment%2520in%2520the%2520retina%2520of%2520the%2520APPswe%252FPS1DeltaE9%2520transgenic%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2009%26volume%3D50%26spage%3D793%26epage%3D800%26doi%3D10.1167%2Fiovs.08-2384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanke, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marron, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seligmann, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garland, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, A. F.</span></span> <span> </span><span class="NLM_article-title">Characterization of carfilzomib-resistant non-small cell lung cancer cell lines</span>. <i>J. Cancer Res. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">1317</span>– <span class="NLM_lpage">1327</span>, <span class="refDoi"> DOI: 10.1007/s00432-018-2662-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1007%2Fs00432-018-2662-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=29766327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsFCgt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2018&pages=1317-1327&author=N.+T.+Hankeauthor=E.+Imlerauthor=M.+T.+Marronauthor=B.+E.+Seligmannauthor=L.+L.+Garlandauthor=A.+F.+Baker&title=Characterization+of+carfilzomib-resistant+non-small+cell+lung+cancer+cell+lines&doi=10.1007%2Fs00432-018-2662-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of carfilzomib-resistant non-small cell lung cancer cell lines</span></div><div class="casAuthors">Hanke, Neale T.; Imler, Elliot; Marron, Marilyn T.; Seligmann, Bruce E.; Garland, Linda L.; Baker, Amanda F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer Research and Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1317-1327</span>CODEN:
                <span class="NLM_cas:coden">JCROD7</span>;
        ISSN:<span class="NLM_cas:issn">0171-5216</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: We previously showed that carfilzomib (CFZ) has potent anti-proliferative and cytotoxic activity in a broad range of lung cancer cell lines.  Here we investigate possible mechanisms of CFZ acquired resistance in lung cancer cell lines.  Methods: CFZ-resistant non-small cell lung cancer (NSCLC) cell lines were developed by exposing A549 and H520 cells to stepwise increasing concns. of CFZ.  Resistance to CFZ and cross-resistance to bortezomib and other chemotherapy drugs was measured using the MTT assay.  Cytotoxicity to CFZ was detd. using a CytoTox assay.  Western blot was used to measure apoptosis, autophagy, and drug efflux transporter-related proteins.  Quant. targeted whole transcriptome sequencing and quant. RT-PCR was used to measure gene expression.  Flow cytometry was used to analyze intracellular accumulation of doxorubicin.  Results: The CFZ IC50 value of the resistant cells increased vs. parental lines (2.5-fold for A549, 122-fold for H520).  Resistant lines showed reduced expression of apoptosis and autophagy markers and reduced death vs. parental lines following CFZ treatment.  Both resistant lines exhibited higher P-glycoprotein (Pgp) gene (TempO-Seq anal., increased 1.2-fold in A549, > 9000-fold in H520) and protein expression levels vs. parental lines.  TempO-Seq anal. indicated other drug resistance pathways were upregulated.  The resistant cell lines demonstrated less accumulation of intracellular doxorubicin, and were cross-resistant to other Pgp client drugs: bortezomib, doxorubicin, and paclitaxel, but not cisplatin.  Conclusions: Upregulation of Pgp appears to be an important, but not the only, mechanism of CFZ resistance in NSCLC cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7UAttywNQ0LVg90H21EOLACvtfcHk0ljDsx0QYsPN7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsFCgt7k%253D&md5=a67a0ddeb3793a04efc3e9daf34ef7e9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2Fs00432-018-2662-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00432-018-2662-0%26sid%3Dliteratum%253Aachs%26aulast%3DHanke%26aufirst%3DN.%2BT.%26aulast%3DImler%26aufirst%3DE.%26aulast%3DMarron%26aufirst%3DM.%2BT.%26aulast%3DSeligmann%26aufirst%3DB.%2BE.%26aulast%3DGarland%26aufirst%3DL.%2BL.%26aulast%3DBaker%26aufirst%3DA.%2BF.%26atitle%3DCharacterization%2520of%2520carfilzomib-resistant%2520non-small%2520cell%2520lung%2520cancer%2520cell%2520lines%26jtitle%3DJ.%2520Cancer%2520Res.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D144%26spage%3D1317%26epage%3D1327%26doi%3D10.1007%2Fs00432-018-2662-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, H. W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderl, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arastu-Kapur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of highly selective inhibitors of the immunoproteasome low molecular mass polypeptide 2 (LMP2) subunit</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">417</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00496</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00496" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktVahtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=413-417&author=H.+W.+B.+Johnsonauthor=J.+L.+Anderlauthor=E.+K.+Bradleyauthor=J.+Buiauthor=J.+Jonesauthor=S.+Arastu-Kapurauthor=L.+M.+Kellyauthor=E.+Loweauthor=D.+C.+Moebiusauthor=T.+Muchamuelauthor=C.+Kirkauthor=Z.+Wangauthor=D.+McMinn&title=Discovery+of+highly+selective+inhibitors+of+the+immunoproteasome+low+molecular+mass+polypeptide+2+%28LMP2%29+subunit&doi=10.1021%2Facsmedchemlett.6b00496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit</span></div><div class="casAuthors">Johnson, Henry W. B.; Anderl, Janet L.; Bradley, Erin K.; Bui, John; Jones, Jeffrey; Arastu-Kapur, Shirin; Kelly, Lisa M.; Lowe, Eric; Moebius, David C.; Muchamuel, Tony; Kirk, Christopher; Wang, Zhengping; McMinn, Dustin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">413-417</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Building upon the success of bortezomib (VELCADE) and carfilzomib (KYPROLIS), the design of a next generation of inhibitors targeting specific subunits within the immunoproteasome is of interest for the treatment of autoimmune disease.  There are three catalytic subunits within the immunoproteasome (low mol. mass polypeptide-7, -2, and multicatalytic endopeptidase complex subunit-1; LMP7, LMP2, and MECL-1), and a campaign was undertaken to design a potent and selective LMP2 inhibitor with sufficient properties to allow for sustained inhibition in vivo.  Screening a focused library of epoxyketones revealed a series of potent dipeptides that were optimized to provide the highly selective inhibitor KZR-504 (12).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL-9Mx7yA1VLVg90H21EOLACvtfcHk0lja4Q6YoChzkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktVahtLs%253D&md5=5abf3912c1dbcc6f77d271235c75b17c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00496%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DH.%2BW.%2BB.%26aulast%3DAnderl%26aufirst%3DJ.%2BL.%26aulast%3DBradley%26aufirst%3DE.%2BK.%26aulast%3DBui%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DArastu-Kapur%26aufirst%3DS.%26aulast%3DKelly%26aufirst%3DL.%2BM.%26aulast%3DLowe%26aufirst%3DE.%26aulast%3DMoebius%26aufirst%3DD.%2BC.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DKirk%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DMcMinn%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520highly%2520selective%2520inhibitors%2520of%2520the%2520immunoproteasome%2520low%2520molecular%2520mass%2520polypeptide%25202%2520%2528LMP2%2529%2520subunit%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D413%26epage%3D417%26doi%3D10.1021%2Facsmedchemlett.6b00496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elghoul, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, Q. P.</span></span> <span> </span><span class="NLM_article-title">P-Glycoprotein inhibition sensitizes human breast cancer cells to proteasome inhibitors</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">1239</span>– <span class="NLM_lpage">1248</span>, <span class="refDoi"> DOI: 10.1002/jcb.25783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1002%2Fjcb.25783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=27813130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmslertw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2017&pages=1239-1248&author=R.+R.+Deshmukhauthor=S.+Kimauthor=Y.+Elghoulauthor=Q.+P.+Dou&title=P-Glycoprotein+inhibition+sensitizes+human+breast+cancer+cells+to+proteasome+inhibitors&doi=10.1002%2Fjcb.25783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors</span></div><div class="casAuthors">Deshmukh, Rahul R.; Kim, Seongho; Elghoul, Yasmine; Dou, Q. Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1239-1248</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Although effective for the treatment of hematol. malignancies, the FDA approved proteasome inhibitors bortezomib and carfilzomib have limited efficacy in solid tumors including triple neg. breast cancer (TNBC).  Chemotherapy is the only option for treating TNBC due to the absence of specific therapeutic targets.  Therefore, development of new TNBC therapeutic strategies has been warranted.  We studied whether P-glycoprotein (P-gp) inhibition could sensitize TNBC cells to proteasome inhibitors.  When verapamil, a P-gp inhibitor, was combined with the proteasome inhibitor MG132, bortezomib, or carfilzomib, the cytotoxic effects and apoptosis in TNBC MDA-MB-231 cells were enhanced, compared to each treatment alone.  Furthermore, addn. of verapamil improved proteasome-inhibitory properties of MG132, bortezomib, or carfilzomib in MDA-MB-231 cells, as shown by the increased accumulation of ubiquitinated proteins and proteasome substrates such as IκBα and p27kip1.  Addnl., when nicardipine, another P-gp inhibitor, was combined with bortezomib or carfilzomib, enhanced inhibition of MDA-MB-231 cell proliferation was obsd.  These findings indicate that P-gp inhibitors could sensitize TNBC cells to structurally and functionally diverse proteasome inhibitors and might provide new treatment strategy for TNBC.  J. Cell. Biochem. 9999: 1-10, 2016. cpr 2016 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonNLKDRZBk2LVg90H21EOLACvtfcHk0lja4Q6YoChzkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmslertw%253D%253D&md5=f0bf11f094c669c7446118a062e55d7b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fjcb.25783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.25783%26sid%3Dliteratum%253Aachs%26aulast%3DDeshmukh%26aufirst%3DR.%2BR.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DElghoul%26aufirst%3DY.%26aulast%3DDou%26aufirst%3DQ.%2BP.%26atitle%3DP-Glycoprotein%2520inhibition%2520sensitizes%2520human%2520breast%2520cancer%2520cells%2520to%2520proteasome%2520inhibitors%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2017%26volume%3D118%26spage%3D1239%26epage%3D1248%26doi%3D10.1002%2Fjcb.25783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verbrugge, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaraf, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dijkmans, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Uyl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oerlemans, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Heijden, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Gruijl, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheper, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, G.</span></span> <span> </span><span class="NLM_article-title">Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">174</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.187542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1124%2Fjpet.111.187542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=22235146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVagtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=174-182&author=S.+E.+Verbruggeauthor=Y.+G.+Assarafauthor=B.+A.+Dijkmansauthor=G.+L.+Schefferauthor=M.+Alauthor=D.+den+Uylauthor=R.+Oerlemansauthor=E.+T.+Chanauthor=C.+J.+Kirkauthor=G.+J.+Petersauthor=J.+W.+van+der+Heijdenauthor=T.+D.+de+Gruijlauthor=R.+J.+Scheperauthor=G.+Jansen&title=Inactivating+PSMB5+mutations+and+P-glycoprotein+%28multidrug+resistance-associated+protein%2FATP-binding+cassette+B1%29+mediate+resistance+to+proteasome+inhibitors%3A+ex+vivo+efficacy+of+%28immuno%29proteasome+inhibitors+in+mononuclear+blood+cells+from+patients+with+rheumatoid+arthritis&doi=10.1124%2Fjpet.111.187542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis</span></div><div class="casAuthors">Verbrugge, Sue Ellen; Assaraf, Yehuda G.; Dijkmans, Ben A. C.; Scheffer, George L.; Al, Marjon; den Uyl, Debby; Oerlemans, Ruud; Chan, Elena T.; Kirk, Christopher J.; Peters, Godefridus J.; van der Heijden, Joost W.; de Gruijl, Tanja D.; Scheper, Rik J.; Jansen, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">174-182</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bortezomib (BTZ), a registered proteasome inhibitor (PI) for multiple myeloma, has also been proposed as a potential antirheumatic agent.  Its reported side effects, however, make it unappealing for long-term administration, and resistance may also develop.  To overcome this, second-generation PIs became available.  Here, we investigated whether a novel class of peptide epoxyketone-based PIs, including carfilzomib, N-((S)-3-methoxy-1-(((S)-3-methoxy-1-(((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide (ONX0912), and (S)-3-(4-methoxyphenyl)-N-((S)-1-((S)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide (ONX0914), might escape two established BTZ-resistance mechanisms: (1) mutations in the proteasome β5 subunit (PSMB5) targeted by these PIs, and (2) drug efflux mediated by ATP-binding cassette transporters.  THP1 myeloid sublines with acquired resistance to BTZ (54- to 235-fold) caused by mutations in the PSMB5 gene displayed marked cross-resistance but less pronounced cross-resistance to carfilzomib (9- to 32-fold), ONX0912 (39- to 62-fold), and ONX0914 (27- to 97-fold).  As for ATP-binding cassette transporter-mediated efflux, lymphoid CEM/VLB cells with P-glycoprotein (Pgp)/multidrug resistance 1 overexpression exhibited substantial resistance to carfilzomib (114-fold), ONX0912 (23-fold), and ONX0914 (162-fold), whereas less resistance to BTZ (4.5-fold) was obsd.  Consistently, β5 subunit-assocd. chymotrypsin-like proteasome activity was significantly less inhibited in these CEM/VLB cells.  Ex vivo anal. of peripheral blood mononuclear cells from therapy-naive patients with rheumatoid arthritis revealed that, although basal Pgp levels were low, P-glycoprotein expression compromised the inhibitory effect of carfilzomib and ONX0914.  However, the use of P121 (reversin 121), a Pgp transport inhibitor, restored parental cell inhibitory levels in both CEM/VLB cells and peripheral blood mononuclear cells.  These results indicate that the pharmacol. activity of these PIs may be hindered by drug resistance mechanisms involving PSMBS mutations and PI extrusion via Pgp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLjyDKKBsD_7Vg90H21EOLACvtfcHk0lgeErM0ZeF63Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVagtr8%253D&md5=5b87626879dfdca4f1003e35833af2e0</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187542%26sid%3Dliteratum%253Aachs%26aulast%3DVerbrugge%26aufirst%3DS.%2BE.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DDijkmans%26aufirst%3DB.%2BA.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DAl%26aufirst%3DM.%26aulast%3Dden%2BUyl%26aufirst%3DD.%26aulast%3DOerlemans%26aufirst%3DR.%26aulast%3DChan%26aufirst%3DE.%2BT.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3Dvan%2Bder%2BHeijden%26aufirst%3DJ.%2BW.%26aulast%3Dde%2BGruijl%26aufirst%3DT.%2BD.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26aulast%3DJansen%26aufirst%3DG.%26atitle%3DInactivating%2520PSMB5%2520mutations%2520and%2520P-glycoprotein%2520%2528multidrug%2520resistance-associated%2520protein%252FATP-binding%2520cassette%2520B1%2529%2520mediate%2520resistance%2520to%2520proteasome%2520inhibitors%253A%2520ex%2520vivo%2520efficacy%2520of%2520%2528immuno%2529proteasome%2520inhibitors%2520in%2520mononuclear%2520blood%2520cells%2520from%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D174%26epage%3D182%26doi%3D10.1124%2Fjpet.111.187542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">Development of novel epoxyketone-based proteasome inhibitors as a strategy to overcome cancer resistance to carfilzomib and bortezomib</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4444</span>– <span class="NLM_lpage">4455</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01943</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01943" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntFaqsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4444-4455&author=M.+J.+Leeauthor=D.+Bhattaraiauthor=J.+Yooauthor=Z.+Millerauthor=J.+E.+Parkauthor=S.+Leeauthor=W.+Leeauthor=J.+J.+Driscollauthor=K.+B.+Kim&title=Development+of+novel+epoxyketone-based+proteasome+inhibitors+as+a+strategy+to+overcome+cancer+resistance+to+carfilzomib+and+bortezomib&doi=10.1021%2Facs.jmedchem.8b01943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib</span></div><div class="casAuthors">Lee, Min Jae; Bhattarai, Deepak; Yoo, Jisu; Miller, Zach; Park, Ji Eun; Lee, Sukyeong; Lee, Wooin; Driscoll, James J.; Kim, Kyung Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4444-4455</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Over the past 15 years, proteasome inhibitors (PIs), namely bortezomib, carfilzomib (Cfz) and ixazomib, have significantly improved the overall survival and quality-of-life for multiple myeloma (MM) patients.  However, a significant portion of MM patients do not respond to PI therapies.  Drug resistance is present either de novo or acquired after prolonged therapy through mechanisms that remain poorly defined.  The lack of a clear understanding of clin. PI resistance has hampered the development of next-generation PI drugs to treat MM patients who no longer respond to currently available therapies.  Here, the authors designed and synthesized novel epoxyketone-based PIs by structural modifications at the P1' site.  The authors show that a Cfz analog, harboring a hydroxyl substituent at its P1' position was highly cytotoxic against cancer cell lines displaying de novo or acquired resistance to Cfz.  These results suggest that peptide epoxyketones incorporating P1'-targeting moieties may have the potential to bypass resistance mechanisms assocd. with Cfz and to provide addnl. clin. options for patients resistant to Cfz.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6IBXmFPMA87Vg90H21EOLACvtfcHk0lgeErM0ZeF63Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntFaqsbY%253D&md5=65447e8e68a7d1b6d8435b99138f5803</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01943%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DBhattarai%26aufirst%3DD.%26aulast%3DYoo%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DZ.%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DDriscoll%26aufirst%3DJ.%2BJ.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DDevelopment%2520of%2520novel%2520epoxyketone-based%2520proteasome%2520inhibitors%2520as%2520a%2520strategy%2520to%2520overcome%2520cancer%2520resistance%2520to%2520carfilzomib%2520and%2520bortezomib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4444%26epage%3D4455%26doi%3D10.1021%2Facs.jmedchem.8b01943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">Next-generation proteasome inhibitors for cancer therapy</span>. <i>Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>198</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.trsl.2018.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2Fj.trsl.2018.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=29654740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsVeht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2018&pages=1-16&author=J.+E.+Parkauthor=Z.+Millerauthor=Y.+Junauthor=W.+Leeauthor=K.+B.+Kim&title=Next-generation+proteasome+inhibitors+for+cancer+therapy&doi=10.1016%2Fj.trsl.2018.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Next-generation proteasome inhibitors for cancer therapy</span></div><div class="casAuthors">Park, Ji Eun; Miller, Zachary; Jun, Yearin; Lee, Wooin; Kim, Kyung Bo</div><div class="citationInfo"><span class="NLM_cas:title">Translational Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-16</span>CODEN:
                <span class="NLM_cas:coden">TRRECL</span>;
        ISSN:<span class="NLM_cas:issn">1878-1810</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Over 2 decades ago, the proteasome was considered a risky or even untenable therapeutic target.  Today, proteasome inhibitors are a mainstay in the treatment of multiple myeloma (MM) and have sales in excess of 3 billion US dollars annually.  More importantly, the availability of proteasome inhibitors has greatly improved the survival and quality of life for patients with MM.  Despite the remarkable success of proteasome inhibitor therapies to date, the potential for improvement remains, and the development and optimal use of proteasome inhibitors as anticancer agents continues to be an active area of research.  In this review, we briefly discuss the features and limitations of the 3 proteasome inhibitor drugs currently used in the clinic and provide an update on current efforts to develop next-generation proteasome inhibitors with the potential to overcome the limitations of existing proteasome inhibitor drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ5nMmurd6-7Vg90H21EOLACvtfcHk0li909tTrEdPbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsVeht7o%253D&md5=25d9295ddb58861676c56ed4b72af110</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.trsl.2018.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trsl.2018.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DMiller%26aufirst%3DZ.%26aulast%3DJun%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DNext-generation%2520proteasome%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DTransl.%2520Res.%26date%3D2018%26volume%3D198%26spage%3D1%26epage%3D16%26doi%3D10.1016%2Fj.trsl.2018.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marsault, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, M. L.</span></span> <span> </span><span class="NLM_article-title">Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1961</span>– <span class="NLM_lpage">2004</span>, <span class="refDoi"> DOI: 10.1021/jm1012374</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1012374" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVSjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1961-2004&author=E.+Marsaultauthor=M.+L.+Peterson&title=Macrocycles+are+great+cycles%3A+applications%2C+opportunities%2C+and+challenges+of+synthetic+macrocycles+in+drug+discovery&doi=10.1021%2Fjm1012374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocycles Are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocycles in Drug Discovery</span></div><div class="casAuthors">Marsault, Eric; Peterson, Mark L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1961-2004</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Macrocycles occupy a unique segment of chem. space.  In the past decade, their chem. diversity expanded significantly, supported by advances in bioinformatics and synthetic methodol.  As a consequence, this structural type has now been successfully tested on most biol. target classes.  The goal of this article is to put into perspective the current applications, opportunities, and challenges assocd. with synthetic macrocycles in drug discovery.  Accordingly, the first part of this article is dedicated to the drug discovery aspects of macrocycles and highlights salient features of their medicinal chem.  This section is organized by target class, a choice aimed at providing the reader an appreciation of the structural diversity generated for each class.  To give the reader an appreciation of the tools available to construct macrocyclic scaffolds, the site and method of the pivotal macrocyclization step are indicated in the figures.  Readers are referred to the source articles for further details.  In the second part, the technologies and synthetic approaches that already have demonstrated utility or possess a high potential for macrocycle-based drug discovery are discussed.  Finally, a perspective on the future of synthetic macrocycles in medicinal chem. is offered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrygQLE6JraHrVg90H21EOLACvtfcHk0li909tTrEdPbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVSjtbo%253D&md5=97c1120896e90a85790a9ac1274259f3</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm1012374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1012374%26sid%3Dliteratum%253Aachs%26aulast%3DMarsault%26aufirst%3DE.%26aulast%3DPeterson%26aufirst%3DM.%2BL.%26atitle%3DMacrocycles%2520are%2520great%2520cycles%253A%2520applications%252C%2520opportunities%252C%2520and%2520challenges%2520of%2520synthetic%2520macrocycles%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1961%26epage%3D2004%26doi%3D10.1021%2Fjm1012374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Driggers, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrett, N. K.</span></span> <span> </span><span class="NLM_article-title">The exploration of macrocycles for drug discovery--an underexploited structural class</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">608</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1038/nrd2590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1038%2Fnrd2590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=18591981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvFShsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=608-624&author=E.+M.+Driggersauthor=S.+P.+Haleauthor=J.+Leeauthor=N.+K.+Terrett&title=The+exploration+of+macrocycles+for+drug+discovery%2D%2Dan+underexploited+structural+class&doi=10.1038%2Fnrd2590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The exploration of macrocycles for drug discovery - an underexploited structural class</span></div><div class="casAuthors">Driggers, Edward M.; Hale, Stephen P.; Lee, Jinbo; Terrett, Nicholas K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">608-624</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Natural products comprised of a macrocycle ring structure have proven their therapeutic applications as antibiotics, immunosuppressants as well as anticancer agents.  Despite this, macrocyclic compds. remain under-explored.  Terrett and colleagues review the properties and features of current macrocycle drugs, emphasizing the vast potential of synthetic macrocycles in drug discovery.  Macrocyclic natural products have evolved to fulfil numerous biochem. functions, and their profound pharmacol. properties have led to their development as drugs.  A macrocycle provides diverse functionality and stereochem. complexity in a conformationally pre-organized ring structure.  This can result in high affinity and selectivity for protein targets, while preserving sufficient bioavailability to reach intracellular locations.  Despite these valuable characteristics, and the proven success of more than 100 marketed macrocycle drugs derived from natural products, this structural class has been poorly explored within drug discovery.  This is in part due to concerns about synthetic intractability and non-drug-like properties.  This Review describes the growing body of data in favor of macrocyclic therapeutics, and demonstrates that this class of compds. can be both fully drug-like in its properties and readily prepd. owing to recent advances in synthetic medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDtW8LpE4ru7Vg90H21EOLACvtfcHk0li909tTrEdPbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvFShsbc%253D&md5=16e091818053e5b163b81078a8d03094</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrd2590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2590%26sid%3Dliteratum%253Aachs%26aulast%3DDriggers%26aufirst%3DE.%2BM.%26aulast%3DHale%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DTerrett%26aufirst%3DN.%2BK.%26atitle%3DThe%2520exploration%2520of%2520macrocycles%2520for%2520drug%2520discovery--an%2520underexploited%2520structural%2520class%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D608%26epage%3D624%26doi%3D10.1038%2Fnrd2590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, J. J.</span></span> <span> </span><span class="NLM_article-title">Lead discovery and optimization strategies for peptide macrocycles</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">471</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.07.083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2Fj.ejmech.2014.07.083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=25109255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GktrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2015&pages=471-479&author=A.+Bhatauthor=L.+R.+Robertsauthor=J.+J.+Dwyer&title=Lead+discovery+and+optimization+strategies+for+peptide+macrocycles&doi=10.1016%2Fj.ejmech.2014.07.083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Lead discovery and optimization strategies for peptide macrocycles</span></div><div class="casAuthors">Bhat, Abhijit; Roberts, Lee R.; Dwyer, John J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">471-479</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Peptide macrocycles represent a chem. space where the best of biol. tools can synergize with the best of chem. approaches in the quest for leads against undruggable targets.  Peptide macrocycles offer some key advantages in both lead discovery and lead optimization phases of drug discovery when compared to natural product and synthetic macrocycles.  In addn., they are uniquely positioned to capitalize on the therapeutic potential of peptides because cyclization can help drive selectivity, potency and overcome the common limitations of metabolic instability of peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrYEBhURBm07Vg90H21EOLACvtfcHk0li909tTrEdPbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GktrrM&md5=2e12788610c87e9c774dcf3804855cf4</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.07.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.07.083%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DL.%2BR.%26aulast%3DDwyer%26aufirst%3DJ.%2BJ.%26atitle%3DLead%2520discovery%2520and%2520optimization%2520strategies%2520for%2520peptide%2520macrocycles%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D94%26spage%3D471%26epage%3D479%26doi%3D10.1016%2Fj.ejmech.2014.07.083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, D. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of peptide macrocycles</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1151</span>– <span class="NLM_lpage">1163</span>, <span class="refDoi"> DOI: 10.1080/17460441.2016.1245720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1080%2F17460441.2016.1245720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=27718641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSqs7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1151-1163&author=A.+M.+Whiteauthor=D.+J.+Craik&title=Discovery+and+optimization+of+peptide+macrocycles&doi=10.1080%2F17460441.2016.1245720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of peptide macrocycles</span></div><div class="casAuthors">White, Andrew M.; Craik, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1151-1163</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Macrocyclic peptides are generally more resistant to proteolysis and often have higher potency than linear peptides and so they are excellent leads in drug design.  Their study is significant because they offer potential as a new generation of drugs that are potent and specific, and thus might have fewer side effects than traditional small mol. drugs.  This article covers macrocyclic drug leads based on nature-derived cyclic peptides as well as synthetic cyclic peptides and close derivs.  The natural peptides include cyclotides, sunflower-derived peptides, theta-defensins and orbitides.  Technologies to make engineered cyclic peptides covered here include cyclization via amino acid linkers, CLIPS, templates, and stapled peptides.  Macrocyclic peptides are promising drug leads and several are in clin. trials.  The authors believe they offer key advantages over traditional small mol. drugs, as well as some advantages over protein-based 'biologics' such as antibodies or growth factors.  These include the ability to penetrate cells and attack intracellular targets such as protein-protein interactions as well as to hit extracellular targets.  Some macrocyclic peptides such as cyclotides offer the potential for prodn. in plants, thus reducing manuf. costs and potentially increasing opportunities for their distribution to developing countries at low cost.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_0bCIvweBD7Vg90H21EOLACvtfcHk0lhopoNSDVRG_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSqs7jP&md5=fb6f9faf28fed8e2a5533623fc5e2a19</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1245720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1245720%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DA.%2BM.%26aulast%3DCraik%26aufirst%3DD.%2BJ.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520peptide%2520macrocycles%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26spage%3D1151%26epage%3D1163%26doi%3D10.1080%2F17460441.2016.1245720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cacciatore, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornasari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Stefano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerasa, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aydin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moretto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesce, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">di Giacomo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costantini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Giovanni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speranza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felaco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patruno, A.</span></span> <span> </span><span class="NLM_article-title">Development of glycine-alpha-methyl-proline-containing tripeptides with neuroprotective properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">563</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2Fj.ejmech.2015.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=26717205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1yiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=553-563&author=I.+Cacciatoreauthor=E.+Fornasariauthor=A.+Di+Stefanoauthor=L.+Marinelliauthor=L.+S.+Cerasaauthor=H.+Turkezauthor=E.+Aydinauthor=A.+Morettoauthor=A.+Ferroneauthor=M.+Pesceauthor=V.+di+Giacomoauthor=M.+Realeauthor=E.+Costantiniauthor=P.+Di+Giovanniauthor=L.+Speranzaauthor=M.+Felacoauthor=A.+Patruno&title=Development+of+glycine-alpha-methyl-proline-containing+tripeptides+with+neuroprotective+properties&doi=10.1016%2Fj.ejmech.2015.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Development of glycine-α-methyl-proline-containing tripeptides with neuroprotective properties</span></div><div class="casAuthors">Cacciatore, Ivana; Fornasari, Erika; Di Stefano, Antonio; Marinelli, Lisa; Cerasa, Laura Serafina; Turkez, Hasan; Aydin, Elanur; Moretto, Alessandro; Ferrone, Alessio; Pesce, Mirko; di Giacomo, Viviana; Reale, Marcella; Costantini, Erica; Di Giovanni, Pamela; Speranza, Lorenza; Felaco, Mario; Patruno, Antonia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">553-563</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Herein is described the synthesis of novel glycine-α-methyl-proline-contg. tripeptides with the aim of obtaining derivs. highly stable in human plasma and able to counteract neuroinflammatory processes that are distinctive of neurodegenerative pathologies.  The syntheses of glycine-α-methyl-proline-contg. tripeptides were all achieved both by introducing the methylproline residue into the Gly-Pro-Arg (GPR) sequence in place of the native Pro in P2 position and replacing the basic amino acid Arg in P3 position by Lys or His.  Results showed that all novel tripeptides are stable in human plasma (t1/2 > 51 h) and that glycinyl-α-methyl-prolinyl-histidine- generating stable intramol. H-bond in a C11-turn by interaction of His imidazole ring and Gly carbonyl group - restored physiol. levels of nitric oxide deriving from neuronal NOS (nNOS) activity, thus preventing the inflammatory response by suppression of the NF-kB activity and, consequently, the expression of inflammatory genes such as inducibile NOS (iNOS).  Therefore, glycinyl-α-methyl-prolinyl-histidine could be a lead compd. for further development of peptidomimetics able to contrast neuroinflammatory processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphRkGI_EPT5bVg90H21EOLACvtfcHk0lhopoNSDVRG_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1yiug%253D%253D&md5=36458c81a6d1c59c627f1e659d0ba993</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DCacciatore%26aufirst%3DI.%26aulast%3DFornasari%26aufirst%3DE.%26aulast%3DDi%2BStefano%26aufirst%3DA.%26aulast%3DMarinelli%26aufirst%3DL.%26aulast%3DCerasa%26aufirst%3DL.%2BS.%26aulast%3DTurkez%26aufirst%3DH.%26aulast%3DAydin%26aufirst%3DE.%26aulast%3DMoretto%26aufirst%3DA.%26aulast%3DFerrone%26aufirst%3DA.%26aulast%3DPesce%26aufirst%3DM.%26aulast%3Ddi%2BGiacomo%26aufirst%3DV.%26aulast%3DReale%26aufirst%3DM.%26aulast%3DCostantini%26aufirst%3DE.%26aulast%3DDi%2BGiovanni%26aufirst%3DP.%26aulast%3DSperanza%26aufirst%3DL.%26aulast%3DFelaco%26aufirst%3DM.%26aulast%3DPatruno%26aufirst%3DA.%26atitle%3DDevelopment%2520of%2520glycine-alpha-methyl-proline-containing%2520tripeptides%2520with%2520neuroprotective%2520properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D108%26spage%3D553%26epage%3D563%26doi%3D10.1016%2Fj.ejmech.2015.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eildal, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuhr-Hansen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeskamp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottschalk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristensen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stromgaard, K.</span></span> <span> </span><span class="NLM_article-title">Cell-permeable and plasma-stable peptidomimetic inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1333</span>– <span class="NLM_lpage">1346</span>, <span class="refDoi"> DOI: 10.1021/jm1013924</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013924" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1333-1346&author=A.+Bachauthor=J.+N.+Eildalauthor=N.+Stuhr-Hansenauthor=R.+Deeskampauthor=M.+Gottschalkauthor=S.+W.+Pedersenauthor=A.+S.+Kristensenauthor=K.+Stromgaard&title=Cell-permeable+and+plasma-stable+peptidomimetic+inhibitors+of+the+postsynaptic+density-95%2FN-methyl-D-aspartate+receptor+interaction&doi=10.1021%2Fjm1013924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-Permeable and Plasma-Stable Peptidomimetic Inhibitors of the Postsynaptic Density-95/N-Methyl-d-Aspartate Receptor Interaction</span></div><div class="casAuthors">Bach, Anders; Eildal, Jonas N. N.; Stuhr-Hansen, Nicolai; Deeskamp, Rasmus; Gottschalk, Marie; Pedersen, Soren W.; Kristensen, Anders S.; Stromgaard, Kristian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1333-1346</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The protein-protein interaction between the NMDA receptor and its intracellular scaffolding protein, PSD-95, is a potential target for treating ischemic brain diseases, neuropathic pain, and Alzheimer's disease.  We have previously demonstrated that N-alkylated tetrapeptides are potent inhibitors of this interaction, and here, this template is exploited for the development of blood plasma-stable and cell-permeable inhibitors.  Initially, we explored both the amino acid sequence of the tetrapeptide and the nature of the N-alkyl groups, which consolidated N-cyclohexylethyl-ETAV (1) as the most potent and selective compd.  Next, the amide moieties of N-methylated ETAV were systematically replaced with thioamides, demonstrating that one of three amide bonds could be replaced without compromising the affinity.  Subsequent optimization of the N-alkyl groups and evaluation of cell permeability led to identification of N-cyclohexylethyl-ETASV (54) as the most potent, plasma-stable and cell-permeable inhibitor, which is a promising tool in unraveling the therapeutic potential of the PSD-95/NMDA receptor interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxlYJ9ewixrrVg90H21EOLACvtfcHk0lhozRm_2kfNPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFeitrw%253D&md5=e4517970b5bcd0b2790181619bec9a41</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm1013924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013924%26sid%3Dliteratum%253Aachs%26aulast%3DBach%26aufirst%3DA.%26aulast%3DEildal%26aufirst%3DJ.%2BN.%26aulast%3DStuhr-Hansen%26aufirst%3DN.%26aulast%3DDeeskamp%26aufirst%3DR.%26aulast%3DGottschalk%26aufirst%3DM.%26aulast%3DPedersen%26aufirst%3DS.%2BW.%26aulast%3DKristensen%26aufirst%3DA.%2BS.%26aulast%3DStromgaard%26aufirst%3DK.%26atitle%3DCell-permeable%2520and%2520plasma-stable%2520peptidomimetic%2520inhibitors%2520of%2520the%2520postsynaptic%2520density-95%252FN-methyl-D-aspartate%2520receptor%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1333%26epage%3D1346%26doi%3D10.1021%2Fjm1013924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chua, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hautmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruning, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutschow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, A. D.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic protease inhibitors with reduced peptide character</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7828</span>– <span class="NLM_lpage">7831</span>, <span class="refDoi"> DOI: 10.1002/anie.201404301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1002%2Fanie.201404301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptlOju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=7828-7831&author=K.+C.+Chuaauthor=M.+Pietschauthor=X.+Zhangauthor=S.+Hautmannauthor=H.+Y.+Chanauthor=J.+B.+Bruningauthor=M.+Gutschowauthor=A.+D.+Abell&title=Macrocyclic+protease+inhibitors+with+reduced+peptide+character&doi=10.1002%2Fanie.201404301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic Protease Inhibitors with Reduced Peptide Character</span></div><div class="casAuthors">Chua, Krystle C. H.; Pietsch, Markus; Zhang, Xiaozhou; Hautmann, Stephanie; Chan, Hon Y.; Bruning, John B.; Guetschow, Michael; Abell, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">7828-7831</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">There is a real need for simple structures that define a β-strand conformation, a secondary structure that is central to peptide-protein interactions.  For example, protease substrates and inhibitors almost universally adopt this geometry upon active site binding.  A planar pyrrole is used to replace two amino acids of a peptide backbone to generate a simple macrocycle that retains the required geometry for active site binding.  The resulting β-strand templates have reduced peptide character and provide potent protease inhibitors with the attachment of an appropriate amino aldehyde to the C-terminus.  Picomolar inhibitors of cathepsin L and S are reported and the mode of binding of one example to the model protease chymotrypsin is defined by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLoSjiRph32bVg90H21EOLACvtfcHk0lhozRm_2kfNPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptlOju7g%253D&md5=f195f61bf6c368ce1bdaf71f347372db</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fanie.201404301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201404301%26sid%3Dliteratum%253Aachs%26aulast%3DChua%26aufirst%3DK.%2BC.%26aulast%3DPietsch%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHautmann%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DH.%2BY.%26aulast%3DBruning%26aufirst%3DJ.%2BB.%26aulast%3DGutschow%26aufirst%3DM.%26aulast%3DAbell%26aufirst%3DA.%2BD.%26atitle%3DMacrocyclic%2520protease%2520inhibitors%2520with%2520reduced%2520peptide%2520character%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D7828%26epage%3D7831%26doi%3D10.1002%2Fanie.201404301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Besse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolze, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasche, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinhold, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span> <span> </span><span class="NLM_article-title">Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1038%2Fleu.2017.212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=28676669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1eqt77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=391-401&author=A.+Besseauthor=S.+C.+Stolzeauthor=L.+Rascheauthor=N.+Weinholdauthor=G.+J.+Morganauthor=M.+Krausauthor=J.+Baderauthor=H.+S.+Overkleeftauthor=L.+Besseauthor=C.+Driessen&title=Carfilzomib+resistance+due+to+ABCB1%2FMDR1+overexpression+is+overcome+by+nelfinavir+and+lopinavir+in+multiple+myeloma&doi=10.1038%2Fleu.2017.212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma</span></div><div class="casAuthors">Besse, A.; Stolze, S. C.; Rasche, L.; Weinhold, N.; Morgan, G. J.; Kraus, M.; Bader, J.; Overkleeft, H. S.; Besse, L.; Driessen, C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">391-401</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Proteasome inhibitor (PI) carfilzomib (CFZ) has activity superior to bortezomib (BTZ) and is increasingly incorporated in multiple myeloma (MM) frontline therapy and relapsed settings.  Most MM patients ultimately experience PI-refractory disease, an unmet medical need with poorly understood biol. and dismal outcome.  Pharmacol. targeting of ABCB1 improved patient outcomes, including MM, but suffered from adverse drug effects and insufficient plasma concns.  Proteomics anal. identified ABCB1 overexpression as the most significant change in CFZ-resistant MM cells.  We addressed the functional role of ABCB1 overexpression in MM and obsd. significantly upregulated ABCB1 in peripheral blood malignant plasma cells (PCs) vs untreated patients' bone marrow PC.  ABCB1 overexpression reduces the proteasome-inhibiting activity of CFZ due to drug efflux, in contrast to BTZ.  Likewise, the cytotoxicity of established anti-MM drugs was significantly reduced in ABCB1-expressing MM cells.  In search for potential drugs targeting ABCB1 in clin. trials, we identified the HIV protease inhibitors nelfinavir (NFV) and lopinavir (LPV) as potent functional modulators of ABCB1-mediated drug export, most likely via modulation of mitochondria permeability transition pore.  NFV and LPV restored CFZ activity at therapeutically relevant drug levels and thus represent ready-to-use drugs to be tested in clin. trials to target ABCB1 and to re-sensitize PC to established myeloma drugs, in particular CFZ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmgYUIhFu_qLVg90H21EOLACvtfcHk0lhozRm_2kfNPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1eqt77L&md5=8e100e4a939f21362c4eb75a3da81e37</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.212%26sid%3Dliteratum%253Aachs%26aulast%3DBesse%26aufirst%3DA.%26aulast%3DStolze%26aufirst%3DS.%2BC.%26aulast%3DRasche%26aufirst%3DL.%26aulast%3DWeinhold%26aufirst%3DN.%26aulast%3DMorgan%26aufirst%3DG.%2BJ.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DBader%26aufirst%3DJ.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DBesse%26aufirst%3DL.%26aulast%3DDriessen%26aufirst%3DC.%26atitle%3DCarfilzomib%2520resistance%2520due%2520to%2520ABCB1%252FMDR1%2520overexpression%2520is%2520overcome%2520by%2520nelfinavir%2520and%2520lopinavir%2520in%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D391%26epage%3D401%26doi%3D10.1038%2Fleu.2017.212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span> <span> </span><span class="NLM_article-title">Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2197</span>– <span class="NLM_lpage">2205</span>, <span class="refDoi"> DOI: 10.1021/mp300044b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300044b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC38XptFCju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=2197-2205&author=L.+Aoauthor=Y.+Wuauthor=D.+Kimauthor=E.+R.+Jangauthor=K.+Kimauthor=D.+M.+Leeauthor=K.+B.+Kimauthor=W.+Lee&title=Development+of+peptide-based+reversing+agents+for+p-glycoprotein-mediated+resistance+to+carfilzomib&doi=10.1021%2Fmp300044b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carfilzomib</span></div><div class="casAuthors">Ao, Lin; Wu, Ying; Kim, Donghern; Jang, Eun Ryoung; Kim, Kyunghwa; Lee, Do-min; Kim, Kyung Bo; Lee, Wooin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2197-2205</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Carfilzomib is a novel class of peptidyl epoxyketone proteasome inhibitor and has demonstrated promising activity in multiple clin. trials to treat patients with multiple myeloma and other types of cancers.  Here, we investigated mol. mechanisms underlying acquired resistance to carfilzomib and a potential strategy to restore cellular sensitivity to carfilzomib.  H23 and DLD-1 cells (human lung and colon adenocarcinoma cell lines) with acquired resistance to carfilzomib displayed marked cross-resistance to YU-101, a closely related proteasome inhibitor, and paclitaxel, a known substrate of Pgp.  However, carfilzomib-resistant cells remained sensitive to bortezomib, a clin. used dipeptide with boronic acid pharmacophore.  In accordance with these observations, carfilzomib-resistant H23 and DLD-1 cells showed marked upregulation of P-glycoprotein (Pgp) as compared to their parental controls, and coincubation with verapamil, a Pgp inhibitor, led to an almost complete restoration of cellular sensitivity to carfilzomib.  These results indicate that Pgp upregulation plays a major role in the development of carfilzomib resistance in these cell lines.  In developing a potential strategy to overcome carfilzomib resistance, we as a proof of concept prepd. a small library of peptide analogs derived from the peptide backbone of carfilzomib and screened these mols. for their activity to restore carfilzomib sensitivity when cotreated with carfilzomib.  We found that compds. as small as dipeptides are sufficient in restoring carfilzomib sensitivity.  Taken together, we found that Pgp upregulation plays a major role in the development of resistance to carfilzomib in lung and colon adenocarcinoma cell lines and that small peptide analogs lacking the pharmacophore can be used as agents to reverse acquired carfilzomib resistance.  Our findings may provide important information in developing a potential strategy to overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrslgMOfDD53rVg90H21EOLACvtfcHk0lgiCCkdfEpRuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptFCju7c%253D&md5=ba90f3b18f9e4cc80cf1fc72d523fb5c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fmp300044b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300044b%26sid%3Dliteratum%253Aachs%26aulast%3DAo%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DJang%26aufirst%3DE.%2BR.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DD.%2BM.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DLee%26aufirst%3DW.%26atitle%3DDevelopment%2520of%2520peptide-based%2520reversing%2520agents%2520for%2520p-glycoprotein-mediated%2520resistance%2520to%2520carfilzomib%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D2197%26epage%3D2205%26doi%3D10.1021%2Fmp300044b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S. J.</span></span> <span> </span><span class="NLM_article-title">Suppression of canine ATP binding cassette ABCB1 in Madin-Darby canine kidney type II cells unmasks human ABCG2-mediated efflux of olaparib</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1124/jpet.118.250225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1124%2Fjpet.118.250225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=30396915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktFGjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2019&pages=79-87&author=Y.+K.+Songauthor=J.+E.+Parkauthor=Y.+Ohauthor=S.+Hyungauthor=Y.+S.+Jeongauthor=M.+S.+Kimauthor=W.+Leeauthor=S.+J.+Chung&title=Suppression+of+canine+ATP+binding+cassette+ABCB1+in+Madin-Darby+canine+kidney+type+II+cells+unmasks+human+ABCG2-mediated+efflux+of+olaparib&doi=10.1124%2Fjpet.118.250225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of canine ATP binding cassette ABCB1 in madin-darby canine kidney type II cells unmasks human ABCG2-mediated efflux of olaparibs</span></div><div class="casAuthors">Song, Yoo-Kyung; Park, Ji Eun; Oh, Yunseok; Hyung, Sungwoo; Jeong, Yoo-Seong; Kim, Min-Soo; Lee, Wooin; Chung, Suk-Jae</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-87, S1-S8</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Endogenous canine ATP binding cassette B1 (cABCB1) is expressed abundantly in Madin-Darby canine kidney type II (MDCKII) cells, and its presence often complicates phenotyping of the transport process.  Errors in estg. the cor. efflux ratio (cER), as a result of the variable expression of cABCB1, were examd. for the dual substrates of ABCB1 and ABCG2 in MDCKII cells expressing human ABCG2 (hABCG2). cABCB1 mRNA and protein expression was 60% and 55% lower, resp., inMDCKII cells expressing hABCG2 comparedwith the wild type, suggesting that the expression of endogenous cABCB1 became variable after the expression of hABCG2.  To minimize the contribution of endogenous efflux, cABCB1 was suppressed kinetically (using verapamil as a selective inhibitor) or biochem. (transfecting short-hairpin RNA against cABCB1).  Under these suppression conditions, cER values for irinotecan and topotecan (dual substrates of ABCB1 and ABCG2) were elevated by more than 4-fold and 2-fold, resp., compared with cER values without the suppression.  The cER of olaparib was similarly increased to 3- and 5-fold in MDCKII cells under the kinetic and biochem. suppression of cABCB1, resp., suggesting that hABCG2-mediated efflux cannot be ruled out for olaparib.  Since the substrate selectivity for ABCB1 and ABCG2 overlapped considerably, the possibility of an inaccurate estn. of cER must be considered for dual substrates in the case of the variable expression of cABCB1 in MDCKII cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc02WPiUzhv7Vg90H21EOLACvtfcHk0lgiCCkdfEpRuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktFGjs74%253D&md5=e5e721b1643376cde1fd768868546a83</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1124%2Fjpet.118.250225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.118.250225%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DY.%2BK.%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DOh%26aufirst%3DY.%26aulast%3DHyung%26aufirst%3DS.%26aulast%3DJeong%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DChung%26aufirst%3DS.%2BJ.%26atitle%3DSuppression%2520of%2520canine%2520ATP%2520binding%2520cassette%2520ABCB1%2520in%2520Madin-Darby%2520canine%2520kidney%2520type%2520II%2520cells%2520unmasks%2520human%2520ABCG2-mediated%2520efflux%2520of%2520olaparib%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2019%26volume%3D368%26spage%3D79%26epage%3D87%26doi%3D10.1124%2Fjpet.118.250225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abuznait, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaddoumi, A.</span></span> <span> </span><span class="NLM_article-title">Role of ABC transporters in the pathogenesis of Alzheimer’s disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">820</span>– <span class="NLM_lpage">831</span>, <span class="refDoi"> DOI: 10.1021/cn300077c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn300077c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVylu73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=820-831&author=A.+H.+Abuznaitauthor=A.+Kaddoumi&title=Role+of+ABC+transporters+in+the+pathogenesis+of+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fcn300077c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Role of ABC Transporters in the Pathogenesis of Alzheimer's Disease</span></div><div class="casAuthors">Abuznait, Alaa H.; Kaddoumi, Amal</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">820-831</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common form of age-related dementia that begins with memory loss and progresses to include severe cognitive impairment.  A major pathol. hallmark of AD is the accumulation of beta amyloid peptide (Aβ) in senile plaques in the brain of AD patients.  The exact mechanism by which AD takes place remains unknown.  However, an increasing no. of studies suggests that ATP-binding cassette (ABC) transporters, which are localized on the surface of brain endothelial cells of the blood-brain barrier (BBB) and brain parenchyma, may contribute to the pathogenesis of AD.  Recent studies have unraveled important roles of ABC transporters including ABCB1 (P-glycoprotein, P-gp), ABCG2 (breast cancer resistant protein, BCRP), ABCC1 (multidrug resistance protein 1, MRP1), and the cholesterol transporter ABCA1 in the pathogenesis of AD and Aβ peptides deposition inside the brain.  Therefore, understanding the mechanisms by which these transporters contribute to Aβ deposition in the brain is important for the development of new therapeutic strategies against AD.  This review summarizes and highlights the accumulating evidence in the literature which describe the role of altered function of various ABC transporters in the pathogenesis and progression of AD and the implications of modulating their functions for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdBjHwrzdoO7Vg90H21EOLACvtfcHk0lgiCCkdfEpRuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVylu73N&md5=608c06826463e2b58ed23bf93feb92e0</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fcn300077c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn300077c%26sid%3Dliteratum%253Aachs%26aulast%3DAbuznait%26aufirst%3DA.%2BH.%26aulast%3DKaddoumi%26aufirst%3DA.%26atitle%3DRole%2520of%2520ABC%2520transporters%2520in%2520the%2520pathogenesis%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D820%26epage%3D831%26doi%3D10.1021%2Fcn300077c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farsiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groelle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mace, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamison, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrabi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollini, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dilley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowes Rickman, C.</span></span> <span> </span><span class="NLM_article-title">Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">E279</span>– <span class="NLM_lpage">E287</span>, <span class="refDoi"> DOI: 10.1073/pnas.1100901108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1073%2Fpnas.1100901108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=21690377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpt12qtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=E279-E287&author=J.+D.+Dingauthor=L.+V.+Johnsonauthor=R.+Herrmannauthor=S.+Farsiuauthor=S.+G.+Smithauthor=M.+Groelleauthor=B.+E.+Maceauthor=P.+Sullivanauthor=J.+A.+Jamisonauthor=U.+Kellyauthor=O.+Harrabiauthor=S.+S.+Bolliniauthor=J.+Dilleyauthor=D.+Kobayashiauthor=B.+Kuangauthor=W.+Liauthor=J.+Ponsauthor=J.+C.+Linauthor=C.+Bowes+Rickman&title=Anti-amyloid+therapy+protects+against+retinal+pigmented+epithelium+damage+and+vision+loss+in+a+model+of+age-related+macular+degeneration&doi=10.1073%2Fpnas.1100901108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration</span></div><div class="casAuthors">Ding, Jin-Dong; Johnson, Lincoln V.; Herrmann, Rolf; Farsiu, Sina; Smith, Stephanie G.; Groelle, Marybeth; Mace, Brian E.; Sullivan, Patrick; Jamison, Jeffrey A.; Kelly, Una; Harrabi, Ons; Bollini, Sangeetha Subbarao; Dilley, Jeanette; Kobayashi, Dione; Kuang, Bing; Li, Wenlin; Pons, Jaume; Lin, John C.; Rickman, Catherine Bowes</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">E279-E287, SE279/1-SE279/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Age-related macular degeneration (AMD) is a leading cause of visual dysfunction worldwide.  Amyloid β (Aβ) peptides, Aβ1-40 (Aβ40) and Aβ1-42 (Aβ42), have been implicated previously in the AMD disease process.  Consistent with a pathogenic role for Aβ, we show here that a mouse model of AMD that invokes multiple factors that are known to modify AMD risk (aged human apolipoprotein E 4 targeted replacement mice on a high-fat, cholesterol-enriched diet) presents with Aβ-contg. deposits basal to the retinal pigmented epithelium (RPE), histopathol. changes in the RPE, and a deficit in scotopic electroretinog. response, which is reflective of impaired visual function.  Strikingly, these electroretinog. deficits are abrogated in a dose-dependent manner by systemic administration of an antibody targeting the C termini of Aβ40 and Aβ42.  Concomitant redn. in the levels of Aβ and activated complement components in sub-RPE deposits and structural preservation of the RPE are assocd. with anti-Aβ40/42 antibody immunotherapy and visual protection.  These observations are consistent with the redn. in amyloid plaques and improvement of cognitive function in mouse models of Alzheimer's disease treated with anti-Aβ antibodies.  They also implicate Aβ in the pathogenesis of AMD and identify Aβ as a viable therapeutic target for its treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooGlkfZz8fUrVg90H21EOLACvtfcHk0ljShAx_ejy77Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpt12qtrg%253D&md5=2961014310520880e0f400f367952057</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1100901108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1100901108%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DJ.%2BD.%26aulast%3DJohnson%26aufirst%3DL.%2BV.%26aulast%3DHerrmann%26aufirst%3DR.%26aulast%3DFarsiu%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DS.%2BG.%26aulast%3DGroelle%26aufirst%3DM.%26aulast%3DMace%26aufirst%3DB.%2BE.%26aulast%3DSullivan%26aufirst%3DP.%26aulast%3DJamison%26aufirst%3DJ.%2BA.%26aulast%3DKelly%26aufirst%3DU.%26aulast%3DHarrabi%26aufirst%3DO.%26aulast%3DBollini%26aufirst%3DS.%2BS.%26aulast%3DDilley%26aufirst%3DJ.%26aulast%3DKobayashi%26aufirst%3DD.%26aulast%3DKuang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DPons%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%2BC.%26aulast%3DBowes%2BRickman%26aufirst%3DC.%26atitle%3DAnti-amyloid%2520therapy%2520protects%2520against%2520retinal%2520pigmented%2520epithelium%2520damage%2520and%2520vision%2520loss%2520in%2520a%2520model%2520of%2520age-related%2520macular%2520degeneration%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3DE279%26epage%3DE287%26doi%3D10.1073%2Fpnas.1100901108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Development of macrocyclic peptides containing epoxyketone with oral availability as proteasome inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9177</span>– <span class="NLM_lpage">9204</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00819</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00819" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVantLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9177-9204&author=D.+Liauthor=X.+Zhangauthor=X.+Maauthor=L.+Xuauthor=J.+Yuauthor=L.+Gaoauthor=X.+Huauthor=J.+Zhangauthor=X.+Dongauthor=J.+Liauthor=T.+Liuauthor=Y.+Zhouauthor=Y.+Hu&title=Development+of+macrocyclic+peptides+containing+epoxyketone+with+oral+availability+as+proteasome+inhibitors&doi=10.1021%2Facs.jmedchem.8b00819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Development of macrocyclic peptides containing epoxyketone with oral availability as proteasome inhibitors</span></div><div class="casAuthors">Li, Daqiang; Zhang, Xiaotuan; Ma, Xiaodong; Xu, Lei; Yu, Jianjun; Gao, Lixin; Hu, Xiaobei; Zhang, Jiankang; Dong, Xiaowu; Li, Jia; Liu, Tao; Zhou, Yubo; Hu, Yongzhou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9177-9204</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Macrocyclization has been frequently utilized for optimizing peptide or peptidomimetic-based compds.  In an attempt to obtain potent, metabolically stable, and orally available proteasome inhibitors, 30 oprozomib-derived macrocyclic peptides with structural diversity in their N-terminus and linker were successively designed and synthesized for structure-activity relationship (SAR) studies.  As a consequence, the macrocyclic peptides with N-methyl-pyrazole, imidazole, and pyrazole as their resp. N-termini exhibited favorable in vitro activity and metabolic stability, which translated into their potent in vivo proteasome inhibitory activity after oral administration.  In particular, pyrazole-contg. compd. (I), as the most distinguished one among this series, displayed excellent chymotrypsin-like (ChT-L, β5) inhibitory potency (IC50 = 16 nM), low nanomolar antiproliferative activity against all three of the tested cell lines, and superior metabolic stability in mouse liver microsome (MLM), as well as favorable inhibition against ChT-L compared to that of oprozomib in BABL/c mice following administration at a comparatively low dose, thereby representing a promising candidate for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYHTTVYr92xrVg90H21EOLACvtfcHk0ljShAx_ejy77Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVantLzP&md5=958573573fe76d3b80e74fb0d7373c95</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00819%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DDevelopment%2520of%2520macrocyclic%2520peptides%2520containing%2520epoxyketone%2520with%2520oral%2520availability%2520as%2520proteasome%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9177%26epage%3D9204%26doi%3D10.1021%2Facs.jmedchem.8b00819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pogue, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dua, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukiw, W. J.</span></span> <span> </span><span class="NLM_article-title">Progressive inflammatory pathology in the retina of aluminum-fed 5xFAD transgenic mice</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1016/j.jinorgbio.2015.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2Fj.jinorgbio.2015.07.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=26213226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ChsL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2015&pages=206-209&author=A.+I.+Pogueauthor=P.+Duaauthor=J.+M.+Hillauthor=W.+J.+Lukiw&title=Progressive+inflammatory+pathology+in+the+retina+of+aluminum-fed+5xFAD+transgenic+mice&doi=10.1016%2Fj.jinorgbio.2015.07.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Progressive inflammatory pathology in the retina of aluminum-fed 5xFAD transgenic mice</span></div><div class="casAuthors">Pogue, A. I.; Dua, P.; Hill, J. M.; Lukiw, W. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">206-209</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">At least 57 murine transgenic models for Alzheimer's disease (Tg-AD) have been developed to overexpress the 42 amino acid amyloid-beta (Aβ42) peptide in the central nervous system (CNS).  These 'humanized murine Tg-AD models' have greatly expanded our understanding of the contribution of Aβ42 peptide-mediated pro-inflammatory neuropathol. to the AD process.  A no. of independent labs. using different amyloid-overexpressing Tg-AD models have shown that supplementation of murine Tg-AD diets and/or drinking water with aluminum significantly enhances Aβ42 peptide-mediated inflammatory pathol. and AD-type cognitive change compared to animals receiving control diets.  In humans AD-type pathol. appears to originate in the limbic system and progressively spreads into primary processing and sensory regions such as the retina.  In these studies, for the first time, we assess the propagation of Aβ42 and inflammatory signals into the retina of 5xFAD Tg-AD amyloid-overexpressing mice whose diets were supplemented with aluminum.  The two most interesting findings were (1) that similar to other Tg-AD models, there was a significantly accelerated development of Aβ42 and inflammatory pathol. in 5xFAD Tg-AD mice fed aluminum; and (2) in aluminum-supplemented animals, markers for inflammatory pathol. appeared in both the brain and the retina as evidenced by an evolving presence of Aβ42 peptides, and accompanied by inflammatory markers-cyclooxygenase-2 (COX-2) and C-reactive protein (CRP).  The results indicate that in the 5xFAD Tg-AD model aluminum not only enhances an Aβ42-mediated inflammatory degeneration of the brain but also appears to induce AD-type pathol. in an anatomically-linked primary sensory area that involves vision.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyaBfODuNRIbVg90H21EOLACvtfcHk0ljShAx_ejy77Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ChsL7I&md5=fcc91f8161110282e337a698565a5161</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2015.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2015.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DPogue%26aufirst%3DA.%2BI.%26aulast%3DDua%26aufirst%3DP.%26aulast%3DHill%26aufirst%3DJ.%2BM.%26aulast%3DLukiw%26aufirst%3DW.%2BJ.%26atitle%3DProgressive%2520inflammatory%2520pathology%2520in%2520the%2520retina%2520of%2520aluminum-fed%25205xFAD%2520transgenic%2520mice%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2015%26volume%3D152%26spage%3D206%26epage%3D209%26doi%3D10.1016%2Fj.jinorgbio.2015.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljubimov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross-Cisneros, F. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadun, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svendsen, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Ocular changes in TgF344-AD rat model of Alzheimer’s disease</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.1167/iovs.13-12888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1167%2Fiovs.13-12888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=24398104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Gltr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=523-534&author=Y.+Tsaiauthor=B.+Luauthor=A.+V.+Ljubimovauthor=S.+Girmanauthor=F.+N.+Ross-Cisnerosauthor=A.+A.+Sadunauthor=C.+N.+Svendsenauthor=R.+M.+Cohenauthor=S.+Wang&title=Ocular+changes+in+TgF344-AD+rat+model+of+Alzheimer%E2%80%99s+disease&doi=10.1167%2Fiovs.13-12888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Ocular changes in TgF344-AD rat model of Alzheimer's disease</span></div><div class="casAuthors">Tsai, Yuchun; Lu, Bin; Ljubimov, Alexander V.; Girman, Sergey; Ross-Cisneros, Fred N.; Sadun, Alfredo A.; Svendsen, Clive N.; Cohen, Robert M.; Wang, Shaomei</div><div class="citationInfo"><span class="NLM_cas:title">Investigative Ophthalmology & Visual Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">523-534</span>CODEN:
                <span class="NLM_cas:coden">IOVSDA</span>;
        ISSN:<span class="NLM_cas:issn">1552-5783</span>.
    
            (<span class="NLM_cas:orgname">Association for Research in Vision and Ophthalmology</span>)
        </div><div class="casAbstract">Purpose. Alzheimer's disease (AD) is the most common neurodegenerative disorder characterized by progressive decline in learning, memory, and executive functions.  In addn. to cognitive and behavioral deficits, vision disturbances have been reported in early stage of AD, well before the diagnosis is clearly established.  To further investigate ocular abnormalities, a novel AD transgenic rat model was analyzed.  Methods. Transgenic (Tg) rats (TgF344-AD) heterozygous for human mutant APPswe/PS1DE9 and age-matched wild type (WT) rats, as well as 20 human postmortem retinal samples from both AD and healthy donors were used.  Visual function in the rodent was analyzed using the optokinetic response and luminance threshold recording from the superior colliculus.  Immunohistochem. on retinal and brain sections was used to detect various markers including amyloid-β (Aβ) plaques.  Results. As expected, Aβ plaques were detected in the hippocampus, cortex, and retina of Tg rats.  Plaque-like structures were also found in two AD human whole-mount retinas.  The choroidal thickness was significantly reduced in both Tg rat and in AD human eyes when compared with age-matched controls.  Tg rat eyes also showed hypertrophic retinal pigment epithelial cells, inflammatory cells, and upregulation of complement factor C3.  Although visual acuity was lower in Tg than in WT rats, there was no significant difference in the retinal ganglion cell no. and retinal vasculature.  Conclusions. In this study, we obsd. pathol. changes in the choroid and in RPE cells in the TgF344-AD rat model; choroidal thinning was obsd. further in human AD retina.  Along with Aβ deposition, the inflammatory response was manifested by microglial recruitment and complement activation.  Further studies are needed to elucidate the significance and mechanisms of these pathol. changes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozYhkpwg3wIrVg90H21EOLACvtfcHk0lgLwospMmToZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Gltr7P&md5=f4c76f60b0aca2d0942b782a955f9789</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1167%2Fiovs.13-12888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.13-12888%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DLjubimov%26aufirst%3DA.%2BV.%26aulast%3DGirman%26aufirst%3DS.%26aulast%3DRoss-Cisneros%26aufirst%3DF.%2BN.%26aulast%3DSadun%26aufirst%3DA.%2BA.%26aulast%3DSvendsen%26aufirst%3DC.%2BN.%26aulast%3DCohen%26aufirst%3DR.%2BM.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DOcular%2520changes%2520in%2520TgF344-AD%2520rat%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2014%26volume%3D55%26spage%3D523%26epage%3D534%26doi%3D10.1167%2Fiovs.13-12888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasool, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glabe, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span> <span> </span><span class="NLM_article-title">Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer’s transgenic mice</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">2099</span>– <span class="NLM_lpage">2110</span>, <span class="refDoi"> DOI: 10.2353/ajpath.2009.090159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.2353%2Fajpath.2009.090159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=19834067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2009&pages=2099-2110&author=B.+Liuauthor=S.+Rasoolauthor=Z.+Yangauthor=C.+G.+Glabeauthor=S.+S.+Schreiberauthor=J.+Geauthor=Z.+Tan&title=Amyloid-peptide+vaccinations+reduce+%7Bbeta%7D-amyloid+plaques+but+exacerbate+vascular+deposition+and+inflammation+in+the+retina+of+Alzheimer%E2%80%99s+transgenic+mice&doi=10.2353%2Fajpath.2009.090159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid-peptide vaccinations reduce β-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice</span></div><div class="casAuthors">Liu, Bingqian; Rasool, Suhail; Yang, Zhikuan; Glabe, Charles G.; Schreiber, Steven S.; Ge, Jian; Tan, Zhiqun</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2099-2110</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is pathol. characterized by accumulation of β-amyloid (Aβ) protein deposits and/or neurofibrillary tangles in assocn. with progressive cognitive deficits.  Although numerous studies have demonstrated a relationship between brain pathol. and AD progression, the Alzheimer's pathol. hallmarks have not been found in the AD retina.  A recent report showed Aβ plaques in the retinas of APPswe/PS1ΔE9 transgenic mice.  We now report the detection of Aβ plaques with increased retinal microvascular deposition of Aβ and neuroinflammation in Tg2576 mouse retinas.  The majority of Aβ-immunoreactive plaques were detected from the ganglion cell layer to the inner plexiform layer, and some plaques were obsd. in the outer nuclear layer, photoreceptor outer segment, and optic nerve.  Hyperphosphorylated tau was labeled in the corresponding areas of the Aβ plaques in adjacent sections.  Although Aβ vaccinations reduced retinal Aβ deposits, there was a marked increase in retinal microvascular Aβ deposition as well as local neuroinflammation manifested by microglial infiltration and astrogliosis linked with disruption of the retinal organization.  These results provide evidence to support further investigation of the use of retinal imaging to diagnose AD and to monitor disease activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWWEOKqgNBzLVg90H21EOLACvtfcHk0lgLwospMmToZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSjtbo%253D&md5=b93c29a69c5a842cd61e1ccc694e9a40</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2009.090159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2009.090159%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DRasool%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DGlabe%26aufirst%3DC.%2BG.%26aulast%3DSchreiber%26aufirst%3DS.%2BS.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DZ.%26atitle%3DAmyloid-peptide%2520vaccinations%2520reduce%2520%257Bbeta%257D-amyloid%2520plaques%2520but%2520exacerbate%2520vascular%2520deposition%2520and%2520inflammation%2520in%2520the%2520retina%2520of%2520Alzheimer%25E2%2580%2599s%2520transgenic%2520mice%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2009%26volume%3D175%26spage%3D2099%26epage%3D2110%26doi%3D10.2353%2Fajpath.2009.090159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masuzzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanagh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krantic, S.</span></span> <span> </span><span class="NLM_article-title">Amyloidosis in retinal neurodegenerative diseases</span>. <i>Front. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">127</span> <span class="refDoi"> DOI: 10.3389/fneur.2016.00127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.3389%2Ffneur.2016.00127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=27551275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BC2szjsVarsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&author=A.+Masuzzoauthor=V.+Dinetauthor=C.+Cavanaghauthor=F.+Mascarelliauthor=S.+Krantic&title=Amyloidosis+in+retinal+neurodegenerative+diseases&doi=10.3389%2Ffneur.2016.00127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloidosis in Retinal Neurodegenerative Diseases</span></div><div class="casAuthors">Masuzzo Ambra; Dinet Virginie; Mascarelli Frederic; Krantic Slavica; Cavanagh Chelsea</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neurology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127</span>
        ISSN:<span class="NLM_cas:issn">1664-2295</span>.
    </div><div class="casAbstract">As a part of the central nervous system, the retina may reflect both physiological processes and abnormalities related to pathologies that affect the brain.  Amyloidosis due to the accumulation of amyloid-beta (Aβ) was initially regarded as a specific and exclusive characteristic of neurodegenerative alterations seen in the brain of Alzheimer's disease (AD) patients.  More recently, it was discovered that amyloidosis-related alterations, similar to those seen in the brain of Alzheimer's patients, also occur in the retina.  Remarkably, these alterations were identified not only in primary retinal pathologies, such as age-related macular degeneration (AMD) and glaucoma, but also in the retinas of Alzheimer's patients.  In this review, we first briefly discuss the biogenesis of Aβ, a peptide involved in amyloidosis.  We then discuss some pathological aspects (synaptic dysfunction, mitochondrial failure, glial activation, and vascular abnormalities) related to the neurotoxic effects of Aβ.  We finally highlight common features shared by AD, AMD, and glaucoma in the context of Aβ amyloidosis and further discuss why the retina, due to the transparency of the eye, can be considered as a "window" to the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgVWH_vPmpkd0Q2ypr7jHkfW6udTcc2ea24LvuiqW2M7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szjsVarsg%253D%253D&md5=10b9324619c0d85505d60e69989d9ef8</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.3389%2Ffneur.2016.00127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffneur.2016.00127%26sid%3Dliteratum%253Aachs%26aulast%3DMasuzzo%26aufirst%3DA.%26aulast%3DDinet%26aufirst%3DV.%26aulast%3DCavanagh%26aufirst%3DC.%26aulast%3DMascarelli%26aufirst%3DF.%26aulast%3DKrantic%26aufirst%3DS.%26atitle%3DAmyloidosis%2520in%2520retinal%2520neurodegenerative%2520diseases%26jtitle%3DFront.%2520Neurol.%26date%3D2016%26volume%3D7%26doi%3D10.3389%2Ffneur.2016.00127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sivak, J. M.</span></span> <span> </span><span class="NLM_article-title">The aging eye: common degenerative mechanisms between the Alzheimer’s brain and retinal disease</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">871</span>– <span class="NLM_lpage">880</span>, <span class="refDoi"> DOI: 10.1167/iovs.12-10827</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1167%2Fiovs.12-10827" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=23364356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsFGhsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=871-880&author=J.+M.+Sivak&title=The+aging+eye%3A+common+degenerative+mechanisms+between+the+Alzheimer%E2%80%99s+brain+and+retinal+disease&doi=10.1167%2Fiovs.12-10827"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease</span></div><div class="casAuthors">Sivak, Jeremy M.</div><div class="citationInfo"><span class="NLM_cas:title">Investigative Ophthalmology & Visual Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">871-880, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">IOVSDA</span>;
        ISSN:<span class="NLM_cas:issn">1552-5783</span>.
    
            (<span class="NLM_cas:orgname">Association for Research in Vision and Ophthalmology</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a common, incurable, and progressive dementia, characterized by loss of learning and memory and the neuropathol. accumulation of amyloid plaques and neurofibrillary tangles in the brain.  A no. of similarities between AD pathol. and several distinct retinal degenerations have been described, particularly with respect to either glaucoma or age-related macular degeneration (AMD), each a leading cause of vision loss and blindness worldwide.  Although comparisons between these diseases may provide important new insights into their pathogenic mechanisms, glaucoma and AMD result in markedly different degenerations.  Therefore, analyses of the differences and the similarities between these conditions may prove equally productive.  Common mechanisms that appear to underlie all three diseases are explored here, as well as potential use of the retina as a biomarker for AD diagnosis and progression.  Based on this comparison, past and current efforts to transfer therapeutic strategies between diseases are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxGcgyGvaPBbVg90H21EOLACvtfcHk0liMv6QAhMOpzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsFGhsr8%253D&md5=704d22062819dd71e3de0eb234f9ee1e</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1167%2Fiovs.12-10827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.12-10827%26sid%3Dliteratum%253Aachs%26aulast%3DSivak%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520aging%2520eye%253A%2520common%2520degenerative%2520mechanisms%2520between%2520the%2520Alzheimer%25E2%2580%2599s%2520brain%2520and%2520retinal%2520disease%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2013%26volume%3D54%26spage%3D871%26epage%3D880%26doi%3D10.1167%2Fiovs.12-10827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaarniranta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salminen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haapasalo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soininen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiltunen, M.</span></span> <span> </span><span class="NLM_article-title">Age-related macular degeneration (AMD): Alzheimer’s disease in the eye?</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">631</span>, <span class="refDoi"> DOI: 10.3233/JAD-2011-101908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.3233%2FJAD-2011-101908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=21297256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFyrs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=615-631&author=K.+Kaarnirantaauthor=A.+Salminenauthor=A.+Haapasaloauthor=H.+Soininenauthor=M.+Hiltunen&title=Age-related+macular+degeneration+%28AMD%29%3A+Alzheimer%E2%80%99s+disease+in+the+eye%3F&doi=10.3233%2FJAD-2011-101908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Age-Related Macular Degeneration (AMD): Alzheimer's Disease in the Eye?</span></div><div class="casAuthors">Kaarniranta, Kai; Salminen, Antero; Haapasalo, Annakaisa; Soininen, Hilkka; Hiltunen, Mikko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">615-631</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A review.  Age-related macular degeneration (AMD) is a late-onset, neurodegenerative retinal disease that shares several clin. and pathol. features with Alzheimer's disease (AD), including stress stimuli such as oxidative stress and inflammation.  In both diseases, the detrimental intra- and extracellular deposits have many similarities.  Aging, hypercholesterolemia, hypertension, obesity, arteriosclerosis, and smoking are risk factors to develop AMD and AD.  Cellular aging processes have similar organelle and signaling assocn. in the retina and brain tissues.  However, it seems that these diseases have a different genetic background.  In this review, differences and similarities of AMD and AD are thoroughly discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKjxD56K88lrVg90H21EOLACvtfcHk0liMv6QAhMOpzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFyrs78%253D&md5=fee8550e40303de5941b33d9d37c1885</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.3233%2FJAD-2011-101908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2011-101908%26sid%3Dliteratum%253Aachs%26aulast%3DKaarniranta%26aufirst%3DK.%26aulast%3DSalminen%26aufirst%3DA.%26aulast%3DHaapasalo%26aufirst%3DA.%26aulast%3DSoininen%26aufirst%3DH.%26aulast%3DHiltunen%26aufirst%3DM.%26atitle%3DAge-related%2520macular%2520degeneration%2520%2528AMD%2529%253A%2520Alzheimer%25E2%2580%2599s%2520disease%2520in%2520the%2520eye%253F%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2011%26volume%3D24%26spage%3D615%26epage%3D631%26doi%3D10.3233%2FJAD-2011-101908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohno-Matsui, K.</span></span> <span> </span><span class="NLM_article-title">Parallel findings in age-related macular degeneration and Alzheimer’s disease</span>. <i>Prog. Retinal Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1016/j.preteyeres.2011.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1016%2Fj.preteyeres.2011.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=21440663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A280%3ADC%252BC3MrptlygtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=217-238&author=K.+Ohno-Matsui&title=Parallel+findings+in+age-related+macular+degeneration+and+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.preteyeres.2011.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Parallel findings in age-related macular degeneration and Alzheimer's disease</span></div><div class="casAuthors">Ohno-Matsui Kyoko</div><div class="citationInfo"><span class="NLM_cas:title">Progress in retinal and eye research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">217-38</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Age is a common risk factor for Alzheimer's disease (AD) and age-related macular degeneration (AMD).  Because of the increasing age of the population, these two age-related diseases have recently received a great deal of attention.  In addition to age as a risk factor, AD and AMD have many characteristics in common.  An important characteristic common to both diseases is the presence of amyloid β (Aβ) in the senile plaques of the AD brain and in the drusen of AMD patients.  We have focused on the role of Aβ as a key regulator of the progression from drusen to AMD, and our results have shown that Aβ causes an imbalance of angiogenesis-related factors in the retinal pigment epithelial (RPE) cells.  Mice that lack the Aβ-degrading enzyme neprilysin develop RPE degeneration, and the sub-RPE deposits that are formed have features similar to those of AMD in humans.  These data suggest that a common pathogenic mechanism might exist between AMD and AD.  Thus, therapeutic approaches that have targeted Aβ in patients with AD can also be applied to AMD.  In this review, we summarise recent findings on the shared characteristics and perspectives between AMD and AD, beginning with the mechanism of Aβ deposition and including a discussion of Aβ-targeted therapeutic approaches for both AD and AMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRA2QyQ5wswajToTC3aBaesfW6udTcc2eYDmkmbfGh1TLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrptlygtA%253D%253D&md5=3169ac32125230c40b2d637c21915757</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.preteyeres.2011.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.preteyeres.2011.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DOhno-Matsui%26aufirst%3DK.%26atitle%3DParallel%2520findings%2520in%2520age-related%2520macular%2520degeneration%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DProg.%2520Retinal%2520Eye%2520Res.%26date%3D2011%26volume%3D30%26spage%3D217%26epage%3D238%26doi%3D10.1016%2Fj.preteyeres.2011.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiquita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues-Neves, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baptista, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carecho, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelo-Branco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosio, A. F.</span></span> <span> </span><span class="NLM_article-title">The retina as a window or mirror of the brain changes detected in Alzheimer’s disease: critical aspects to unravel</span>. <i>Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5416</span>– <span class="NLM_lpage">5435</span>, <span class="refDoi"> DOI: 10.1007/s12035-018-1461-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=10.1007%2Fs12035-018-1461-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=30612332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVGjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2019&pages=5416-5435&author=S.+Chiquitaauthor=A.+C.+Rodrigues-Nevesauthor=F.+I.+Baptistaauthor=R.+Carechoauthor=P.+I.+Moreiraauthor=M.+Castelo-Brancoauthor=A.+F.+Ambrosio&title=The+retina+as+a+window+or+mirror+of+the+brain+changes+detected+in+Alzheimer%E2%80%99s+disease%3A+critical+aspects+to+unravel&doi=10.1007%2Fs12035-018-1461-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The Retina as a Window or Mirror of the Brain Changes Detected in Alzheimer's Disease: Critical Aspects to Unravel</span></div><div class="casAuthors">Chiquita, Samuel; Rodrigues-Neves, Ana C.; Baptista, Filipa I.; Carecho, Rafael; Moreira, Paula I.; Castelo-Branco, Miguel; Ambrosio, Antonio F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurobiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">5416-5435</span>CODEN:
                <span class="NLM_cas:coden">MONBEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-7648</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease is the most frequent cause of dementia worldwide, representing a global health challenge, with a massive impact on the quality of life of Alzheimer's disease patients and their relatives.  The diagnosis of Alzheimer's disease constitutes a real challenge, because the symptoms manifest years after the first degenerative changes occurring in the brain and the diagnosis is based on invasive and/or expensive techniques.  Therefore, there is an urgent need to identify new reliable biomarkers to detect Alzheimer's disease at an early stage.  Taking into account the evidence for visual deficits in Alzheimer's disease patients, sometimes even before the appearance of the first disease symptoms, and that the retina is an extension of the brain, the concept of the retina as a window to look into the brain or a mirror of the brain has received increasing interest in recent years.  However, only a few studies have assessed the changes occurring in the retina and the brain at the same time points.  Unlike previous reviews on this subject, which are mainly focused on brain changes, we organized this review by comprehensively summarizing findings related with structural, functional, cellular, and mol. parameters in the retina reported in both Alzheimer's disease patients and animal models.  Moreover, we sepd. the studies that assessed only the retina, and those that assessed both the retina and brain, which are few but allow establishing correlations between the retina and brain.  This review also highlights some inconsistent results in the literature as well as relevant missing gaps in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozpdva0-jg97Vg90H21EOLACvtfcHk0liMv6QAhMOpzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVGjsb0%253D&md5=0ebea22232c4bbedc69172a357757766</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1007%2Fs12035-018-1461-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12035-018-1461-6%26sid%3Dliteratum%253Aachs%26aulast%3DChiquita%26aufirst%3DS.%26aulast%3DRodrigues-Neves%26aufirst%3DA.%2BC.%26aulast%3DBaptista%26aufirst%3DF.%2BI.%26aulast%3DCarecho%26aufirst%3DR.%26aulast%3DMoreira%26aufirst%3DP.%2BI.%26aulast%3DCastelo-Branco%26aufirst%3DM.%26aulast%3DAmbrosio%26aufirst%3DA.%2BF.%26atitle%3DThe%2520retina%2520as%2520a%2520window%2520or%2520mirror%2520of%2520the%2520brain%2520changes%2520detected%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520critical%2520aspects%2520to%2520unravel%26jtitle%3DMol.%2520Neurobiol.%26date%3D2019%26volume%3D56%26spage%3D5416%26epage%3D5435%26doi%3D10.1007%2Fs12035-018-1461-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNF','PDB','3UNF'); return false;">PDB: 3UNF</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i84"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00291">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_57408"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00291?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00291</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Proteasome catalytic subunit inhibition of DB-60 (<b>20</b>) in different cell lines; <sup>1</sup>H/<sup>13</sup>C NMR spectra of all macrocyclic compounds and HPLC elution profile of the lead compound DB-60 (<b>20</b>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_002.csv">CSV</a>)</p></li><li><p class="inline">Molecular docking models (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_003.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_001.pdf">jm1c00291_si_001.pdf (2.9 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_002.csv">jm1c00291_si_002.csv (2.22 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00291/suppl_file/jm1c00291_si_003.pdb">jm1c00291_si_003.pdb (240.63 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00291&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00291%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00291" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799c7e9bf2d2212","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
